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A systematic review of the clinical effectiveness and
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Background: Obsessive–compulsive disorder (OCD) is a relatively common and disabling condition.
Objectives: To determine the clinical effectiveness, acceptability and cost-effectiveness of pharmacological
and psychological interventions for the treatment of OCD in children, adolescents and adults.
Data sources: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Trials Registers,
which includes trials from routine searches of all the major databases. Searches were conducted from
inception to 31 December 2014.
Review methods: We undertook a systematic review and network meta-analysis (NMA) of the clinical
effectiveness and acceptability of available treatments. Outcomes for effectiveness included mean
differences in the total scores of the Yale–Brown Obsessive–Compulsive Scale or its children’s version and
total dropouts for acceptability. For the cost-effectiveness analysis, we developed a probabilistic model
informed by the results of the NMA. All analyses were performed using OpenBUGS version 3.2.3
(members of OpenBUGS Project Management Group; see www.openbugs.net).
Results: We included 86 randomised controlled trials (RCTs) in our systematic review. In the NMA we
included 71 RCTs (54 in adults and 17 in children and adolescents) for effectiveness and 71 for
acceptability (53 in adults and 18 in children and adolescents), comprising 7643 and 7942 randomised
patients available for analysis, respectively. In general, the studies were of medium quality. The results of
the NMA showed that in adults all selective serotonin reuptake inhibitors (SSRIs) and clomipramine had
greater effects than drug placebo. There were no differences between SSRIs, and a trend for clomipramine
to be more effective did not reach statistical significance. All active psychological therapies had greater
effects than drug placebo. Behavioural therapy (BT) and cognitive therapy (CT) had greater effects than
psychological placebo, but cognitive–behavioural therapy (CBT) did not. BT and CT, but not CBT, had
greater effects than medications, but there are considerable uncertainty and methodological limitations
that should be taken into account. In children and adolescents, CBT and BT had greater effects than drug
placebo, but differences compared with psychological placebo did not reach statistical significance. SSRIs
as a class showed a trend for superiority over drug placebo, but the difference did not reach statistical
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significance. However, the superiority of some individual drugs (fluoxetine, sertraline) was marginally
statistically significant. Regarding acceptability, all interventions except clomipramine had good tolerability.
In adults, CT and BT had the highest probability of being most cost-effective at conventional National
Institute for Health and Care Excellence thresholds. In children and adolescents, CBT or CBT combined
with a SSRI were more likely to be cost-effective. The results are uncertain and sensitive to assumptions
about treatment effect and the exclusion of trials at high risk of bias.
Limitations: The majority of psychological trials included patients who were taking medications. There
were few studies in children and adolescents.
Conclusions: In adults, psychological interventions, clomipramine, SSRIs or combinations of these are all
effective, whereas in children and adolescents, psychological interventions, either as monotherapy or
combined with specific SSRIs, were more likely to be effective. Future RCTs should improve their design, in
particular for psychotherapy or combined interventions.
Study registration: The study is registered as PROSPERO CRD42012002441.
Funding details: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Obsessive–compulsive disorder (OCD) is a medical condition that affects 1–1.5% of the generalpopulation. It can begin in childhood. Several psychological therapies and drugs have been found to
reduce symptoms and increase quality of life. Few studies, however, have directly compared these
treatments. The current project assessed all treatment options for this condition. It aimed to establish if
available treatments work equally well, taking into account their costs. Our review included 86 studies
involving a total of over 8000 patients. In adults, we found that all treatments produced better results than
an inactive pill. Specific psychological therapies were also more effective than non-specific therapy.
Combinations of both drugs and therapy were also more effective than an inactive pill. Behavioural
therapy and cognitive therapy showed a greater effect than drugs. However, there are many uncertainties
regarding this difference. In children and adolescents, specific psychological therapies had greater effects
than an inactive pill. The differences with non-specific psychological treatment or drugs were smaller.
We may need to take into account the costs of treatments and the long-term results to make the best
treatment options available. The findings of this review generally support the previously published
guidelines on the management of OCD.
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Scientific summary
Background
Obsessive–compulsive disorder (OCD) is the fourth most common mental disorder in the UK and ranks
10th in the World Health Organization’s leading causes of disability worldwide. The course of the disorder
is usually chronic and may lead to considerable disability without treatment. Despite its prevalence, the
disorder is under-recognised and undertreated. The total costs of OCD have been estimated, in the USA,
to be US$8.4B in 1990, which is 5.7% of the estimated US$147.8B cost of all mental illness and 18.0%
of the costs of all anxiety disorders. Specific information on indirect and total costs of OCD and the
cost-effectiveness of alternative treatments is limited in the UK and elsewhere.
Objectives
The main aim of this review was to determine the clinical effectiveness, acceptability and cost-effectiveness
of pharmacological and psychological interventions for the treatment of OCD.
More specifically, the aims were the following:
1. to undertake a systematic review of the clinical effectiveness and acceptability of pharmacological and
psychological interventions for the treatment of OCD in all age groups
2. to perform a network meta-analysis (NMA) of all randomised evidence (both direct and indirect), with
the aim to rank all treatments in terms of efficacy and acceptability
3. to develop a probabilistic economic model of alternative treatments (pharmacological and psychological)
for the management of OCD in order to evaluate the relative cost-effectiveness of these treatments.
Methods
Search methods and inclusion criteria
We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Group Controlled Trials
Registers from inception to 31 December 2014. Reports of trials for inclusion in the Group’s registers are
collated from routine searches of MEDLINE, EMBASE and PsycINFO, the Cochrane Central Register of
Controlled Trials and review-specific searches of additional databases. A systematic review of economic
evaluations of pharmacological and psychological interventions in OCD was also conducted using standard
methods for evidence synthesis.
Only randomised controlled trials were eligible for inclusion. Studies that focused exclusively on treatment-
refractory patients were not included. Active pharmacological interventions included any antidepressant
medication with some serotonergic properties. Active psychological interventions included behavioural
therapy (BT) (exposure and response prevention), cognitive–behavioural therapy (CBT) and cognitive
therapy (CT). We used a standard methodology for data extraction.
Outcomes
For the clinical effectiveness analysis, we used the severity of OCD symptoms at the end of study or the change
in symptoms from baseline as measured by the Yale–Brown Obsessive–Compulsive Scale in adults or the
Children’s Yale–Brown Obsessive–Compulsive Scale in children and adolescents. For the acceptability analysis,
we used the total dropout rates. For the cost-effectiveness analysis, the model evaluated the cost-effectiveness
of pharmacological interventions, psychological interventions and combinations of both from a NHS perspective.
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Data synthesis
Pairwise analyses and NMAs were conducted in a Bayesian framework using OpenBUGS version 3.2.3
(members of OpenBUGS Project Management Group; see www.openbugs.net). Pairwise meta-analyses
were conducted in a single model, assuming independent treatment effects and a shared heterogeneity
parameter. In the NMA program code, we incorporated an additional class hierarchy, such that
interventions with a similar mechanism of action were grouped together in a class in which pooled effects
might be assumed to be ‘similar’. Random-effects models were used, accounting for the correlation
between trial-specific effects in multiarm studies. Vague priors were used for all parameters. We report the
relative effectiveness of each treatment compared with every other treatment, as well as the probability
that each treatment is the most effective on each outcome.
For the cost-effectiveness analysis, we developed a decision-analytics model to evaluate the cost-
effectiveness [cost per quality-adjusted life-year (QALY) gained] of pharmacotherapies, psychological
interventions and combinations of both from a NHS perspective over a 5-year time frame. All active
interventions that were included in the NMA were compared in the model. We elected to evaluate
selective serotonin reuptake inhibitors (SSRIs) at the class level in the cost-effectiveness analysis. In total,
the cost-effectiveness of eight interventions in the adult model and five interventions in the children/
adolescent model were compared. The model comprises a decision tree covering the initial response to
treatment at 12 weeks and a Markov model to simulate the course, costs and outcomes (utilities) of OCD
from 12 weeks to 5 years. The model draws on evidence from the NMA to inform the probability of
response (full, partial and no response) and dropout during the initial 12 weeks. Initial pharmacological
and psychological therapy costs are estimated based on data on mean daily dose and total number of
therapist contact hours provided in the trials identified by the systematic review. Longer-term mortality,
symptom course and NHS costs and utilities were estimated based on epidemiological and economic
studies identified through reviews of the literature. The model uses probabilistic analysis to quantify the
stochastic uncertainty around estimates of cost-effectiveness. The importance of parameter and structural
uncertainty is also tested through a series of deterministic sensitivity analyses. The cost-effectiveness of
each intervention is summarised using the net benefit statistic at thresholds of £20,000 and £30,000 per
QALY gained. The probability that each intervention is the most cost-effective at a range of willingness-to-pay
thresholds (£0–50,000 per QALY) is summarised using cost-effectiveness acceptability curves.
Results
Systematic review
A total of 1083 abstracts were screened and 86 studies reported in 85 papers were included in the review
(64 in adults and 22 in children and adolescents), involving 8611 randomised patients (7306 adults and
1305 children and adolescents). In the total sample, 23 different interventions were tested in 194 arms. In
adults, interventions with more studies were clomipramine (n= 17), fluvoxamine (n= 16) and BT (n= 15),
whereas in children and adolescents CBT (n= 9), fluoxetine (n= 4), clomipramine (n= 4) and sertraline
(n= 4) were the most frequently studied treatments. Regarding quality, the majority of the studies did not
describe adequately the random sequence generation and the allocation sequence concealment. In the
adult subset, < 50% of the trials reported results based on the intention-to-treat principle. Studies of
clomipramine and studies of psychological interventions only were more likely to report completers’
analysis. In addition, several studies with psychological arms have used waitlist controls and, therefore,
these comparisons were unblinded from the patient’s perspective.
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Network meta-analysis
Clinical effectiveness in adults
A total of 54 studies were included in this analysis, involving 6652 randomised patients. All active
interventions, apart from venlafaxine and hypericum, had a greater effect on symptom reduction than drug
placebo. Regarding the pharmacological interventions, SSRIs as a class had greater effects than placebo
[class effect mean difference (MD) –3.49, 95% credible interval (CrI) –5.12 to –1.81] with small differences
between them. There was a trend for clomipramine to have a greater effect than SSRIs, but the 95% CrI
included the null value. Regarding the psychological interventions, all active psychotherapies had greater
effects than drug placebo; BT and CT had the largest effects and small differences were observed between
them (class effect MD –1.12, 95% CrI –1.95 to 4.19 for the comparison between BT and CT). Regarding
the comparison between psychological interventions and psychological placebo, both BT and CT had
greater effects (MD –10.33, 95% CrI –13.38 to –7.29 and MD –9.21, 95% CrI –13.10 to –5.34,
respectively) but the effect of CBT was not significantly different from psychological placebo (MD –1.22,
95% CrI –5.54 to 3.03). Regarding the comparison between psychological and pharmacological
interventions, both BT and CT had greater effects than SSRIs as a class or clomipramine. The difference
with CBT was smaller and the 95% CrI included the null value. Combinations of medications and
psychotherapy showed large effects compared with drug placebo, with small differences between the
effects of psychotherapy as monotherapy. In terms of ranking, BT and CT were the two best treatments,
followed by combinations of drug and psychotherapy, CBT and clomipramine. Sensitivity analyses for
incomplete outcome data showed that the effect of clomipramine and CT may have been overestimated,
because most of the studies reported completers’ analyses.
Clinical effectiveness in children and adolescents
Seventeen studies were included in the analysis, involving 991 randomised patients. CBT and BT had
greater effects than drug placebo. Compared with psychological placebo, both therapies, and especially
CBT, showed a non-significant trend for a greater effect. SSRIs as a class showed a non-significant trend
for a greater effect compared with drug placebo. Individual SSRIs, however, reached marginal statistical
significance. Compared with SSRIs as a class, both psychological therapies (BT and CBT) showed a
non-significant trend for a greater effect. Similar results were found for clomipramine. It should be noted
that a limitation of the CBT trials is that, in four of the seven included studies, the control group was the
waitlist (unblinded comparison), and in such studies the effect of CBT was larger than in CBT trials that did
not use the waitlist as the control. The combination of sertraline with CBT was associated with the largest
effect compared with drug placebo, but compared with CBT as monotherapy, the combination had similar
effects. These results should be interpreted with caution owing to the use of the waitlist control in CBT
trials. Sensitivity analyses gave results with similar trends.
Acceptability
All active interventions except clomipramine showed good tolerability in adults compared with placebo.
In children and adolescents, BT showed a non-significant trend towards worse tolerability, but this finding
was based on two small trials. CBT in children and adolescents showed very good tolerability, and the
combination of sertraline with CBT was ranked first in acceptability.
Cost-effectiveness analysis
The selection of the most cost-effective therapy for adults or children and adolescents with OCD is not
clear-cut. In both populations, the most effective therapies were also among the more expensive therapies;
there is a trade-off between the higher upfront costs of psychological therapies and the potential for them
to improve outcomes and reduce long-term costs of care. In the primary economic evaluation in adults,
psychological therapies, specifically CT and BT, had the highest probability of being most cost-effective at
the conventional National Institute for Health and Care Excellence (NICE) thresholds (£20,000–30,000 per
QALY) and above. CBT had a low probability of being cost-effective in adults at all cost-effectiveness
thresholds. This was predominantly because of the substantially lower estimated effect size of CBT
compared with CT and BT and the higher intensity and, therefore, cost of CBT evaluated in randomised
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controlled trials. At lower willingness-to-pay thresholds (< £10,000 per QALY), pharmacotherapy had a
relatively high probability of being cost-effective.
There is substantially less trial evidence in children and adolescents. Of the five interventions compared,
SSRIs had the highest probability of being most cost-effective at lower willingness-to-pay thresholds
(< £15,000 per QALY). At the conventional NICE thresholds (£20,000–30,000 per QALY) and above,
CBT or CBT combined with a SSRI was more likely to be cost-effective.
Discussion
These results confirm previously published guidelines, based on direct evidence only, that a range of
pharmacological and psychological interventions is effective in the short-term management of OCD. One
of the advantages of the present analysis is that the use of a NMA allows the simultaneous comparison of
multiple competing treatments in a single statistical model, even if treatments have not been directly
compared. As there was no imbalance in the presence of potential effect modifiers, we can assume that
there was no inconsistency between the direct and indirect sources of evidence.
The results of the NMA show that all active psychotherapies, in particular BT in adults and CBT in children
and adolescents, had greater effects than drug placebo. CT in adults also showed a large effect compared
with BT, but it is worth noting that this therapy had very few direct links with other interventions apart
from BT, and the evidence is mainly based on completers’ analyses. CBT in adults showed a small effect
compared with the other two psychotherapies and its effect was not statistically significantly different from
that of psychological placebo. In children and adolescents, CBT had a large effect, but a limitation is that
most of the trials have used a waitlist control, and in these studies the effect of CBT was higher than in
studies that used other control treatments.
Selective serotonin reuptake inhibitors had very good tolerability, but their effect in adults, although larger
than that of drug placebo, was worse than that of psychotherapies. It should be pointed out that the
majority of the psychotherapy trials included patients with stable medication use (mainly SSRIs) but who
met diagnostic criteria for OCD and the severity of whose disease was above the cut-off point for inclusion
in the study. It is likely that this may have influenced the results in favour of psychotherapies. In addition,
there is evidence that longer-term treatment with medications may have beneficial effects over and above
the effects reported in the short term. It should also be noted that several psychotherapy trials have used
waitlists as their control and, therefore, the patients receiving the active intervention were not blinded
to treatment. In children and adolescents, the effect of SSRIs as a class was non-significant, although
individual drugs (sertraline and fluoxetine) were marginally more effective than drug placebo. The
combination, however, of sertraline with CBT had the largest effect, which was comparable to the
combination of drug placebo and CBT.
In adults, clomipramine showed a non-significant trend for superiority over SSRIs, but the exclusion of
studies with completers’ analysis attenuated this difference. However, clomipramine was associated with
worse tolerability. Therefore, the results of the present analysis support the recommendation for the use
of clomipramine as a second-line pharmacological treatment.
Combinations of medications with psychotherapies showed large effects that are comparable to
psychotherapy monotherapies (although, as mentioned previously, most of the included patients in
‘monotherapy’ arms were also taking stable doses of SSRIs or clomipramine). Tolerability of the
combinations was generally good and was excellent in children and adolescents.
The results of the economic evaluation reflect considerable uncertainty from many different sources.
Results are sensitive to assumptions about the sustainability of treatment effects beyond the initial
treatment period and exclusion of trials at high risk of bias.
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Conclusions
The results of this review support a range of effective options, both pharmacological and psychological,
for the management of OCD in all age groups. Regarding the relative effectiveness, our review highlighted
the great uncertainty surrounding the published randomised evidence. Although specific psychological
interventions were found to have larger effects than medications, there are important methodological
limitations that need to be taken into account in future research before a final decision can be made.
Regarding cost-effectiveness, current recommendations are not inconsistent with the evidence synthesised
in this report, but, depending on the assumptions, economic implications between interventions may arise.
Future randomised controlled trials should improve methods of investigating the relative effectiveness of
pharmacological versus psychological interventions or combinations of them and take into account issues
of blinding in psychotherapy trials.
Study registration
This study is registered as PROSPERO CRD42012002441.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
Descriptions of obsessive–compulsive symptoms have been reported since the late medieval period, mainly in
relation to religious or moral issues.1 Several nineteenth- and early twentieth-century physicians showed great
interest in these phenomena, including Carl Westphal in 1877 [who used the term ‘Zwangsvorstellung’ to
describe obsessive–compulsive disorder (OCD)], Julius Donath in 1897 (who invented the term ‘anancasmus’
from the Greek word of the same root meaning ‘to compel’) and Pierre Janet in 1906 (who associated
the symptom of obsessions with the ‘psychasthenic’ condition).2 By 1906, the term ‘Obsessional Insanity’
had been included in the ‘Nomenclature of Diseases’ of the Royal College of Physicians in London, and
Emil Kraepelin included in his textbooks the similar condition of ‘Zwangsneurose’.2 It is interesting that all the
main symptoms of the current description of OCD have been described very accurately in the past, including
the egodystonic nature of obsessions, the presence of both obsessions and compulsions in the majority of
patients, the preservation of insight (the ‘folie avec conscience’ – insanity with insight – of the French
psychopathologists), the accompanying anxiety, the common comorbidity with depression, the chronic and
fluctuating course, and the tendency of patients to hide their symptoms and not seek help from doctors.
Diagnostic criteria: disease classification
The first two versions of the Diagnostic and Statistical Manual of Mental Disorders (DSM) of the American
Psychiatric Association were heavily influenced by the psychodynamic concepts of mental illness and
defined obsessive and compulsive phenomena accordingly. In the first edition (DSM-I), the term ‘Obsessive
Compulsive Reaction’ was used; the term ‘reaction’ referred to the way in which a person reacts to
unconscious intrapsychic conflicts using defence mechanisms.3 This was classified under the broader
category of ‘Psychoneurotic Disorders’. In the second edition (DSM-II), the term ‘Obsessive Compulsive
Neurosis’ was used.4 Next editions of the manual abandoned the effort of classifying mental disorders in
accordance with aetiology and adopted an atheoretical model based on descriptive phenomenology and
empirical research. This was mainly done to increase the reliability of psychiatric diagnosis. The World
Health Organization (WHO) followed along the same path and published clinical descriptions and specific
diagnostic criteria for research.5 From 1980 (DSM-III) to 2000, when the fourth edition of DSM was
published (DSM-IV), there were few differences in the conceptualisation of OCD.6 The disorder is classified
under the broad category of ‘Anxiety Disorders’ and the two main characteristics are the presence of either
obsessions or compulsions. Obsessions are defined as recurring and persistent thoughts, images or
impulses that are intrusive and inappropriate and cause much distress and anxiety. Owing to their content,
the patient tries to resist and control these thoughts or to suppress the resulting anxiety with compulsions.
These are repetitive behaviours or mental acts that may aim to reduce the anxiety brought on by the
obsession or that the person feels driven to perform in accordance with a rigid sequence or idiosyncratic
rules. Quite often, these behaviours are not connected in a realistic way with what they aim to neutralise
or prevent, or they are clearly excessive. In order for these symptoms to be considered clinically significant,
they should have a considerable impact on the everyday functioning of the individual.
In the latest edition of the DSM (DSM-V),7 there have been some slight changes to the definition of the
disorder, some of the most important of which are the following:
(a) OCD has been separated from the broader category of ‘Anxiety Disorders’ and it is now described
under the category of ‘Obsessive–Compulsive and Related Disorders’ which also includes body
dysmorphic disorder, hoarding disorder, trichotillomania and excoriation disorder.
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(b) It is acknowledged that there is a spectrum of insight and that some patients may have absent insight
or ‘delusional’ beliefs. Therefore, in DSM-V insight is coded as ‘good/fair’ (obsessions are recognised
as excessive and abnormal ideas), ‘poor’ (obsessions take the form of overvalued ideas) or ‘absent’
(obsessions share some characteristics with delusions). An absent insight does not preclude the
diagnosis of OCD. As Leckman et al.8 point out, it is assumed that patients with currently absent
insight have shown some insight in the past during the course of their disorder.
(c) Hoarding disorder is now a separate disorder and not a subtype of OCD.
(d) A form of OCD related to chronic tics is now included as a new subtype, as there is evidence that this
subtype has a younger age at onset and different treatment response.8
(e) The definition of OCD according to the International Classification of Diseases, Tenth Edition (ICD-10),
is very similar to that of the DSM, with slight and not essential differences.8
(f) The ICD-10 does not include separate definitions of obsessions and compulsions but the emphasis is
placed on their shared characteristics.
(g) The DSM implies that obsessions and compulsions have a functional relationship (in the sense that
compulsions are behaviours that aim to reduce the distress caused by the obsessions), whereas the
ICD does not suggest such a connection.
Form and content of obsessions and compulsions
Previous studies of the phenomenology of OCD have described both the form and the content of
obsessions and compulsions. Khanna et al.9 described the following forms for obsessions (in order of
frequency): fears, thoughts, doubts, urges, convictions and images; and, for compulsion: repeating, rituals,
checking and avoiding.
The thematic content of obsessions and compulsions has been described in detail by Rasmussen and
Eisen10 and Foa et al.11 Rasmussen and Eisen10 have used data from their large cohort of 560 OCD patients
(diagnosed in accordance with DSM-III or DSM-III-R criteria), whereas Foa et al.11 reported data from
425 patients with OCD (in accordance with DSM-IV criteria). Although there are some differences between
these two studies, it is generally accepted that common themes of obsessions are (all figures from
Foa et al.11) worries about dirt/contamination (40%), aggressive obsessions (25%), content related to
sexual or religious themes (12%), need for symmetry (10%), somatic/hypochondriac concerns (7%) and
unacceptable urges (4%). In the Rasmussen and Eisen10 cohort, pathological doubt (regarding responsibility
for a terrible event) was the second most common content, reported in 40% of patients (this theme is
related to aggressive ideas or harm-related content in the Foa et al.11 study). Regarding compulsions,
common themes include checking (28%), cleaning/washing (27%), repeating/counting (13%), mental
rituals (11%), ordering/symmetry compulsions (6%) and hoarding-related compulsions (4%).
Given that there may be a functional relationship between obsessions and compulsions, some studies have
investigated the structure of symptoms using the statistical techniques of factor or cluster analysis.
Recently, Bloch et al.12 carried out a meta-analysis of all studies that used factor-analytic methods to
investigate the symptom structure of the most commonly used symptom scale, the Yale–Brown
Obsessive–Compulsive Scale (YBOCS) (n= 21 studies involving 5124 participants). They concluded that four
distinct factors explained 79% of the variance in the total sample: (1) a symmetry factor, which included
symmetry obsessions and ordering, repeating and counting compulsions; (2) a factor associated with
‘forbidden’ thoughts, which included aggressive, sexual and religious obsessions; (3) a cleaning factor,
including dirt/contamination obsessions and cleaning compulsions; and (4) a hoarding factor. The results
were quite similar in both the children and adolescents and adults subsamples.
Although most patients have a main/primary theme for their obsession or compulsion, it is not uncommon
to report other themes of milder intensity or frequency.9 Mataix-Cols et al.13 investigated the longitudinal
stability of symptoms in 117 adult patients and concluded that symptoms were quite stable at 2 years’
follow-up and that shifts between symptom dimensions were relatively rare.
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Phenomenological differences between the two genders
The phenomenological differences between the two genders have been recently reviewed by de Mathis
et al.14 Men are younger at onset, and this is sometimes associated with the presence of chronic tics and a
worse prognosis. Most phenomenological studies conclude that men are more likely to develop obsessions
with a sexual/religious theme, whereas women more often develop dirt/contamination obsessions and
cleaning compulsions.15,16 Some studies also report that symmetry/ordering obsessions are more common
in men,15,17 whereas in women the presence of obsessions (either fears or impulses) with an aggressive
content may be more common.15,18
Phenomenology in children and adolescents
Obsessive–compulsive disorder may start very early in childhood,19 and it is interesting to investigate
differences in the presentation of symptoms between children and adults. Geller et al.20 compared
symptom dimensions in a sample of 101 patients aged < 18 years, including a subsample of children
(n= 46) and a subsample of adolescents (n= 55), and compared this with a reference adult patient sample
previously reported in Rasmussen and Eisen.21 Regarding obsessions, they reported significant differences
between both the children and adolescents samples and the adults sample as regards the presence of
aggressive/catastrophic obsessions (less common in the adult sample) and sexual/religious obsessions
(which were more common in the adolescent sample). In addition, they reported that confessing/asking
compulsions were more common in children. Similar studies have also confirmed that contamination
obsessions and washing/cleaning compulsions are very common in children and adolescents.22,23
Measurement of disease severity
Several instruments have been developed to assess symptom severity in OCD. These include both
clinician-administered interviews and self-report questionnaires (or parent report in the case of the
paediatric population). Grabill et al.24 included four clinician-administered instruments and 10 self-report
questionnaires in their review of this issue.
Of the clinician-administered instruments, the YBOCS25 is the most widely used instrument to assess
symptom severity and is considered the gold standard in OCD literature, especially to assess change in
symptoms after treatment.26 This is a semistructured clinician-administered instrument assessing the
severity and frequency of obsessions and compulsions. It yields three scores, an obsessions severity score,
a compulsions severity score and a total score (ranging from 0 to 40 for the total). Good psychometric
properties have been reported for both clinical and non-clinical samples of patients.24 A cut-off score of
16 is often used in clinical trials for patients to be eligible for inclusion in a study. This score distinguishes
patients with moderate-to-severe symptoms from patients with mild or subclinical symptoms and has
demonstrated good sensitivity.26 Other versions of the YBOCS include a self-report version26 and a modified
version (YBOCS-II)27 to take into account more recent research on the phenomenology of OCD. An
adaptation of the same scale for children and adolescents has been also developed, the Children’s
Yale–Brown Obsessive–Compulsive Scale (CYBOCS),28 which has been used extensively in paediatric OCD
trials. Studies of the factor structure of the YBOCS have generally confirmed the existence of two factors
(severity of obsessions and severity of compulsions), although a third factor of resistance has been
replicated in some studies.24,29
Aetiology
Obsessive–compulsive disorder is a complex neuropsychiatric disorder, and several genetic, biological and
psychological factors may have an important role in the aetiology of the condition. Although aetiological
research in the OCD field is very active, the clinical heterogeneity and complexity of the disorder have
resulted in the limited translational capacity of basic research into clinical practice.30
Genetic factors
Family studies among relatives of both adults and children and adolescents with OCD have consistently
shown that OCD is familial and that the risk of OCD is higher in first-degree relatives of patients. For
example, in the Pauls et al. study,31 the rate of OCD in relatives of patients was significantly higher than in
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controls (10.3% vs. 1.9%). Similar results were reported by Nestadt et al.32 (11.7% vs. 2.7%). Studies in
children have reported an even higher familial association, with odds ratios (ORs) ranging from 12 to 30.33–35
Although family studies point to a possible genetic aetiology in OCD, twin studies are more suitable to
distinguish between genetic and environmental factors. Adoption twin studies have not been conducted in
the OCD field36 and, therefore, most twin studies have compared the concordance rates in monozygotic
versus dizygotic twin pairs. van Grootheest et al.36 reviewed these studies and a meta-analysis of all
available twin studies has been published more recently.37 The conclusion of these studies is that
approximately 40% of the variance in OCD can be explained by additive genetic factors, whereas 50% of
the variance can be explained by non-shared environmental factors. Surprisingly, shared environmental
factors (e.g. parental style or practices) were not associated with phenotypic variance.
Genetic linkage studies and the two published genome-wide association studies have been recently
reviewed by Pauls et al.33 The genetic linkage studies have identified two genomic regions (on
chromosomes 9 and 15) that may be associated with an increased risk of OCD. Given that OCD is most
probably a multigenic disorder, genetic linkage studies have limited power to identify multiple genes with
a small-to-moderate effect. Genome-wide association studies may be more suitable, but the results of two
such studies are inconclusive. It has been suggested that larger samples may be needed for the results to
reach genome-wide significance.33
Taken together, findings from genetic research support the hypothesis that multiple genes, regulating
parts of the serotonergic, dopaminergic and glutamatergic systems, may be related to an increased
vulnerability to OCD, but non-shared environmental factors also play an important part in the development
of the disorder.
Biological factors
There is a consensus, mainly due to functional imaging studies, that a dysregulation in the frontostriatal
circuit is involved in the pathophysiology of OCD.33 Studies have consistently shown an increased activation
of the orbitofrontal and possibly the anterior cingulate cortex, and an hyperactivity of the head of the
caudate nucleus. Increased activation of the caudate leads, through a positive feedback loop, to an
increase in the excitatory glutamatergic output from the thalamus to the frontal cortex.33 This results in
exaggerated worries about danger, despite direct evidence from the senses that contradict this danger.33,38
Recent experimental studies in animals using the technique of optogenetics have shown that repeated
stimulation of the orbitofrontal cortex and the ventromedial striatum generates a progressive increase in
compulsive behaviours in animals (e.g. increased grooming) that is reversed by the chronic, but not acute,
administration of fluoxetine.39
Psychological factors
The psychological model of OCD postulates that patients interpret their unwanted intrusive thoughts
(obsessions) in a maladaptive way. Salkovskis40 suggested that faulty appraisals related to inflated
responsibility are very important. Apart from inflated responsibility, other maladaptive appraisals include
the overimportance of thoughts, the need to control those thoughts and the exaggerated estimate of the
probability that an unwanted event will occur (thought–action fusion).41 These appraisals lead to anxiety
and the need to engage in neutralising behaviours (such as compulsions, avoidance and reassurance
seeking) to prevent harm. Compulsions are positively reinforced because they reduce the anxiety caused by
the faulty appraisals in the short term. However, in the long term they prevent habituation and fear
extinction from happening and thereby help in the maintenance of obsessions. Therefore, compulsive
behaviour is considered as a maladaptive response to obsessions. Based on these theories, both
cognitive–behavioural therapy (CBT) and behavioural therapy (BT) [exposure and response prevention (ERP)]
have been successfully used for the treatment of OCD.
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Epidemiology
Prevalence in adults
The descriptive epidemiology of OCD has been recently reviewed by Fontenelle et al.19 and Torres and
Lima.42 Before 1980, the prevailing view was that OCD is a relatively severe but rare psychiatric disorder.
This view was mainly based on the frequently cited 1953 study by Rudin,43 which estimated a prevalence
of 0.05% in the general population.10 However, even in this early period, which preceded modern
diagnostic criteria, some studies showed a different situation for OCD prevalence. Among them, the
careful psychiatric epidemiological study by Brunetti,44 in the small community of Roussillon in south-east
France, reported a higher prevalence of 1%, which is a figure very close to estimates in more recent
studies. The view that OCD is a rare disease changed after the large American epidemiological study of the
1980s, the Epidemiologic Catchment Area (ECA) study.45 This study used a fully structured diagnostic
interview, designed to be used by lay interviewers, and included OCD in the assessment. The OCD data
were analysed by Karno et al.46 They reported a lifetime prevalence for OCD in adults of 2.5% and a
6-month prevalence of 1.5%, which was considerably higher than previous estimates. Prevalence of OCD
was higher in women than in men (with a ratio of 1 : 4). The diagnostic interview schedule (DIS) that was
used for the assessment has been criticised for its inability to assess reliably anxiety and phobic disorders.47
Nelson and Rice48 in a subsequent study examined the stability of the OCD diagnosis in the ECA data set
using longitudinal data from the second wave, 12 months after the baseline measurement. They found
that 80% of the participants who met lifetime criteria for OCD at baseline did not meet the same criteria
at the second assessment. A clinical revalidation of OCD diagnosis in a subset of the ECA study showed a
prevalence of clinically validated OCD of 0.3%, which was considerably lower than the DIS assessment.47
Similarly, in a German study,49 the lifetime prevalence in accordance with the DIS was 2%, whereas
according to clinicians it was 1%. More recent epidemiological studies using the Composite International
Diagnostic Interview have resulted in a much broader range of prevalence rates of OCD in adults, from
0.9% lifetime prevalence in the Netherlands50 to 3% 1-month prevalence in Canada.51 In this Canadian
study, a clinical revalidation of the data resulted in a lower prevalence of 0.6%, whereas another 0.6% of
patients met criteria for ‘subclinical’ OCD. According to the authors,51 the differences between the results
of the diagnostic interviews and clinicians’ diagnoses are attributable to the following factors: (1) common
or everyday worries are sometimes confused with obsessions in diagnostic interviews; and (2) it is likely
that epidemiological interviews may overestimate the intensity or frequency of obsessions or compulsions.
Apart from DIS and the Composite International Diagnostic Interview, other studies have used the revised
Clinical Interview Schedule and the Mini International Neuropsychiatric Interview. In one study,52 the
1-month prevalence with the revised Clinical Interview Schedule was 1.1%. In Italy, Faravelli et al.53
reported a lifetime prevalence of 2.4% using the Mini International Neuropsychiatric Interview. In Greece,
Skapinakis et al.54 reported a 1-month prevalence of 1.7% using the revised Clinical Interview Schedule.
There is great variability in the estimation of the prevalence of OCD in the general population and this is
partly explained by the different samples and methodologies used. Taking into account the majority of the
studies, a conservative estimate of the lifetime prevalence of OCD, using diagnostic interviews in the
general population, is approximately 2%, and the 1- to 6-month prevalence is between 1% and 1.5%.
These estimates would be reduced by approximately half if clinicians had been involved in the assessments.
Prevalence in children and adolescents
The prevalence of OCD in children and adolescents has been investigated in several studies either in the
general population or in more selected samples (e.g. school-based surveys). Of the general population
studies, three are particularly useful as a result of their large samples or their representativeness: (1) a
British study55 in a nationally representative sample of 10,000 children aged 5–15 years, which reported a
low prevalence of current OCD at 0.2%; (2) a US study56 in a sample of 4500 children aged 9, 11 and
13 years, which also reported a 3-month prevalence of 0.2%; and (3) a study from the Netherlands57 in a
nationally representative sample of 2916 adolescents aged 13–18 years, which reported a 6-month
prevalence of 1%. It is worth noting that in both the Dutch study57 and in another community study in the
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USA,58 the authors found that relying solely on parents’ reports of symptoms may underestimate the true
burden of OCD symptoms. This is especially relevant for studies of children < 12 years old, in which it is
less likely that children will be directly asked to report their symptoms.
Incidence
The incidence of OCD has been studied less than the prevalence. A review by Fontenelle et al.19 reported
four studies in adults with an annual incidence ranging from 0.05% to 0.7%. The two most prominent
studies are (1) a longitudinal study undertaken in the USA using a subset of the original ECA study59 which
specifically investigated the incidence of OCD; and (2) a longitudinal extension of the NEtherlands MEntal
health Survey and Incidence Study (NEMESIS).60 The former reported an incidence of 0.55 per 1000
person-years (approximately 0.05% per year), whereas the latter reported an incidence of 0.2% per year.
Regarding children and adolescent samples, a school-based study conducted in the USA among 488
adolescents aged 13–15 years61 reported an annual incidence of OCD of 0.7% [95% confidence interval
(CI) 0.12% to 1.34%].
Prevalence differences between men and women
Most studies conducted in the general population have shown a higher prevalence in women than men,
with the female-to-male ratio ranging between 1.2 and 3.8 in several studies.42,62 In one British study,52 the
ratio was 1.44. These findings show that the clinical observation that the number of women in clinical
samples far outweighs the number of men is not the result of help-seeking bias.
Regarding children and adolescents, most studies in non-clinical samples seem to support a 1 : 1 ratio for
prevalence in boys and girls,55,61,63 although there are some studies reporting a higher prevalence for
boys.64,65 In clinical samples, there is an excess of boys, possibly owing to younger age at onset and more
severe symptomatology.62,63
Socioeconomic status
Fontenelle and Hasler,62 in their review of the analytical epidemiology of OCD, mention several studies that
have shown a positive association between a higher socioeconomic status or education and OCD. However,
other studies did not confirm this, or found a negative association (e.g. the study by Torres et al.52). It can be
concluded from these studies that OCD, in contrast to other psychiatric disorders, displays no clear social
gradient, although there is even a small possibility of a mild positive association. Regarding employment
status, in most studies, individuals with OCD are more likely to be unemployed or economically
inactive,46,52,62 although this possibly reflects the generally negative association of the common mental
disorders with employment status and is not specific to OCD. A similar observation can be made for marital
or family status: individuals with OCD are more likely to be unmarried or to live alone, as is common for all
other mental disorders.62
Comorbidity
Several studies with clinical samples have confirmed that OCD is often comorbid with other psychiatric
disorders.66–68 In most clinical studies, the most common comorbidity is mood disorders, a finding that is
compatible with the view that patients with OCD will often seek help from a mental health specialist when
they develop depression or some other psychiatric disorder. The reported prevalence of comorbid disorders
differs from study to study depending on the methodology and the time frame used (e.g. 1 month, 1 year,
lifetime). In a Dutch sample of 420 outpatients with OCD,67 24% had comorbid current depression/
dysthymia and 13% had any anxiety disorder [most often social phobia (3.6%) and panic disorder (2.6%)].
These figures are much higher than the reported prevalence in the general population. One study reported
that alcohol use disorders in patients with OCD were less common than in the general population.67
Another study from the USA, which included 334 outpatients from the adult OCD clinic at the National
Institute of Mental Health,66 assessed the lifetime prevalence of comorbid disorders. Approximately 66%
of patients had experienced major depression at some time in their lives, whereas one in four had
experienced social phobia, panic disorder or dysthymia. It is worth noting that in this cohort, lifetime
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alcohol dependence was high, at 25%. In women, the prevalence of eating disorders was increased
(26% of the sample). Data from the Brown cohort68 showed that a minority of patients (< 10%) had not
experienced any other disorder in their life. As reported elsewhere, depression was the most common
comorbid condition (67% lifetime prevalence and 15% current episode). Other common diagnoses in this
cohort were social phobia (28% lifetime, 19% current), panic disorder (18% lifetime, 7% current) and
alcohol dependence (23% lifetime, 4.5% current). Eating disorders were also common in this cohort
(10% lifetime prevalence for the entire sample).
Studies conducted in the general population have confirmed that these patterns of comorbidity are not the
result of help-seeking bias. In the British Psychiatric Morbidity Survey,52 37% of participants with OCD also
met criteria for current depression. In addition, comorbidity with anxiety disorders, such as panic disorder
(22%) and social phobia (17%), and with alcohol dependence (33% in men, 11% in women) was
particularly high. In the replication study of the National Comorbidity Survey in the USA,69 participants who
met criteria for OCD had an increased lifetime prevalence for other mood and anxiety disorders (40% for
depression, 44% for social phobia, 20% for panic disorder, 38% for alcohol dependence). These figures
are very similar to those reported from the first large epidemiological survey of OCD in the US general
population, the ECA study.46
The association of OCD with bipolar disorder has attracted research interest over the past decade. Several
studies have reported that OCD patients have a lifetime history of bipolar disorder, mainly type 2 bipolar
disorder (bipolar II), with prevalence rates that are much higher than in the general population (up to 15%
in some samples70). Conversely, an OCD history is often reported in patients with bipolar disorder (up to
35% in a German study71). In a recent review of this issue,72 it is pointed out that there are disagreements
between studies regarding the extent of this comorbidity. For example, in a French study that included
mainly type 1 bipolar disorder (bipolar I) patients,73 history of OCD was quite low (at 3%), in contrast to
histories of panic disorder and phobic disorders, which were higher (16% and 11%, respectively).
The relationship between obsessive–compulsive symptoms and psychotic disorders in general, or
schizophrenia in particular, has been noted since the early twentieth century,74,75 but only recently has this
association been studied more systematically.72 A recent meta-analysis of this topic identified 37 studies
that aimed to estimate the prevalence of OCD in patients with schizophrenia and related disorders.76 This
analysis reported a mean OCD prevalence of 12.3% (95% CI 9.7% to 15.4%), which is much higher than
that of the general population. Obsessive–compulsive symptoms were even more common. Eisen et al.,77
in a study that used a very careful methodology, reported that the prevalence of OCD in 77 patients with
psychotic disorders (schizophrenia, n= 52; schizoaffective disorder, n= 25) was 7.8% (6/77 patients). It is
worth noting, however, that five of these six patients with OCD had schizoaffective disorder (5/25, 20%)
and only one had schizophrenia (1/52 patients, 1.9%). Another interesting study from the Netherlands,
among patients with first-episode psychosis or at ultra-high risk for developing psychosis,75 reported that
the prevalence of OCD was 1.5%, whereas that of obsessive–compulsive symptoms not meeting full
diagnostic criteria for OCD was 9.3%. The authors note that these figures are very similar to those
reported from general population samples. The prevalence of both the disorder and the symptoms was
lower in those patients who met criteria for schizophrenia rather than schizophreniform or schizoaffective
disorders. No significant differences were found between the time of onset of obsessive–compulsive
symptoms prior to or after the onset of the first episode of psychosis. OCD did not precede the
onset of psychosis in patients with both disorders. These findings are compatible with the view that
obsessive–compulsive symptoms may be either prodromal symptoms of first-episode psychosis or a
secondary side effect of antipsychotic medications.75 Studies that have investigated the presence of
psychotic symptoms among patients with OCD are few. In the Brown cohort,78 6% of OCD patients had a
comorbid psychotic disorder (4% schizophrenia; 2% delusional disorder). In NEMESIS,79 the presence of
obsessive–compulsive symptoms at baseline predicted the onset of psychotic symptoms at follow-up and
vice versa. From these studies, it is concluded that although there seems to be an association between
symptoms of OCD and psychotic disorders, this association is bidirectional and complex.
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Suicidality
In the past, OCD was considered a relatively rare condition,19 with a low risk for suicide, at least compared
with other mental disorders.80,81 More recent studies, however, have changed this view. In Brazil, a large
clinical study of outpatients with OCD (n= 582) found that 11% of the sample had attempted suicide at
least once in their lifetime.81 Studies in unselected samples of the general population have confirmed these
findings. In the UK, a history of suicide attempt was reported by 26% of the participants who met criteria
for OCD, compared with 14.5% of those with other common mental disorders, a statistically significant
difference.52 These studies were cross-sectional and assessed suicidality retrospectively. There are few
longitudinal studies that have reported suicidal behaviour. In a prospective clinical study in Spain,82
218 outpatients with OCD were followed up for a mean duration of 4 years. Two patients (0.9%)
committed suicide and 11 (5%) attempted suicide. Risk factors for suicidal behaviour were the presence of
symmetry/ordering obsessions and the initial severity of depressive symptoms. In NEMESIS,83 the cumulative
incidence of suicide attempts in participants with OCD, after 3 years’ follow-up, was 0.4%, a very low
figure compared with other common mental disorders and the lowest among the anxiety disorders.
Incidence of suicidal behaviour was also low in a meta-analysis that used data from patients who had
participated in randomised controlled trials (RCTs) submitted to the US Food and Drug Administration
(FDA).84 In that analysis, the annual incidence of suicide attempts in OCD patients was approximately
1.47% (1468/100,000 per year) and the suicide rate was 0.11% (105/100,000 per year). It is worth noting
that these figures were comparable with the other anxiety disorders covered in this analysis and
significantly lower compared with the figures for depression (2.9% and 0.8%, respectively) that have been
reported in a separate paper with the same methodology.85
In conclusion, the results of these studies show that suicide risk in OCD is higher than in the general
population by a factor of 10 or more, but is comparable to risk in popuations with other anxiety disorders.
It is lower than the risk associated with depression, but it should be pointed out that, because OCD is
often comorbid with depression, the incidence in real clinical practice might be higher. In a secondary
analysis of the NEMESIS sample, for example, the suicide risk (either attempt or ideation) was higher in
participants who met criteria for both depression and anxiety disorders.86
The study of suicidal behaviour in child/adolescent OCD samples is not so extensive. A recent study of
54 patients aged 7–17 years from a tertiary centre in the USA87 reported that 13% of the sample (n= 7)
had clinically significant suicidal ideation during the past month. Significant associations were found
with the presence of symmetry/ordering obsessions and obsessions of sexual or religious content, with
increasing age and with the presence of depressive symptoms.
Natural history: prognosis
Historically, OCD was considered a disorder with a poor prognosis. This view was challenged by the
seminal study of Pollitt.88 Pollitt’s study used a very strict methodology in a period in which there was no
specific form of treatment other than leucotomy (with uncertain effects). To avoid any possible treatment
effects of this procedure, Pollitt presents his results on the course of OCD separately for patients with or
without leucotomy. According to this study, the longitudinal course of the illness was good: complete
remission was observed in 24% of the patients after a mean duration of follow-up of 3.4 years (range
0.5–15 years), whereas 36% had a mild illness (i.e. 60% of the patients had a benign course). A study
conducted in Sweden by Skoog and Skoog89 included 144 patients with OCD who were examined by one
of the authors between 1954 and 1956 by means of a semistructured clinical interview. The patients were
re-examined by the same researcher after 40 years using the same methodology. Rates of complete
remission (20%) were comparable to those in the Pollitt study,88 whereas 28% of patients had mild
symptoms at follow-up. Therefore, in this study almost half of the patients had a good course.
With the advent of new and effective treatments in the 1980s [BT/CBT, clomipramine and selective
serotonin reuptake inhibitors (SSRIs)], it is interesting to review longitudinal studies of the prognosis of
OCD in patients who received such treatments. Two such studies have been published recently.
Bloch et al.90 investigated the longitudinal course of illness (10–20 years) in 83 patients with OCD who
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participated in clinical trials in their centre (Yale). The authors reported that 20% of the sample
experienced complete remission, whereas another 30% experienced partial remission. Almost half of the
patients still had symptoms that would make them eligible for inclusion in a new clinical trial (a score on
the YBOCS of ≥ 16). It is worth noting that 70% of these patients were receiving medication at follow-up
and approximately half had received BT or CBT at some point in their lives (after the baseline assessment).
Similar results were reported in the study of the Brown cohort that included 213 patients with OCD.91
Complete remission at 5 years’ mean follow-up was observed in 17% of the sample, whereas partial
remission was observed in 22% of patients. This study also assessed the rates of relapse after partial or
complete remission, which were quite high (59%). In another study from Italy, which included
55 outpatients with OCD treated with SSRIs, the rates for complete and partial remission at 3 years’
follow-up were 22% and 34%, respectively.92
The main conclusion that can be drawn from the above discussion is that remission rates in the modern
era have not improved compared with those reported in earlier studies88,89 despite the wide availability of
effective treatments. It is difficult, however, to interpret this finding, as changes in diagnostic preferences
or criteria may have resulted in non-comparable groups of patients being selected for inclusion in
these studies.
Regarding the factors that are associated with a poor prognosis, several studies report that an early onset,
more severe initial symptoms, a longer duration of illness and comorbidity with depression are all
associated with a poor prognosis.89,92–95 In the Brown cohort,91 patients with primary hoarding obsessions/
compulsions had a worse prognosis with very low remission rates, whereas patients with primary
obsessions regarding an inflated sense of responsibility for harm had a better prognosis. In the Yale
cohort,90 an initial good response to SSRIs was a good prognostic factor. In other studies, the presence of
schizotypal92 or obsessive–compulsive personality disorder91 was associated with a poor prognosis.
The long-term prognosis of OCD in children and adolescents has been reviewed by Stewart et al.,96 who
included 16 studies from various settings. Stewart et al.96 report a mean remission of 40% after a mean
duration of 5.7 years’ follow-up. When including partial remission, this rate is increased to 59%. Focusing
on the studies that have used non-clinical samples, the remission rate is even higher, at 74%. Some more
recent studies from the USA97,98 and the UK99 have also been published. The results of more recent studies
are similar to those seen in the Stewart et al. review,96 despite the use of selected samples from tertiary
centres. In the Yale cohort,98 58% of the patients had complete remission after a mean follow-up duration
of 9 years. In the Maudsley cohort,99 approximately 60% of the patients had at least a partial remission
after 5 years’ mean follow-up. From these findings it can be concluded that remission rates in children and
adolescents may be higher than those in adults. Regarding factors associated with a poor prognosis, the
following have been reported: duration of illness,96,99 early onset96 and presence of hoarding obsessions/
compulsions.98 A better prognosis has been reported in patients with chronic tics98 and in patients who
showed a good initial treatment response.96
Impact on quality of life and functioning
As a chronic disorder, OCD can have a severe impact on everyday functioning and quality of life. Two
systematic reviews have recently investigated the published literature on this issue.100,101 Most studies have
used clinical samples and compared several dimensions of quality of life in OCD and other psychiatric
disorders, chronic physical disorders and the general population. Fewer studies have used non-selected
samples in the community,101,102 but these have confirmed that OCD, even in individuals living in the
community who have not made contact with services, can have a detrimental effect on quality of life
compared with the healthy population. In a study in Asia, OCD was associated with a worse quality of life
than in other common mental disorders.103 Studies have reported that contact104 or relationships with
family members103 may be more severely affected in patients with OCD than in patients with other
mental disorders.
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Most studies in clinical samples have compared quality of life in patients with OCD with that in patients
with other mental disorders, chronic physical disorders or population norms. One of the most cited studies
that compared the quality of life in patients with depression and anxiety disorders used data from patients
who took part in several multicentre RCTs of sertraline.105 According to this study, patients with OCD had
a better overall quality of life compared with patients with depression and comparable to other anxiety
disorders, with the exception of post-traumatic stress disorder. Olatunji et al.106 carried out a meta-analysis
of 33 studies that examined quality of life in patients with anxiety disorders. Six of these studies focused
on OCD and their findings show that OCD is associated with a worse quality of life for patients than for
the general population, but other anxiety disorders may have a more harmful effect (e.g. social phobia or
post-traumatic stress disorder). In the clinical samples, the dimension of quality of life more severely
affected in OCD is the one associated with social relationships.101
Some studies have investigated quality of life as a long-term outcome in RCTs of psychopharmacological or
psychosocial interventions.100 These studies have concluded that changes in quality of life can be quite
delayed and certainly are not expected in the short term. In the psychopharmacology trials, these changes
may become evident after 1 year of continuous treatment.107 It should be pointed out that because OCD is
often comorbid with other disorders, in particular depression, this may lead to further worsening of quality
of life and, generally, is an important factor in determining levels of functional impairment.100
Studies conducted in child and adolescent samples are limited and assess functional impairment more
often than quality of life. It should be noted that these are related but not identical concepts.108
Two recent studies have investigated quality of life in children and adolescents with OCD.108,109 Both
confirmed the negative effect of the disorder on the quality of life of patients compared with healthy
children. An important factor that predicted a worse quality of life was the presence of comorbid
internalising or externalising disorders.
Current service provision
Treatment options
Primary care
General practitioners (GPs) encounter patients with a range of OCD severity; milder presentations are not
uncommon, although the major influence on people with mental disorders seeking help from their doctor
is severity.110 Many patients who see their GP with OCD symptoms are also suffering from comorbid
depression or anxiety. Data from the 2000 British National Psychiatric Morbidity Survey have shown that
less than 15% of patients with non-comorbid OCD were receiving any treatment for emotional problems,
compared with 56% of patients with comorbid OCD and depression or other anxiety disorders.52
In recent years, it has been possible in the UK to refer patients with OCD to the Improving Access to
Psychological Therapies service, and this has made both low-intensity and high-intensity CBT interventions
more widely available. The National Institute for Health and Care Excellence (NICE) Clinical Guideline (CG)
31 states that low-intensity treatments, including ERP of up to 10 therapist hours per patient, are offered
to those with milder degrees of functional impairment. This intervention includes brief self-help materials
and may include group CBT. Those who do not respond to this or who find it difficult to engage are often
treated with a SSRI. This also can have the benefit of treating coexisting symptoms of depression and
anxiety. Although response may be seen fairly quickly for depressive symptoms, it is not uncommon for
considerably longer response times to be seen for OCD symptoms, and SSRIs should be given at an
adequate dose for at least 12 weeks and perhaps even longer before treatment can be said to be
ineffective.111 In more chronic and severe cases it may be necessary to go on to offer high-intensity
individual CBT, including ERP, as well as a SSRI.
BACKGROUND
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Secondary care
Those who do not experience a clinically significant improvement following these treatments are likely to
be referred to secondary care for further assessment. Psychiatric services will often offer further CBT or BT
and may switch medications from SSRIs to clomipramine.112 If this is not successful, treatment with an
antipsychotic in addition to the antidepressant may be considered.111,113
Tertiary care for treatment-refractory patients
In order to be considered treatment refractory, patients are required to score very highly on symptoms
scales such as the YBOCS (≥ 30/40) and to have received at least two courses of CBT from an accredited
therapist as well as two courses of a SSRI (or one course of a SSRI and one of clomipramine) at maximally
tolerated doses as well as one attempt at pharmacological augmentation. Many patients referred to
specialised services (usually judged to be at level 5 of the NICE stepped care pathway and, therefore, not
eligible for highly specialised services) give a history of not receiving adequate treatment locally, despite
high levels of distress and disability. There would appear to be problems in finding suitably trained and
experienced clinicians for patients with severe OCD nationwide. OCD is a severe, chronic mental disorder
and patients in remission have a high chance of relapse even after specialist care (around 60% over
5 years91). Full relapse is associated with major loss in health-related quality of life.114 Ongoing co-ordinated
clinical care from local mental health services is required for long periods to reduce the risks of relapse or
to ensure early intervention to prevent full relapse occurring. The need for long-term responsive care in
local NHS community services for individuals with OCD needs to be better recognised.
Patients eligible for highly specialised services
In recognition of the high levels of distress and serious functional impairment associated with severe and
enduring OCD (and body dysmorphic disorder), patients with severe illness who have not responded to
substantial evidence-based treatment with medication or CBT (at level 6 of the NICE stepped care
pathway) may be referred for treatment from the highly specialised Obsessive–Compulsive Disorder and
Body Dysmorphic Disorder Service commissioned by NHS England (see www.england.nhs.uk/). The aim of
the service is to improve the mental health state of both adolescents and adults suffering with the most
profound OCD/body dysmorphic disorder, who have failed all previous evidence-based pharmacological
and psychological treatments (including home-based treatments). The service provides treatment across the
lifespan (children, adolescents and adults), including intensive clinic-based, home-based and inpatient CBT,
as well as specialist pharmacotherapy at the following centres:
(a) Hertfordshire Partnership NHS Foundation Trust, Queen Elizabeth II Hospital, Welwyn Garden City,
UK (adults)
(b) South London and Maudsley Hospital Anxiety Disorders Residential Unit; Centre for Anxiety Disorders
and Trauma (adults); Child and Adolescent OCD Service, London, UK
(c) South West London and St George’s NHS Trust, Springfield Hospital (adults), London, UK
(d) The Priory Hospital Adolescent Inpatient Unit, London, UK.
A similar service is available in Scotland from the Advanced Interventions Service located at Ninewells
Hospital, Dundee. This service additionally provides specialist neurosurgery for the most extreme cases of
severe, refractory mental disorder including OCD (see www.advancedinterventions.org.uk/index.php/
the-service).
Current guidelines
Table 1 presents the most recent published guidelines for the management of OCD. The most recent
clinical practice guidelines for the pharmacological treatment of OCD have been published by the British
Association for Psychopharmacology.111 The Canadian Anxiety Disorders Association has also published
guidelines for both pharmacological and psychological interventions for all anxiety disorders including a
separate section for OCD.115 The American Psychiatric Association had recently updated its previous
detailed clinical practice guideline (see http://psychiatryonline.org).116 The World Federation of Societies
of Biological Psychiatry published its guidelines for all anxiety disorders, including OCD, in 2008.117
DOI: 10.3310/hta20430 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 43
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Skapinakis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
11
In addition, NICE published a very comprehensive clinical practice guideline for OCD and body dysmorphic
disorder in 2005 (NICE CG31).118 NICE has recently placed the 2005 OCD guideline on a ‘static’ list of
guidelines that will not be reviewed again within the next 5 years unless there is important new evidence
of either efficacy or safety. NICE has also published a quick reference guide, which includes a detailed
version of their stepped care model for treating OCD in all age groups (see www.nice.org.uk/nicemedia/
live/10976/29945/29945.pdf).
Description of technology under assessment
Medications
Pharmacotherapy with the tricyclic antidepressant clomipramine or a SSRI (paroxetine, fluvoxamine,
fluoxetine, citalopram, escitalopram and sertraline) has shown efficacy in OCD.119 Meta-analyses of seven
RCTs of clomipramine120 and 17 randomised, double-blind placebo-controlled trials of various SSRIs121 have
been performed. The trials were generally short term (i.e. of 4–12 weeks’ duration) and showed that all
these compounds were superior to placebo. Patients were roughly twice as likely to respond to a SSRI as to
placebo. Data on comparisons between different SSRIs and between SSRIs and clomipramine are limited
but have shown no significant differences in efficacy. The SSRIs are recommended as the first-line
pharmacological treatment for OCD, with clomipramine reserved for those who do not respond to or
TABLE 1 Recent published guidelines for OCD
Authors, year,
country Organisation Title Citation
Baldwin et al.
2014, UK111
British Association for
Psychopharmacology
Evidence-based pharmacological
treatment of anxiety disorders,
post-traumatic stress disorder and
obsessive–compulsive disorder:
a revision of the 2005 guidelines
from the British Association for
Psychopharmacology
J Psychopharmacol 2014;28:403–39
Katzman et al.
2014,
Canada115
Anxiety Disorders
Association of Canada
Canadian clinical practice
guidelines for the management of
anxiety, posttraumatic stress and
obsessive–compulsive disorders
BMC Psychiatry 2014;14(Suppl. 1):1
Koran et al.
2007, USA116
American Psychiatric
Association
Practice guideline for the
treatment of patients with
obsessive–compulsive disorder
Am J Psychiatry 2007;164(Suppl. 7):5–53
(an updated supplement of this
guideline up to March 2013 by the
same authors is also available at:
http://psychiatryonline.org/pb/assets/
raw/sitewide/practice_guidelines/
guidelines/ocd-watch.pdf)
Bandelow et al.
2008,
worldwide117
World Federation of
Societies of Biological
Psychiatry
World Federation of Societies of
Biological Psychiatry (WFSBP)
guidelines for the pharmacological
treatment of anxiety,
obsessive–compulsive and
post-traumatic stress disorders –
first revision
World J Biol Psychiatry 2008;9:248–312
NICE, 2005,
UK118
NICE/Royal College of
Psychiatrists/British
Psychological Society
Obsessive–Compulsive
Disorder: Core Interventions
in the Treatment of
Obsessive–Compulsive Disorder
and Body Dysmorphic Disorder
CG31
NICE. Obsessive–Compulsive Disorder:
Core Interventions in the Treatment of
Obsessive–compulsive Disorder and
Body Dysmorphic Disorder CG31.
London: NICE
BACKGROUND
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
tolerate SSRIs, owing to the more favourable adverse event profile.111,116,118 SSRIs tend to take longer to be
effective (between 4 and 12 weeks) when used for OCD than when used for other disorders, such as
depression and anxiety. A positive dose–response relationship has been observed with several SSRIs
(paroxetine, fluoxetine and escitalopram), and higher doses of SSRI are often required.116,118,119
Approximately 40–70% of patients respond to a SSRI, but the long-term improvement in total symptom
severity is relatively low, averaging 20–40%,122,123 as is the remission rate, with full remission ranging from
approximately 10%123 to 40%.124 A long duration of untreated illness,94 coexisting tic116 and hoarding
symptoms125 have all been associated with a poorer treatment response to clomipramine and the SSRIs.
The findings of acute treatment studies indicate that the proportion of responding patients increases
steadily over time. Long-term (up to 12 months) double-blind RCTs demonstrate an advantage for
continuing with medication in patients who have responded to acute treatment.126,127 A randomised
placebo-controlled trial with paroxetine as an active comparator found that a low dosage of escitalopram
became efficacious only in the second half of a 24-week study.124 Most (but not all) placebo-controlled
relapse prevention studies in patients who have responded to previous acute treatment reveal a significant
advantage for staying on active medication (escitalopram, fluoxetine at higher daily doses, paroxetine and
sertraline), compared with switching to placebo, for up to 12 months,128 but the optimal duration of
continuation treatment is uncertain.129 For these reasons, it is recommended that clinicians continue drug
treatment for at least 12 months in patients who have responded to treatment.111 As approximately 50%
of patients with OCD relapse if they discontinue medication after up to 1 year of successful treatment, it is
advisable to counsel patients about the risk of relapse prior to drug discontinuation and, if relapse occurs,
medication is usually reinstated and continued indefinitely.130
Adverse events with medications
Selective serotonin reuptake inhibitors are generally safe and well tolerated, according to the placebo-referenced
treatment trials that reported adverse event-related withdrawal rates of approximately 5–15%. As a group,
however, SSRIs may cause unwanted nausea, insomnia, somnolence, dizziness and diarrhoea. Sexual side
effects include reduced libido and delayed orgasm, and can affect up to 30% of individuals.131 Fluoxetine
has a long half-life and fewer discontinuation effects, which can be advantageous for patients who forget
to take their tablets. It has also been extensively used in pregnancy and generally shown to be safe.132 The
recent demonstration of prolongation of the electrocardiogram QT-interval associated with higher dose
levels of citalopram (and, to a lesser extent, escitalopram)133 argues for a degree of caution in using higher
doses of these compounds in OCD, especially if individuals are taking other medications that increase the
QT interval. However, a recent large study found no elevated risks of ventricular arrhythmia or all-cause,
cardiac or non-cardiac mortality associated with citalopram doses exceeding 40mg per day.133
Clomipramine can also be associated with potentially dangerous side effects. Cardiotoxicity and cognitive
impairment occur much more often with clomipramine than with SSRIs. In addition, there is an increased
risk of convulsions in patients taking clomipramine (up to 2%). Overdose on clomipramine can prove fatal,
and this needs to be borne in mind when prescribing for OCD, in view of the elevated suicide risk associated
with the illness. Clomipramine is also associated with greater impairment of sexual performance (up to 80%
of patients) compared with SSRIs, with weight gain and with troublesome anticholinergic effects.134
Suicide in children with obsessive–compulsive disorder receiving selective
serotonin reuptakes inhibitors
Meta-analyses examining the effects of SSRIs in children aged 6–18 years have been performed, following
warnings from the US FDA that SSRIs in the young may increase the risk of suicidal thoughts and
behaviours. A pooled analysis of childhood OCD studies comparing ‘numbers needed to treat’ with those
‘needed to harm’ revealed no suicidal actions and a positive risk ratio for the use of sertraline in children
and adolescents with OCD.135
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In the recent study by Bridge et al.,136 27 RCTs of SSRIs, of which six were in OCD, were identified. There
were no completed suicides. The pooled absolute rates of either suicidal ideation or suicide attempt
(treatment vs. placebo) in OCD (1% vs. 0.3%) compared favourably with the pooled absolute clinical
response rates (treatment vs. placebo; 52% vs. 32%). The authors concluded that the benefits of SSRIs
probably outweigh the risks in the OCD paediatric population, with the doctor–patient relationship playing
an important part.
Psychotherapy
The general principles of the psychological model of OCD have been described (see Aetiology). Based on
this model, a number of psychological treatments have been developed. A comprehensive historical review
of these treatments is given by Abramowitz.137 Two main treatments have been developed, a behaviourally
oriented treatment (ERP) and a treatment based on the cognitive model of OCD.40
Exposure and response prevention was first described in a clinical setting by Meyer,138 and the relative
success of this method soon replaced other behaviourally oriented methods such as Wolpe’s systematic
desensitisation.137 According to Abramowitz,137 in ERP, first, the patient undergoes prolonged exposure to
situations or stimuli that provoke obsessional fears and, second, the patient is advised to refrain from
performing the compulsive behaviour (response prevention). Response prevention helps the patient learn
that anxiety will eventually decrease on its own over time and also that obsessions are not really dangerous
or do have catastrophic consequences.137 The intensity of the treatment differs, but typical forms of
therapy include at least 16 sessions over 8 weeks. Some of the sessions are supervised by the therapist and
the patient also practises self-exposure between sessions.137 Owing to the nature of the treatment, some
patients may not tolerate the distress associated with the exposure or they may not be willing to refrain
totally from the ritualistic behaviour. Despite the difficulties in applying this treatment, ERP has established
its effectiveness both in research and practical settings.118
The cognitive model of obsessions is primarily based on the work of Salkovskis,40 who suggested that,
although disturbing, intrusive and unacceptable thoughts (normal obsessions) are experienced by all,139
patients with abnormal obsessions appraise the intrusions in a pathological way. Salkovskis suggested that
such appraisals ‘appear to relate specifically to ideas of being responsible for damage or harm coming to
oneself or to others’.40 Compulsions are viewed as efforts by the individual to prevent any harmful
consequences or to reduce the unwanted intrusions. Apart from Salkovskis’ ‘inflated responsibility’, other
faulty appraisals of intrusions have been described by the Obsessive Compulsive Cognitions Working
Group,140 such as the overimportance of thoughts, the excessive concern about the importance of
controlling one’s thoughts, the overestimation of threat and the intolerance of uncertainty. Based on the
cognitive model, cognitive therapy (CT) that does not require the use of ERP techniques has been
developed, although behavioural experiments are used to help patients modify their views about the risks
associated with obsessions.137 CBT for OCD combines both ERP techniques and cognitive restructuring.137
There is now evidence that both therapies are effective in the management of OCD and have comparable
efficacy to ERP with a slightly improved tolerability.118
Reasons for conducting this review
Two criteria have been taken into account in order to examine the need for a new review regarding the
management of OCD:
(a) the need to update previous systematic reviews and/or meta-analyses, especially if new trials have
been conducted since the publication of previous reviews, which could potentially change
current recommendations
(b) the need to synthesise existing and updated evidence to answer the questions that matter most to
clinicians and patients/carers using, if necessary, previously unavailable methodological techniques.
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Although the number of new trials since previously published systematic reviews (e.g. NICE118) is relatively
small, these were studies that reported direct comparisons between treatments that were not previously
available. In addition, previous reviews have focused only on the available direct pairwise comparisons of
active (either pharmacological or psychological) versus inactive interventions (drug placebo, waitlists,
psychological placebo). Although these comparisons may be suitable for regulatory agencies or to establish
efficacy, they may not be equally useful in directing real clinical practice or cost-effectiveness analyses. As a
result, previous reviews could not rank the treatments depending on their efficacy or acceptability using all
available evidence (both direct and indirect), and their results are inconclusive. Owing to these problems,
it has been suggested that evidence for the superiority of a given treatment against another in OCD is
absent and that clinicians’ or patients’ choices are based on preference, side-effect profile for drugs or
comorbidity. The present review and economic evaluation aims to fill this gap in the knowledge, by
applying appropriate statistical techniques of evidence synthesis that allow the ranking of treatments,
taking into account both direct and indirect evidence, and will provide clinicians with a framework for
decision-making for the optimum management of patients of all ages with OCD.
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Chapter 2 Definition of the decision problem
This review addresses the research question: what is the clinical effectiveness, acceptability and cost-effectiveness of pharmacological and psychological (behavioural or cognitive–behavioural) interventions
for the management of OCD?
Decision problem
Population
Children and adolescents, and adults with OCD.
Intervention and relevant comparators
Any antidepressant medication with some serotonergic properties used in the management of OCD
(including amitriptyline, imipramine, clomipramine, all SSRIs, all serotonin–noradrenaline reuptake
inhibitors, mirtazapine and hypericum), BT (therapy that includes some kind of exposure and/or response
prevention), CT or CBT and any drug/psychotherapy combination of these interventions. Comparators
included drug placebo, psychological placebo, waitlist and any other comparator from the list of
interventions that would allow an indirect comparison with network meta-analysis (NMA).
Outcomes
The primary outcome for effectiveness was the reduction in symptoms of OCD as measured at the end
of the study period by the YBOCS scale (or the CYBOCS). The secondary outcome was acceptability,
as measured by the total number of dropouts in each intervention arm.
Subgroup analyses
Regarding the preplanned subgroup analyses, where sufficient data were available, metaregression/
subgroup analyses were conducted to explore the impact of:
1. publication date
2. length of trial
3. inclusion of patients with comorbid depression
4. pharmaceutical sponsorship of drug trials.
Overall aims and assessment objectives
The main aim of this review was to determine the clinical effectiveness, acceptability and cost-effectiveness
of pharmacological and psychological interventions for the treatment of OCD.
More specifically, the aims of this review were to:
1. undertake a systematic review of the clinical effectiveness and acceptability of pharmacological and
psychological interventions (behavioural or cognitive–behavioural) for the treatment of OCD in children
and adolescents, and in adults
2. use both direct and indirect evidence to simultaneously compare all multiple treatments
(pharmacological and psychological) in a single analysis (multiple treatments meta-analysis) with the aim
of ranking all treatments in terms of efficacy and acceptability
3. develop a probabilistic economic model of alternative treatments (pharmacological and psychological)
for the management of OCD in order to evaluate the relative cost-effectiveness of these treatments.
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Chapter 3 Systematic review methods: assessment
of clinical effectiveness
Methods for reviewing clinical effectiveness
For this systematic review meta-analysis we followed the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) recommendations141 and the guidelines for conducting systematic reviews
reported in the Cochrane Handbook.142
The protocol is registered with PROSPERO database number CRD42012002441 and can be accessed at
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID =CRD42012002441.
Identification of trials: search strategy
Search dates
We carried out searches between 1 December 2012 and 31 May 2014. A detailed description of the
specific search strategy used is given in Appendix 1.
Search strategy
Electronic databases
We searched the twin Cochrane Collaboration Depression, Anxiety and Neurosis (CCDAN) Controlled Trials
Registers (CCDANCTR). The CCDAN maintain two clinical trials registers at its editorial base in Bristol, UK:
a references register (CCDANCTR-References) and a studies-based register (CCDANCTR-Studies). The
CCDANCTR-References Register contains more than 27,000 reports of trials in depression, anxiety
disorders (including OCD) and other neurotic disorders. Approximately 65% of these references have been
tagged to individual, coded trials. The coded trials are held in the CCDANCTR-Studies Register and records
are linked between the two registers through the use of unique study identification (ID) tags. Coding of
trials is based on the EU-Psi coding manual (see http://psitri.stakes.fi/). Reports of trials for inclusion in the
Group’s registers are collated from routine (weekly), generic searches of MEDLINE, EMBASE and PsycINFO;
quarterly searches of the Cochrane Central Register of Controlled Trials and review-specific searches of
additional databases. Reports of trials are also sourced from international trials registers using WHO’s
trials portal, the International Clinical Trials Registry Platform (see http://apps.who.int/trialsearch/), drug
companies, the hand-searching of key journals, conference proceedings and other (non-Cochrane)
systematic reviews and meta-analyses. Details of CCDAN’s generic search strategies can be found in the
‘Specialized Register’ section of the Cochrane Depression, Anxiety and Neurosis Group’s website.
The CCDANCTR-Studies Register was initially searched (September–December 2012) using the following
index terms:
Condition = obsess* or compulsi*
AND
Intervention = (Citalopram or (Clomipramin* or Clorimipramin* or Chlomipramin* or Chlorimipramin*) or
Escitalopram or Fluoxetine or Fluvoxamine or Paroxetine or Sertraline or Venlafaxine or Duloxetine or
Mirtazapine or SSRI* or Serotonin or cognitive* or behavi* or exposure or “response prevention”).
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The CCDANCTR-References Register was initially searched using a more sensitive set of free-text terms
(to identify additional untagged/uncoded reports of trials):
((obsess* or compulsi* or OCD) AND (Citalopram or (Clomipramin* or Clorimipramin* or Chlomipramin*
or Chlorimipramin*) or Escitalopram or Fluoxetine or Fluvoxamine or Paroxetine or Sertraline or Venlafaxine
or Duloxetine or Mirtazapine or SSRI* or (Serotonin and (uptake or reuptake or re-uptake)) or SNRI* or
CBT or cognitive* or behavioral or behavioural or exposure or ERP or “response prevention” or ((*therap*
or train* or treatment*) and (behavi* or expos*)))).
As the number of studies retrieved in this initial search was not very large (643 studies), in order to
increase the sensitivity of the search we decided to repeat the search using the condition only (obsess* or
compulsi*) without any other terms.
Reference checking
The reference lists of all selected studies, as well as the references of previous systematic reviews,
meta-analyses and evidence-based guidelines, were additionally inspected for potential studies or reports that
had not been identified through our electronic search. We also searched papers that had cited previous
meta-analyses or systematic reviews using Google Scholar (Google Inc., Mountain View, CA, USA) to identify
potential new studies that had not been identified. No additional records were identified through this source.
Ongoing clinical trials
We also searched the controlled trials registers of the following organisations to identify ongoing studies
that could potentially have published preliminary results or reports:
(a) ClinicalTrials.gov
(b) Controlled-Trials.com
(c) WHO’s trials portal (International Clinical Trials Registry Platform).
We used the generic term (obsessive or compulsive) for these searches and we filtered the results by
condition (OCD) and type of study (controlled intervention). We checked 145 records from
https://clinicaltrials.gov, 19 from www.controlled-trials.com and 23 from WHO’s portal for ongoing
clinical trials.
Abstract appraisal
All abstracts identified through the search process were transferred into a Microsoft Excel® 2013 (Microsoft
Corporation, Redmond, WA, USA) spreadsheet and were independently screened for potential inclusion by
two reviewers (PS and HB). In cases of uncertainty (or disagreement), the full text was obtained. Abstracts
excluded at this stage were not relevant to the present study either because they were observational
studies or the interventions were not covered by the report (e.g. if they had investigated lithium,
electroconvulsive therapy or repetitive transcranial magnetic stimulation vs. placebo). The full texts of all
controlled trials studies that included at least one intervention covered by the report were obtained even if
it was clear from the abstract that this should be excluded (e.g. because the comparator intervention was
not covered or the patient population was treatment refractory). These studies were excluded at the
full-text stage. Similarly, we obtained the full text of studies with special populations of OCD (e.g. hoarding
patients) even if these would be excluded at the full-text stage.
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Study selection: inclusion and exclusion criteria
Studies were included (or excluded) in accordance with the following criteria:
(a) Study design: RCT. Trials with a crossover design were not excluded and we tried to extract all
available data up to the point of the crossover. Quasi-randomised trials (such as those allocating by
using alternate days of week) were excluded. Owing to the aim of the review, we included trials
irrespective of blinding (because otherwise a lot of psychotherapy trials might not be eligible for
inclusion). Sensitivity analyses examined the possible effect of unblinded or single-blinded trials.
(b) Patient population.
¢ Age: all patients aged ≤ 74 years (if patients aged ≥ 75 years were included, mean age should be
within the range).
¢ Diagnosis: a primary diagnosis of OCD in accordance with standardised diagnostic criteria
(ICD, DSM, Feighner or research diagnostic criteria). Studies that specifically focused on treatment-
resistant OCD were excluded. Treatment resistance should have been defined within the study
using specific criteria. Most often, studies will have used a first, uncontrolled, treatment phase, in
which all patients received the same intervention and the non-responders (usually showing < 25%
reduction in the YBOCS scale) were eligible for the second randomised phase. Studies that had
included patients that could be considered refractory to treatment outside the context of the
particular study (e.g. because they might have tried medications or other interventions in the past
unsuccessfully) were not excluded. It is worth noting that most psychotherapy trials have included
patients who were symptomatic despite being stable on medications before entering the study.
¢ Comorbidities: these will be accepted if OCD was the primary disorder. However, studies that
included patients with schizophrenia or bipolar disorder were excluded.
¢ Diagnostic criteria: the authors should have used established diagnostic criteria to diagnose OCD
(either ICD, or any version of DSM, or Research Diagnostic Criteria or Feigner criteria). The method
of assessment of these criteria (either through typical clinical examination or use of more formal
diagnostic interviews) was not a reason for exclusion.
(c) Experimental intervention.
¢ For pharmacological interventions: any antidepressant medication with some serotonergic
properties (including: amitriptyline, imipramine, clomipramine, all SSRIs, all serotonin-noradrenaline
reuptake inhibitors, mirtazapine). Studies that have used hypericum were included, whereas other
non-standard approaches were excluded (e.g. studies that have used folic acid, herbal medicines
other than hypericum, vitamins or omega-3 supplements).
Studies that had used a mainly noradrenergic medication as the experimental intervention of
interest [e.g. reboxetine (Edronax®, Pfizer) or nortriptyline] were excluded.
¢ For psychological interventions: we included trials that have used as their main intervention (1) BT
(therapy that included some kind of exposure and/or response prevention); (2) CBT; or (3) CT
(therapy that included some kind of cognitive restructuring intervention). We excluded studies that
used therapies based on psychodynamic principles (including interpersonal psychotherapy or other
insight-oriented therapies exploring unconscious mental processes), Gestalt therapy, systemic
therapy and family therapy. We also excluded studies that used behavioural-type therapies with no
exposure component (e.g. behavioural activation, social skills training) and biofeedback as their
experimental intervention.
(d) Comparator intervention.
¢ For pharmacological interventions: drug placebo or any other antidepressant with some
serotonergic properties, or any other psychotherapy from those eligible (BT, CT, CBT), or other
inactive type of therapy considered as ‘control’.
¢ For psychological interventions: any type of psychological placebo (including attention placebo) or
non-specific therapy (including supportive therapy), or waitlist/no treatment, or any other BT/CT/CBT
type of therapy, or drug placebo, or any other antidepressant with some serotonergic properties.
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(e) Focus of analysis: Between-group comparison of treatments should be reported. Studies that report
only additional secondary analyses (e.g. predictors of treatment outcome) were excluded. Studies that
did not report continuous outcome were not included in the quantitative synthesis.
Study inclusion assessment
Inclusion/exclusion criteria were independently assessed by two reviewers (HB and PS) and validated by one
reviewer (PS). The standardised data extraction form (see Data extraction) included a section on inclusion/
exclusion criteria. This section was transferred to an Excel spreadsheet and we recorded all necessary
information for the inclusion or exclusion of studies that had passed through abstract screening. For
excluded studies, we noted the main reason for exclusion.
Data extraction
We used a standardised data extraction form to extract detailed information on included studies. This
form also included a section on inclusion and exclusion criteria that was used for all studies that passed
through the abstract screening. We originally developed this form in a Microsoft Word® 2013 (Microsoft
Corporation, Redmond, WA, USA) document format, but to facilitate data extraction, we transferred the
various sections of this form into several Excel spreadsheets. All information extracted was directly recorded
onto these spreadsheets on a computer.
Initial data extraction was carried out independently by two reviewers (HB and PS). As the agreement
between the reviewers was high, one reviewer independently extracted the remaining papers (HB) and a
second reviewer (PS) validated the extraction. Potential discrepancies were discussed by the reviewers and,
if necessary, by all other collaborators during the meetings.
Data extracted from papers included the following information:
(a) inclusion and exclusion criteria (study design, experimental intervention, control intervention,
age range, primary diagnosis, diagnostic criteria, focus of analysis)
(b) details of participants (country, treatment setting, age, diagnostic classification, primary severity scale
used, comorbidities)
(c) details of experimental and control interventions
(d) details of continuous outcome (primary scale used, end of treatment follow-up time)
(e) risk-of-bias assessment
(f) results [baseline, end of treatment continuous measures for YBOCS or other primary scale, change
from baseline, mean difference (MD) between arms, completers analysis or use of methods for
handling missing data such as last observation carried forward]
(g) dropouts (total dropouts per arm).
Risk-of-bias assessment: quality assessment strategy
To assess the methodological quality of included trials we used the criteria for quality assessment
recommended by the Cochrane Handbook for Systematic Reviews of Interventions.142 Two reviewers
independently assessed and a second reviewer validated these criteria, which mainly focus on descriptions
of sequence generation, allocation concealment, blinding, completeness of outcome data and selective
outcome reporting, and other potential sources of bias (such as attrition rates). Studies were given a
quality rating of ‘low’, ‘unclear’ or ‘high’ risk of bias in accordance with these criteria. If there was
disagreement on quality assessment, the final rating was made by consensus with the involvement (if
necessary) of another member of the review group. Studies with a high risk of bias were included in the
main analysis, but we also examined in a sensitivity analysis the effect of excluding them.
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Methods of network meta-analysis
Primary outcome
Pairwise analysis and NMA were conducted for the primary outcomes of reduction in OCD symptoms
(as measured by the YBOCS in adults or the CYBOCS in children and adolescents) and for acceptability
(as measured by total number of dropouts per study). A NMA is the simultaneous comparison of multiple
competing treatments in a single statistical model.143,144 In exploiting both direct and indirect evidence,
a NMA produces estimates of the relative effects of each treatment compared with all others in the
network, even if treatments have not been directly compared. It is then possible to calculate the probability
of a treatment being better, or worse, for a specific outcome.
Derivation of primary outcome and handling of missing data
For the primary outcome, data are continuous and were reported as either (1) mean scores at baseline and at
follow-up for treatment and control groups; or (2) mean change from baseline scores in each group. If both
formats were reported, we chose the mean change from baseline score as our preferred summary, which
captures correlations in measures within individuals.145 If mean change from baseline was not reported, we
used mean score at follow-up for each group, as this gives an unbiased estimate of treatment effect if
randomisation is adequate.145 If data were missing on either the total number of patients randomised or mean
YBOCS/CYBOCS scores, the study was excluded from the quantitative analysis. Where possible, missing
standard deviations (SDs) were derived from reported statistics following guidance in the Cochrane Handbook
for Systematic Reviews of Interventions.142 If derivation of missing SDs was not possible, they were estimated
based on a prediction from a hierarchical model for SDs in those studies that did report them. Here, we
assumed that any missing SD is exchangeable (i.e. broadly similar) with the reported SDs. (Further detail and
code is available in Appendix 8.) For the secondary outcome, data are dichotomous and were extracted on
intention-to-treat principles. Any participant dropout that occurred after the point of randomisation was
included in our analysis.
Assessment of transitivity
The assumption of transitivity is the crucial starting point for a NMA.146 Transitivity suggests that
intervention A is similar when it appears in A versus B and A versus C studies.147 It can be examined by
comparing the distribution of potential effect modifiers across the different comparisons148 because if there
is an imbalance in the presence of effect modifiers across the A versus B and A versus C comparisons,
the conclusions about B versus C may be in doubt.
Study-level characteristics that were considered potential effect modifiers were mean baseline symptom
severity, gender, participant age, length of trial follow-up, proportion of participants with concurrent
mental illness (depression) and year of trial publication. We examined the study characteristics tables
(see Tables 10 and 11) and concluded that, with the exception of participant age, the assumption of
transitivity was likely to hold across the trials and comparisons. We considered that the assumption may
be breached on the basis of participant age, because it would appear that children and adolescents
were more likely than adults to be randomised to a psychological therapy. Indeed, of pharmacological
treatments, only sertraline and fluvoxamine are licensed for use in patients aged < 18 years in the UK, and
NICE also mentions fluoxetine in cases with significant comorbid depression.118 Therefore, we decided that,
contrary to our protocol specification, we would analyse children and adolescents separately to adults.
Pairwise and network meta-analysis
Network diagrams were drawn using Stata version 13 (StataCorp LP, College Station, TX, USA) to ensure
that treatments formed a connected network for both outcomes and populations considered.149
Pharmacological placebo was considered as the reference treatment throughout all analyses.
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All analyses were conducted in a Bayesian framework and were undertaken using OpenBUGS version
3.2.3 (members of OpenBUGS Project Management Group; see www.openbugs.net). Pairwise
meta-analyses were conducted in a single model assuming independent treatment effects and a shared
heterogeneity parameter.150 We used the NMA programme code given by Dias et al.145 and modified to
incorporate an additional class hierarchy,151 such that interventions with a similar mechanism of action
were grouped together in a class in which pooled effects might be assumed to be ‘similar’. This approach
allows both the relative effectiveness of the individual treatments and that of the classes to be estimated.
On the basis of the systematic review and clinical expertise, it was assumed that only the SSRIs citalopram,
escitalopram, fluoxetine, fluvoxamine, paroxetine and sertraline could be considered a ‘class’ on this
criterion. Psychological therapies were analysed as individual treatments. Non-specific psychological
therapies (‘psychological placebo’) were distinguished from waitlist controls. In psychological therapies we
did not distinguish between individual or group delivery format. In addition, we did not distinguish
treatments based on drug dose or intensity of psychological treatment. (All OpenBUGS code is available in
Appendix 8.)
Random-effects models were used, accounting for the correlation between trial-specific effects in multiarm
studies.145 Vague priors were used for all parameters, including the prior for within-class variability.
Convergence was checked based on two chains using the Brooks–Gelman–Rubin diagnostic plots and
visually using history plots available in OpenBUGS. In all cases, the first 50,000 iterations were discarded as
‘burn-ins’. Reported estimates are based in the subsequent 100,000 iterations. We report the relative
effectiveness of each treatment versus every other treatment and also the probability that each treatment
is the most effective on each outcome.
Model fit and assessment of statistical inconsistency
Heterogeneity was assessed by examining the posterior median of the between-studies heterogeneity
parameter from the random-effects model. Goodness of fit was measured by the posterior mean of the
residual deviance. In a well-fitting model, the residual deviance should be close to the number of data
points. Model comparison was based on the deviance information criterion (DIC).152 A difference of 3 or
more points was considered meaningful.145 A key assumption of NMA is that of consistency between the
direct and indirect evidence. To assess inconsistency, we compared the fit of a model assuming consistency
with that of a model assuming independent treatment effects.153 In addition, we also compared the results
of the pairwise meta-analysis with the NMA. As a further proxy measure, where the NMA effect estimate
did not fall within the 95% credible intervals (CrIs) from the pairwise analysis, we defined these
as inconsistent.
Sensitivity analysis and meta-regression
Sensitivity analyses were conducted, excluding studies at high risk of bias on the following domains as
defined by the Cochrane Collaboration’s risk-of-bias assessment tool:142
1. allocation concealment
2. outcome assessor blinding
3. incomplete outcome data
4. studies with high levels of attrition (overall attrition > 25% or differential attrition > 15%).
Separate meta-regressions were also conducted assuming a common interaction term for the following
study-level characteristics:
1. length of trial (including follow-up)
2. year of publication of trial
3. pharmaceutical sponsorship of drug trials.
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Chapter 4 Results of the systematic review
Quantity of research available
Our initial search of CCDANCTR resulted in 1028 citations. An updated search in March 2014 yielded
another 74 citations, bringing the total number of citations from this source to 1102. No additional trials
that met the criteria of the review of having a projected end-of-study period before the end of the current
project were identified from our search of the registers of ongoing clinical trials. After removing some
duplicate entries, a total of 1083 abstracts were initially screened and 905 (84%) were excluded, as they
were not relevant to the study aims.
A total of 178 full papers were retrieved as being potentially relevant to the study aims. Sixty-eight of
these papers were excluded for one or more reasons (see Studies excluded).
Of the remaining 110 papers, 25 papers were assigned to the waiting status for one of the following
reasons: (1) article written in Chinese (n= 17); (2) article written in Arabic (n= 1); (3) congress report with
no further publication and no usable data reported (n= 2); (4) unable to locate articles in several languages
(n= 1 in Japanese, n= 1 in Turkish and n= 1 in German); (5) inconsistent results reported in another
publication (thesis) of the same data (n= 1, author has been contacted); and (6) unable to decide if paper
reports duplicate data with previous publication (n= 1, authors have been contacted). A detailed list of the
papers that have been assigned to the waiting status can be found in Appendix 3.
Eighty-five papers provided data for the analysis of at least one outcome. One paper154 reported the results
of two clomipramine trials and, therefore, the included papers included data on 86 trials. Figure 1 presents
the results of the search in the form of the PRISMA flow chart.
Studies excluded
Sixty-eight papers were excluded from the analysis. A detailed table of the excluded studies and the
reasons for exclusion can be found in Appendix 2. Table 2 shows the main reasons for exclusion.
General summary characteristics of the included studies
We included 86 unique studies reported in 85 publications. It can be seen from Table 3 that 64 studies
(74%) were conducted in adult patients, whereas 22 studies (26%) were conducted in child and
adolescent samples. The majority of the studies (84%) had only two arms. Approximately half of the
studies were conducted after the 2000s and 14% were conducted before the 1990s.
In total, 8611 patients were randomised (7306 adults and 1305 children and adolescents) into 194 arms
including 23 different interventions or combinations of interventions. Table 4 summarises data on the
number of randomised patients in arms/studies.
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TABLE 2 Main reason for exclusion of studies
Main reason for exclusion Number of papers
Duplicate publication 17
Control intervention not covered 11
Non-randomised design 10
Data not usable 9
Preliminary congress abstract report 8
Aim of the study not relevant (secondary analyses, relapse prevention studies) 5
Diagnosis not focused on OCD 4
Treatment-refractory patient population 2
Main intervention not covered 2
Total 68
Records identified through
database searching 
(n = 1102)
S
cr
e
e
n
in
g
In
cl
u
d
e
d
E
li
g
ib
il
it
y
Id
e
n
ti
fi
ca
ti
o
n
Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 1083)
Records screened
(n = 1083)
Records excluded
(n = 905)
Full-text articles assessed
for eligibility
(n = 178)
Full-text articles
excluded, with reasons
(n = 68)
Studies included in
qualitative synthesis
(n = 110)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 85)
Studies waiting
assessment
(n = 25)
• CCDANCTR-Studies, n = 552
• CCDANCTR-References, n = 550
FIGURE 1 The PRISMA flow diagram.141
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TABLE 3 Number of included studies/arms/patients by age group and date of publication
Characteristics of studies n (%)
Total studies included 86 (100)
Number of studies by age group
Adults 64 (74)
Children/adolescents 22 (26)
Total number of arms 194
Adults 148 (76)
Children/adolescents 46 (24)
Number of studies by number of arms
Two-arm studies: total 72 (84
Adults 51 (80)
Children/adolescents 21 (95)
Three-arm studies: total 6 (7)
Adults 6 (9)
Children/adolescents 0
Four-arm studies: total 8 (9)
Adults 7 (11)
Children/adolescents 1 (5)
Total patients randomised 8611
Adults 7306 (85)
Children/adolescents 1305 (15)
Number of studies by date of publication
1980–90 12 (14)
1991–2000 32 (37)
2001–14 42 (49)
TABLE 4 Number of patients randomised per study/arm
Type of study Number of arms Number of patients Minimum Maximum Mean SD
Per arm 194 arms 8611 5 241 44 40
Per study/arm
Two-arm studies 72 studies 5745 10 325 80 72
Three-arm studies Six studies 789 21 406 131 158
Four-arm studies Eight studies 2077 29 466 260 155
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Country of publication
Figure 2 presents summary data on the country of publication of included studies. The majority of the
studies (52% in total; 48% in adults vs. 66% in children/adolescents) were conducted in North America
(33 studies in the USA, eight in Canada and four in both for the total sample). Five studies (all in adults)
were multinational, that is, defined as having recruited patients from three or more countries (one
fluoxetine vs. placebo; one citalopram vs. placebo; one paroxetine vs. placebo and clomipramine; one
escitalopram vs. placebo and paroxetine; and one fluvoxamine vs. clomipramine study). Countries with
more than three studies were the Netherlands (five studies), and Australia, Brazil and UK (three studies
each). A total of seven studies (six in adults and one in children/adolescents) were conducted in Asia
(three in Japan, three in Iran and one in China). There were no studies from Africa.
Types of interventions
Fifty-six of the included arms (29%) involved a supposedly inactive intervention, either drug placebo
(18.5%) or psychological placebo (4.5%), or a waitlist control (6%). Table 5 shows the number of
arms/number of patients per type of intervention in the total sample and Figure 3 presents a relevant
bar diagram.
It can be seen that in adults (Table 6), the most used active intervention was clomipramine (12%),
followed by fluvoxamine (10%). Paroxetine, however, had the second largest sample of randomised
patients after clomipramine. Overall, 48% of the arms in the adult set involved an active drug intervention,
22% involved an active psychological intervention and 4% involved a combination treatment. In children
and adolescents (Table 7), the most used active intervention was CBT (18% of the arms), followed
by sertraline (11.5%, either alone or in combination with CBT) and fluoxetine (9% of the arms).
Approximately 30% of the arms in children and adolescent samples included a medication, 25% of the
arms included a psychological intervention and 7% included a combination of both types of treatments.
USA and Canada
Multinational
The Netherlands
Australia
Brazil
UK
Iran
Italy
Japan
France
Spain
Sweden
China
France and Belgium
France and Spain
Germany
Country of publication
45 (52%)
5 (6%)
5 (6%)
4 (5%)
4 (5%)
4 (5%)
3 (3%)
3 (3%)
3 (3%)
2 (2%)
2 (2%)
2 (2%)
1 (1%)
1 (1%)
1 (1%)
1 (1%)
FIGURE 2 Country of publication [n (%) of included studies].
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TABLE 5 Number of arms/number of patients per type of intervention: total sample
Intervention
Number of
arms
Number of
patients
% of
arms
% of
patients
Mean
per arm Minimum Maximum
Placebo 36 2005 18.5 23.3 56 6 139
Clomipramine 21 1013 11 11.8 48 8 142
CBT 17 446 9 5.2 26 7 70
Fluvoxamine 17 641 9 7.5 38 5 127
BT 16 418 8 4.8 26 9 69
Fluoxetine 14 754 7 8.8 54 7 90
Waitlist 12 194 6 2.2 16 6 24
Paroxetine 11 1017 5.5 11.8 92 9 205
Sertraline 10 711 5 8.2 71 10 241
CT 9 252 5 2.9 28 10 49
Psychological placebo 8 251 4.5 2.9 31 9 75
Citalopram 5 325 2.5 3.8 65 11 102
Other drug 3 52 1.5 0.6 17 10 30
Fluvoxamine and BT 3 55 1.5 0.6 18 5 30
Escitalopram 2 232 1 2.7 116 116 116
Sertraline and CBT 2 42 1 0.5 21 14 28
Venlafaxine 2 101 1 1.2 50 26 75
Clomipramine and BT 1 33 0.5 0.4 33 33 33
Fluvoxamine and CBT 1 7 0.5 0.1 7 7 7
Placebo+ BT 1 30 0.5 0.3 30 30 30
Placebo+CBT 1 16 0.5 0.2 16 16 16
Serotonergic medication 1 6 0.5 0.1 6 6 6
Serotonergic medication+CBT 1 10 0.5 0.1 10 10 10
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TABLE 6 Number of arms/number of patients per type of intervention: adult subset
Intervention
Number of
arms
Number of
patients
% of
arms
% of
patients
Mean
per arm Minimum Maximum
Placebo 26 1605 18 22.1 60 8 139
Clomipramine 17 955 12 13.2 53 8 142
Fluvoxamine 15 579 10 7.9 39 7 127
BT 14 395 9 5.4 28 9 69
Fluoxetine 10 640 6.7 8.6 64 23 90
Paroxetine 10 917 6.7 12.5 92 9 205
CBT 9 240 6 3.3 27 7 70
CT 9 252 6 3.4 28 10 49
Sertraline 7 571 4.7 7.8 82 10 241
Waitlist 7 111 4.7 1.5 16 6 24
Psychological placebo 6 209 4 2.8 35 9 75
Citalopram 4 311 2.8 4.2 78 11 102
Other drug 3 52 2 0.7 17 10 30
Escitalopram 2 232 1.3 3.2 116 116 116
Fluvoxamine and BT 2 50 1.3 0.7 25 20 30
Venlafaxine 2 101 1.3 1.4 50 26 75
Clomipramine+ BT 1 33 0.7 0.5 33 33 33
Fluvoxamine+CBT 1 7 0.7 0.1 7 7 7
Placebo+ BT 1 30 0.7 0.5 30 30 30
Serotonergic medication 1 6 0.7 0.1 6 6 6
Serotonergic medication+CBT 1 10 0.7 0.1 10 10 10
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FIGURE 3 Number of arms per type of intervention: total sample. SRI, serotonin reuptake inhibitor.
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Specific characteristics of individual studies
Tables 8 and 9 present specific characteristics of individual studies for the adult (n= 64 studies) and child
and adolescent (n= 22 studies) subsets of data, respectively. The following data are presented for each
individual study: study ID (including year of publication), total sample size (original number of randomised
patients), number of arms, type of included interventions (grouped into three categories: medication arms
only, psychological therapy arms only and arms with a combination of treatment interventions), specific
intervention used in each arm, duration of the trial in weeks (primary end point), mean age of the total
sample of randomised patients, percentage of female patients, primary scale used for the assessment of
obsessive–compulsive symptoms, percentage of patients with depression comorbidity (grouped into six
categories: none, < 25%, 25–50%, > 50%, unspecified and unclear), sponsorship of the study from drug
companies (grouped into three categories: yes, no and unclear. This is not applicable for studies with
psychological arms only. It should be noted that specific details of the interventions (mean dose, range of
dose, number of psychotherapeutic sessions and mean duration of each session) are given for all studies in
Appendix 6.
For the adult subset, the median number of randomised patients per study was 66 (range 16–466); 60% of
the studies included drug arms only and 12% included combined arms; median duration of follow-up
per study was 12 weeks (range 3–24 weeks); median percentage of female patients per study was 52.5%
(range 0–94%); 85% of the studies used the YBOCS as their primary symptom scale, 54% of the studies
excluded patients with major depression, and 60% of the studies that used at least one drug or combined
arm were sponsored by the pharmaceutical industry. Of the 12 psychotherapy studies that used an inactive
control condition, seven (58%) used a waitlist control (five CBT trials, one BT and one CT trial).
For the children and adolescents subset, the median number of randomised patients per study was 42
(range 9–207); 43% of the studies included drug arms only and 24% included combined arms; median
duration per study was 12 weeks (range 5–43 weeks); median percentage of female patients per study
was 42% (range 30–63%); 95% of the studies used the CYBOCS as their primary symptom scale; 24% of
TABLE 7 Number of arms/number of patients per type of intervention: children and adolescents subset
Intervention
Number of
arms
Number of
patients
% of
arms
% of
patients
Mean
per arm Minimum Maximum
Placebo 10 400 20.4 30.3 43 6 107
CBT 8 206 18 16 26 11 49
Waitlist 5 83 11.3 6.4 17 10 24
Fluoxetine 4 114 9.1 8.9 28 7 71
Clomipramine 4 58 7 3.8 16 8 31
Sertraline 3 42 7 3.3 21 14 28
BT 2 23 4.5 1.8 11 10 13
Fluvoxamine 2 62 4.5 4.8 31 5 57
Psychological placebo 2 42 4.5 3.3 21 20 22
Sertraline+CBT 2 140 4.5 10.9 47 20 92
Citalopram 1 14 2.3 1.1 14 14 14
Fluvoxamine+ BT 1 5 2.3 0.4 5 5 5
Paroxetine 1 100 2.3 7.8 100 100 100
Placebo+CBT 1 16 2.3 1.2 16 16 16
DOI: 10.3310/hta20430 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 43
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Skapinakis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
TABLE 8 Study-level characteristics: adult subset
Study ID n
Number
of arms
Intervention
type Arm 1 Arm 2 Arm 3 Arm 4
Duration,
weeks
Mean
age,
years
Female,
% Scale used
Comorbid
depression Sponsorship
Albert et al.,
2002155
73 2 Drug VEN CLO 12 29.65 47.9 YBOCS No No
Ananth et al.,
1981156
20 2 Drug CLO AMI 4 36.9 65 Severity
Questionnaire
Yes Unclear
Anderson and
Rees, 2007157
38 2 Therapy CBT Waitlist 10 33.18 • YBOCS Yes NA
Andersson et al.,
2012158
101 2 Therapy CBT PsychPLA 10 34 66 YBOCS Yes NA
Belloch et al.,
2008159
33 2 Therapy BT CT 24 32 • YBOCS Yes NA
Belotto-Silva et al.,
2012160
158 2 Combination FLX CBT 12 34.04 55 YBOCS Yes No
Bergeron et al.,
2002161
150 2 Drug FLX SER 24 36.53 54 YBOCS No Yes
Bisserbe et al.,
1997162
168 2 Drug SER CLO 16 39.77 63 YBOCS No Yes
CCSG1, 1991154 239 2 Drug CLO PLA 10 35.4 61 YBOCS No Yes
CCSG2, 1991154 281 2 Drug CLO PLA 10 35.6 51.5 YBOCS No Yes
Chouinard et al.,
1990163
87 2 Drug SER PLA 8 37.25 15 YBOCS No Yes
Cordioli et al.,
2003164
47 2 Therapy CBT Waitlist 12 36.5 51 YBOCS Yes NA
Cottraux et al.,
1993165
60 3 Combination FLV BT BT+ FLV 24 • 63 OCD
symptom
scales
Yes No
Cottraux et al.,
2001166
65 2 Therapy BT CT 16 35.78 74 YBOCS No NA
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Study ID n
Number
of arms
Intervention
type Arm 1 Arm 2 Arm 3 Arm 4
Duration,
weeks
Mean
age,
years
Female,
% Scale used
Comorbid
depression Sponsorship
Denys et al.,
2003167
150 2 Drug PAR VEN 12 35 62 YBOCS No Yes
Emmelkamp and
Beens, 1991168
30 2 Therapy CT BT 4 • 76 Maudsley
OCI
Yes NA
Emmelkamp et al.,
1988169
20 2 Therapy CT BT 8 29.9 • Maudsley
OCI
Yes NA
Fals-Stewart et al.,
1993170
66 2 Therapy BT PsychPLA 12 30.5 55 YBOCS No NA
Foa et al., 2005171 149 4 Combination BT CLO BT+CLO PLA 12 34.8 48 YBOCS No No
Freeman et al.,
1994172
66 2 Drug FLV CLO 10 33.01 47 YBOCS No Yes
Freeston et al.,
1997173
29 2 Therapy CBT Waitlist 16 35.8 45 YBOCS Yes NA
GlaxoSmithKline,
2005174
241 3 Drug PLA PAR CLO 12 37.95 39 YBOCS No Yes
GlaxoSmithKline,
2005175
146 2 Drug PAR CLO 10 30.85 62 YBOCS No Yes
Goodman et al.,
1989176
46 2 Drug PLA FLV 6 37 55 YBOCS Yes No
Goodman et al.,
1996177
160 2 Drug PLA FLV 10 36.65 50 YBOCS No Yes
Greist et al.,
1995126
325 2 Drug SER PLA 12 38. 64 52 YBOCS No Yes
Greist et al.,
2002178
144 2 Therapy BT PsychPLA 10 39 42 YBOCS Yes NA
Hohagen et al.,
1998179
60 2 Combination BT+ PLA BT+ FLV 10 35.5 59 YBOCS Yes No
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TABLE 8 Study-level characteristics: adult subset (continued )
Study ID n
Number
of arms
Intervention
type Arm 1 Arm 2 Arm 3 Arm 4
Duration,
weeks
Mean
age,
years
Female,
% Scale used
Comorbid
depression Sponsorship
Hollander et al.,
2003180
253 2 Drug PLA FLV 12 37.4 64 YBOCS No Yes
Hollander et al.,
2003181
348 4 Drug PLA PAR-20 PAR-40 PAR-60 12 41.36 26 YBOCS No Yes
Jaurrieta et al.,
2008182
38 2 Therapy CBT Waitlist 20 31.6 40.4 YBOCS Yes NA
Jenike et al.,
1990183
19 2 Drug SER PLA 10 39.7 21 YBOCS No Yes
Jenike et al.,
1990184
40 2 Drug PLA FLV 10 35.9 47 YBOCS No Yes
Jenike et al.,
1997185
44 2 Drug PLA FLX 10 34.86 48 YBOCS No No
Jones and
Menzies, 1998186
23 2 Therapy CT Waitlist 8 38.52 90 Maudsley
OCI
Unclear NA
Kamijima et al.,
2004187
191 2 Drug PLA PAR 12 37.8 62 YBOCS Yes Unclear
Khodarahimi,
2009188
40 2 Therapy Waitlist BT 6 24.6 0 YBOCS No NA
Kobak et al.,
2005189
60 2 Drug PLA Hypericum 12 37.72 • YBOCS No No
Koran et al.,
1996190
79 2 Drug FLV CLO 10 • 45 YBOCS No Yes
Kronig et al.,
1999191
167 2 Drug SER PLA 12 36.76 45 YBOCS No Yes
Lindsay et al.,
1997192
18 2 Therapy BT PsychPLA 3 32.8 66 YBOCS Yes NA
López-Ibor et al.,
1996193
55 2 Drug FLX CLO 8 34 62 YBOCS No Yes
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Study ID n
Number
of arms
Intervention
type Arm 1 Arm 2 Arm 3 Arm 4
Duration,
weeks
Mean
age,
years
Female,
% Scale used
Comorbid
depression Sponsorship
Mavissakalian
et al., 1985194
16 2 Drug CLO PLA 12 35.9 56 OCNS Yes Yes
McLean et al.,
2001195
93 2 Therapy CT BT 12 35 48 YBOCS Yes NA
Milanfranchi et al.,
1997196
26 2 Drug CLO FLV 9 27.35 42 YBOCS No Yes
Montgomery et al.,
1993197
217 4 Drug PLA FLX-20 FLX-40 FLX-60 8 37.16 47 YBOCS Yes Yes
Montgomery et al.,
2001198
401 4 Drug PLA CIT-20 CIT-40 CIT-60 12 37.82 54 YBOCS Yes Yes
Mundo et al.,
1997199
30 3 Drug FLV PAR CIT 10 30.78 30 YBOCS No No
Mundo et al.,
2001200
227 2 Drug CLO FLV 10 35.2 45 YBOCS No Yes
Nakajima et al.,
1996201
94 2 Drug FLV PLA 8 34.38 46 YBOCS Unclear Unclear
Nakatani et al.,
2005202
31 3 Combination PsychPLA FLV BT 12 33.66 68 YBOCS No No
O’Connor et al.,
1999203
29 4 Combination SRI Waitlist CBT CBT+ SRI 20 35.94 37 YBOCS Yes No
O’Connor et al.,
2006204
21 2 Drug PLA FLV 20 35.76 57 YBOCS No No
Perse et al.,
1987205
20 2 Drug PLA FLV 8 • • Maudsley
OCI
Yes Yes
Shareh et al.,
2010206
21 3 Combination FLV CBT FLV+CBT 10 26.84 53 YBOCS No No
Sousa et al.,
2006207
56 2 Combination SER CBT 12 38.5 77 YBOCS No No
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TABLE 8 Study-level characteristics: adult subset (continued )
Study ID n
Number
of arms
Intervention
type Arm 1 Arm 2 Arm 3 Arm 4
Duration,
weeks
Mean
age,
years
Female,
% Scale used
Comorbid
depression Sponsorship
Stein et al.,
2007124
466 4 Drug PLA PAR ESCIT-10 ESCIT-20 12 37.75 57 YBOCS No Yes
Thoren et al.,
1980208
16 2 Drug CLO PLA 5 38.9 94 OCD
symptom
scale
Yes No
Tollefson et al.,
1994127
355 4 Drug PLA FLX-20 FLX-40 FLX-60 13 36.9 55.2 YBOCS Yes Yes
Van Oppen et al.,
1995209
71 2 Therapy CT BT 16 34.71 53 YBOCS Yes NA
Volavka et al.,
1985210
23 2 Drug CLO IMI 12 29.94 52 SRONS No Yes
Whittal et al.,
2005211
83 2 Therapy CT BT 12 34.89 62.5 YBOCS Yes NA
Whittal et al.,
2010212
73 2 Therapy CT PsychPLA 12 31.5 46.6 YBOCS Yes NA
Zohar and Judge,
1996213
406 3 Drug PLA PAR CLO 12 37.94 52 YBOCS No Yes
AMI, amitriptyline; CCSG, Clomipramine Collaborative Study Group; CIT, citalopram; CLO, clomipramine; ESCIT, escitalopram; FLV, fluvoxamine; FLX, fluoxetine; IMI, imipramine;
NA, not applicable; OCI, obsessive–compulsive inventory; OCNS, Obsessive–Compulsive Neurotic Scale; OCR, Obsessive–Compulsive Rating Scale; PAR, paroxetine; PLA, placebo;
PsychPLA, psychological placebo; SER, sertraline; SRI, serotonin reuptake inhibitor; SRONS, Self-Rating Obsessional Neurotic Scale; VEN, venlafaxine.
Bullet points (•) indicate missing information (i.e. data not provided for this characteristic).
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TABLE 9 Study-level characteristics: children and adolescents subset
Study ID n
Number
of arms Arm 1 Arm 2 Arm 3 Arm 4
Duration,
weeks
Mean
age,
years Female, %
Scale
used
Comorbid
depression Sponsorship
Alaghband-Rad and
Hakimshooshtary, 2009215
29 2 FLX CIT 6 • 41 CYBOCS Unclear Unclear
Asbahr et al., 2005216 40 2 SER CBT 12 13.05 35 CYBOCS Yes No
Barrett et al., 2004217 48 2 CBT Waitlist 14 11.25 48 CYBOCS Yes NA
Bolton and Perrin, 2008218 20 2 BT Waitlist 7 13.2 30 CYBOCS Yes NA
Bolton et al., 2011219 60 2 CBT Waitlist 12 14.6 57 CYBOCS No NA
de Haan et al., 1998220 23 2 CLO BT 12 13.43 50 CYBOCS No No
DeVeaugh-Geiss et al., 1992221 60 2 CLO PLA 8 14.25 35 CYBOCS No Yes
Flament et al., 1985222 19 2 CLO PLA 5 14.5 26 OCR
scale
Yes No
Freeman et al., 2008223 42 2 CBT PsychPLA 14 7.11 57 CYBOCS Yes NA
Geller et al., 2001224 103 2 FLX PLA 13 11.4 52 CYBOCS Yes Yes
GlaxoSmithKline, 2001225 207 2 PAR PLA 10 11.3 42 CYBOCS Unclear Yes
Liebowitz et al., 2002226 43 2 FLX PLA 8 12.65 42 CYBOCS Yes Yes
March et al., 1990227 16 2 CLO PLA 10 15 31 YBOCS Yes Yes
March et al., 1998228 187 2 SER PLA 12 12.6 • CYBOCS Yes Yes
Neziroglu et al., 2000229 10 2 FLV FLV+ BT 43 14.5 40 CYBOCS Yes Unclear
Piacentini et al., 2011230 71 2 CBT PsychPLA 14 12.2 63.4 CYBOCS Yes NA
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TABLE 9 Study-level characteristics: children and adolescents subset (continued )
Study ID n
Number
of arms Arm 1 Arm 2 Arm 3 Arm 4
Duration,
weeks
Mean
age,
years Female, %
Scale
used
Comorbid
depression Sponsorship
Riddle et al., 1992231 13 2 FLX PLA 8 12.7 61 CYBOCS Yes No
Riddle et al., 2001232 120 2 FLV PLA 10 13.03 47 CYBOCS No Yes
Storch et al., 2011233 31 2 CBT Waitlist 12 11.1 39 CYBOCS Yes NA
Storch et al., 2013234 30 2 SER+CBT CBT+ PLA 18 12.13 40 CYBOCS Yes No
Williams et al., 2010235 21 2 CBT Waitlist 12 13.6 38 CYBOCS Yes NA
The Pediatric OCD Treatment
Study, 2004236
112 4 SER CBT SER+CBT PLA 12 11.77 50 CYBOCS No No
AMI, amitriptyline; CIT, citalopram; CLO, clomipramine; FLV, fluvoxamine; FLX, fluoxetine; NA, not applicable; PAR, paroxetine; PLA, placebo; PsychPLA, psychological placebo;
SER, sertraline.
Bullet points (•) indicate missing information (i.e. data not provided for this characteristic).
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the studies excluded patients with major depression; and 50% of the studies that used at least one drug
or combined arm were sponsored by the pharmaceutical industry. Of the seven psychotherapy studies that
used an inactive control condition, five (71%) used a waitlist control (four CBT trials and one BT trial).
Individual studies per included active intervention
For ease of reference, we also present separate tables with the included studies for each active
intervention (Tables 10 and 11 for adults and children and adolescent subsets, respectively). We present
the following information: study ID (including year of publication); total sample size (original number of
randomised patients); specific intervention used in each arm; duration of the trial in weeks (primary end
point); and primary scale used for the assessment of obsessive–compulsive symptoms. It should be noted
that some studies appear more than once because they compared an active drug with another active drug.
TABLE 10 Study-level characteristics per type of intervention: adult subset
Study ID n Arm 1 Arm 2 Arm 3 Arm 4
Duration
(weeks) Scale used
Fluoxetine studies (n = 6)
Jenike et al., 1997185 44 FLX PLA 10 YBOCS
Montgomery et al., 1993197 217 FLX-20 FLX-40 FLX-60 PLA 8 YBOCS
Tollefson et al., 1994127 355 FLX-20 FLX-40 FLX-60 PLA 13 YBOCS
López-Ibor et al., 1996193 55 FLX CLO 8 YBOCS
Bergeron et al., 2002161 150 FLX SER 24 YBOCS
Belotto-Silva et al., 2012160 158 FLX CBT 12 YBOCS
Total 979
Fluvoxamine studies (n = 16)
Perse et al., 1987205 20 FLV PLA 8 Maudsley OCI
Goodman et al., 1989176 46 FLV PLA 6 YBOCS
Jenike et al., 1990184 40 FLV PLA 10 YBOCS
Goodman et al., 1996177 160 FLV PLA 10 YBOCS
Nakajima et al., 1996201 94 FLV PLA 8 YBOCS
Hollander et al., 2003181 253 FLV PLA 12 YBOCS
O’Connor et al., 2006204 21 FLV PLA 20 YBOCS
Freeman et al., 1994172 66 FLV CLO 10 YBOCS
Koran et al., 1996190 79 FLV CLO 10 YBOCS
Milanfranchi et al., 1997196 26 FLV CLO 9 YBOCS
Mundo et al., 2001200 227 FLV CLO 10 YBOCS
Mundo et al., 1997199 30 FLV PAR CIT 10 YBOCS
Nakatani et al., 2005202 31 FLV BT PsychPLA 12 YBOCS
Cottraux et al., 1993165 60 FLV FLV+ BT BT 24 OCD symptom
scales
Hohagen et al.,1998179 60 FLV+ BT PLA+ BT 10 YBOCS
Shareh et al., 2010206 21 FLV FLV+CBT CBT 10 YBOCS
Total 1234
continued
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TABLE 10 Study-level characteristics per type of intervention: adult subset (continued )
Study ID n Arm 1 Arm 2 Arm 3 Arm 4
Duration
(weeks) Scale used
Clomipramine studies (n = 17)
Thoren et al., 1980208 16 CLO PLA 5 OCD symptom
scale
Mavissakalian et al., 1985194 16 CLO PLA 12 OCNS
CCSG1, 1991154 239 CLO PLA 10 YBOCS
CCSG2, 1991154 281 CLO PLA 10 YBOCS
Ananth et al., 1981156 20 CLO AMI 4 Severity
questionnaire
Volavka et al., 1985210 23 CLO IMI 12 SRONS
Freeman et al., 1994172 66 CLO FLV 10 YBOCS
Koran et al., 1996190 79 CLO FLV 10 YBOCS
Milanfranchi et al., 1997196 26 CLO FLV 9 YBOCS
Mundo et al., 2001200 227 CLO FLV 10 YBOCS
López-Ibor et al., 1996193 55 CLO FLX 8 YBOCS
GlaxoSmithKline, 2005175 146 CLO PAR 10 YBOCS
GlaxoSmithKline, 2005174 241 CLO PAR PLA 12 YBOCS
Zohar and Judge, 1996213 406 CLO PAR PLA 12 YBOCS
Bisserbe et al., 1997162 168 CLO SER 16 YBOCS
Albert et al., 2002155 73 CLO VEN 12 YBOCS
Foa et al., 2005171 149 CLO CLO+ BT BT PLA 12 YBOCS
Total 2231
Paroxetine studies (n = 8)
Hollander et al., 2003180 348 PAR-20 PAR-40 PAR-60 PLA 12 YBOCS
Kamijima et al., 2004187 191 PAR PLA 12 YBOCS
GlaxoSmithKline, 2005175 146 PAR CLO 10 YBOCS
GlaxoSmithKline, 2005174 241 PAR CLO PLA 12 YBOCS
Zohar and Judge, 1996213 406 PAR CLO PLA 12 YBOCS
Mundo et al., 1997199 30 PAR CIT FLV 10 YBOCS
Stein et al., 2007124 466 PAR ESCIT-10 ESCIT-20 PLA 12 YBOCS
Denys et al., 2003167 150 PAR VEN 12 YBOCS
Total 1978
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TABLE 10 Study-level characteristics per type of intervention: adult subset (continued )
Study ID n Arm 1 Arm 2 Arm 3 Arm 4
Duration
(weeks) Scale used
Sertraline studies (n = 7)
Chouinard et al., 1990163 87 SER PLA 8 YBOCS
Jenike et al., 1990183 19 SER PLA 10 YBOCS
Greist et al., 1995126 325 SER PLA 12 YBOCS
Kronig et al., 1999191 167 SER PLA 12 YBOCS
Bisserbe et al., 1997162 168 SER CLO 16 YBOCS
Bergeron et al., 2002161 150 SER FLX 24 YBOCS
Sousa et al., 2006207 56 SER CBT 12 YBOCS
Total 972
Citalopram studies (n = 2)
Montgomery et al., 2001198 401 CIT-20 CIT-40 CIT-60 PLA 12 YBOCS
Mundo et al., 1997199 30 CIT FLV PAR 10 YBOCS
Total 431
Escitalopram studies (n = 1)
Stein et al., 2007124 466 PLA PAR ESCIT-10 ESCIT-
20
12 YBOCS
Other medications (n = 3)
Ananth et al., 1981156 20 AMI CLO 4 Severity
questionnaire
Volavka et al., 1985210 23 IMI CLO 12 SRONS
Kobak et al., 2005189 60 Hypericum PLA 12 YBOCS
Total 103
Venlafaxine studies (n = 2)
Albert et al., 2002155 73 VEN CLO 12 YBOCS
Denys et al., 2003167 150 VEN PAR 12 YBOCS
Total 223
BT studies (n = 15)
Fals-Stewart et al., 1993170 66 BT PsychPLA 12 YBOCS
Lindsay et al., 1997192 18 BT PsychPLA 3 YBOCS
Greist et al., 2002178 144 BT PsychPLA 10 YBOCS
Khodarahimi, 2009188 40 BT Waitlist 6 YBOCS
Foa et al., 2005171 149 BT BT+CLO CLO PLA 12 YBOCS
Cottraux et al., 1993165 60 BT BT+ FLV FLV 24 OCD symptom
scales
Nakatani et al., 2005202 31 BT FLV PsychPLA 12 YBOCS
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TABLE 10 Study-level characteristics per type of intervention: adult subset (continued )
Study ID n Arm 1 Arm 2 Arm 3 Arm 4
Duration
(weeks) Scale used
Hohagen et al., 1998179 60 BT+ FLV BT+ PLA 10 YBOCS
Emmelkamp and Beens,
1991168
30 BT CT 4 Maudsley OCI
Van Oppen et al., 1995209 71 BT CT 16 YBOCS
Emmelkamp et al., 1988169 20 BT CT 8 Maudsley OCI
Cottraux et al., 2001166 65 BT CT 16 YBOCS
McLean et al., 2001195 93 BT CT 12 YBOCS
Whittal et al., 2005211 83 BT CT 12 YBOCS
Belloch et al., 2008159 33 BT CT 24 YBOCS
Total 963
CBT studies (n = 9)
Andersson et al., 2012158 101 CBT PsychPLA 10 YBOCS
Freeston et al., 1997173 29 CBT Waitlist 16 YBOCS
Cordioli et al., 2003164 47 CBT Waitlist 12 YBOCS
Anderson and Rees, 2007157 38 CBT Waitlist 10 YBOCS
Jaurrieta et al., 2008182 38 CBT Waitlist 20 YBOCS
Belotto-Silva et al., 2012160 158 CBT FLX 12 YBOCS
Shareh et al., 2010206 21 CBT CBT+ FLV FLV 10 YBOCS
Sousa et al., 2006207 56 CBT SER 12 YBOCS
O’Connor et al., 1999203 29 CBT CBT+ SRI SRI Waitlist 20 YBOCS
Total 517
CT studies (n = 9)
Whittal et al., 2010212 73 CT PsychPLA 12 YBOCS
Jones and Menzies, 1998186 23 CT Waitlist 8 Maudsley OCI
Emmelkamp et al., 1988169 20 CT BT 8 Maudsley OCI
Emmelkamp and Beens,
1991168
30 CT BT 4 Maudsley OCI
Van Oppen et al., 1995209 71 CT BT 16 YBOCS
Cottraux et al., 2001166 65 CT BT 16 YBOCS
McLean et al., 2001195 93 CT BT 12 YBOCS
Whittal et al., 2005211 83 CT BT 12 YBOCS
Belloch et al., 2008159 33 CT BT 24 YBOCS
Total 491
AMI, amitriptyline; CCSG, Clomipramine Collaborative Study Group; CIT, citalopram; CLO, clomipramine;
ESCIT, escitalopram; FLV, fluvoxamine; FLX, fluoxetine; IMI, imipramine; OCI, obsessive–compulsive inventory;
PAR, paroxetine; PLA, placebo; PsychPLA, psychological placebo; SER, sertraline; SRONS, Self-Rating Obsessional Neurotic
Scale; VEN, venlafaxine.
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TABLE 11 Study-level characteristics per type of intervention: children and adolescents subset
Study ID n Arm 1 Arm 2 Arm 3 Arm 4 Duration (weeks) Scale used
Fluoxetine studies (n = 4)
Riddle et al., 1992231 13 FLX PLA 8 CYBOCS
Geller et al., 2001224 103 FLX PLA 13 CYBOCS
Liebowitz et al., 2002226 43 FLX PLA 8 CYBOCS
Alaghband-Rad and
Hakimshooshtary, 2009215
29 FLX CIT 6 CYBOCS
Total 188
Fluvoxamine studies (n = 2)
Riddle et al., 2001232 120 FLV PLA 10 CYBOCS
Neziroglu et al., 2000229 10 FLV FLV+ BT 43 CYBOCS
Total 130
Clomipramine studies (n = 4)
Flament et al., 1985222 19 CLO PLA 5 OCR scale
March et al., 1990227 16 CLO PLA 10 YBOCS
DeVeaugh-Geiss et al.,
1992221
60 CLO PLA 8 CYBOCS
de Haan et al., 1998220 23 CLO BT 12 CYBOCS
Total 99
Paroxetine studies (n = 1)
GlaxoSmithKline, 2001225 207 PAR PLA 10 CYBOCS
Sertraline studies (n = 4)
March et al., 1998228 187 SER PLA 12 CYBOCS
The Pediatric OCD
Treatment Study, 2004236
112 SER SER+CBT CBT PLA 12 CYBOCS
Asbahr et al., 2005216 40 SER CBT 12 CYBOCS
Storch et al., 2013234 30 SER+CBT PLA+CBT 18 CYBOCS
Total 369
Citalopram studies (n = 1)
Alaghband-Rad and
Hakimshooshtary, 2009215
29 CIT FLX 6 CYBOCS
BT studies (n = 3)
Bolton and Perrin, 2008218 20 BT Waitlist 7 CYBOCS
de Haan et al., 1998220 23 BT CLO 12 CYBOCS
Neziroglu et al., 2000229 10 BT+ FLV FLV 43 CYBOCS
Total 53
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TABLE 11 Study-level characteristics per type of intervention: children and adolescents subset (continued )
Study ID n Arm 1 Arm 2 Arm 3 Arm 4 Duration (weeks) Scale used
CBT studies (n = 9)
Freeman et al., 2008223 42 CBT PsychPLA 14 CYBOCS
Piacentini et al., 2011230 71 CBT PsychPLA 14 CYBOCS
Barrett et al., 2004217 48 CBT Waitlist 14 CYBOCS
Williams et al., 2010235 21 CBT Waitlist 12 CYBOCS
Bolton et al., 2011219 60 CBT Waitlist 12 CYBOCS
Storch et al., 2011233 31 CBT Waitlist 12 CYBOCS
The Pediatric OCD
Treatment Study, 2004236
112 CBT SER 12 CYBOCS
Asbahr et al., 2005216 40 CBT SER 12 CYBOCS
Storch et al., 2013234 30 CBT+ PLA CBT+ SER 18 CYBOCS
Total 455
AMI, amitriptyline; CIT, citalopram; CLO, clomipramine; FLV, fluvoxamine; FLX, fluoxetine; OCR, Obsessive–Compulsive
Rating Scale; PAR, paroxetine; PLA, placebo; PsychPLA, psychological placebo; SER, sertraline.
Quality of included trials (risk-of-bias assessment)
The methodological quality of included trials is summarised in Table 12 and Figure 4 for the adult subset
and Table 13 and Figure 5 for the children and adolescents subset. We used the criteria for quality
assessment recommended by the Cochrane Handbook for Systematic Reviews of Interventions.142 We have
included the following criteria: random sequence generation; allocation sequence concealment; blinding of
participants; blinding of those delivering the intervention; blinding of the outcome assessor; completeness
of outcome data; and selective outcome reporting and other potential sources of bias. Studies were given
a quality rating of ‘low’, ‘unclear’ or ‘high’ risk of bias in accordance with these criteria. For the last
criterion of ‘any other potential source of bias’, we categorised studies as high risk if the overall attrition
rate was > 25% or if there was evidence of differential attrition between arms of > 15%. The tables
present the summary results for each criterion, and a more detailed table in Appendix 7 includes a
description of the reason behind the specific categorisation. Studies with a high risk of bias were included
in the main analysis but we also examined, in a sensitivity analysis, the effect of excluding them.
Figures 4 and 5 show that the majority of the studies in the adult subset have not described adequately
the random sequence generation or the way in which they have concealed the allocation sequence.
Similar findings are reported for the children and adolescents subset.
We have also extracted data on the type of analysis (whether or not the authors have performed an intention-
to-treat analysis) and the method of handling missing data. Tables 14 and 15 present this information for
adults and for children and adolescents, respectively. It can be seen that the majority (81%) of the children
and adolescents studies have used intention-to-treat analysis, compared with 43% of the adult studies.
The last observation carried forward was the most common method for imputing missing observations.
In the adult subset, 54% of the trials either did not report intention-to-treat results or did not describe the
way in which missing data were handled. Tabulation per type of intervention showed that in studies with
medication arms only, the percentage was 41% (16 out of 39), compared with 77% (14 out of 18) of
trials with psychological interventions only and 62% (5/8) of trials with combined arms. The majority of the
studies with medication arms only involved clomipramine (10/16 studies that did not report such data),
whereas those studies of psychological interventions involved either CT or compared CT and
BT (9/14 studies that did not report such data).
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TABLE 12 Methodological quality summary: reviewers' judgements about each methodological criterion: adult subset
Study ID
Sequence
generation
Allocation
sequence
concealment
Blinding of
participants
Blinding of those
delivering the
intervention
Blinding of
the outcome
assessor
Incomplete
outcome data
Selective
outcome
reporting
Any other potential
threats to validity
Albert et al., 2002155 Unclear Unclear High High Low High High High
Ananth et al., 1981156 Unclear Unclear Low Low Unclear High Low Low
Anderson and Rees, 2007157 Unclear Unclear High High Unclear Low High Low
Andersson et al., 2012158 Low Unclear High High Low Low Low Low
Belloch et al., 2008159 Unclear Unclear High High Low High Low Low
Belotto-Silva et al., 2012160 Low Low High High Low Low Low Low
Bergeron et al., 2002161 Unclear Unclear Unclear Unclear Unclear Low Low High
Bisserbe et al., 1997162 Unclear Unclear Unclear Unclear Unclear Low High High
CCSG1, 1991154 Unclear Unclear Low Low Unclear Unclear High High
CCSG2, 1991154 Unclear Unclear Low Low Unclear Unclear High High
Chouinard et al., 1990163 Unclear Unclear Unclear Unclear Unclear Low High Low
Cordioli et al., 2003164 Low Low High High Low Low Low Low
Cottraux et al., 1993165 Unclear Unclear Unclear Unclear Unclear High Low High
Cottraux et al., 2001166 Unclear Unclear High High Low High High Low
Denys et al., 2003167 Unclear Unclear Low Low Low Low Low Low
Emmelkamp and Beens, 1991168 Unclear Unclear High High Low High Low High
Emmelkamp et al., 1988169 Unclear Unclear High High Low High Low Low
Fals-Stewart et al., 1993170 Unclear Unclear High High Unclear High High Low
Foa et al., 2005171 Low Unclear Unclear Low Low Low Low High
Freeman et al., 1994172 Unclear Unclear Unclear Unclear Unclear Low High High
Freeston et al., 1997173 Unclear Unclear High High High Low Low Low
GlaxoSmithKline, 2005174 Unclear Unclear Unclear Unclear Unclear Low Low High
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TABLE 12 Methodological quality summary: reviewers' judgements about each methodological criterion: adult subset (continued )
Study ID
Sequence
generation
Allocation
sequence
concealment
Blinding of
participants
Blinding of those
delivering the
intervention
Blinding of
the outcome
assessor
Incomplete
outcome data
Selective
outcome
reporting
Any other potential
threats to validity
GlaxoSmithKline, 2005175 Unclear Unclear Unclear Unclear Unclear Unclear Low High
Goodman et al., 1989176 Unclear Unclear Low Low Low Low Low High
Goodman et al., 1996177 Unclear Unclear Unclear Unclear Unclear Low High Low
Greist et al., 1995126 Unclear Unclear Unclear Unclear Unclear Unclear Low High
Greist et al., 2002178 Unclear Unclear High High High Low Low Low
Hohagen et al., 1998179 Unclear Unclear Unclear Unclear Low Unclear Low High
Hollander et al., 2003180 Unclear Unclear Unclear Unclear Unclear Low High Low
Hollander et al., 2003181 Low Low Low Low Unclear Low High Low
Jaurrieta et al., 2008182 Low Low High High Unclear Low High Low
Jenike et al., 1990183 Unclear Unclear Low Low Unclear Low Low Low
Jenike et al., 1990184 Unclear Unclear Low Low Low High High Low
Jenike et al., 1997185 Unclear Unclear Unclear Unclear Unclear Low Low Unclear
Jones and Menzies, 1998186 Unclear Unclear High High High Unclear Low Low
Kamijima et al., 2004187 Unclear Unclear Unclear Unclear Unclear Low High Low
Khodarahimi, 2009188 Low Unclear High High Unclear High Low Low
Kobak et al., 2005189 Unclear Unclear Low Low Unclear Low Low Low
Koran et al., 1996190 Low Unclear Low Low Unclear Low Low High
Kronig et al., 1999191 Low Unclear Unclear Unclear Unclear Low High High
Lindsay et al., 1997192 Unclear Unclear High High Unclear Unclear Unclear Low
López-Ibor et al., 1996193 Unclear Unclear Unclear Unclear Unclear Low Low Low
Mavissakalian et al., 1985194 Unclear Unclear Unclear Unclear Unclear High High Low
McLean et al., 2001195 Low Unclear High High Unclear High Low Low
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Study ID
Sequence
generation
Allocation
sequence
concealment
Blinding of
participants
Blinding of those
delivering the
intervention
Blinding of
the outcome
assessor
Incomplete
outcome data
Selective
outcome
reporting
Any other potential
threats to validity
Milanfranchi et al., 1997196 Unclear Unclear Low Low Unclear High Low Low
Montgomery et al., 1993197 Unclear Unclear Unclear Unclear Unclear Low Low Low
Montgomery et al., 2001198 Unclear Unclear Unclear Unclear Unclear Low Low Low
Mundo et al., 1997199 Unclear Unclear High High Low Low Low Low
Mundo et al., 2001200 Unclear Unclear Unclear Unclear Unclear Low High Low
Nakajima et al., 1996201 Unclear Unclear Unclear Unclear Unclear Low Low Low
Nakatani et al., 2005202 Unclear Low High Unclear Low High Low Low
O’Connor et al., 1999203 High Unclear High High Low High High Low
O’Connor et al., 2006204 Unclear Low Low Low Low High Low Low
Perse et al., 1987205 Unclear Unclear Unclear Unclear Low High High Low
Shareh et al., 2010206 Unclear Unclear High High Unclear High Low High
Sousa et al., 2006207 Low Unclear High High Low Low High Low
Stein et al., 2007124 Low Low Low Low Low Low Low Low
Thoren et al., 1980208 Unclear Unclear Low Low Unclear High High Low
Tollefson et al., 1994127 Unclear Unclear Unclear Unclear Unclear Low High High
Van Oppen et al., 1995209 Unclear Unclear High High Unclear High High Low
Volavka et al., 1985210 Low Low Low Low Unclear High Low Low
Whittal et al., 2005211 Unclear Unclear High High Low High Low Low
Whittal et al., 2010212 Unclear Unclear High High Unclear High Low Low
Zohar and Judge, 1996213 Unclear Unclear Unclear Unclear Unclear Low Low High
CCSG, Clomipramine Collaborative Study Group; high, high risk of bias; low, low risk of bias; unclear, unclear risk of bias.
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FIGURE 4 Methodological quality graph for the adult subset (n= 64): reviewers’ judgements about each criterion as
percentages across all included studies.
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TABLE 13 Methodological quality summary: reviewers’ judgements about each methodological criterion: children and adolescents subset
Study ID
Sequence
generation
Allocation
sequence
concealment
Blinding of
participants
Blinding of those
delivering the
intervention
Blinding of
the outcome
assessor
Incomplete
outcome data
Selective
outcome
reporting
Any other potential
threats to validity
Alaghband-Rad and
Hakimshooshtary, 2009215
Unclear Unclear Unclear Unclear Unclear High High High
Asbahr et al., 2005216 Unclear Unclear High High Low Low High Low
Barrett et al., 2004217 Low Unclear High High Unclear Unclear High Low
Bolton and Perrin, 2008218 Low Low High High High Low Low Low
Bolton et al., 2011219 Low Low High High Low Low Low Low
de Haan et al., 1998220 Unclear Unclear High High Unclear Low Low Low
DeVeaugh-Geiss et al., 1992221 Unclear Unclear Unclear Unclear Unclear Low High Low
Flament et al., 1985222 Unclear Unclear Low Low Low Unclear High Low
Freeman et al., 2008223 Unclear Unclear High High Low Low Low High
Geller et al., 2001224 Unclear Unclear Unclear Unclear Unclear Low Low High
GlaxoSmithKline, 2001225 Low Unclear Low Low Unclear High Low High
Liebowitz et al., 2002226 Unclear Unclear Unclear Unclear Low Low Low Low
March et al., 1990227 Unclear Unclear Low Low Unclear Low Low Low
March et al., 1998228 Low Unclear Low Low Unclear Low High Low
Neziroglu et al., 2000229 Unclear Unclear High High Unclear Low Low Low
Piacentini et al., 2011230 Unclear Unclear High High Low Low Low Low
Riddle et al., 1992231 Unclear Low Low Low Unclear Low Low Low
Riddle et al., 2001232 Unclear Unclear Low Low Low Low Low High
Storch et al., 2011233 Low Unclear High High Low Low Low Low
Storch et al., 2013234 Low Unclear Unclear Unclear Low Low Low High
Williams et al., 2010235 Low Low High High Low Low High Low
The Pediatric OCD
Treatment Study, 2004236
Low Low Unclear Unclear Low Low Low Low
High, high risk of bias; low, low risk of bias; unclear, unclear risk of bias.
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TABLE 14 Type of analysis and handling of missing data: adult subset
Intention-to-treat analysis Number of studies % of studies
Yes 28 44
No 26 41
Unclear 8 12
Not applicable 2 3
Total 64 100
Imputation method
Last observation carried forward 25 39
Linear mixed-effects models 1 2
Unclear 10 16
No 26 40
Not applicable 2 3
Total 64 100
TABLE 15 Type of analysis and handling of missing data: children and adolescents subset
Intention-to-treat analysis Number of studies % of studies
Yes 17 77
No 3 14
Unclear 2 9
Total 22 100
Imputation method
Last observation carried forward 14 65
Mixed-effects models 1 4
Other 1 4
Unclear 2 9
No 3 14
Not applicable 1 4
Total 22 100
Any other potential threats to validity
Selective outcome reporting
Incomplete outcome data
Blinding of the outcome assessor
Blinding of those delivering the
intervention
Blinding of participants
Allocation sequence concealment
Sequence generation
High risk
Unclear
Low risk
0 10 20 30 40 50
Percentage of studies
60 70 80 90 100
FIGURE 5 Methodological quality graph for the children and adolescents subset (n= 22): reviewers’ judgements
about each criterion as percentages across all included studies.
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Chapter 5 Network meta-analysis results (adults)
Clinical effectiveness: symptom reduction in the Yale–Brown
Obsessive–Compulsive Scale
Description of the data set
Table 16 presents the raw data used for the YBOCS analysis in the adult subset of the data (a complete
copy of the full data extraction is available in Appendix 4). Of the 64 studies eligible for inclusion in the
NMA, 9 were excluded because they had not used the YBOCS scale.156,165,168,169,186,194,205,208,210 This decision
was made in light of the well-documented methodological and interpretational difficulties associated
with the standardised MD.142 The excluded studies are summarised here for completeness: these studies
involved a total of 288 randomised patients (4% of the total randomised patients in the adult subset) and
four clomipramine arms, three BT arms, three CT arms, two fluvoxamine arms, one amitriptyline arm, one
imipramine arm and three placebo arms. One additional study was excluded because it was not part of the
connected network.179 Therefore, 54 studies were included in this analysis (see Table 16).
Table 17 presents summary data per type of intervention for the studies included in the NMA (number of
arms and number of randomised patients per intervention).
Network meta-analysis: results
Network geometry
Figure 6 shows the network geometry of the YBOCS outcome in the adult subset, and Table 18 presents
summary data per type of intervention (number of patients randomised, total number of links with other
treatments, number of unique treatments compared). Overall, of the 136 pairwise comparisons that can be
made among the 17 treatment conditions, only 37 (27%) were studied directly by head-to-head
comparison in 54 studies involving 6652 randomised patients. It should be noted, however, that 24 of
these 37 direct comparisons are made in single trials. Each circle (node) represents an intervention and is
proportional to the number of participants randomised to each treatment (i.e. the larger the node, the
greater the number of participants randomised to each intervention). Placebo (n= 1515), paroxetine
(n= 902), clomipramine (n= 831), fluoxetine (n= 633), sertraline (n= 565), fluvoxamine (n= 521),
citalopram (n= 311), BT (n= 287), CBT (n= 231), escitalopram (n= 226), psychological placebo (n= 196),
CT (n= 172), venlafaxine (n= 98) and waitlist (n= 97) had a sample approximately ≥ 100 (Table 18). Lines
represent the available direct evidence and are proportional to the number of trials making a randomised
comparison of each pair of treatments. Figure 6 includes 79 randomised pairwise comparisons and the
most common comparisons are those between placebo versus paroxetine (n= 7), placebo versus
fluvoxamine (n= 6), placebo versus fluoxetine, placebo versus clomipramine, CBT versus waitlist and BT
versus psychological placebo (n= 5 each), placebo versus sertraline and fluvoxamine versus clomipramine
(n= 4 each). Nodes with the most connections (links) in the network (see Table 24) are drug placebo
(n= 35 links with 10 different interventions), clomipramine (n= 17 links with eight different interventions),
fluvoxamine (n= 16 links with seven different interventions), paroxetine (n= 15 links with six different
interventions), BT (n= 14 links with seven different interventions), CBT (n= 9 links with six different
interventions), fluoxetine (n= 8 links with four different interventions), sertraline (n= 7 links with four
different interventions), psychological placebo (n= 6 links with four different interventions), waitlist (n= 6
links with two different interventions), citalopram (n= 5 links with two different interventions) and CT
(n= 5 links with two different interventions).
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TABLE 16 Raw data used for the YBOCS analysis (adult subset) sorted by study ID and number of arms
Study ID t[i,1] y[i,1] n[i,1] sd[i,1] t[i,2] y[i,2] n[i,2] sd[i,2] t[i,3] y[i,3] n[i,3] sd[i,3] t[i,4] y[i,4] n[i,4] sd[i,4] Arms
Albert et al., 2002155 8 18.36 25 7.11 9 17.3 40 6.15 NA NA NA NA NA NA NA NA 2
Anderson and Rees, 2007157 2 23.5 14 6.4 11 16.7 17 6.8 NA NA NA NA NA NA NA NA 2
Andersson et al., 2012158 11 12.94 49 6.26 17 18.88 51 4.18 NA NA NA NA NA NA NA NA 2
Belloch et al., 2008159 10 8.31 13 8.75 12 6.8 16 3.55 NA NA NA NA NA NA NA NA 2
Belotto-Silva et al., 2012160 3 20.29 88 8.05 11 19.97 70 8.48 NA NA NA NA NA NA NA NA 2
Bergeron et al., 2002161 3 –9.7 72 7.7 6 –9.6 76 7.9 NA NA NA NA NA NA NA NA 2
Bisserbe et al., 1997162 6 –14.3 86 NA 9 –11.71 81 NA NA NA NA NA NA NA NA NA 2
CCSG1 1991154 1 25.11 108 6.34 9 16.23 102 7.37 NA NA NA NA NA NA NA NA 2
CCSG2 1991154 1 25.59 119 5.78 9 14.7 120 7.45 NA NA NA NA NA NA NA NA 2
Chouinard et al., 1990163 1 –1.48 44 NA 6 –3.79 43 NA NA NA NA NA NA NA NA NA 2
Cordioli et al., 2003164 2 23.2 24 5.5 11 15.1 23 7.8 NA NA NA NA NA NA NA NA 2
Cottraux et al., 2001166 10 –12.1 30 7.8 12 –12.5 30 8.2 NA NA NA NA NA NA NA NA 2
Denys et al., 2003167 5 –7.8 72 5.4 8 –7.2 73 7.5 NA NA NA NA NA NA NA NA 2
Fals-Stewart et al., 1993170 10 –8.1 31 NA 17 –1.8 32 NA NA NA NA NA NA NA NA NA 2
Foa et al., 2005171 1 22.2 26 6.4 9 18.2 36 7.8 10 11 29 7.9 15 10.5 31 8.2 4
Freeman et al., 1994172 4 –8.6 28 NA 9 –7.8 19 NA NA NA NA NA NA NA NA NA 2
Freeston et al., 1997173 2 22 14 6 11 12.2 15 9.6 NA NA NA NA NA NA NA NA 2
Goodman et al., 1989176 1 28 21 7 4 19.4 21 7 NA NA NA NA NA NA NA NA 2
Goodman et al., 1996177 1 –1.71 78 4.88 4 –3.95 78 6.28 NA NA NA NA NA NA NA NA 2
Greist et al., 1995126 1 –3.41 84 6.19 6 –5.57 240 6.19 NA NA NA NA NA NA NA NA 2
Greist et al., 2002178 10 17.6 55 6.2 17 24.1 66 6.7 NA NA NA NA NA NA NA NA 2
GlaxoSmithKline, 2005174 1 –4.61 75 7.53 5 –5.61 79 7.47 9 –7.73 78 7.42 NA NA NA NA 3
GlaxoSmithKline, 2005175 5 –14.26 72 6.33 9 –13.19 69 6.48 NA NA NA NA NA NA NA NA 2
Hollander et al., 2003180 1 –5.6 120 7.67 4 –8.5 117 7.57 NA NA NA NA NA NA NA NA 2
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Study ID t[i,1] y[i,1] n[i,1] sd[i,1] t[i,2] y[i,2] n[i,2] sd[i,2] t[i,3] y[i,3] n[i,3] sd[i,3] t[i,4] y[i,4] n[i,4] sd[i,4] Arms
Hollander et al., 2003181 1 –3.33 89 NA 5 –4.14 88 NA 5 –6.35 86 NA 5 –7.34 85 NA 4
Jaurrieta et al., 2008182 2 24.6 19 8.9 11 17.8 19 8.4 NA NA NA NA NA NA NA NA 2
Jenike et al., 1990183 1 22.3 9 7.8 6 20.6 10 9.2 NA NA NA NA NA NA NA NA 2
Jenike et al., 1990184 1 21.8 20 7.6 4 18.8 18 4 NA NA NA NA NA NA NA NA 2
Jenike et al., 1997185 1 18.7 18 6.1 3 16.2 19 6.3 NA NA NA NA NA NA NA NA 2
Kamijima et al., 2004187 1 20.3 94 7.38 5 15.8 94 8.09 NA NA NA NA NA NA NA NA 2
Khodarahimi, 2009188 2 36.45 20 2.24 10 5.58 20 2.39 NA NA NA NA NA NA NA NA 2
Kobak et al., 2005189 1 19.87 30 7.46 13 19.75 30 7.46 NA NA NA NA NA NA NA NA 2
Koran et al., 1996190 4 17.8 34 7.7 9 17 39 8.55 NA NA NA NA NA NA NA NA 2
Kronig et al., 1999191 1 –4.14 79 NA 6 –8.5 85 NA NA NA NA NA NA NA NA NA 2
Lindsay et al., 1997192 10 11 9 3.81 17 25.89 9 5.8 NA NA NA NA NA NA NA NA 2
López-Ibor et al., 1996193 3 –7.5 30 9.29 9 –8.9 24 7.13 NA NA NA NA NA NA NA NA 2
McLean et al., 2001195 12 16.1 31 6.7 10 13.2 32 7.2 NA NA NA NA NA NA NA NA 2
Milanfranchi et al., 1997196 4 18.4 13 9.2 9 16.5 12 11 NA NA NA NA NA NA NA NA 2
Montgomery et al., 1993197 1 –3.7 56 5.98 3 –5.13 52 6.41 3 –4.76 52 6.89 3 –6.07 54 6.92 4
Montgomery et al., 2001198 1 –5.6 101 6.9 7 –8.4 102 7.3 7 –8.9 98 7 7 –10.4 100 6.9 4
Mundo et al., 1997199 4 16.2 10 8.9 5 21.6 9 7.6 7 19.8 11 10.1 NA NA NA NA 3
Mundo et al., 2001200 4 –12.2 115 NA 9 –12 112 NA NA NA NA NA NA NA NA NA 2
Nakajima et al., 1996201 1 –1.9 33 7.2 4 –7.1 60 7.03 NA NA NA NA NA NA NA NA 2
Nakatani et al., 2005202 4 20.2 10 9.4 10 12.9 10 4.9 17 28.4 8 5.5 NA NA NA NA 3
O’Connor et al., 1999203 2 17.5 6 4 11 13.3 6 8.6 NA NA NA NA NA NA NA NA 2
O’Connor et al., 2006204 1 25.4 10 3.5 4 24 11 4.7 NA NA NA NA NA NA NA NA 2
Shareh et al., 2010206 4 16.66 6 3.2 11 7 7 2.38 14 8.5 6 2.42 NA NA NA NA 3
Sousa et al., 2006207 6 –7.36 25 NA 11 –10.8 25 NA NA NA NA NA NA NA NA NA 2
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TABLE 16 Raw data used for the YBOCS analysis (adult subset) sorted by study ID and number of arms (continued )
Study ID t[i,1] y[i,1] n[i,1] sd[i,1] t[i,2] y[i,2] n[i,2] sd[i,2] t[i,3] y[i,3] n[i,3] sd[i,3] t[i,4] y[i,4] n[i,4] sd[i,4] Arms
Stein et al., 2007124 1 –8.46 113 8.08 5 –11.67 116 8.40 16 –11.43 112 8.25 16 –12.14 114 8.22 4
Tollefson et al., 1994127 1 –0.8 89 5.66 3 –5.44 266 7.88 NA NA NA NA NA NA NA NA 2
Van Oppen et al., 1995209 10 17.9 29 9 12 13.4 28 9.4 NA NA NA NA NA NA NA NA 2
Whittal et al., 2005211 10 10.41 29 7.6 12 10.6 30 7.1 NA NA NA NA NA NA NA NA 2
Whittal et al., 2010212 12 6.43 37 4.77 17 9.1 30 6.48 NA NA NA NA NA NA NA NA 2
Zohar and Judge, 1996213 1 –4.2 99 7.2 5 –6.4 201 7.1 9 –7 99 6.8 NA NA NA NA 3
CCSG, Clomipramine Collaborative Study Group; NA, not applicable.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine,
9= clomipramine, 10= BT, 11=CBT, 12=CT, 13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo; t[i,2], type of treatment
[i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4]; y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline
(negative) for arm [1]; y[i,2], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean YBOCS scores at end of study
(positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total
number of patients for arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of patients for arm [4]; sd[i,1], SD of mean total
score or change from baseline for arm [1]; sd[i,2], SD of mean total score or change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3];
sd[i,4], SD of mean total score or change from baseline for arm [4].
N
E
T
W
O
R
K
M
E
T
A
-A
N
A
LY
S
IS
R
E
S
U
LT
S
(A
D
U
LT
S
)
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
5
4
TABLE 17 Summary raw YBOCS data per type of intervention (adult subset)
Intervention Number of arms Number of patients
Placebo 23 1515
Waitlist 6 97
Fluoxetine 8 633
Fluvoxamine 13 521
Paroxetine 10 902
Sertraline 7 565
Citalopram 4 311
Venlafaxine 2 98
Clomipramine 13 831
BT 11 287
CBT 9 231
CT 6 172
Hypericum 1 30
CBT+ fluvoxamine 1 6
BT+ clomipramine 1 31
Escitalopram 2 226
Psychological placebo 6 196
Total 123 6652
PL PSYPL
SER
VEN
WL
BT
BTCLO
CBT
CBTFLV
CITCLO
CT
ESCIT
FLV
FLX
HYP
PAR
FIGURE 6 Network diagram for YBOCS analysis representing individual treatments (adult subset). BTCLO,
BT+ clomipramine; CBTFLV, CBT+ fluvoxamine; CIT, citalopram; CLO, clomipramine; ESCIT, escitalopram; FLV,
fluvoxamine; FLX, fluoxetine; HYP, hypericum; PAR, paroxetine; PL, placebo; PSYPL, psychological placebo; SER,
sertraline; VEN, venlafaxine; WL, waitlist. Reproduced from Skapinakis P, Caldwell DM, Hollingworth W, Bryden P,
Fineberg N, Salkovskis P, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-
compulsive disorder in adults: a systematic review and network meta-analysis [published online ahead of print
June 15 2016]. Lancet Psychiatry 2016. © Skapinakis et al. Open Access article distributed under the terms of CC BY.214
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Consistency of evidence
We examined model fit using the posterior mean of the residual deviance, the degree of between-study
heterogeneity and the DIC. We compared a model assuming consistency of treatment effects with a model
assuming independent treatment effects. Table 19 presents the results of this comparison for the
adult population.
The posterior mean of the residual deviance was 104.6 in the NMA, assuming consistency, compared with
107 data points (equivalent to the number of trial arms/data observations), suggesting adequate model fit.
The posterior mean residual deviance from the independent treatment-effects model was 105.8. In
addition, figures for the DIC are similar in both models (differences of < 3 or 5 are not considered
important145), suggesting that the model assuming consistency has a similar fit to the model assuming
independent treatment effects. However, we note a considerable reduction in heterogeneity when we
relax the consistency assumption – the upper bound of the 95% CrI for the posterior median SD for the
TABLE 18 Summary data per type of intervention for the YBOCS analysis, sorted by number of randomised
patients (adult subset)
Intervention
Number of patients
randomised
Number of pairwise
comparisons (links)
Number of unique
treatment comparisons
Placebo 1515 35 10
Clomipramine 831 17 8
Fluvoxamine 521 16 7
Paroxetine 902 15 6
BT 287 14 7
CBT 231 9 6
Fluoxetine 633 8 4
Sertraline 565 7 4
Psychological placebo 196 7 4
Waitlist 97 6 2
Citalopram 311 5 3
CT 172 5 2
Escitalopram 226 4 2
Venlafaxine 98 2 2
CBT+ fluvoxamine 6 2 2
BT+ clomipramine 31 2 3
Hypericum 30 1 1
TABLE 19 Posterior summaries from random-effects consistency and independent treatment-effect models
(outcome: YBOCS; adult subset)
Model
Number of
data points
Residual deviance
(posterior mean)
SD, posterior median
(95% CrI) DIC
Random-effects consistency 107a 104.6a 3.10 (2.46 to 3.95) 480.8
Random-effects inconsistency 107a 105.8a 1.75 (1.18 to 2.53) 479.1
a Posterior mean residual deviance and number of data points are calculated for studies that reported a SD. SD is the
between-trial variation in treatment effects (heterogeneity parameter).
NETWORK META-ANALYSIS RESULTS (ADULTS)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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independent effects model (upper credible limit 2.53) only just overlaps the lower bound of the 95% CrI
for the consistency model (lower credible limit 2.46). We further explore this heterogeneity in subgroup
and sensitivity analyses. As a further informal check, we note that the results of the NMA and the results
of the pairwise comparisons (see Table 20) are in the same direction, with no evidence that the NMA
effect estimate falls outside the 95% CrIs from the pairwise analysis. Overall, we conclude that there is no
evidence for inconsistency in this network of trials, although heterogeneity may be moderate to high.
Data synthesis
The results of the NMA are presented in Table 20. We present the mean and 95% CrIs for the MD in
YBOCS scores. We present both the direct, head-to-head and pairwise comparisons (as estimated from the
independent effects model) and the results of the NMA (consistency model). All reported results for
the NMA are at the class level, with the exception of the results for individual SSRIs, which are at the
treatment level. Note that for treatments that did not form a class with multiple treatments (e.g.
venlafaxine, clomipramine), the effect estimates from either the class or treatment level will be identical.
For simplicity, we present only the MDs and 95% CrIs for all interventions compared with the reference
intervention (drug placebo). A detailed table with all possible comparisons (both for the direct and NMA) is
given in Appendix 8.
TABLE 20 Outcome 1: MD in YBOCS scores at end of study. Mean and 95% CrIs compared with drug placebo
(adult subset)
Intervention
Posterior distribution of the treatment effect
(mean YBOCS difference)
Posterior treatment rank,
median (95% CrI)
Direct NMA
Mean 95% CrI Mean 95% CrI
Placebo 15 (14 to 16)
Waitlist NA NA 5.62 0.91 to 10.26 17 (16 to 17)
SSRIs (class effect) –3.49 –5.12 to –1.81
Fluoxetine –2.66 –4.72 to –0.54 –3.46 –5.27 to –1.58 11 (6 to 14)
Fluvoxamine –3.58 –5.51 to –1.70 –3.60 –5.29 to –1.95 10 (6 to 14)
Paroxetine –2.84 –4.48 to –1.17 –3.42 –5.10 to –1.61 11 (6 to 14)
Sertraline –2.85 –5.18 to –0.50 –3.50 –5.30 to –1.63 10 (6 to 14)
Citalopram –3.65 –6.25 to –1.06 –3.49 –5.62 to –1.31 10 (5 to 14)
Escitalopram –3.28 –6.38 to –0.20 –3.48 –5.61 to –1.23 10 (5 to 14)
Venlafaxine NA NA –3.22 –8.26 to 1.88 12 (4 to 16)
Clomipramine –6.28 –8.15 to –4.34 –4.72 –6.85 to –2.60 7 (4 to 13)
BT –11.76 –16.87 to –6.62 –14.48 –18.61 to –10.23 1 (1 to 3)
CBT NA NA –5.37 –9.10 to –1.63 6 (4 to 14)
CT NA NA –13.36 –18.40 to –8.21 2 (1 to 4)
Hypericum –0.08 –5.30 to 5.11 –0.15 –7.46 to 7.12 15 (4 to 17)
CBT+ fluvoxamine NA NA –7.50 –13.89 to –1.17 4 (2 to 14)
BT+ clomipramine –12.25 –17.29 to –7.09 –12.97 –19.18 to –6.74 3 (1 to 4)
Psychological placebo NA NA –4.15 –8.65 to 0.49 8 (4 to 15)
NA, not applicable.
NMA MDs come from the class-level result, whereas treatment rankings are estimated from the individual-level
treatment analysis.
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Waitlist was the only group that showed a statistically significant worse effect than drug placebo. All active
interventions, apart from venlafaxine and hypericum, had a greater effect than drug placebo on OCD
symptom reduction (as measured by the total YBOCS scores). Venlafaxine showed a similar non-significant
trend, whereas the effect of hypericum was indistinguishable from that of placebo.
Regarding the pharmacological interventions, SSRIs as a class had greater effects than drug placebo (class
effect MD –3.49, 95% CrI –5.12 to –1.81). Regarding the individual effects of SSRIs, they were very similar
with small differences between them. However, this was not unexpected because the grouping of
treatments into a ‘class’ will have the effect of drawing individual treatment effects towards the class
mean. All remaining treatments were analysed as individual treatments (within the class-level model). The
relative effect of clomipramine was also greater than drug placebo (MD –4.72, 95% CrI –6.85 to –2.60).
There was a trend for clomipramine to have a greater effect than SSRIs, but the 95% CrI included the null
value (MD –1.23, 95% CrI –3.41 to 0.94). Venlafaxine showed a trend for a greater effect than drug
placebo, but the 95% CrI also included the null value (MD –3.21, 95% CrI –8.26 to 1.88). It should be
noted, however, that this result is based on two trials without direct comparison to placebo and a total
number of 98 randomised patients. Therefore, this result should be interpreted with caution.
Regarding psychological interventions, all active psychotherapies had greater effects than drug placebo,
with BT and CT having the largest effects, with small differences between them (MD –1.12, 95% CrI
–1.95 to 4.19). Regarding the comparison between psychological interventions and psychological placebo,
both BT and CT had greater effects (MD –10.33, 95% CrI –13.38 to –7.29 and MD –9.21, 95% CrI –13.1
to –5.34, respectively) but the effect of CBT was not significantly different from psychological placebo
(MD –1.22, 95% CrI –5.54 to 3.03). In addition, both BT and CT had greater effects than CBT (MD –9.11,
95% CrI –13.18 to –4.97 and MD –7.99, 95% CrI –12.97 to –3.01, respectively). It should be noted,
however, that CBT has not been compared directly with any of the psychological interventions and CT has
been compared directly with BT only.
Regarding the comparison between psychological and pharmacological interventions, both BT and CT had
greater effects than SSRIs as a class (MD –10.99, 95% CrI –15.14 to –6.75 for the comparison between BT
and SSRIs; class effect MD –9.87, 95% CrI –14.91 to –4.74 for the comparison between CT and SSRIs).
The difference with CBT was smaller and the 95% CrI included the null value (MD –1.88, 95% CrI –5.52
to 1.76) for the comparison between CBT and SSRIs. It should be noted, however, that of the three types
of psychotherapy, CBT has been directly compared with SSRIs more extensively, whereas for CT there is no
such direct comparison.
Similar results were observed for the comparison between different types of psychotherapy and
clomipramine (MD –9.76, 95% CrI –14.02 to –5.40 for the comparison between BT and clomipramine;
MD –8.63, 95% CrI –13.79 to –3.38 for the comparison between CT and clomipramine; MD –0.65,
95% CrI –4.60 to 3.29 for the comparison between CBT and clomipramine).
Combinations of medications and psychotherapy show large effects compared with placebo, with small
differences between the effects of psychotherapy as monotherapy. It should be noted, however, that these
results are based on a very limited number of patients and/or comparisons, especially for the combination
of CBT with fluvoxamine. We recommend extreme caution in the interpretation of these results.
Table 20 also presents the median posterior treatment ranks with 95% CrIs. BT and CT were the most
highly ranked treatments, followed by combinations of drug and psychotherapy, CBT and clomipramine.
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Sensitivity analyses: outcome 1 – YBOCS (adult subset)
Low overall attrition and no evidence of imbalanced attrition
For this analysis, we excluded 21 studies in the adult subset for which overall levels of attrition were
> 25% or differential attrition was > 15%. The 33 studies included124,127,154,157–159,163,164,166,167,170,175,178,
181–185,187,192,193,196,198–200,202,203,206,207,209,212 and the raw data used are presented in Appendix 9. Overall,
15 interventions (SSRIs were analysed individually and within a single class) were included and the total
number of randomised patients was 3804 (57% of the patients originally used in our full analysis). MDs
and 95% CrIs compared with placebo are presented in Table 21.
Compared with the results of the full data (see Table 20), there is a trend for a larger effect for SSRIs,
clomipramine and CBT and a trend for a smaller effect for BT and CT. CBT (either as a monotherapy or in
combination with fluvoxamine) has an effect that is very similar to the other psychological therapies.
Clomipramine showed a non-statistically significant trend for superiority over SSRIs (MD –2.33, 95% CrI
–4.94 to 0.29). All comparisons between clomipramine and psychological therapies had 95% CrIs that
crossed zero (e.g. for the comparison between BT and clomipramine: MD –4.62, 95% CrI –4.63 to 1.46).
However, the statistical power of these comparisons may be compromised as a result of the smaller
number of studies/randomised patients included.
Low risk of bias in the domain: incomplete outcome assessment
Thirty-four studies from the adult subset were judged to be of ‘low risk’ in this domain (see Table 12) and
were included in the analysis. The studies included and the raw data used are presented in Appendix 9.
Overall, 15 interventions were included and the total number of randomised patients was 5074 (76% of the
patients originally used in our full analysis). MDs and 95% CrIs relative to placebo are presented in Table 22.
TABLE 21 Sensitivity analysis (low overall attrition): outcome 1 – MD in YBOCS scores at end of study. Mean and
95% CrIs compared with drug placebo (adult subset)
Intervention
Posterior distribution of the treatment effect
(mean YBOCS difference)
Posterior treatment rank,
median (95% CrI)Mean 95% CrI
Placebo Reference Reference 15 (13 to 15)
Waitlist –3.32 –8.98 to 2.38 12 (5 to 15)
SSRIs (class effect) –4.09 –6.07 to –2.06
Fluoxetine –4.10 –6.31 to –1.84 10 (6 to 14)
Fluvoxamine –4.26 –6.64 to –2.00 9 (6 to 13)
Paroxetine –4.10 –6.03 to –2.09 10 (6 to 13)
Sertraline –4.05 –6.41 to –1.62 10 (6 to 14)
Citalopram –4.01 –6.25 to –1.63 10 (6 to 14)
Escitalopram –4.03 –6.30 to –1.61 10 (6 to 14)
Venlafaxine –4.32 –8.72 to 0.12 9 (3 to 14)
Clomipramine –6.42 –8.93 to –3.85 5 (3 to 10)
BT –11.04 –16.84 to –5.19 2 (1 to 5)
CBT –10.13 –14.52 to –5.69 3 (1 to 5)
CT –10.63 –17.08 to –4.16 2 (1 to 7)
CBT+ fluvoxamine –10.31 –16.14 to –4.52 3 (1 to 7)
Psychological placebo –2.85 –8.33 to 2.77 13 (5 to 15)
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Compared with the results of the full data (see Table 20), there is a trend for a smaller effect for
clomipramine, which is similar to the effect of the SSRIs. However, the combination of clomipramine with
BT is now the highest ranked treatment, although the CrIs for ranks suggest that it may have a similar
effectiveness to BT as monotherapy. It should be noted that in this analysis all CT studies have been
excluded (eight out of nine CT studies have been assessed as being at high risk of incomplete outcome
assessment bias, mainly because they had performed a completers analysis).
Low risk of bias in the domain: blinding of the outcome assessor
Seventeen studies that had reported the YBOCS outcome from the adult subset were judged to be at
‘low risk’ in this domain and were included in the analysis. The studies included and the raw data used are
presented in Appendix 9. Overall, 15 interventions were included and the total number of randomised
patients was 1461 (22% of the patients originally used in our full analysis). MDs and 95% CrI compared
with placebo are presented in Table 23.
Compared with the results of the full data (see Table 20), there are small differences and the power of this
analysis, owing to the small number of included studies, is low.
TABLE 22 Sensitivity analysis (low risk of bias in ‘incomplete outcome assessment’): outcome 1 – MD in YBOCS
scores at end of study. Mean and 95% CrIs compared with drug placebo (adult subset)
Intervention
Posterior distribution of the treatment effect
(mean YBOCS difference)
Posterior treatment rank,
median (95% CrI)Mean 95% CrI
Placebo Reference Reference 13 (12 to 15)
Waitlist 2.06 –1.51 to 5.61 15 (12 to 15)
SSRIs (class effect) –3.32 –4.25 to –2.46
Fluoxetine –3.37 –4.37 to –2.43 7 (4 to 11)
Fluvoxamine –3.44 –4.48 to –2.53 7 (4 to 11)
Paroxetine –3.04 –3.92 to –1.99 9 (5 to 12)
Sertraline –3.49 –4.66 to –2.50 6 (4 to 11)
Citalopram –3.37 –4.58 to –2.24 7 (4 to 11)
Escitalopram –3.29 –4.45 to –2.07 7 (4 to 11)
Venlafaxine –2.46 –5.49 to 0.57 11 (3 to 14)
Clomipramine –3.16 –4.39 to –1.95 9 (4 to 12)
BT –8.70 –11.78 to –5.75 2 (1 to 3)
CBT –5.76 –8.23 to –3.31 3 (2 to 7)
Hypericum –0.10 –4.34 to 4.11 13 (4 to 15)
BT+ clomipramine –10.67 –14.42 to –6.90 1 (1 to 2)
Psychological placebo –0.92 –4.10 to 2.09 12 (4 to 14)
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Acceptability (total dropouts)
Description of the data set
Table 24 presents the raw data used for the dropout analysis in the adult subset of the data. From the
64 studies eligible for inclusion in the NMA, 11 were excluded: eight studies either did not report dropout
data or did not report dropout data separately for each arm;179,182,187,188,194,201,204,208 and three studies
were excluded because there were no dropouts (zero dropouts) in all arms.183,192,199 Therefore, 53 studies were
included in this analysis.124,126,127,154–178,180,181,184–186,189–191,193,195–198,200,202,203,205–207,209–213
Table 24 also presents raw dropout rates. It can be seen that the range of dropouts was 0–43%, with a
median of 18%. Table 25 presents summary dropout rate per type of intervention (minimum, maximum
and median of raw dropout rates).
Network meta-analysis: results
Network geometry
Figure 7 shows the network geometry for total dropouts in the adult subset. Overall, of the
190 comparisons that can be made among the 20 treatment conditions, only 38 (20%) were studied directly
in 53 studies involving 6743 randomised patients. It should be noted, however, that 24 of the 38 direct
comparisons are made in single trials. As before, circles (treatment nodes) represent the interventions used
in the network and are proportional to the number of participants randomised to a treatment. Placebo
(n= 1439), clomipramine (n= 937), paroxetine (n= 813), fluoxetine (n= 640), sertraline (n= 561),
fluvoxamine (n= 497), BT (n= 366), citalopram (n= 300), escitalopram (n= 232), CBT (n= 221),
psychological placebo (n= 200) and venlafaxine (n= 101) had a sample size of > 100. Lines (network
TABLE 23 Sensitivity analysis (low risk of bias in ‘blinding of outcome assessor’): outcome 1 – MD in YBOCS scores
at end of study. Mean and 95% CrIs compared with drug placebo (adult subset)
Intervention
Posterior distribution of the treatment effect
(mean YBOCS difference)
Posterior treatment rank,
median (95% CrI)Mean 95% CrI
Placebo Reference Reference 13 (11 to 15)
Waitlist 3.23 –2.16 to 8.44 15 (12 to 15)
SSRIs (class effect) –3.30 –5.59 to –0.65
Fluoxetine –3.42 –6.62 to 0.07 8 (4 to 12)
Fluvoxamine –3.85 –5.99 to –1.95 7 (4 to 11)
Paroxetine –3.20 –5.29 to –0.90 9 (5 to 12)
Sertraline –2.71 –5.65 to 2.03 10 (5 to 13)
Citalopram –3.27 –6.50 to 0.42 8 (4 to 13)
Escitalopram –3.36 –5.38 to –1.21 8 (4 to 12)
Venlafaxine –2.73 –5.97 to 0.47 10 (4 to 13)
Clomipramine –4.05 –7.30 to –0.73 6 (4 to 12)
BT –11.79 –15.17 to –8.28 2 (1 to 3)
CBT –4.11 –7.63 to –0.34 5 (4 to 12)
CT –12.23 –16.66 to –7.80 2 (1 to 3)
BT+ clomipramine –11.85 –16.07 to –7.82 2 (1 to 3)
Psychological placebo 2.33 –1.49 to 6.36 14 (13 to 15)
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TABLE 24 Raw data used for the dropout analysis (adult subset)
Study ID t[i,1], % r[i,1], % n[i,1], % dr[i,1], % t[i,2], % r[i,2], % n[i,2], % dr[i,2], % t[i,3], % r[i,3], % n[i,3], % dr[i,3], % t[i,4], % r[i,4], % n[i,4], % dr[i,4], %
Albert et al.,
2002155
8 1 26 4 9 7 47 15 NA NA NA NA NA NA NA NA
Ananth et al.,
1981156
9 1 10 10 13 2 10 20 NA NA NA NA NA NA NA NA
Anderson and
Rees, 2007157
2 3 17 18 11 4 21 19 NA NA NA NA NA NA NA NA
Andersson et al.,
2012158
11 2 50 4 18 0 51 0 NA NA NA NA NA NA NA NA
Belloch et al.,
2008159
10 2 15 13 12 2 18 11 NA NA NA NA NA NA NA NA
Belotto-Silva
et al., 2012160
3 33 88 38 11 18 70 26 NA NA NA NA NA NA NA NA
Bergeron et al.,
2002161
3 22 73 30 6 22 77 29 NA NA NA NA NA NA NA NA
Bisserbe et al.,
1997162
6 23 86 27 9 35 82 43 NA NA NA NA NA NA NA NA
CCSG1, 1991154 1 13 121 11 9 17 118 14 NA NA NA NA NA NA NA NA
CCSG2, 1991154 1 12 139 9 9 14 142 10 NA NA NA NA NA NA NA NA
Chouinard et al.,
1990163
1 4 44 9 6 6 43 14 NA NA NA NA NA NA NA NA
Cordioli et al.,
2003164
2 1 24 4 11 1 23 4 NA NA NA NA NA NA NA NA
Cottraux et al.,
1993165
4 7 20 35 10 5 20 25 14 4 20 20 NA NA NA NA
Cottraux et al.,
2001166
10 3 33 9 12 2 32 6 NA NA NA NA NA NA NA NA
Denys et al.,
2003167
5 9 75 12 8 4 75 5 NA NA NA NA NA NA NA NA
Emmelkamp and
Beens, 1991168
10 4 15 27 12 5 15 33 NA NA NA NA NA NA NA NA
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Study ID t[i,1], % r[i,1], % n[i,1], % dr[i,1], % t[i,2], % r[i,2], % n[i,2], % dr[i,2], % t[i,3], % r[i,3], % n[i,3], % dr[i,3], % t[i,4], % r[i,4], % n[i,4], % dr[i,4], %
Emmelkamp
et al., 1988169
10 1 10 10 12 1 10 10 NA NA NA NA NA NA NA NA
Fals-Stewart
et al., 1993170
10 3 34 9 18 0 32 0 NA NA NA NA NA NA NA NA
Foa et al.,
2005171
1 12 32 38 9 20 47 43 10 16 37 43 16 14 33 42
Freeman et al.,
1994172
4 6 34 18 9 13 32 41 NA NA NA NA NA NA NA NA
Freeston et al.,
1997173
2 0 14 0 11 3 15 20 NA NA NA NA NA NA NA NA
GlaxoSmithKline,
2005174
1 20 77 26 5 28 82 34 9 28 82 34 NA NA NA NA
GlaxoSmithKline,
2005175
5 1 73 1 9 4 73 5 NA NA NA NA NA NA NA NA
Goodman et al.,
1989176
1 6 23 26 4 2 23 9 NA NA NA NA NA NA NA NA
Goodman et al.,
1996177
1 17 80 21 4 23 80 29 NA NA NA NA NA NA NA NA
Greist et al.,
1995126
1 24 84 29 6 65 241 27 NA NA NA NA NA NA NA NA
Greist et al.,
2002178
10 14 69 20 18 9 75 12 NA NA NA NA NA NA NA NA
Hollander et al.,
2003180
1 31 126 25 4 43 127 34 NA NA NA NA NA NA NA NA
Hollander et al.,
2003181
1 15 89 17 5 14 88 16 5 20 86 23 5 19 85 22
Jenike et al.,
1990184
1 0 20 0 4 2 20 10 NA NA NA NA NA NA NA NA
Jenike et al.,
1997185
1 3 21 14 3 4 23 17 NA NA NA NA NA NA NA NA
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TABLE 24 Raw data used for the dropout analysis (adult subset) (continued )
Study ID t[i,1], % r[i,1], % n[i,1], % dr[i,1], % t[i,2], % r[i,2], % n[i,2], % dr[i,2], % t[i,3], % r[i,3], % n[i,3], % dr[i,3], % t[i,4], % r[i,4], % n[i,4], % dr[i,4], %
Jones and
Menzies, 1998186
2 1 11 9 12 1 12 8 NA NA NA NA NA NA NA NA
Kobak et al.,
2005189
1 9 30 30 19 8 30 27 NA NA NA NA NA NA NA NA
Koran et al.,
1996190
4 8 37 22 9 15 42 36 NA NA NA NA NA NA NA NA
Kronig et al.,
1999191
1 25 81 31 6 25 86 29 NA NA NA NA NA NA NA NA
López-Ibor et al.,
1996193
3 5 30 17 9 3 25 12 NA NA NA NA NA NA NA NA
McLean et al.,
2001195
10 12 44 27 12 18 49 37 NA NA NA NA NA NA NA NA
Milanfranchi
et al., 1997196
4 0 13 0 9 1 13 8 NA NA NA NA NA NA NA NA
Montgomery
et al., 1993197
1 15 57 26 3 14 53 26 3 13 52 25 3 14 55 25
Montgomery
et al., 2001198
1 17 101 17 7 15 100 15 7 15 98 15 7 16 102 16
Mundo et al.,
2001200
4 19 115 17 9 26 112 23 NA NA NA NA NA NA NA NA
Nakatani et al.,
2005202
4 1 11 9 10 1 11 9 18 1 9 11 NA NA NA NA
O’Connor et al.,
1999203
2 0 6 0 11 1 7 14 NA NA NA NA NA NA NA NA
Perse et al.,
1987205
1 2 10 20 4 2 10 20 NA NA NA NA NA NA NA NA
Shareh et al.,
2010206
4 1 7 14 11 0 7 0 15 1 7 14 NA NA NA NA
Sousa et al.,
2007208
6 3 28 11 11 3 28 11 NA NA NA NA NA NA NA NA
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Study ID t[i,1], % r[i,1], % n[i,1], % dr[i,1], % t[i,2], % r[i,2], % n[i,2], % dr[i,2], % t[i,3], % r[i,3], % n[i,3], % dr[i,3], % t[i,4], % r[i,4], % n[i,4], % dr[i,4], %
Stein et al.,
2007124
1 16 115 14 5 29 119 24 17 24 116 21 17 21 116 18
Tollefson et al.,
1994127
1 13 89 15 3 12 87 14 3 22 89 25 3 22 90 24
Van Oppen et al.,
1995209
10 7 36 19 12 7 35 20 NA NA NA NA NA NA NA NA
Volavka et al.,
1985210
9 3 11 27 20 4 12 33 NA NA NA NA NA NA NA NA
Whittal et al.,
2005211
10 13 42 31 12 11 41 27 NA NA NA NA NA NA NA NA
Whittal et al.,
2010212
12 3 40 8 18 3 33 9 NA NA NA NA NA NA NA NA
Zohar and Judge,
1996213
1 40 100 40 5 53 205 26 9 36 101 36 NA NA NA NA
CCSG, Clomipramine Collaborative Study Group; NA, not applicable.
Notes
t[i], type of treatment per arm [i] (1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine, 9= clomipramine, 10= BT, 11=CBT,
12=CT, 13= amitriptyline, 14= fluvoxamine and BT, 15= fluvoxamine and CBT, 16= clomipramine and BT, 17= escitalopram, 18= psychological placebo, 19= hypericum,
20= imipramine); r[i], number of dropouts in arm[i]; n[i], total number of patients in arm [i]; dr[i], dropout rate (%) in arm[i].
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TABLE 25 Summary raw dropout rates per type of intervention (adult subset)
Intervention
Dropout rates (%)
Number of armsMinimum Maximum Median
Placebo 0 40 21 20
Waitlist 0 18 4 5
Fluoxetine 14 38 25 10
Fluvoxamine 0 35 17 12
Paroxetine 1 34 23 8
Sertraline 11 29 27 6
Citalopram 15 16 15 3
Venlafaxine 4 5 4.5 2
Clomipramine 5 43 23 15
BT 9 43 20 12
CBT 0 26 12.5 8
CT 6 37 11 9
Amitriptyline 20 20 NA 1
BT+ fluvoxamine 20 20 NA 1
CBT+ fluvoxamine 14 14 NA 1
BT+ clomipramine 42 42 NA 1
Escitalopram 18 21 19.5 2
Psychological placebo 0 12 9 5
Hypericum 27 27 NA 1
Imipramine 33 33 NA 1
NA, not available.
BTFLV
BTCLO
BT
AMI
WL
VEN
SER
PSYPL
PL
PAR
IMI
HYP
FLX
FLV
ESCIT
CT
CLO
CIT CBTFLV CBT
FIGURE 7 Network diagram for dropouts representing individual treatments (adult subset). AMI, amitriptyline;
BTCLO, BT+ clomipramine; BTFLV, BT+ fluvoxamine; CBTFLV, CBT+ fluvoxamine; CIT, citalopram;
CLO, clomipramine; ESCIT, escitalopram; FLV, fluvoxamine; FLX, fluoxetine; HYP, hypericum; IMI, imipramine;
PAR, paroxetine; PL, placebo; PSYPL, psychological placebo; SER, sertraline; VEN, venlafaxine; WL, waitlist.
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edges) are proportional to the number of direct randomised comparisons. Figure 7 includes 79 randomised
pairwise comparisons and the most common comparisons are those between placebo versus fluoxetine
(n= 7) and BT versus CT (n= 7). Nodes with the most connections (links) in the network are drug placebo
(n= 33 links), clomipramine (n= 19 links), BT (n= 16 links), fluvoxamine (n= 15 links), paroxetine (n= 11
links), fluoxetine (n= 10 links), CBT (n= 9 links) and CT (n= 9 links).
Consistency of evidence
We examined model fit using the posterior mean of the residual deviance, the degree of between-study
heterogeneity and the DIC. We compared a model assuming consistency of treatment effects with a model
assuming independent treatment effects. For the ‘consistency’ model all SSRIs were analysed as a class and
individually. Table 26 presents the results of this comparison for the adult set.
The posterior mean of the residual deviance was 118.2 in model assuming consistency compared with the
number of data points (n= 123), suggesting adequate model fit. The posterior mean residual deviance
from the independent treatment-effects model was 120.3 In addition, the lower value of the DIC for the
consistency model suggests that it is preferred over the independent effects model. In addition, the results
of the NMA and the results of the pairwise comparisons (see Table 27) are in the same direction, with no
evidence that the NMA effect estimate falls outside the 95% CrIs from the pairwise analysis. Overall, there
is no evidence for inconsistency.
Data synthesis
The results of the NMA are presented in Table 27. We present posterior median ORs for dropouts relative
to drug placebo (reference treatment). We present both the direct head-to-head comparisons from
pairwise meta-analysis (from independent effects model) and the results of the NMA from the model
assuming consistency. For simplicity, we present only the ORs compared with the drug placebo. A more
detailed table with all possible comparisons (both for the direct and NMA) is given in Appendix 8.
Clomipramine was the only intervention with a statistically significant higher likelihood of dropout than
placebo, with an OR of 1.52 (95% CrI 1.16 to 2.01). Amitriptyline, imipramine and the combination of
CBT with fluvoxamine had larger ORs than clomipramine, suggesting increased odds of dropout. However,
these results are based on just one trial, the 95% CrIs are wide and include the null value of no difference.
Therefore, these results should be interpreted with caution. SSRIs as a class were not more likely than
placebo to lead to attrition. Differences with individual SSRIs were very small and insignificant. There was a
non-significant trend for venlafaxine to be associated with a lower dropout rate than placebo but this was
based on only two trials. All psychological therapies were not more likely than placebo to lead to dropout.
Table 27 also presents the posterior median treatment ranks with 95% CrIs. As before, it is the tricyclics,
particularly clomipramine, that are ranked lowest (i.e. they are less tolerable). In general, all psychological
therapies delivered as monotherapy are ranked more highly than pharmacological treatments.
Combinations of psychological treatments with medication result in lower ranks than psychological
monotherapy, but the evidence is based on single trials with small sample sizes. We again suggest caution
in the interpretation of these findings.
TABLE 26 Posterior summaries from random-effects consistency and independent treatment-effect models
(outcome: dropouts; adult subset)
Model
Number of
data points
Residual deviance,
posterior mean
SD,a posterior median,
(95% CrI) DIC
Random-effects consistency 123 118.2 0.13 (0.01 to 0.32) 610.3
Random-effects independent effect 123 120.3 0.12 (0.01 to 0.32) 626.0
a SD is the between-trial variation in treatment effects (heterogeneity parameter).
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Sensitivity analyses: outcome 2, dropouts – adult subset
Low overall attrition and no evidence of imbalanced attrition
For this analysis we included 40124,127,154,156–160,163,164,166,167,169–171,175,177,178,180,181,184–186,189,193,195–198,200,202,203,205–207,209–212
and excluded 13 studies. The studies included and the raw data used are presented in Appendix 9. Overall,
18 interventions were included and the total number of randomised patients was 4767 (70.7% of the
patients originally used in our full analysis). MDs and 95% CrIs compared with placebo are presented in
Table 28. It can be seen that compared with the full data set reported in Table 27, the results are essentially
similar, with the tricyclic drugs, in particular clomipramine, being most poorly tolerated.
Low risk of bias in the domain: incomplete outcome assessment
For this analysis we included 29124,127,157,158,160–164,167,171–174,176–178,180,181,185,189–191,193,197,198,200,207,213 and excluded
24 studies. The studies included and the raw data used are presented in Appendix 9. Overall, 15
interventions were included and the total number of randomised patients was 4868 (72% of the patients
originally used in our full analysis). MDs and 95% CrIs compared with placebo are presented in Table 29.
It can be seen that compared with the full data set reported in Table 27, the results are essentially similar.
TABLE 27 Outcome 2: dropouts. Median ORs (95% CrI) compared with drug placebo (adult subset)
Intervention
Direct NMA
Posterior treatment rank
(median and 95% CrI)Median OR 95% CrI Median OR 95% CrI
Placebo Reference Reference Reference Reference 9 (5 to 16)
Waitlist NA NA 0.40 0.10 to 1.50 2 (1 to 17)
Psychological placebo NA NA 0.52 0.19 to 1.45 4 (1 to 15)
SSRIs (class effect) 1.08 0.85 to 1.36
Fluoxetine 1.25 0.79 to 2.03 1.12 0.88 to 1.54 13 (7 to 18)
Fluvoxamine 1.38 0.88 to 2.18 1.09 0.85 to 1.41 12 (6 to 17)
Paroxetine 1.08 0.78 to 1.52 1.09 0.86 to 1.38 12 (6 to 17)
Sertraline 0.98 0.63 to 1.55 1.04 0.78 to 1.33 10 (5 to 16)
Citalopram 0.90 0.49 to 1.75 1.06 0.74 to 1.41 11 (5 to 17)
Escitalopram 1.09 0.64 to 1.97 1.08 0.80 to 1.46 12 (5 to 17)
Venlafaxine NA NA 0.39 0.11 to 1.15 2 (1 to 13)
Clomipramine 1.25 0.88 to 1.76 1.52 1.16 to 2.01 17 (13 to 19)
Amitriptyline NA NA 4.51 0.30 to 138.6 19 (2 to 20)
Imipramine NA NA 1.96 0.29 to 16.07 18 (2 to 20)
Hypericum 0.83 0.25 to 2.80 0.85 0.25 to 2.73 7 (1 to 19)
BT 1.27 0.52 to 3.08 1.04 0.52 to 2.08 10 (4 to 18)
CBT NA NA 0.77 0.40 to 1.59 6 (2 to 17)
CT NA NA 1.01 0.43 to 2.30 9 (3 to 19)
BT+ fluvoxamine NA NA 0.61 0.13 to 2.35 4 (1 to 19)
CBT+ fluvoxamine NA NA 2.13 0.04 to 74.15 18 (1 to 20)
BT+ clomipramine 1.23 0.48 to 3.05 1.27 0.53 to 2.93 15 (4 to 19)
NA, not applicable.
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TABLE 28 Sensitivity analysis (low overall attrition): outcome 2 – dropouts. Median ORs (95% CrI) compared with
drug placebo (adult subset)
Intervention
Posterior distribution of the treatment effect
(mean YBOCS difference)
Posterior treatment rank,
median (95% CrI)Median OR 95% CrI
Placebo Reference Reference 8 (4 to 12)
Waitlist 0.36 0.09 to 1.43 3 (1 to 13)
SSRIs (class effect) 1.28 0.94 to 1.73
Fluoxetine 1.32 0.95 to 1.87 12 (7 to 17)
Fluvoxamine 1.31 0.98 to 1.76 12 (7 to 16)
Paroxetine 1.34 0.97 to 1.90 13 (7 to 17)
Sertraline 1.28 0.80 to 1.97 12 (6 to 17)
Citalopram 1.22 0.75 to 1.67 11 (5 to 16)
Escitalopram 1.27 0.88 to 1.79 11 (6 to 16)
Venlafaxine 0.52 0.10 to 1.84 5 (1 to 16)
Clomipramine 1.58 1.04 to 2.59 15 (8 to 18)
BT 0.44 0.05 to 2.77 4 (2 to 17)
CBT 0.84 0.42 to 1.62 7 (3 to 15)
CT 0.45 0.06 to 2.70 4 (1 to 16)
Amitriptyline 3.94 0.23 to 162.7 17 (2 to 18)
CBT+ fluvoxamine 1.94 0.06 to 79.68 16 (1 to 18)
Psychological placebo 0.24 0.02 to 1.46 2 (1 to 11)
Hypericum 0.83 0.23 to 2.91 7 (1 to 17)
Imipramine 2.05 0.27 to 15.90 16 (2 to 18)
TABLE 29 Sensitivity analysis (low risk of bias in ‘incomplete outcome assessment’): outcome 2 – dropouts. Median
ORs (95% CrI) compared with drug placebo (adult subset)
Intervention
Posterior distribution of the treatment effect
(mean YBOCS difference)
Posterior treatment rank,
median (95% CrI)Median OR 95% CrI
Placebo Reference Reference 7 (3 to 12)
Waitlist 0.39 0.08 to 1.81 2 (1 to 14)
SSRIs (class effect) 1.10 0.84 to 1.43
Fluoxetine 1.15 0.88 to 1.59 10 (5 to 14)
Fluvoxamine 1.09 0.81 to 1.43 9 (4 to 13)
Paroxetine 1.12 0.86 to 1.48 10 (5 to 14)
Sertraline 1.07 0.76 to 1.42 8 (4 to 13)
Citalopram 1.08 0.72 to 1.49 9 (3 to 14)
Escitalopram 1.10 0.78 to 1.52 9 (4 to 14)
Venlafaxine 0.44 0.10 to 1.61 2 (1 to 14)
Clomipramine 1.55 1.10 to 2.17 14 (10 to 15)
BT 1.23 0.50 to 2.91 12 (3 to 15)
CBT 0.80 0.37 to 1.73 5 (2 to 14)
BT+ clomipramine 1.33 0.52 to 3.39 13 (3 to 15)
Psychological placebo 0.51 0.14 to 1.82 3 (1 to 14)
Hypericum 0.84 0.25 to 2.90 5 (1 to 15)
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Low risk of bias in the domain: blinding of the outcome assessor
For this analysis we included 18124,155,158–160,164,166–169,171,175,184,202,203,205,207,211 and excluded 35 studies.
The studies included and the raw data used are presented in Appendix 9. Overall, 14 interventions
were included and the total number of randomised patients was 1581 (23.5% of the patients originally
used in our full analysis). MDs and 95% CrIs compared with placebo are presented in Table 30. The power
of the analysis is compromised, but the results show the same trends with the full analysis.
Rankograms (both outcomes)
Table 31 presents the probabilities that each treatment is among the best three or worst three for both
outcomes (YBOCS/dropouts) – a dropout rate that is among the top three means better tolerability
(i.e. fewer dropouts). In Appendix 8 we present complete data for all rank probabilities for both outcomes.
Based on these data, we also present rankograms (plots of the probabilities for each treatment taking each
possible rank) in Figure 8. These results show that there is a great deal of uncertainty surrounding the
overall rankings of the active treatments used to treat OCD in adults. Although we observe that BT has a
50% probability of being the most effective treatment for reducing OCD symptoms, there is a 50%
probability that it is not the best treatment, which represents a large degree of uncertainty.
TABLE 30 Sensitivity analysis (low risk of bias in ‘blinding of the outcome assessor’): outcome 2 – dropouts. Median
ORs (95% CrI) compared with drug placebo (adult subset)
Intervention
Posterior distribution of the treatment effect
(mean YBOCS difference)
Posterior treatment rank,
median (95% CrI)Median OR 95% CrI
Placebo Reference Reference 6 (2 to 12)
Waitlist 0.45 0.01 to 31.84 2 (1 to 14)
SSRIs (class effect) 1.39 0.46 to 8.44
Fluoxetine 1.60 0.45 to 47.92 11 (4 to 14)
Fluvoxamine 1.11 0.36 to 2.71 7 (2 to 13)
Paroxetine 1.55 0.67 to 3.74 10 (4 to 14)
Sertraline 1.38 0.31 to 31.95 10 (2 to 14)
Escitalopram 1.34 0.62 to 3.05 9 (3 to 14)
Venlafaxine 0.48 0.10 to 1.79 3 (1 to 11)
Clomipramine 1.36 0.46 to 4.24 9 (3 to 14)
BT 1.23 0.39 to 3.83 8 (3 to 14)
CBT 1.13 0.27 to 32.32 7 (2 to 14)
CT 1.10 0.27 to 4.30 7 (2 to 14)
BT+ clomipramine 1.24 0.36 to 4.26 8 (2 to 14)
Psychological placebo 0.31 0.01 to 4.51 2 (1 to 14)
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TABLE 31 Summary of rank probabilities (top three/bottom three): adult subset
Outcomea Treatment
Probability treatment being in:
Top three Bottom three
YBOCS Placebo 0.00 0.92
Dropout Placebo 0.00 0.00
YBOCS Waitlist 0.00 1.00
Dropout Waitlist 0.66 0.02
YBOCS Fluoxetine 0.00 0.02
Dropout Fluoxetine 0.00 0.03
YBOCS Fluvoxamine 0.00 0.01
Dropout Fluvoxamine 0.00 0.01
YBOCS Paroxetine 0.00 0.02
Dropout Paroxetine 0.00 0.01
YBOCS Sertraline 0.00 0.02
Dropout Sertraline 0.00 0.00
YBOCS Citalopram 0.00 0.02
Dropout Citalopram 0.01 0.01
YBOCS Venlafaxine 0.01 0.19
Dropout Venlafaxine 0.69 0.00
YBOCS Clomipramine 0.00 0.00
Dropout Clomipramine 0.00 0.39
YBOCS BT 1.00 0.00
Dropout BT 0.01 0.06
YBOCS CBT 0.00 0.01
Dropout CBT 0.12 0.02
YBOCS CT 0.95 0.00
Dropout CT 0.03 0.08
YBOCS Hypericum 0.00 0.66
Dropout Hypericum 0.21 0.13
YBOCS CBT+ fluvoxamine 0.14 0.02
Dropout CBT+ fluvoxamine 0.20 0.56
YBOCS BT+ clomipramine 0.89 0.00
Dropout BT+ clomipramine 0.02 0.24
YBOCS Escitalopram 0.00 0.02
Dropout Escitalopram 0.01 0.02
YBOCS Psychological placebo 0.00 0.09
Dropout Psychological placebo 0.50 0.00
Dropout Amitriptyline 0.06 0.76
Dropout BT+ fluvoxamine 0.41 0.06
Dropout Imipramine 0.07 0.59
a For dropouts, being in the top three means better tolerability (i.e. fewer dropouts).
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FIGURE 8 Rankograms for adults: dropout (black lines); YBOCS (green lines). (a) placebo; (b) waitlist; (c) fluoxetine;
(d) fluvoxamine; (e) paroxetine; (f) sertraline; (g) citalopram; (h) venlafaxine; (i) clomipramine; (j) BT; (k) CBT;
(l) CT; (m) hypericum; (n) CBT+ fluvoxamine; (o) BT+ clomipramine; (p) escitalopram; (q) psychological placebo;
(r) amitriptyline; (s) BT+ fluvoxamine; and (t) imipramine. Reproduced from Skapinakis P, Caldwell DM,
Hollingworth W, Bryden P, Fineberg N, Salkovskis P, et al. Pharmacological and psychotherapeutic interventions
for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis
[published online ahead of print June 15 2016]. Lancet Psychiatry 2016. © Skapinakis et al. Open Access article
distributed under the terms of CC BY.214 (continued )
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FIGURE 8 Rankograms for adults: dropout (black lines); YBOCS (green lines). (a) placebo; (b) waitlist; (c) fluoxetine;
(d) fluvoxamine; (e) paroxetine; (f) sertraline; (g) citalopram; (h) venlafaxine; (i) clomipramine; (j) BT; (k) CBT; (l) CT;
(m) hypericum; (n) CBT+ fluvoxamine; (o) BT+ clomipramine; (p) escitalopram; (q) psychological placebo;
(r) amitriptyline; (s) BT+ fluvoxamine; and (t) imipramine. Reproduced from Skapinakis P, Caldwell DM,
Hollingworth W, Bryden P, Fineberg N, Salkovskis P, et al. Pharmacological and psychotherapeutic interventions
for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis
[published online ahead of print June 15 2016]. Lancet Psychiatry 2016. © Skapinakis et al. Open Access article
distributed under the terms of CC BY.214 (continued )
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FIGURE 8 Rankograms for adults: dropout (black lines); YBOCS (green lines). (a) placebo; (b) waitlist; (c) fluoxetine;
(d) fluvoxamine; (e) paroxetine; (f) sertraline; (g) citalopram; (h) venlafaxine; (i) clomipramine; (j) BT; (k) CBT; (l) CT;
(m) hypericum; (n) CBT+ fluvoxamine; (o) BT+ clomipramine; (p) escitalopram; (q) psychological placebo;
(r) amitriptyline; (s) BT+ fluvoxamine; and (t) imipramine. Reproduced from Skapinakis P, Caldwell DM,
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FIGURE 8 Rankograms for adults: dropout (black lines); YBOCS (green lines). (a) placebo; (b) waitlist; (c) fluoxetine;
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FIGURE 8 Rankograms for adults: dropout (black lines); YBOCS (green lines). (a) placebo; (b) waitlist; (c) fluoxetine;
(d) fluvoxamine; (e) paroxetine; (f) sertraline; (g) citalopram; (h) venlafaxine; (i) clomipramine; (j) BT; (k) CBT; (l) CT;
(m) hypericum; (n) CBT+ fluvoxamine; (o) BT+ clomipramine; (p) escitalopram; (q) psychological placebo;
(r) amitriptyline; (s) BT+ fluvoxamine; and (t) imipramine. Reproduced from Skapinakis P, Caldwell DM,
Hollingworth W, Bryden P, Fineberg N, Salkovskis P, et al. Pharmacological and psychotherapeutic interventions
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Meta-regression
Table 32 presents the study-level covariates that could potentially influence the treatment effect (effect
modification). It can be seen that the meta-regressions do not suggest an effect of adjusting for each
covariate and the 95% CrIs all cross the null value. In addition, model fit was not improved and
heterogeneity was not reduced in the covariate models when compared with the main consistency model
reported in Table 20.
TABLE 32 Meta-regression of effect modifiers
Included covariate Coefficient (95% CrI)
Subset: adults (outcome: YBOCS)
Publication date (continuous) 0.14 (–0.11 to 0.39)
Trial length (continuous) 0.31 (–0.26 to 0.86)
Comorbid depression (binary, 1= yes) –1.24 (–4.34 to 1.78)
Pharmaceutical industry sponsorship (binary, 1= yes) –0.40 (–4.33 to 3.41)
Subset: adult (outcome: dropouts)
Publication date 0.03 (–0.01 to 0.06)
Trial length 0.05 (–0.07 to 0.18)
Comorbid depression (yes/no) –0.13 (–0.68 to 0.36)
Pharmaceutical industry sponsorship (binary, 1= yes) 0.27 (–0.54 to 1.04)
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Chapter 6 Network meta-analysis results
(children and adolescents)
Clinical effectiveness: symptom reduction (Children’s
Yale–Brown Obsessive–Compulsive Scale)
Description of the data set
Table 33 presents the raw data used for the dropout analysis in the children and adolescents subset of the
data (for a complete copy of the data extraction, see Appendix 5). Of the 22 studies eligible for inclusion
in the NMA,215–236 four were excluded: Flament et al. did not use the CYBOCS scale; March et al.228
contained a population of 10- to 18-year-olds and used the adult YBOCS rather than the CYBOCS
to assess symptoms; Asbahr et al.216 did not report the follow-up measures; Alaghband-Rad and
Hakimshooshtary215 did not report the number at follow-up or any uncertainty around the CYBOCS; and
GlaxoSmithKline225 did not report a follow-up CYBOCS or a change from baseline. The studies excluded
from the analysis involved a total of 311 randomised patients, but 207 of whom were included in the
GlaxoSmithKline225 paroxetine versus placebo study, whereas 104 patients were included in the remaining
four studies. In total, 17 studies were included in the analysis.217–221,223,224,228–236
Table 34 presents summary data per type of intervention for the studies included in the NMA (number of
arms and number of randomised patients per intervention).
Network meta-analysis: results
Network geometry
Figure 9 shows the network geometry of the CYBOCS comparison in the children and adolescent subsets
and Table 35 presents summary data per type of intervention (number of patients randomised, total
number of links with other treatments, number of unique treatments compared). Overall, of the
66 pairwise comparisons that can be made among the 12 treatment conditions, only 15 (23%) were
studied directly by head-to-head comparison in 17 studies involving 991 randomised patients. It should be
noted, however, that 11 of these 15 direct comparisons were made in single trials. Figure 9 includes
22 randomised pairwise comparisons and the most common comparisons are those between CBT and
waitlist (n= 4), fluoxetine and placebo (n= 3), sertraline and placebo (n= 2), and CBT and psychological
placebo (n= 2). Placebo (n= 275), CBT (n= 184), sertraline (n= 120) and fluoxetine (n= 99) had a sample
approximately ≥ 100 (Table 35). Nodes with the most connections (links) in the network (Table 35) are
drug placebo (n= 9 links with six different interventions), CBT (n= 9 links with five different interventions),
waitlist (n= 5 links with two different interventions), sertraline (n= 4 links with three different
interventions), the combination of sertraline and CBT (n= 4 links with four different interventions) and
fluoxetine (n= 3 links with placebo).
Consistency of evidence
We examined model fit using the posterior mean of the residual deviance, the degree of between-study
heterogeneity and the DIC. We compared a model assuming consistency of treatment effects with a model
assuming independent treatment effects. For the consistency model, all SSRIs were analysed as a class and
individually. Table 36 presents the results of this comparison for the children and adolescents subset.
The posterior mean of the residual deviance was 35.04 compared with the number of data points (n= 34),
suggesting adequate model fit. The posterior mean residual deviance was 34.27 in the independent effects
model; however, heterogeneity was not reduced and may be considered low to moderate. In addition,
the DIC suggests that we can select the model assuming consistency as our preferred choice. The results
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TABLE 33 Raw data used for the CYBOCS analysis (children and adolescent subset) sorted by study ID and number of arms
Study ID t[,1] y[,1] n[,1] sd[,1] t[,2] y[,2] n[,2] sd[,2] t[,3] y[,3] n[,3] sd[,3] t[,4] y[,4] n[,4] sd[,4] Arms
Barrett et al., 2004217 2 24.04 24 4.14 9 8.36 22 6.93 NA NA NA NA NA NA NA NA 2
Bolton and Perrin, 2008218 2 21.1 10 5.9 8 13.9 10 10.74 NA NA NA NA NA NA NA NA 2
Bolton et al., 2011219 2 23.3 24 8.3 9 9.5 36 8 NA NA NA NA NA NA NA NA 2
de Haan et al., 1998220 7 17.6 10 11.8 8 9.1 12 9.1 NA NA NA NA NA NA NA NA 2
DeVeaugh-Geiss et al., 1992221 1 –2.4 29 NA 7 –10 31 NA NA NA NA NA NA NA NA NA 2
Freeman et al., 2008223 3 17.1 20 7.57 9 14.45 22 8.16 NA NA NA NA NA NA NA NA 2
Geller et al., 2001224 1 –5.2 32 7.4 4 –9.5 71 9.2 NA NA NA NA NA NA NA NA 2
Liebowitz et al., 2002226 1 18.55 22 11.44 4 14.71 21 8.73 NA NA NA NA NA NA NA NA 2
March et al., 1998228 1 –3.4 95 7.99 6 –6.8 92 8.34 NA NA NA NA NA NA NA NA 2
Neziroglu et al., 2000229 5 19.2 5 3.56 10 16.4 5 5.18 NA NA NA NA NA NA NA NA 2
Piacentini et al., 2011230 3 17.2 22 10.04 9 13.3 49 9.31 NA NA NA NA NA NA NA NA 2
Riddle et al., 1992231 1 14.8 6 7 4 13.6 7 5.7 NA NA NA NA NA NA NA NA 2
Riddle et al., 2001232 1 20.9 63 8.5 5 18.2 57 8.6 NA NA NA NA NA NA NA NA 2
Storch et al., 2011233 2 18.53 15 8.11 9 11.13 16 10.53 NA NA NA NA NA NA NA NA 2
Storch et al., 2013234 11 15.43 14 9.72 12 15.56 16 6.62 NA NA NA NA NA NA NA NA 2
Williams et al., 2010235 2 19.6 10 6.42 9 12.09 11 7.46 NA NA NA NA NA NA NA NA 2
The Pediatric OCD
Treatment Study, 2004236
1 21.5 28 5.4 6 16.5 28 9.1 9 14 28 9.5 11 11.2 28 8.6 4
NA, not applicable.
Notes
[i]: type of treatment per arm [i] (1= placebo, 2=waitlist, 3= psychological placebo, 4= fluoxetine, 5= fluvoxamine, 6= sertraline, 7= clomipramine, 8= behavioural therapy, 9=CBT,
10= fluvoxamine and BT, 11= sertraline and CBT, 12= placebo and CBT); y[i]:total mean CYBOCS scores at end of study (positive) or mean change from baseline (negative);
n[i]: total number of patients in arm [i]; sd[i]: SD of mean total score or change from baseline [i].
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FIGURE 9 Network diagram for CYBOCS analysis representing individual treatments (children and adolescents
subset). Circles (nodes) represent the types of interventions compared in the network and they are proportional to
the number of participants randomised to a treatment. Lines are proportional to the number of direct randomised
comparisons. BTFLV, BT+ fluvoxamine; CBTPL, CBT+placebo; CBTSER, CBT+ sertraline; CLO, clomipramine;
FLV, fluvoxamine; FLX, fluoxetine; PL, placebo; PSYPL, psychological placebo; SER, sertraline; WL, waitlist.
TABLE 34 Summary raw CYBOCS data per type of intervention (children and adolescents subset)
Intervention Number of arms Number of patients
Placebo 7 275
Waitlist 5 83
Psychological placebo 2 42
Fluoxetine 3 99
Fluvoxamine 2 62
Sertraline 2 120
Clomipramine 2 41
BT 2 22
CBT 7 184
BT+ fluvoxamine 1 5
CBT+ sertraline 2 42
CBT+ placebo 1 16
Total 36 991
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of the NMA and the results of the pairwise comparisons (see Table 37) are in the same direction, with no
evidence that the NMA effect estimate falls outside the 95% CrIs from the pairwise analysis. Overall, we
conclude that there is no evidence of inconsistency in this network of evidence.
Data synthesis
The results of the NMA are presented in Table 37. We present the mean and 95% CrIs for the MD in
CYBOCS scores at the end of study between the treatments compared. We present both the direct,
head-to-head and pairwise comparisons (from the model assuming independent effects) and the results of
the NMA (consistency model). For simplicity, we present only the MD and 95% CrIs for all interventions
compared with the reference intervention (drug placebo). A more detailed table with all possible
comparisons (both for the direct analysis and NMA) is given in Appendix 8.
Selective serotonin reuptake inhibitors as a class showed a trend for a greater effect than drug placebo,
but the 95% CrIs included the null value. Individual SSRIs, however, reached marginal statistical
significance, in particular sertraline (MD –3.90, 95% CrI –7.47 to –0.60). Although clomipramine showed a
greater effect in the direct pairwise analysis (MD –7.62, 95% CrI –14.21 to –0.97), in the network analysis
this effect was attenuated (MD –5.64, 95% CrI –11.36 to 0.64). It should be noted, however, that this
result is based on two small studies with 41 patients randomised to clomipramine.
TABLE 35 Summary data per type of intervention for the CYBOCS analysis, sorted by number of randomised
patients (children and adolescents subset)
Intervention
Number of patients
randomised
Number of pairwise
comparisons (links)
Number of unique
treatment comparisons
Placebo 275 9 6
CBT 184 9 5
Sertraline 120 4 3
Fluoxetine 99 3 1
Waitlist 83 5 2
Fluvoxamine 62 2 2
Psychological placebo 42 2 1
CBT+ sertraline 42 4 4
Clomipramine 41 2 2
BT 22 2 2
CBT+ placebo 16 1 1
BT+ fluvoxamine 5 1 1
TABLE 36 Posterior summaries from random-effects consistency and inconsistency models (outcome: CYBOCS –
children and adolescents subset)
Model
Number of data
points
Residual deviance,
posterior meana
SD,b posterior median
(95% CrI) DIC
Random-effects consistency 34 35.04 1.88 (0.13 to 5.23) 64.2
Random-effects inconsistency 34 34.27 1.81 (0.08 to 5.78) 64.4
a The posterior mean residual deviance and number of data points are calculated for studies that reported a SD. Studies
for which we predicted a SD could not be included in the residual deviance calculation. The DIC was calculated
externally to OpenBUGS and does not include trials where SD was estimated.
b The SD is the between-trial variation in treatment effects (heterogeneity parameter).
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Behavioural therapy and CBT had greater effects than drug placebo (MD –8.47, 95% CrI –16.98 to –0.39
and MD –8.66, 95% CrI –14.38 to –3.14, respectively). Compared with psychological placebo, there was a
trend for a greater effect, especially in CBT, but the 95% CrIs included the null value.
Compared with SSRIs as a class, both psychological therapies (BT and CBT) showed a trend for a greater
effect, although the 95% CrIs included the null value (BT: MD –4.89, 95% CrI –14.6 to 4.28; CBT: MD
–5.09, 95% CrI –12.33 to 1.86). Similar results were found for clomipramine.
The combination of sertraline with CBT was compared in four arms within two studies with a total number
of 42 randomised patients. This was associated with the largest effect compared with drug placebo
(MD –10.30, 95% CrI –16.16 to –4.58), but the same was observed for the combination of CBT with
placebo (MD –10.22, 95% CrI –19.84 to –0.61). Compared with sertraline as monotherapy, the
combination of sertraline and CBT had a greater effect (MD –6.40, 95% CrI –12.35 TO –0.40), but
compared with CBT as monotherapy, the combination had similar effects (MD –1.64, 95% CrI –8.26 to
5.06). The combination of CBT with sertraline showed a trend for a greater effect than psychological
placebo but the 95% CrI included the null value.
Table 37 also presents the posterior median treatment ranks with 95% CrIs. CBT as monotherapy or
combined with sertraline or drug placebo were ranked as the highest performing treatments, followed
by BT.
TABLE 37 Outcome 1: MD in CYBOCS scores at end of study. Mean and 95% CrIs compared with drug placebo
(children and adolescents subset)
Intervention
Direct NMA Posterior
treatment
rank, median
(95% CrI)
Mean CYBOCS
score 95% CrI
Mean CYBOCS
score 95% CrI
Placebo Reference Reference Reference Reference 11 (9 to 12)
Waitlist NA NA 3.10 –3.79 to 9.03 12 (8 to 12)
Psychological
placebo
NA NA –5.37 –12.9 to 2.01 6 (2 to 11)
SSRIs (class effect) –3.57 –8.57 to 1.51
Fluoxetine –3.52 –7.59 to 0.81 –3.58 –7.01 to –0.08 8 (4 to 11)
Fluvoxamine –2.69 –8.73 to 3.35 –3.27 –7.39 to 1.13 9 (4 to 11)
Sertraline –3.99 –8.45 to 0.21 –3.90 –7.47 to –0.60 8 (4 to 10)
Clomipramine –7.62 –14.21 to –0.97 –5.64 –11.36 to 0.64 6 (2 to 11)
BT NA NA –8.47 –16.98 to –0.39 4 (1 to 10)
CBT –7.30 –13.95 to –0.88 –8.66 –14.38 to –3.14 3 (1 to 7)
BT+ fluvoxamine NA NA –6.12 –14.49 to 2.45 6 (1 to 12)
CBT+ sertraline –10.12 –16.58 to –3.84 –10.30 –16.16 to –4.58 2 (1 to 6)
CBT+ placebo NA NA –10.22 –19.84 to –0.61 2 (1 to 10)
NA, not applicable.
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Sensitivity analyses: outcome 1, CYBOCS – subset (children and adolescents)
Low overall attrition and no evidence of imbalanced attrition
For this analysis, we excluded the five studies in the children and adolescents subset for which overall levels
of attrition were > 25% or differential attrition was > 15%. The remaining 12 studies217,219–221,226–231,233,235,236
included and the raw data used are presented in Appendix 9. Overall, 11 interventions were included
and the total number of randomised patients was 686 (69% of the patients originally used in our full
analysis). MDs and 95% CrIs compared with placebo are presented in Table 38. The results are essentially
similar to the original analysis with the full data reported in Table 37, but the power of the analysis is low
owing to the small number of included studies.
Low risk of bias in the domain: incomplete outcome assessment
For this analysis, we included 15218–221,223,224,226,228,230–236 and excluded two studies. The studies included and
the raw data used are presented in Appendix 9. Overall, 12 interventions were included and the total
number of randomised patients was 935 (94% of the patients originally used in our full analysis). MDs and
95% CrIs compared with placebo are presented in Table 39. It can be seen from the table that the results
are essentially similar to the original analysis, with the full data reported in Table 37.
Low risk of bias in the domain: blinding of the outcome assessor
For this analysis, we included nine219,223,226–230,232–236 and excluded eight studies. The studies included and
the raw data used are presented in Appendix 9. Overall, nine interventions were included and the total
number of randomised patients was 530 (53% of the patients originally used in our full analysis). MDs and
95% CrIs compared with placebo are presented in Table 40. Owing to the small number of studies
included, the power is compromised but the results show the same trends with the full analysis reported
in Table 37.
TABLE 38 Sensitivity analysis (low overall attrition): outcome 1 – MD in CYBOCS scores at end of study. Mean and
95% CrIs compared with drug placebo (children and adolescent subset)
Intervention
Posterior distribution of the treatment effect
(mean CYBOCS difference)
Posterior treatment rank,
median (95% CrI)Mean 95% CrI
Placebo Reference Reference 9 (6 to 11)
Waitlist 2.47 –6.72 to 10.43 10 (6 to 11)
Psychological placebo –4.88 –16.98 to 6.95 6 (1 to 10)
SSRIs (class effect) –3.65 –12.37 to 5.01
Fluoxetine –3.18 –9.12 to 2.87 7 (3 to 10)
Fluvoxamine –3.64 –17.44 to 10.31 7 (1 to 11)
Sertraline –4.10 –9.47 to 1.10 6 (3 to 9)
Clomipramine –5.28 –12.97 to 3.28 5 (2 to 10)
BT –8.75 –19.24 to 1.43 3 (1 to 9)
CBT –8.82 –16.67 to –1.38 3 (1 to 7)
BT+ fluvoxamine Not estimable
CBT+ sertraline –10.37 –18.48 to –2.396 2 (1 to 7)
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TABLE 39 Sensitivity analysis (low risk of bias in ‘incomplete outcome assessment’): outcome 1 – MD in CYBOCS
scores at end of study. Mean and 95% CrIs compared with drug placebo (children and adolescents subset)
Intervention
Posterior distribution of the treatment effect
(mean CYBOCS difference)
Posterior treatment rank,
median (95% CrI)Mean 95% CrI
Placebo Reference Reference 11 (9 to 12)
Waitlist 1.36 –5.01 to 7.12 11 (7 to 12)
Psychological placebo –5.08 –11.91 to 1.57 6 (3 to 11)
SSRIs (class effect) –3.55 –8.16 to 1.16
Fluoxetine –3.59 –6.53 to –0.56 8 (4 to 10)
Fluvoxamine –3.21 –6.80 to 0.57 8 (5 to 11)
Sertraline –3.85 –6.92 to –1.01 8 (4 to 10)
Clomipramine –6.14 –11.25 to –0.59 6 (2 to 10)
BT –9.58 –17.62 to –1.61 3 (1 to 9)
CBT –8.36 –13.52 to –3.48 4 (1 to 7)
BT+ fluvoxamine Not estimable
CBT+ sertraline –10.23 –15.40 to –5.20 3 (1 to 6)
CBT+ placebo –10.06 –18.84 to –1.32 3 (1 to 10)
TABLE 40 Sensitivity analysis (low risk of bias in ‘blinding of outcome assessor’): outcome 1 – MD in CYBOCS scores
at end of study. Mean and 95% CrIs compared with drug placebo (children and adolescents subset)
Intervention
Posterior distribution of the treatment effect
(mean CYBOCS difference)
Posterior treatment rank,
median (95% CrI)Mean 95% CrI
Placebo Reference Reference 8 (5 to 9)
Waitlist 3.10 –5.74 to 11.54 9 (5 to 9)
Psychological placebo –3.94 –13.04 to 5.26 5 (1 to 8)
SSRIs (class effect) –3.79 –10.55 to 2.97
Fluoxetine –3.85 –10.08 to 2.40 5 (2 to 8)
Fluvoxamine –3.27 –8.81 to 2.22 6 (2 to 8)
Sertraline –4.27 –9.96 to 1.42 5 (2 to 8)
CBT –7.18 –14.33 to 0.09 3 (1 to 6)
CBT+ sertraline –9.97 –16.91 to –2.86 2 (1 to 5)
CBT+ placebo –9.76 –20.78 to 1.46 2 (1 to 8)
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Acceptability (dropouts)
Description of the data set
Table 41 presents the raw data used for the dropout analysis in the children and adolescents subset of the
data. Of the 22 studies eligible for inclusion in the NMA,215–236 four were excluded: three studies either did
not report dropout data or did not report dropout data separately for each arm;215,217 and one study was
excluded because there were no dropouts (zero dropouts) in all arms.229 Therefore, 18 studies were
included in this analysis.216,218–221,223–228,230–236
Table 41 also presents raw dropout rates. It can be seen that the range of dropouts was 0–43%, with a
median of 14%. Table 42 presents summary dropout rate per type of intervention (minimum, maximum
and median of raw dropout rates).
Network meta-analysis: results
Network geometry
Figure 10 shows the network geometry for total dropouts in the children and adolescents subset. Overall,
of the 66 comparisons that can be made among the 12 treatment conditions, only 15 (23%) were studied
directly by head-to-head evidence in 18 studies involving 1199 randomised patients. It should be noted,
however, that 9 of the 15 direct comparisons are associated with one study each. Placebo (n= 390), CBT
(n= 182), sertraline (n= 140), paroxetine (n= 100) and fluoxetine (n= 99) are the treatments with the
largest sample size. Figure 10 includes 23 randomised pairwise comparisons and the most common
comparisons are those between placebo and fluoxetine (n= 3) and CBT and waitlist (n= 3). Nodes with
the most connections (links) in the network are drug placebo (n= 11 links with seven different treatments),
CBT (n= 9 links with four different treatments), sertraline (n= 5 links with three different treatments),
combination of sertraline and CBT (n= 4 links with three different treatments) and waitlist (n= 4 links with
two different treatments).
Consistency of evidence
We examined model fit using the posterior mean of the residual deviance, the degree of between-study
heterogeneity and the DIC. We compared a model assuming consistency of treatment effects with a model
assuming independent treatment effects. For the consistency model, all SSRIs were analysed as a class and
individually. Table 43 presents the results of this comparison for the children and adolescents subset.
The posterior mean of the residual deviance was 42.0 in the NMA (the consistency model) compared with
the number of data points (n= 38), suggesting adequate model fit. The posterior mean residual deviance
was 41.4 in the independent effect model. The DIC does not differentiate between the two models. In
addition, the results of the NMA and the results of the pairwise comparisons (Table 44) are in the same
direction, with no evidence that the NMA effect estimate falls outside the 95% CrIs from the pairwise
analysis. Overall, we conclude that there is no evidence of inconsistency.
Data synthesis
The results of the NMA are presented in Table 44. We present posterior median ORs for dropouts
compared with drug placebo, which is the reference treatment. We present both pairwise comparisons
(from the independent effects model) for the direct head-to-head comparisons and the results of the NMA.
For simplicity, we present only the ORs compared with drug placebo. A more detailed table with all
possible comparisons (both for the direct and NMA) is given in Appendix 8.
There were no interventions with a statistically significant higher dropout than placebo. However,
clomipramine and BT were associated with the largest median ORs. It should be noted, however, that
the evidence for this comes from three220,221,227 and two studies,218,220 respectively, with small sample sizes
(n= 49 for clomipramine and n= 23 for BT), and in the case of BT, there is no direct comparison
with placebo.
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TABLE 41 Raw data used for the dropout analysis (children and adolescent subset)
Study t[,1] r[,1] n[,1] dr[,]1, % t[,2] r[,2] n[,2] dr[,2], % t[,3] r[,3] n[,3] dr[,3], % t[,4] r[,4] n[,4] dr[,4], %
Asbahr et al., 2005216 7 1 20 5 10 0 20 0 NA NA NA NA NA NA NA NA
Bolton and Perrin, 2008218 2 0 10 0 9 2 10 20 NA NA NA NA NA NA NA NA
Bolton et al., 2011219 2 3 24 13 10 2 36 6 NA NA NA NA NA NA NA NA
DeVeaugh-Geiss et al., 1992221 1 2 29 7 8 4 31 13 NA NA NA NA NA NA NA NA
Freeman et al., 2008223 3 5 20 25 10 6 22 27 NA NA NA NA NA NA NA NA
Geller et al., 2001224 1 12 32 38 4 22 71 31 NA NA NA NA NA NA NA NA
GlaxoSmithKline, 2001225 1 27 107 25 6 35 100 35 NA NA NA NA NA NA NA NA
de Haan et al., 1998220 8 0 10 0 9 1 13 8 NA NA NA NA NA NA NA NA
Liebowitz et al., 2002226 1 4 22 18 4 1 21 5 NA NA NA NA NA NA NA NA
March et al., 1990227 1 0 8 0 8 2 8 25 NA NA NA NA NA NA NA NA
March et al., 1998228 1 13 95 14 7 18 92 20 NA NA NA NA NA NA NA NA
Piacentini et al., 2011230 3 5 22 23 10 8 49 16 NA NA NA NA NA NA NA NA
Riddle et al., 1992231 1 1 6 17 4 1 7 14 NA NA NA NA NA NA NA NA
Riddle et al., 2001232 1 27 63 43 5 19 57 33 NA NA NA NA NA NA NA NA
Storch et al., 2011233 2 0 15 0 10 2 16 13 NA NA NA NA NA NA NA NA
Storch et al., 2013234 11 6 14 43 12 3 16 19 NA NA NA NA NA NA NA NA
Williams et al., 2010235 2 1 10 10 10 1 11 9 NA NA NA NA NA NA NA NA
The Pediatric OCD
Treatment Study, 2004236
1 7 28 25 7 2 28 7 10 3 28 11 11 3 28 11
NA, not applicable.
Notes
t[i]: type of treatment per arm [i] (1= placebo, 2=waitlist, 3= psychological placebo, 4= fluoxetine, 5= fluvoxamine, 6= paroxetine, 7= sertraline, 8= clomipramine, 9= BT,
10=CBT, 11= sertraline+CBT, 12= placebo+CBT); r[i]: number of dropouts in arm[i]; n[i]: total number of patients in arm [i]; dr [i]: dropout rate (%) in arm[i].
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TABLE 42 Summary raw dropout rates per type of intervention (children and adolescents subset)
Intervention
Dropout rates (%)
Number of armsMinimum Maximum Median
Placebo 0 43 18 9
Waitlist 0 12.5 5 4
Psychological placebo 23 25 24 2
Fluoxetine 5 31 14 3
Fluvoxamine 33 33 NA 1
Paroxetine 35 35 NA 1
Sertraline 5 20 7 3
Clomipramine 0 25 13 3
BT 8 20 14 2
CBT 0 27 11 7
CBT+ sertraline 11 43 27 2
CBT+ placebo 19 19 NA 1
NA, not applicable.
CBTSER
CBTPL
CBT
BT
WL
SER
PSYPL
PL
PAR
FLX
FLV
CLO
FIGURE 10 Network diagram for dropouts representing individual treatments (children and adolescent subset).
Circles represent the types of interventions used in the network and they are proportional to the number of
participants randomised to a treatment. Lines (edges) are proportional to the number of direct randomised
comparisons. CBTPL, CBT+placebo; CBTSER, CBT+ sertraline; CLO, clomipramine; FLV, fluvoxamine; FLX, fluoxetine;
PAR, paroxetine; PL, placebo; PSYPL, psychological placebo; SER, sertraline; WL, waitlist.
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Paroxetine was the only SSRI with an OR greater than 1, but this was not statistically significant. SSRIs as a
class were not more likely than placebo to lead to dropout.
Sensitivity analyses: outcome 2 – dropouts, children and adolescents subset
Low overall attrition and no evidence of imbalanced attrition
For this analysis, we included 13216,218–221,226–228,230,231,233,235,236 and excluded five studies. The studies included
and the raw data used are presented in Appendix 9. Overall, nine interventions were included and the
total number of randomised patients was 707 (59% of the patients originally used in our full analysis).
MDs and 95% CrI compared with placebo are presented in Table 45. Compared with the full data set
reported in Table 44, the results are essentially similar.
TABLE 43 Posterior summaries from random-effects consistency and inconsistency models (outcome: dropouts –
children and adolescents subset)
Model
Number of data
points
Residual deviance
(posterior mean)
SD,a posterior median
(95% CrI) DIC
Random-effects consistency 38 42.0 0.36 (0.02 to 1.19) 169.3
Random-effects independent effects 38 41.4 0.58 (0.04 to 1.92) 170.9
a SD is the between-trial variation in treatment effects (heterogeneity parameter).
TABLE 44 Outcome 2: dropouts. Median ORs (95% CrI) compared with drug placebo (children and
adolescents subset)
Intervention
Direct NMA
Posterior treatment rank,
median (95% CrI)Median OR 95% CrI Median OR 95% CrI
Placebo Reference Reference Reference Reference 8 (3 to 11)
Waitlist NA NA 0.53 0.05 to 4.33 4 (1 to 11)
Psychological placebo NA NA 0.58 0.07 to 4.44 5 (1 to 11)
SSRIs (class effect) 0.87 0.23 to 3.00
Fluoxetine 0.56 0.09 to 2.57 0.74 0.25 to 1.68 6 (1 to 10)
Fluvoxamine 0.66 0.06 to 6.95 0.79 0.24 to 2.07 6 (1 to 11)
Paroxetine 1.59 0.16 to 16.65 1.12 0.37 to 3.42 9 (3 to 12)
Sertraline 0.81 0.10 to 3.78 0.89 0.32 to 2.07 7 (2 to 11)
Clomipramine 3.44 0.41 to 41.35 3.06 0.54 to 21.69 11 (4 to 12)
BT NA NA 7.64 0.41 to 423.7 12 (4 to 12)
CBT 0.44 0.02 to 5.08 0.49 0.09 to 2.41 4 (1 to 10)
Sertraline+CBT 0.43 0.02 to 4.91 0.54 0.08 to 3.15 4 (1 to 11)
Placebo+CBT NA NA 0.15 0.01 to 2.26 1 (1 to 10)
NA, not available.
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Low risk of bias in the domain: incomplete outcome assessment
For this analysis, we included 16216,218–221,223,224,226,228,230–236 and excluded two studies. The studies included
and the raw data used are presented in Appendix 9. Overall, 11 interventions were included and the total
number of randomised patients was 984 (82% of the patients originally used in our full analysis). MDs and
95% CrIs compared with placebo are presented in Table 46. Compared with the full data set, reported in
Table 44, the results show the same trends.
TABLE 45 Sensitivity analysis (low overall attrition): outcome 2 – dropouts. Median ORs (95% CrI) compared with
drug placebo (children and adolescents subset)
Intervention Median OR 95% CrI
Posterior treatment rank,
median (95% CrI)
Placebo Reference Reference 6 (2 to 8)
Waitlist 0.46 0.02 to 7.38 3 (1 to 8)
Psychological placebo 0.68 0.02 to 23.59 4 (1 to 9)
SSRIs (class effect) 0.58 0.0005 to 448.1
Fluoxetine 0.41 0.03 to 3.62 3 (1 to 8)
Sertraline 0.79 0.12 to 4.08 5 (1 to 8)
Clomipramine 3.12 0.36 to 36.01 8 (2 to 9)
BT 8.09 0.23 to 695.2 9 (3 to 9)
CBT 0.47 0.04 to 4.39 3 (1 to 7)
CBT+ sertraline 0.54 0.03 to 7.33 4 (1 to 9)
TABLE 46 Sensitivity analysis (low risk of bias in ‘incomplete outcome assessment’): outcome 2 – dropouts. Median
ORs (95% CrI) compared with drug placebo (children and adolescents subset)
Intervention Median 95% CrI
Posterior treatment rank,
median (95% CrI)
Placebo Reference Reference 8 (4 to 11)
Waitlist 0.48 0.04 to 4.17 4 (1 to 10)
Psychological placebo 0.55 0.05 to 4.71 5 (1 to 10)
SSRIs (class effect) 0.70 0.06 to 7.78
Fluoxetine 0.64 0.19 to 1.70 5 (1 to 10)
Fluvoxamine 0.69 0.18 to 2.31 6 (1 to 10)
Sertraline 0.80 0.25 to 2.18 7 (2 to 10)
Clomipramine 2.01 0.23 to 20.91 10 (2 to 11)
BT 5.95 0.27 to 307.3 11 (3 to 11)
CBT 0.48 0.07 to 2.39 4 (1 to 9)
CBT+ sertraline 0.52 0.06 to 3.50 5 (1 to 10)
CBT+ placebo 0.14 0.01 to 2.59 1 (1 to 10)
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Low risk of bias in the domain: blinding of the outcome assessor
For this analysis, we included 10216,219,223,226,230,232–236 and excluded eight studies. The studies included and
the raw data used are presented in Appendix 9. Overall, nine interventions were included and the total
number of randomised patients was 574 (48% of the patients originally used in our full analysis). MDs and
95% CrIs compared with placebo are presented in Table 47. Compared with the full data set reported in
Table 44, the results show similar trends for the included interventions.
Rankograms (both outcomes)
Table 48 presents the probabilities that each treatment is among the best three or worst three for both
outcomes (CYBOCS/dropouts: for dropouts, being in the top three means better tolerability, i.e. lower
dropouts). In Appendix 8 we present complete data for all rank probabilities for both outcomes. Based on
these data, we also present rankograms (plots of the probabilities for each treatment taking each possible
rank) in Figure 11.
Meta-regression
We were not able to explore fully the impact of effect modifiers as we had originally planned, because in
the children and adolescent networks, there were an insufficient number of studies (CYBOCS) and/or
insufficient data (dropouts) for the analysis to be feasible. Therefore, these analyses were not undertaken.
TABLE 47 Sensitivity analysis (low risk of bias in ‘blinding of the outcome assessor’): outcome 2 – dropouts. Median
ORs (95% CrI) compared with drug placebo (children and adolescent subset)
Intervention Median OR 95% CrI
Posterior treatment rank,
median (95% CrI)
Placebo Reference Reference 8 (4 to 9)
Waitlist 0.26 0.01 to 4.36 4 (1 to 9)
Psychological placebo 0.32 0.01 to 5.32 5 (1 to 9)
SSRIs (class effect) 0.38 0.01 to 15.56
Fluoxetine 0.30 0.01 to 2.50 4 (1 to 9)
Fluvoxamine 0.54 0.06 to 3.52 7 (2 to 9)
Sertraline 0.33 0.03 to 2.43 5 (1 to 9)
CBT 0.27 0.02 to 2.50 4 (1 to 8)
CBT+ sertraline 0.36 0.02 to 4.28 5 (2 to 9)
CBT+ placebo 0.10 0.01 to 4.01 1 (1 to 9)
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TABLE 48 Summary of rank probabilities (top three/bottom three): children and adolescents subset
Outcomea Treatment
Probability of treatment being in the
Top three Bottom three
CYBOCS Placebo 0.00 0.95
Dropout Placebo 0.03 0.18
CYBOCS Waitlist 0.00 0.96
Dropout Waitlist 0.42 0.14
CYBOCS Psychological placebo 0.11 0.17
Dropout Psychological placebo 0.36 0.15
CYBOCS Fluoxetine 0.01 0.19
Dropout Fluoxetine 0.21 0.06
CYBOCS Fluvoxamine 0.01 0.26
Dropout Fluvoxamine 0.17 0.09
Dropout Paroxetine 0.05 0.35
CYBOCS Sertraline 0.01 0.13
Dropout Sertraline 0.07 0.12
CYBOCS Clomipramine 0.14 0.11
Dropout Clomipramine 0.02 0.84
CYBOCS BT 0.48 0.05
Dropout BT 0.02 0.89
CYBOCS CBT 0.53 0.00
Dropout CBT 0.43 0.03
CYBOCS CBT+ sertraline 0.78 0.00
Dropout CBT+ sertraline 0.40 0.11
CYBOCS CBT+ placebo 0.66 0.04
Dropout CBT+ placebo 0.82 0.04
CYBOCS BT+ fluvoxamine 0.27 0.14
a For dropouts, being in the top three means better tolerability (i.e. fewer dropouts).
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FIGURE 11 Rankograms for children and adolescents: dropout (black lines); CYBOCS (green lines). (a) Placebo;
(b) waitlist; (c) psychological placebo; (d) fluoxetine; (e) fluvoxamine; (f) sertraline; (g) clomipramine; (h) BT; (i) CBT;
(j) CBT+ sertraline; (k) CBT+placebo; (l) BT+ fluvoxamine; and (m) paroxetine. (continued )
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FIGURE 11 Rankograms for children and adolescents: dropout (black lines); CYBOCS (green lines). (a) Placebo;
(b) waitlist; (c) psychological placebo; (d) fluoxetine; (e) fluvoxamine; (f) sertraline; (g) clomipramine; (h) BT; (i) CBT;
(j) CBT+ sertraline; (k) CBT+placebo; (l) BT+ fluvoxamine; and (m) paroxetine. (continued )
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FIGURE 11 Rankograms for children and adolescents: dropout (black lines); CYBOCS (green lines). (a) Placebo;
(b) waitlist; (c) psychological placebo; (d) fluoxetine; (e) fluvoxamine; (f) sertraline; (g) clomipramine; (h) BT; (i) CBT;
(j) CBT+ sertraline; (k) CBT+placebo; (l) BT+ fluvoxamine; and (m) paroxetine. (continued )
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FIGURE 11 Rankograms for children and adolescents: dropout (black lines); CYBOCS (green lines). (a) Placebo;
(b) waitlist; (c) psychological placebo; (d) fluoxetine; (e) fluvoxamine; (f) sertraline; (g) clomipramine; (h) BT; (i) CBT;
(j) CBT+ sertraline; (k) CBT+placebo; (l) BT+ fluvoxamine; and (m) paroxetine.
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Chapter 7 Assessment of cost-effectiveness
Background
The economic burden of obsessive–compulsive disorder
The total economic burden of OCD for the NHS and society in the UK is difficult to estimate and is not
accurately known.237 Work conducted in the USA during the 1990s suggests that the total costs of OCD
equated to 5.7% of the estimated US$147.8B cost of all mental illness, and 18.0% of the costs of all
anxiety disorders.238 The direct costs to health services and patients of medical care represents only one
aspect of the total burden. Indirect costs to patients and society as a result of lost productivity and wider
impacts on informal care from friends and family members are also substantial.239 Very few studies have
estimated the per-patient health-care costs of OCD or the incremental costs compared with the general
population or patients with other mental health problems.240,241 The limited evidence available suggests
that OCD has a similar health-care burden to depression, but with a relatively higher use of psychotropic
medications.240 The high cost of care for patients with OCD raises the possibility that therapies with a
substantial and sustained effect on symptoms may reduce health-care costs in the long run.
Existing evidence on the cost-effectiveness of treatment for
obsessive–compulsive disorder: primary studies
There are very few primary economic studies of interventions for patients with OCD, particularly economic
evaluations conducted alongside RCTs likely to provide the most internally valid data. Tolin et al.242
collected cost and outcome data alongside a trial comparing stepped with standard ERP therapy in
30 adults with moderate OCD symptoms (YBOCS score of ≥ 16) of at least 12 months’ duration. This study
reported no statistically significant differences in efficacy between interventions, measured by mean
improvement in YBOCS scores or response rates (defined as YBOCS score of ≤ 12) at 3 months’ follow-up.
Total costs, including direct and indirect costs to patients, those who pay for health care (e.g. regional
health-care authorities) and health-care providers (e.g. hospitals), were lower in the stepped care arm
(US$2480 vs. US$4280; p< 0.05). An incremental cost-effectiveness ratio was not calculated and the
small sample size limits interpretation. However, the authors conclude that their results suggest that
stepped ERP care can significantly reduce treatment costs. McCrone et al.243 report an economic evaluation
of a three-arm RCT178 comparing computer-guided BT, clinician-guided BT and a relaxation control therapy
in 218 adults with DSM-IV-defined OCD. In incremental analyses, the authors report that the cost per
one point improvement in YBOCS score of computer-guided therapy (£64, 95% CI £36 to £249) and
clinician-guided therapy (£90, 95% CI £61 to £167) was modest compared with relaxation control.
A Cochrane review of psychological treatments for OCD, noting the lack of evidence on efficiency, called
for future trials to include an economic evaluation.244 Such trials are under way, including the Obsessive
Compulsive Treatment Efficacy Trial,245 which compares the cost-effectiveness of computerised CBT with
guided self-help, and a Dutch trial comparing schema therapy versus clarification-oriented psychotherapy
versus treatment as usual.246 When published, these trials will improve the evidence base on cost-effective
care for OCD. However, they will not answer many of the questions facing clinicians, policy-makers and
health-care funders. A single trial cannot compare the large number of pharmacological and behavioural
therapies available for OCD and typically will not have sufficient follow-up to determine whether or not
initially expensive therapies are justified by better long-term outcomes.247 A decision analysis based on a
NMA of RCTs, estimating costs and outcomes beyond the end of trial follow-up is likely to provide the best
evidence to inform this complex decision.
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Existing evidence on the cost-effectiveness of treatment for
obsessive–compulsive disorder: models
Previous work248 has developed decision-analytic models to evaluate the cost-effectiveness of therapy for
patients with OCD underpinning the NICE appraisal of computerised CBT. These authors developed a
decision tree comparing three interventions (computer-guided BT, clinician-led BT or relaxation) based
predominantly on one RCT in 218 adults with DSM-IV-defined OCD. The decision model tracked
compliance with BT, response among compliers and relapse among responders during 6-month cycles over
an 18-month time horizon. The authors concluded that, subject to substantial uncertainties, therapist-led
CBT is cost-effective compared with relaxation and that computerised CBT has the potential to be cost-
effective, depending on the licence fees for health-care commissioners.248 The authors acknowledged
significant limitations in their model, particularly relating to the indirect method of estimating quality-of-life
(utility) scores for calculating quality-adjusted life-years (QALYs) because data on this parameter are scarce.
In developing their clinical guidelines for the treatment of OCD, NICE118 also describe a crude model for
comparing the cost-per-responder of usual care, SSRIs, CBT and combination therapy. Pooled effect sizes for
each therapy were estimated based on separate pairwise meta-analyses. NICE concluded that CBT alone is
dominated by SSRIs and combination therapy and, therefore, that CBT alone is unlikely to be cost-effective.
However, this conclusion does not appear to be supported by the data (see table 3, p. 214118); furthermore,
no probabilistic sensitivity analyses were conducted to estimate statistical uncertainty about this conclusion.
Our model addresses a broader question than the previous cost per QALY gained model248 by comparing
behavioural and pharmacological interventions. We used a more comprehensive range of evidence, based
on a NMA of RCTs, to inform model estimates of effect size and allowing a full probabilistic assessment
of the relative cost-effectiveness of treatment strategies.
Cost-effectiveness model methods
Overview
The model evaluates the cost-effectiveness (cost per QALY gained) of pharmacotherapies, psychological
interventions and combinations of both from a NHS perspective. In the final section of this chapter, we
discuss the likely implications of a broader societal perspective. The primary model time horizon is 5 years.
The interventions evaluated in trials are relatively inexpensive, meaning that therapies with a sustained
effect on OCD symptoms would be expected to become cost-effective over a relatively short time horizon.
Furthermore, as longitudinal cohort studies of patients with OCD over protracted periods of time are rare,
any extrapolation of trial results over the lifetime of patients would be very speculative. Therefore, we
elected to evaluate cost-effectiveness over a 5-year time horizon. The model uses probabilistic analysis to
quantify the stochastic uncertainty around estimates of cost-effectiveness. The importance of parameter
and structural uncertainty is also tested through sensitivity analyses.
Patient populations and interventions compared
The model evaluates the cost-effectiveness of interventions in two patient populations; children and
adolescents, and adults. This reflects our NMA, which is also stratified by age. The weighted average age of
patients recruited to adult trials is approximately 36 years, compared with 12 years in trials conducted in
children or adolescents. The model structure is identical for the two populations; however, the parameter
values vary to reflect differing treatment effects and long-term probabilities of response and relapse in these
patient populations. All active interventions that were included in the NMA for both outcomes (dropout
and YBOCS/CYBOCS scores) were compared in the cost-effectiveness model. We did not evaluate
pharmacological and psychological placebos and the herbal remedy hypericum, as they are not directly
relevant to NHS decision-makers. In total, there were 13 interventions compared in adult trials, including six
SSRIs (see Table 20), and seven interventions evaluated in trials of children and adolescents, including three
SSRIs (see Table 37). As the NMA revealed no clear difference within SSRIs in effect on symptoms or dropout
rates, we elected to evaluate SSRIs at the class level in the cost-effectiveness analysis. Therefore, the
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cost-effectiveness of eight interventions in the adult model and five interventions in the child and adolescent
model is compared. In sensitivity analyses, we reran the model restricting the evidence on treatment response
and dropout rates to those RCTs considered to have (1) low attrition; (2) low risk of bias on ‘incomplete
outcome assessment’; or (3) low risk of bias on ‘blinding of the outcome assessor’, to evaluate the potential
impact of RCT bias on our findings and mirror the NMA. In the adult model, we also conducted a sensitivity
analysis excluding RCTs that used a waitlist control group for psychological therapies. Blinding of participants
is not possible in these trials and, therefore, they may be more prone to bias.
Model structure
The model comprises a decision tree covering the initial response to treatment at 12 weeks and a Markov
model to simulate the course, costs and outcomes (utilities) of OCD from 12 weeks to 5 years. The initial
12-week period is chosen, as this represents the median follow-up period used in the trials summarised in
our meta-analysis. The structure of the decision tree is the same for all interventions in both adult and child
and adolescent models (Figure 12). Patients are assigned to treatment and will either continue to receive the
prescribed course of treatment during the 12-week period or prematurely discontinue treatment (drop out). In
our primary analysis, we assumed that if a patient drops out of treatment they get no benefit from treatment
(‘no response’). Patients who continue treatment (comply) during the 12-week period are categorised in
accordance with the degree to which their symptoms improve after treatment (‘full response’, ‘partial
response’, ‘no response’). The appropriateness of the assumption that patients who drop out of treatment
have no response depends on the statistical methods used in RCTs when analysing CYBOCS/YBOCS scores. It
would be appropriate in trials reporting ‘per-protocol’ analyses, where mean CYBOCS/YBOCS scores exclude
those who drop out. However, in trials reporting ‘intention-to-treat’ analyses where dropouts are already
included in the CYBOCS/YBOCS effect estimate, it would effectively double-weight poorer outcomes in
patients who drop out. It was often difficult to ascertain whether trials had conducted a pure ‘per-protocol’
analysis or a pure ‘intention-to-treat’ analysis. Therefore, in sensitivity analysis, we test this structural assumption.
After the initial 12 weeks, the course of patients’ OCD symptoms is tracked using a Markov model with
four health states (Figure 13). The Markov model includes a ‘dead’ state; however, in a young cohort of
patients with OCD over a 5-year time horizon this will be a very rare event. The remaining three health
states are connected by bidirectional arrows, meaning that patients in the model can relapse to a more
symptomatic state or achieve partial or full symptom response at any point during the 5 years. In order to
estimate the pathway of a patient cohort through this Markov model, we need information on nine
transition probabilities at each time point (cycle) of the model. The Markov model uses a 12-week
(3-month) cycle length to track OCD symptom response at intervals from 12 weeks to 5 years.
Markov
Complied
Dropout: no response
Full response
Partial response
No response
Markov
Markov
Markov
FIGURE 12 Decision tree structure over the first 12 weeks.
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Model parameters: dropouts and responses during the initial 12 weeks
The results of the NMA are used to estimate the probability that patients will drop out of treatment before
12 weeks. In the meta-analysis, the ORs for dropout, compared with drug placebo, were typically close to
1 and, with the exception of clomipramine in adults, had wide CrIs spanning unity (see Tables 27 and 44).
The equivalent probability of dropout and associated CrIs for each intervention are provided in Table 49
(adults) and Table 50 (children/adolescents).
We also used the results of the NMA to estimate the initial probability of full, partial and no response to
therapy. One challenge in using this modelling approach is that there is no consistent definition in the
literature of how response should be measured or categorised.249 Response may be defined based on the
CYBOCS/YBOCS, using absolute (e.g. YBOCS score of ≤ 12) or relative (e.g. YBOCS score improves by ≥ 25
or 30% or 35% from baseline) thresholds,90,250,251 or using additional measures such as the Clinical Global
Full
response
Partial
response
No
response
Dead
FIGURE 13 Markov model structure for disease course from 12 weeks to 5 years.
TABLE 49 Adult dropout probabilities
Intervention Source Probability 95% CrI Probabilistic analysis
SSRIs NMA 0.21 0.15 to 0.28 5000 MCMC posterior distribution
Venlafaxine NMA 0.10 0.03 to 0.22 5000 MCMC posterior distribution
Clomipramine NMA 0.27 0.20 to 0.36 5000 MCMC posterior distribution
BT NMA 0.21 0.10 to 0.35 5000 MCMC posterior distribution
CBT NMA 0.17 0.08 to 0.29 5000 MCMC posterior distribution
CT NMA 0.21 0.09 to 0.37 5000 MCMC posterior distribution
Fluvoxamine+CBT NMA 0.41 0.01 to 0.96 5000 MCMC posterior distribution
Clomipramine+ BT NMA 0.25 0.11 to 0.44 5000 MCMC posterior distribution
MCMC, Markov chain Monte Carlo.
TABLE 50 Children and adolescents dropout probabilities
Intervention Source Probability 95% CrI Probabilistic analysis
SSRIs NMA 0.20 0.04 to 0.48 5000 MCMC posterior distribution
Clomipramine NMA 0.46 0.11 to 0.87 5000 MCMC posterior distribution
BT NMA 0.62 0.09 to 0.99 5000 MCMC posterior distribution
CBT NMA 0.14 0.02 to 0.42 5000 MCMC posterior distribution
CBT+ sertraline NMA 0.16 0.02 to 0.49 5000 MCMC posterior distribution
MCMC, Markov chain Monte Carlo.
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Impressions252 scale assessment of overall illness improvement or psychiatric status ratings (PSRs).91,97 Not all RCTs
in the NMA reported response rates, and definitions of response varied among those that did. Therefore, it is
not possible to directly estimate response rates from the meta-analysis. Instead, we indirectly estimate the initial
response based on CYBOCS/YBOCS scores. In our primary analysis, we used a CYBOCS/YBOCS score threshold
of < 16 to define full response and a CYBOCS/YBOCS score of ≥ 16 and < 20 to define partial response.
The < 20 threshold corresponds to an approximately 25% improvement or 1 SD improvement upon the
mean baseline YBOCS scores observed in trials. We tested a range of other values in sensitivity analysis.
We estimate a normal distribution for individual CYBOCS/YBOCS scores on placebo (reference). The mean
of this distribution is estimated by fitting a standard normal random-effects meta-analysis model to all
reference (placebo) arms of trials (included in the NMA) that recorded a mean score and standard error at
follow-up. The mean score was estimated using a standard meta-analysis model in which each study
provides an estimate of the mean with associated standard error. The SD of the distribution is estimated by
fitting a normal random-effects distribution to the SDs at follow-up for all treatments that report this. Note
that this assumes that the spread of CYBOCS/YBOCS scores does not depend on treatment. A prediction
from these two random-effects distributions (i.e. predictive distribution for mean and SD response) is used
to describe our uncertainty in the estimated normal distribution parameters. Relative treatment effects
obtained from the NMA were added to the mean reference (placebo) CYBOCS/YBOCS scores, to obtain a
predicted mean CYBOCS/YBOCS score for each intervention, and the SD in absolute scores is assumed to
be equal for all interventions [and equal to that predicted for the reference (placebo)]. This gives us a
prediction for the distribution of absolute CYBOCS/YBOCS scores across individuals for each intervention
at follow-up. Assuming these scores follow a normal distribution, the proportion of patients achieving
a CYBOCS/YBOCS score of < 16 (full response), between 16 and 20 (partial response), and > 20
(no response) were estimated using appropriate evaluations of the cumulative distribution function for
the normal distribution. All of the above is computed at each iteration of a Bayesian Markov chain
Monte Carlo simulation, so that we fully reflect uncertainty and correlations in our estimates of the
proportions in each category for each intervention. The resulting probabilities for response at 12 weeks,
stratified by intervention class and age, are provided in Tables 51 and 52.
TABLE 51 Probability of full, partial and no response at 12 weeks, based on a NMA; adult population stratified
by intervention
Intervention Source
Probability
of full
response 95% CrI
Probability
of partial
response 95% CrI Probabilistic analysis
SSRIs NMA 0.32 0.02 to 0.71 0.22 0.09 to 0.42 5000 MCMC posterior
distribution
Venlafaxine NMA 0.32 0.01 to 0.78 0.20 0.05 to 0.40 5000 MCMC posterior
distribution
Clomipramine NMA 0.39 0.04 to 0.79 0.22 0.10 to 0.43 5000 MCMC posterior
distribution
BT NMA 0.84 0.50 to > 0.99 0.09 < 0.01 to 0.23 5000 MCMC posterior
distribution
CBT NMA 0.42 0.05 to 0.86 0.21 0.08 to 0.42 5000 MCMC posterior
distribution
CT NMA 0.80 0.39 to > 0.99 0.11 < 0.01 to 0.27 5000 MCMC posterior
distribution
Fluvoxamine+CBT NMA 0.54 0.07 to 0.97 0.19 0.02 to 0.38 5000 MCMC posterior
distribution
Clomipramine+ BT NMA 0.78 0.33 to > 0.99 0.11 < 0.01 to 0.29 5000 MCMC posterior
distribution
MCMC, Markov chain Monte Carlo.
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Model parameters: initial pharmacological and psychological therapy costs
The mean daily dose of pharmacological interventions varied between and within trials (see Appendix 6).
In order to estimate the initial costs of pharmacotherapy, we selected a daily dose close to the mean of
the mean daily doses reported in RCTs, stratified by adults and children and adolescents populations
(Table 53). This dose was rounded to the nearest multiple of a tablet/capsule size available. We also used data
on mean daily dose reported in RCTs to define the plausible maximum and minimum daily dose, and tested
the impact of these daily doses on incremental costs and cost-effectiveness in deterministic sensitivity analyses.
TABLE 52 Probability of full, partial and no response at 12 weeks, based on a NMA; child and adolescent
population stratified by intervention
Intervention Source
Probability
of full
response 95% CrI
Probability
of partial
response 95% CrI Probabilistic analysis
SSRIs NMA 0.53 0.05 to 0.97 0.16 0.02 to 0.31 5000 MCMC posterior
distribution
Clomipramine NMA 0.62 0.08 to 0.99 0.14 0.01 to 0.29 5000 MCMC posterior
distribution
BT NMA 0.71 0.13 to > 0.99 0.12 < 0.01 to 0.26 5000 MCMC posterior
distribution
CBT NMA 0.73 0.19 to > 0.99 0.11 < 0.01 to 0.26 5000 MCMC posterior
distribution
CBT+ sertraline NMA 0.78 0.25 to > 0.99 0.10 < 0.01 to 0.24 5000 MCMC posterior
distribution
MCMC, Markov chain Monte Carlo.
TABLE 53 Mean daily dose, cost and minimum and maximum value of pharmacotherapy stratified by drug and
age group
Intervention
Mean dose
across arms,
daily (mg)a
Minimum dose
during the
study (mg)
Maximum dose
during the
study (mg)
Daily dose
in model
(mg)
12-week
cost in
model (£)
Cost of pack
(for dropouts)
(£)
Adults
SSRIs 31.43 9.25
Fluoxetine 49.46 20 80 60 8.48 1.01
Fluvoxamine 252.32 50 300 250 117.81 33.66
Paroxetine 45.95 20 60 50 9.21 3.29
Sertraline 154.25 50 200 150 12.48 4.16
Citalopram 42.73 20 60 40 3.51 1.17
Escitalopram 15 10 20 15 71.10 23.70
Venlafaxine 282.5 225 350 300 14.46 2.41
Clomipramine 196.48 50 300 200 25.80 2.15
Children/adolescents
SSRIs 22.92 9.56
Fluoxetine 32.35 20 80 40 5.66 1.01
Fluvoxamine 165 50 200 150 70.69 33.66
Sertraline 154.36 25 200 150 12.48 4.16
Clomipramine 190 75 200 200 25.80 2.15
a Mean of the mean dose in RCT arms where reported.
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The unit costs for pharmaceuticals were based on the British National Formulary estimates.253 The cheapest
combination of pack sizes was used to derive the cost of pharmacotherapy for 12 weeks (Table 54). The
cost of the SSRI class was estimated by taking an average cost of the SSRIs used in the RCTs, weighted by
the number of participants randomised to each SSRI. We assumed that patients who complied with
therapy would incur pharmaceutical costs throughout the initial 12-week period. We assumed that
patients who dropped out of pharmacotherapy incurred only the cost of one prescription (see Table 53).
The number of psychological therapy sessions showed little consistency within or between BT, CT and CBT
trials (see Appendix 6), ranging from a maximum of 40 to fewer than 10 sessions. Session duration, where
reported, ranged from < 1 hour to 2.5 hours per session. We estimated typical therapist contact hours of
psychological therapy, stratified by therapy type (BT, CT and CBT) and patient group (adults, children/
adolescents) based on the mean number of contact hours estimated from trial reports (Table 55). We used
the contact hours reported in RCTs to define the plausible maximum and minimum contact hours for use
in sensitivity analyses. We used Personal Social Services Research Unit (PSSRU)254 unit costs to value initial
psychological therapy. The estimated hourly face-to-face cost of conducting all types of psychological
therapy (BT, CT and CBT) was assumed to be equal to the CBT hourly cost (£99; 2013 prices) estimated by
the PSSRU. We assumed that patients who dropped out of psychological therapy did so after attending, on
average, one-quarter of sessions, thereby incurring one-quarter of therapy costs. The cost of combinations
of pharmacological and psychological therapies were estimated to be the sum of the components.
TABLE 55 Mean contact hours, cost and minimum and maximum value of psychological therapy, stratified by
therapy type and age group
Intervention
Mean hours
across arms
Minimum
hours
Maximum
hours
Cost per
therapy (£)
Cost for patients
dropping out (£)
Adult
BT 17.17 10 46.5 1699.83 424.96
CBT 20.78 10 60 2057.22 514.31
CT 15.25 8 30 1509.75 377.44
Children/adolescents
BT 22.5 15 30 2227.50 556.88
CBT 15 10 21 1485.00 371.25
TABLE 54 British National Formulary drug costs stratified by pack size and dose
Intervention Units I
Unit dose I
(mg)
Cost I,
£ Units II
Unit dose II
(mg)
Cost II
(£) Units III
Unit dose III
(mg)
Cost III
(£)
SSRIs
Fluoxetine 30 20 1.01 30 60 28.79
Fluvoxamine 60 50 16.83 30 100 16.83
Paroxetine 30 20 1.52 30 30 1.77
Sertraline 28 50 1.92 28 100 2.24
Citalopram 28 10 0.91 28 20 1.00 28 40 1.17
Escitalopram 28 5 8.97 28 10 14.73 28 20 25.20
Venlafaxine 56 37.5 2.15 56 75 2.41
Clomipramine 28 10 1.30 28 25 1.71 28 50 2.15
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Model parameters: mortality, symptoms, costs and utilities in the longer term
Mortality
Epidemiological evidence255 suggests that mortality rates are not higher in individuals with OCD; indeed,
observed mortality rates may be lower than the expected rates. Therefore, we used the Office for National
Statistics all-cause mortality life tables256 to estimate mortality, independent of OCD symptom severity.
Mortality was estimated based on the mean age of patients recruited to the adult and child and
adolescent RCTs, and mortality estimates were weighted to reflect their gender profile (see Appendix 10).
Symptoms
Most trials included in the NMA had relatively short periods of follow-up; there is little evidence from RCTs
on how differences between interventions evident in the short term (e.g. 12 weeks) might be sustained in
the longer term.122 In our primary economic analysis, we assumed that, after the first 12-week period,
the initial choice of therapy did not affect the probability of further remission or relapse. In other words,
initial therapy affected the probability of being in each of the three health states in the Markov model (full,
partial or no response) at 12 weeks, but did not affect transition probabilities thereafter. We tested other
assumptions in sensitivity analyses.
In order to identify evidence on transition probabilities for OCD symptom severity, we conducted a rapid
literature review. We used an adapted version of the Scottish Intercollegiate Guidelines Network MEDLINE
filter for observational studies257 supplemented with text words for OCD and the YBOCS to identify studies
reporting on the long-term course of OCD remission and relapse in adults and in children and adolescents
(see Appendix 10). Of 561 articles initially identified, we selected 24 for full-text review, based on the title
and abstract. On review of the full text, we selected two publications, Mancebo et al.97 and Eisen et al.,91
based on the Brown Longitudinal Obsessive–Compulsive Study (BLOCS) cohort study as containing the
most relevant information on remission and relapse transition probabilities. The BLOCS recruited treatment-
seeking subjects (325 adults and 70 children) with OCD from multiple psychiatric treatment settings in the
USA (71% outpatient OCD clinic, 4% inpatient units, 25% community mental health centres). Subjects
had annual assessments using a semistructured interview. Each assessment recorded a weekly PSR, which
was used to define partial or full remission and any subsequent relapse. PSR is a rating of 6 points based
on OCD symptom severity and functional impairment. A rating of 6 points indicates the most severe
symptoms and impairment, and one indicates no OCD symptoms or impairment. BLOCS defined full
remission as a PSR score of ≤ 2 (minimal or no symptoms and no impairment) for 8 consecutive weeks,
partial remission as a score of 3 (symptoms present for less than 1 hour daily, but not impairing) for
8 consecutive weeks and relapse as a score of 4 or more for 4 consecutive weeks after achieving a full or
partial response.
Eisen et al.91 report the 5-year course of symptoms for 213 adults enrolled in the BLOCS who had at least
3 years of follow-up data. Over 5 years, 36 (16.9%) patients in the sample had full remission and a further
47 (22.1%) had partial remission. However, subsequent relapse was common in those who achieved
partial remission (70%) or full remission (45%). Mancebo et al.97 report the 3-year course of symptoms for
46 children and adolescents, aged 6–18 years, participating in the BLOCS who met the DSM-IV criteria for
OCD at enrolment and completed at least 2 years of follow-up. Of these, 12 (27%) had achieved full
remission by 3 years and a further 12 (27%) were in partial remission; five (21%) of these 24 individuals
subsequently relapsed.
Data used to estimate ‘no response’ to ‘partial response’ and ‘no response’ to ‘full response’ time-varying
transition probabilities in both adult and child and adolescent populations over the first 36 months post
treatment were obtained from Mancebo et al.97 From 36 to 60 months, in the absence of direct evidence
from the BLOCS, the transition probabilities were assumed to remain constant (i.e. equal to the
31–36 month transition probabilities). Six-monthly probabilities were converted to 3-monthly probabilities
to match the model cycle length.
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A plot in Eisen et al.91 displayed the probability of relapse after initial response, stratified by partial and full
response, over 4 years in an adult population. Three-monthly transition probabilities were extracted from
this plot using Digitizeit version 2.0 (Bormisoft, Braunschweig, Germany; www.digitizeit.de/) software
that extracts numerical data from images. The 3-monthly transition probabilities between 48 and
60 months were assumed to remain constant (i.e. equal to the 46- to 48-month probabilities). In children
and adolescents, Mancebo et al.97 report that 5 of 24 subjects (21%) who had partial or full response
subsequently relapsed over a study period of, on average, 88 weeks. However, this study did not provide
further detail on relapse rates over time. Therefore, we assumed that the relapse probability was constant
over the 5-year period and that the relative proportion of relapse from full or partial response was the
same as that observed in the adult population.
These two articles provide evidence on the bidirectional time-varying transition probabilities between full
response and no response (i.e. relapse) and between partial response and no response. However, they do
not provide evidence on the transition probabilities between full and partial response. In our primary
analysis, we arbitrarily assumed no transition between full and partial response, which is equivalent to
assuming the proportion of patients moving from partial to full response is counterbalanced in each cycle
by the proportion of patients moving from full to partial response. We tested other assumptions in
sensitivity analyses. The time-varying transition probabilities for adults and children and adolescents are
presented in Tables 56 and 57, respectively.
TABLE 56 Adult symptom transition probabilities (from 12 weeks to 5 years) among patients surviving in each cycle
Time period for Markov
model (months) Source Rate Aa Ba
Probabilistic
distribution
No response to partial or full response
0–6 Mancebo et al., 201497 0.109 24 221 Beta
7–12 Mancebo et al., 201497 0.091 18 197 Beta
13–18 Mancebo et al., 201497 0.039 7 179 Beta
19–24 Mancebo et al., 201497 0.070 12 172 Beta
25–30 Mancebo et al., 201497 0.038 6 160 Beta
31–36 Mancebo et al., 201497 0.052 8 154 Beta
37+b Mancebo et al., 201497 0.052 8 154 Beta
Proportion of responders who have full response
0–6 Mancebo et al., 201497 0.208 5 24 Beta
7–12 Mancebo et al., 201497 0.278 5 18 Beta
13–18 Mancebo et al., 201497 0.571 4 7 Beta
19–24 Mancebo et al., 201497 0.500 6 12 Beta
25–30 Mancebo et al., 201497 0.667 4 6 Beta
31–36 Mancebo et al., 201497 0.500 4 8 Beta
37+b Mancebo et al., 201497 0.500 4 8 Beta
Partial response to no response (relapse)
0–3 Eisen et al., 201391 0.013 0.59 46.41 Beta
4–6 Eisen et al., 201391 0.170 6.83 40.17 Beta
7–9 Eisen et al., 201391 0.098 4.18 42.82 Beta
10–12 Eisen et al., 201391 0.057 2.54 44.46 Beta
continued
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TABLE 56 Adult symptom transition probabilities (from 12 weeks to 5 years) among patients surviving in
each cycle (continued )
Time period for Markov
model (months) Source Rate Aa Ba
Probabilistic
distribution
13–15 Eisen et al., 201391 0.046 2.07 44.93 Beta
16–18 Eisen et al., 201391 0.000 0.00 47.00 Beta
19–21 Eisen et al., 201391 0.035 1.60 45.40 Beta
22–24 Eisen et al., 201391 0.065 2.87 44.13 Beta
25–27 Eisen et al., 201391 0.000 0.00 47.00 Beta
28–30 Eisen et al., 201391 0.000 0.00 47.00 Beta
31–33 Eisen et al., 201391 0.074 3.24 43.76 Beta
34–36 Eisen et al., 201391 0.074 3.24 43.76 Beta
37–39 Eisen et al., 201391 0.034 1.55 45.45 Beta
40–42 Eisen et al., 201391 0.020 0.94 46.06 Beta
43–45 Eisen et al., 201391 0.031 1.41 45.59 Beta
46–48 Eisen et al., 201391 0.029 1.32 45.68 Beta
49+c Eisen et al., 201391 0.029 1.32 45.68 Beta
Full response to no response (relapse)
0–3 Eisen et al., 201391 0.011 0.38 35.62 Beta
4–6 Eisen et al., 201391 0.107 3.47 32.53 Beta
7–9 Eisen et al., 201391 0.026 0.90 35.10 Beta
10–12 Eisen et al., 201391 0.035 1.22 34.78 Beta
13–15 Eisen et al., 201391 0.068 2.30 33.70 Beta
16–18 Eisen et al., 201391 0.022 0.79 35.21 Beta
19–21 Eisen et al., 201391 0.001 0.04 35.96 Beta
22–24 Eisen et al., 201391 0.000 0.00 36.00 Beta
25–27 Eisen et al., 201391 0.030 1.04 34.96 Beta
28–30 Eisen et al., 201391 0.030 1.04 34.96 Beta
31–33 Eisen et al., 201391 0.048 1.66 34.34 Beta
34–36 Eisen et al., 201391 0.047 1.62 34.38 Beta
37–39 Eisen et al., 201391 0.014 0.50 35.50 Beta
40–42 Eisen et al., 201391 0.010 0.36 35.64 Beta
43–45 Eisen et al., 201391 0.011 0.40 35.60 Beta
46–48 Eisen et al., 201391 0.010 0.36 35.64 Beta
49+c Eisen et al., 201391 0.010 0.36 35.64 Beta
a A and B represent the shape parameters in the beta distribution.
b Transition rates are assumed to be constant from 37 months to 5 years.
c Transition rates are assumed to be constant from 49 months to 5 years.
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Utilities
A rapid literature review was conducted to identify quality-of-life studies in OCD. The review identified 447
abstracts; after initial screening, 12 abstracts were selected for full-text review (see Appendix 10). Most studies
did not use a generic preference-based outcome measure, such as the European Quality of Life-5 Dimensions
(EQ-5D™) or Short Form questionnaire-6 Dimensions (SF-6D),258 both of which allow calculation of QALYs.
Of those studies that did use these measures, several did not report results for the health states (full, partial,
no response) that correspond to the Markov model. We did not find any studies reporting utility values in
children and adolescents with OCD; therefore, we assume that the impact of OCD on health-related quality of
life in adults is generalisable to children and adolescents and use one set of utility values for both age groups.
Hollander et al.114 used data from two double-blind, placebo-controlled RCTs with similar eligibility criteria
in adults with OCD.124,128 Stein et al.124 recruited 466 patients with a mean age of 23 years and a mean
YBOCS score of 27, and Fineberg et al.128 recruited 468 patients with a mean age of 23 years and a
mean YBOCS score of 26.4. In this study, response was defined as a decrease in YBOCS score of ≥ 25%
relative to baseline. In responders, relapse was defined as a subsequent increase in YBOCS score of 5 points
or more, or an unsatisfactory treatment effect as judged by the investigators. Both studies collected Short
TABLE 57 Children and adolescents symptom transition rates (from 12 weeks to 5 years) among patients surviving
in each cycle
Time period for Markov
model (months) Source Rate Aa Ba
Probabilistic
distribution
No response to partial or full remission
0–6 Mancebo et al., 201497 0.087 4 46 Beta
7–12 Mancebo et al., 201497 0.143 6 42 Beta
13–18 Mancebo et al., 201497 0.111 4 36 Beta
19–24 Mancebo et al., 201497 0.156 5 32 Beta
25–30 Mancebo et al., 201497 0.111 3 27 Beta
31–36 Mancebo et al., 201497 0.083 2 24 Beta
37+b Mancebo et al. 201497 0.091 2 22 Beta
Proportion of responders who have full response
0–6 Mancebo et al., 201497 0.500 2 4 Beta
7–12 Mancebo et al., 201497 0.333 2 6 Beta
13–18 Mancebo et al., 201497 0.500 2 4 Beta
19–24 Mancebo et al., 201497 0.600 3 5 Beta
25–30 Mancebo et al., 201497 0.667 2 3 Beta
31–36 Mancebo et al., 201497 0.500 1 2 Beta
37+b Mancebo et al., 201497 0.500 1 2 Beta
Partial response to no response
88.2-week intervalc Mancebo et al., 201497 and
Eisen et al., 201391
0.333 3 9 Beta
Full response to no response
88.2-week intervalc Mancebo et al., 201497 and
Eisen et al., 201391
0.200 2 10 Beta
a A and B represent the shape parameters in the beta distribution.
b Transition rates are assumed to be constant from 37 months to 5 years.
c Transition rate is constant over time.
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Form questionnaire-36 Items data from which SF-6D utility scores were derived. The study estimates SF-6D
utility values for adult patients at baseline (pre-randomisation) and for patients with response; no response;
response and relapse; and response and no relapse at 16 weeks from the start of treatment. The definitions
of response used by Hollander et al.114 in measuring utility values do not correspond exactly with the
definitions of response used by the BLOCS in defining symptom course. Therefore, we had to make
assumptions about the most appropriate utility values to use in our Markov model. The utility values applied
in our primary economic analysis are described in Table 58.
Long-term costs of health care
Patients who fail to respond fully to initial therapy are likely to be prescribed a number of other
pharmacological or psychological therapies with their attendant costs and benefits. Our cost-effectiveness
model aims to predict the impact of initial therapy on longer-term costs and outcomes, but there is
insufficient information to track all treatment switching or therapy combinations likely to occur in practice.
We therefore assumed that the incremental differences in treatment cost after 12 weeks are driven solely
by symptom severity. As previously discussed, the literature on the health-care costs of OCD is very sparse.
The only study in the peer-reviewed literature that we are aware of which has estimated the per-patient
costs of OCD used retrospective claims data from Medicaid enrolees in Florida.248 Hankin et al.240 used
the ICD Ninth Edition diagnosis codes to identify 85 newly diagnosed patients with ‘pure OCD’ and
14,906 patients with newly diagnosed ‘pure depression’ in order to compare health-care costs over a
2-year period. The median 2-year cost of inpatient, outpatient and pharmacy health-care claims were similar
in patients with OCD and depression (US$6588 for OCD vs. US$5347 for depression; Wilcoxon’s signed-rank
p-value 0.27). However, the composition of costs differed; patients with OCD had higher use of psychotropic
medications, whereas patients with depression had higher use of non-psychiatric outpatient care. The authors
note that the long-term costs of OCD may be higher than those of depression because OCD is a chronic
disorder requiring ongoing therapy, whereas depression is episodic in most cases. This study has limited value
in informing our cost-effectiveness model, because it is based on findings from a selected subset of patients
(i.e. eligible for Medicaid) in a US health-care setting in which unit costs are higher than in the NHS and the
analysis does not stratify costs by symptom response to therapy.
In order to estimate a proxy NHS cost in our model for long-term OCD care, we assumed costs to be
similar to patients treated for depression. In a study of 88,935 patients aged > 18 years, diagnosed with
depression, Byford et al.259 found that the mean 12-month NHS costs, including medications, primary care,
psychological therapies and secondary care, were 33% lower among patients who achieved remission
from depressive symptoms than in those who did not [£656 vs. £973 (2005/6 values) or £945 vs. £1402 at
2014 values; p< 0.001]. Therefore, we assumed that the annual NHS costs in patients with OCD who
have no response to therapy were equivalent to patients with depression who do not achieve remission.
Furthermore, in our primary analysis, we assumed that patients with OCD who have a full response to
therapy will have 33% lower NHS costs, and we selected an arbitrary value (17% reduction) for patients
with partial response to therapy. Owing to the weak and indirect evidence on costs, we tested these
assumptions using a wide range of alternative values in our sensitivity analysis (Table 59).
TABLE 58 Utility values
Markov health state Label used Source
Mean utility
value SD
Probabilistic
distribution
Pre-treatment Baseline value Hollander et al., 2010114 0.648 0.103 1 – gamma
Partial response Response Hollander et al., 2010114 0.725 0.108 1 – gamma
No response No response Hollander et al., 2010114 0.664 0.106 1 – gamma
Not used in Markov model Relapse Hollander et al., 2010114 0.684 0.116 1 – gamma
Full response No relapse Hollander et al., 2010114 0.776 0.113 1 – gamma
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Methods of analysis
The model was constructed in Microsoft Excel 2010. A half-cycle correction was applied to estimate costs
and utilities for patients who move between health states during each cycle of the Markov model. Costs
and utilities were discounted at 3.5%, in line with NICE guidelines.260 Verification of the model’s internal
validity was tested using extreme value analysis. The cost-effectiveness of each intervention is summarised
using the net benefit statistic at thresholds of £20,000 and £30,000 (i.e. the amount the NHS is prepared
to pay in order to produce a QALY).260 Parametric uncertainty surrounding the point estimate is estimated
using 95th-percentile intervals from a probabilistic analysis, generated using second-order Monte Carlo
simulation taking 3000 random draws from parameter distributions. The probability that each intervention
is the most cost-effective at a range of willingness-to-pay thresholds (£0–50,000 per QALY) is summarised
using cost-effectiveness acceptability curves (CEACs).261
Sensitivity analyses
We used a series of sensitivity analyses to evaluate the robustness of the cost-effectiveness results to
several of the assumptions made within the model.
1. Risk of bias: we reran the model using the subset of studies that met the NMA criteria of low risk of
bias in (1) overall attrition; (2) incomplete outcome assessment; or (3) blinding of outcome assessor to
assess the potential impact of RCT bias on cost-effectiveness results. In the adult model, we also reran
the model excluding RCTs that used a waitlist control for psychotherapy interventions.
2. Effectiveness in patients who drop out: we reran the model assuming that patients who dropped
out of treatment had lower costs, but identical outcomes to those who completed treatment.
3. Definition of full response: we lowered the threshold for defining full response (≤ 12).
4. Cost of initial therapy: we used minimum and maximum dose and contact hours to assess the impact
of initial therapy costs on cost-effectiveness estimates.
5. Sustained effect of initial therapy: we reduced the time horizon of the model to assess the impact
on cost-effectiveness if treatment effects were sustained for fewer than 5 years.
6. Transition from full to partial response: we varied the net flow of patients from full to partial
response in the Markov model to assess the impact on cost-effectiveness results.
7. Change cost of long-term care: we assessed the impact of assuming higher incremental long-term
costs of care for patients with no response (compared with those with full and partial response).
8. SSRI costs: in both the adult and child and adolescent models we reran the model assuming that SSRI
medication costs were equivalent to the cheapest SSRI, rather than the class average cost. Medication
costs vary considerably among SSRIs and, therefore, if effectiveness is equivalent within the class,
cheaper SSRIs will be more cost-effective.
9. Venlafaxine: in the adult model, we reran analyses excluding venlafaxine, which is not licensed for
OCD despite being evaluated in a small number of RCTs for off-label use.
TABLE 59 Costs per health state (3 months)
Health state Source Cost (£) SE (£)a Distribution
Full response Byford et al., 2011259 236
Partial response Byford et al., 2011259 291
No response Byford et al., 2011259 351 88 Log-normal
Dead 0
SE, standard error.
a Owing to the high uncertainty around the costs, we have assumed a SE of 25% of the cost of no response. The costs
from the other health states are then derived from this cost.
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Cost-effectiveness results: adults
Primary cost-effectiveness analysis
The estimated NHS costs, QALYs and cost-effectiveness of each of the eight interventions in adults
are reported in Table 60. Over a 5-year time period, the high upfront costs of psychological therapies are
not completely offset by lower NHS costs in subsequent years. The three drug groups (SSRIs, clomipramine
and venlafaxine) have the lowest NHS costs (range £5727–5788), strategies including CT and BT have
higher costs (range £6590–6778), and strategies including CBT had the highest estimated costs (range
£7206–7428). The difference in cost between CBT and the other two psychological therapies is
partly attributable to the higher number of contact hours used in adult CBT trials (see Table 55) and partly
attributable to the lower effect size of CBT estimated in the NMA (see Table 51).
Psychological therapies, particularly CT and BT, are estimated to result in the highest QALYs over the
5-year period. The absolute difference in QALYs is quite small [range from 3.208 (SSRIs) to 3.320 (BT)].
However, this range is approximately equivalent to an additional 365 days in ‘full response’ rather than
‘no response’ over the 5-year period. The net monetary benefit (NMB) (£20,000) column summarises
cost-effectiveness if the NHS is willing to pay £20,000 for each QALY gained by patients, which is at the
lower end of NICE’s stated threshold. Table 60 is ordered by this column, with interventions with the lowest
estimated NMB (i.e. least cost-effective) at the top and interventions with the highest estimated NMB
(i.e. most cost-effective) at the bottom. The interventions fall into three clusters based on NMB (£20,000).
Strategies involving CT or BT are most cost-effective (NMB range £59,208–59,695). The additional upfront
costs of the CT and BT strategies, compared with the pharmacological monotherapies are justified by
better outcomes (QALYs). The pharmacological monotherapies have a similar range of cost-effectiveness
[NMB range from £58,373 (SSRIs) to £58,664 (venlafaxine)]. Differences between the pharmacological
monotherapies are driven by the slightly higher costs of SSRIs (see Table 53) and the low probability of
dropout from venlafaxine estimated from two relatively small RCTs (see Table 49). The strategies including
CBT have the poorest cost-effectiveness [NMB range from £57,174 (fluvoxamine+CBT) to £57,337 (CBT)].
The higher upfront costs of CBT, compared with pharmacotherapy, are not justified by the marginal
improvement in symptom response (see Table 51). The 95th percentile intervals around the NMBs (£20,000)
estimated by the probabilistic analysis overlap, indicate that there is no strong evidence that any single
therapy is more cost-effective than the other therapies. The findings are not materially altered if the NHS is
willing to pay more (NMB £30,000) for each QALY gained (Table 60).
TABLE 60 Cost-effectiveness of therapy: adults
Intervention
Total costs
(£)
Total
QALYs
NMB
(£20,000) (£)
Lower 95th
percentile (£)
Upper 95th
percentile (£)
NMB
(£30,000) (£)
Fluvoxamine+CBT 7206 3.219 57,174 53,043 61,108 89,364
CBT 7428 3.238 57,337 53,189 61,367 89,719
SSRIs 5788 3.208 58,373 54,498 62,047 90,453
Clomipramine 5751 3.215 58,549 54,768 62,061 90,699
Venlafaxine 5727 3.220 58,664 54,442 62,675 90,860
Clomipramine+ BT 6778 3.299 59,208 55,120 62,692 92,201
CT 6590 3.313 59,668 55,571 63,112 92,797
BT 6715 3.320 59,695 55,718 63,168 92,899
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The CEAC (Figure 14) depicts the probability that each intervention is the most cost-effective, on the
vertical axis, as a function of increasing NHS willingness to pay for a QALY, on the horizontal axis. The
CEAC demonstrates that at lower willingness-to-pay thresholds (i.e. < £10,000 per QALY), the cheaper
pharmacotherapies (venlafaxine and clomipramine and, to a lesser extent, SSRIs) have higher probabilities of
being most cost-effective. Once the willingness to pay exceeds NICE’s stated threshold (£20,000 per QALY),
strategies involving CT and BT become the most likely to be cost-effective. The CEAC suggests that there
is no clear ‘winner’ in terms of cost-effectiveness, with the difference in probability of being most cost-effective
between the therapies ranked first and second rarely exceeding 0.1 across all willingness-to-pay values.
Therapies including CBT had a very low probability of being most cost-effective across the range of
willingness-to-pay values. These findings are supported by the cost-effectiveness acceptability frontier
(Figure 15), which identifies, with a low degree of certainty, venlafaxine as the most cost-effective (optimal)
therapy at low willingness-to-pay thresholds and BT as the optimal therapy at the thresholds (£20,000–30,000
per QALY) used by NICE.
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FIGURE 14 Cost-effectiveness acceptability curve: adults, primary analysis. CLO, clomipramine; FLV, fluvoxamine;
VEN, venlafaxine.
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FIGURE 15 Cost-effectiveness acceptability frontier: adults, primary analysis. CLO, clomipramine; FLV, fluvoxamine;
VEN, venlafaxine.
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Sensitivity analyses
Full results of all sensitivity analyses are provided in Appendix 10. Here, we focus on the five sensitivity
analyses that had most impact on the interpretation of the cost-effectiveness model.
The exclusion of evidence from RCTs that used waitlist controls decreased the probability that BT and CT
strategies were most cost-effective at the thresholds (£20,000–30,000 per QALY) used by NICE (Figure 16).
The difference in effectiveness between different types of psychological therapy was very small in this sensitivity
analysis (Table 61). However, the higher estimated cost of CBT, owing to the higher number of contact hours
used in adult CBT trials, meant that CBT strategies were less likely to be cost-effective. Clomipramine and BT
had the highest probability of being cost-effective, although this did not exceed 0.4 (Figure 16).
The most cost-effective pharmacotherapy was strongly dependent on assumptions about outcomes in
patients who drop out. If we assume that the outcomes in patients who drop out are fully reflected in
analyses of YBOCS scores in the meta-analysis (i.e. analyses were predominantly intention to treat), then
clomipramine, rather than venlafaxine, is much more likely to be the most cost-effective pharmacotherapy
at lower willingness-to-pay thresholds (Figure 17). The finding that strategies involving CT and BT become
more cost-effective at higher willingness-to-pay thresholds is not affected by this assumption.
TABLE 61 Cost-effectiveness of therapy: adults – excluding RCTs with waitlist controls
Intervention
Total costs
(£)
Total
QALYs
NMB
(£20,000) (£)
Lower 95th
percentile (£)
Upper 95th
percentile (£)
NMB
(£30,000) (£)
CBT 7385 3.256 57,743 53,805 61,290 90,307
Fluvoxamine+CBT 7438 3.266 57,883 53,879 61,846 90,543
SSRIs 5865 3.190 57,930 54,314 61,020 89,827
Clomipramine 5834 3.195 58,065 54,516 61,146 90,015
Venlafaxine 5822 3.197 58,115 54,344 61,527 90,084
CT 6818 3.256 58,296 54,354 61,773 90,853
BT 6920 3.265 58,380 54,612 61,851 91,030
Clomipramine+ BT 6867 3.274 58,605 54,811 62,119 91,341
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FIGURE 16 Cost-effectiveness acceptability curve: adults – excluding RCTs with waitlist controls. CLO, clomipramine;
FLV, fluvoxamine; VEN, venlafaxine.
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The initial cost of therapy, particularly psychological therapies, was also influential. The number of contact
hours of BT, CT and CBT differed greatly across RCTs (see Table 55). The impact of this on NHS costs of
initial therapy was much greater than the range of daily doses used in pharmacotherapy trials. Therefore,
if we assume that all psychological and pharmacological therapies have a cost at the upper end of the
range evaluated in RCTs, pharmacotherapies become relatively cheaper and more cost-effective (Figure 18).
Although psychological therapy (specifically CT) was still estimated to be cost-effective at higher
willingness-to-pay thresholds, cheaper pharmacotherapies (e.g. venlafaxine and clomipramine) remain
relatively cost-effective options at the £20,000-per-QALY threshold.
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FIGURE 17 Cost-effectiveness acceptability curve: adults – effectiveness in patients who drop out.
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
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FIGURE 18 Cost-effectiveness acceptability curve: adults – maximum cost of initial therapy. CLO, clomipramine;
FLV, fluvoxamine; VEN, venlafaxine.
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Assumptions about the sustainability of treatment effects observed in RCTs with short follow-up periods
(e.g. 12 weeks) are influential on the cost-effectiveness results. Our primary analysis assumes that some of
the benefits of more effective therapies (i.e. the psychological therapies, particularly CT and BT) are
sustained beyond the end of the trial, although they gradually diminish as patients who had an initial
response relapse. If we were to assume that all differences in intervention costs and benefits are limited to
the within-trial period, then the initially cheaper pharmacotherapies (venlafaxine and clomipramine) are
predominantly likely to be most cost-effective (Figure 19).
Excluding venlafaxine, which does not have a licensed indication in OCD, affected the choice of optimal
intervention at lower willingness-to-pay thresholds (Figure 20). Under this scenario, clomipramine and,
to a certain extent, SSRIs, become more likely to be cost-effective, but psychological therapies remain most
likely to be cost-effective at the £20,000-per-QALY threshold.
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FIGURE 20 Cost-effectiveness acceptability curve: adults – excluding venlafaxine. CLO, clomipramine;
FLV, fluvoxamine.
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FIGURE 19 Cost-effectiveness acceptability curve: adults – costs and benefits limited to the within-trial period.
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
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Cost-effectiveness results: children and adolescents
Primary cost-effectiveness analysis
The estimated NHS costs, QALYs and cost-effectiveness of each of the five interventions in children and
adolescents are reported in Table 62. As with the adult population, over a 5-year time period, the high
upfront costs of psychological therapies are not completely counterbalanced by lower NHS costs in
subsequent years. The two pharmacotherapies (SSRIs and clomipramine) have the lowest NHS costs (range
£5398–5515), and strategies including BT or CBT have higher costs (range £6418–6762). The cost of CBT
was similar to BT, because RCTs in children and adolescents, unlike those in adults, used a similar number
of contact hours to deliver CBT and BT (see Table 55).
In children and adolescents, strategies including CBT were estimated to result in the highest QALYs over the
5-year period. The absolute difference in QALYs is again relatively small [range from 3.254 (BT) to 3.376
(sertraline and CBT)]. However, this range is approximately equivalent to an additional 397 days in ‘full response’
rather than ‘no response’ over the 5-year period. The NMB (£20,000) column summarises cost-effectiveness if
the NHS is willing to pay £20,000 for each QALY gained by patients, which is at the lower end of NICE’s stated
threshold. Table 61 is ordered by this column, with interventions with the lowest estimated NMB (i.e. least
cost-effective) at the top and interventions with the highest estimated NMB (i.e. most cost-effective) at the
bottom. In contrast to findings in the adult population, BT was estimated to be least cost-effective (NMB
£58,325). The additional upfront costs of BT, compared with the pharmacological monotherapies, were not
justified by better outcomes (QALYs). In fact, the high dropout rate from BT among children and adolescents
(see Table 50), albeit imprecisely estimated from two very small trials,218,220 led to BT being both more expensive
and less effective than SSRIs and clomipramine. The pharmacological monotherapies have a similar range of
cost-effectiveness [NMB range from £60,087 (clomipramine) to £60,828 (SSRIs)]. Differences between the
pharmacological monotherapies are driven by higher dropout rates estimated for clomipramine than SSRIs
(see Table 50). The cost-effectiveness of strategies including CBT was similar to pharmacotherapies [NMB range
from £60,905 (CBT) to £61,107 (sertraline and CBT)]. The 95th percentile intervals around the NMBs (£20,000)
estimated by the probabilistic analysis overlap, which indicates that there is no strong evidence that any single
therapy is more cost-effective than any other therapy. Strategies including CBT became relatively more
cost-effective if the NHS is willing to pay more (NMB £30,000) for each QALY gained (Table 62).
The CEAC (Figure 21) depicts the probability that each intervention is the most cost-effective, on the vertical
axis, as a function of increasing NHS willingness to pay for a QALY, on the horizontal axis. The CEAC
demonstrates that at lower willingness-to-pay thresholds (i.e. < £15,000 per QALY), the pharmacotherapies
(particularly SSRIs) are more likely to be most cost-effective. Once the willingness-to-pay threshold
exceeds £20,000 per QALY, the combined strategy of CBT and sertraline becomes the most likely to be
cost-effective, with a probability exceeding 0.5. BT had a very low probability of being most cost-effective
across the range of willingness-to-pay values. These findings are supported by the cost-effectiveness
acceptability frontier (Figure 22), which identifies SSRIs as probably the most cost-effective (optimal) therapy
at low (< £15,000 per QALY) willingness-to-pay thresholds. At the thresholds (£20,000–30,000 per QALY)
used by NICE, combined CBT and sertraline is the optimal therapy.
TABLE 62 Cost-effectiveness of therapy: children and adolescents
Intervention
Total
costs (£) Total QALYs
NMB
(£20,000) (£)
Lower 95th
percentile (£)
Upper 95th
percentile (£)
NMB
(£30,000) (£)
BT 6762 3.254 58,325 54,212 62,524 90,868
Clomipramine 5515 3.280 60,087 55,775 64,407 92,888
SSRIs 5394 3.311 60,828 56,298 65,162 93,934
CBT 6459 3.368 60,905 56,188 64,974 94,586
Sertraline+CBT 6418 3.376 61,107 56,510 65,215 94,869
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Sensitivity analyses
Full results of all sensitivity analyses are provided in Appendix 10. Here, we focus on the three sensitivity
analyses that had most impact on the findings of the cost-effectiveness model.
The most cost-effective pharmacotherapy was again strongly dependent on assumptions about outcomes
in patients who drop out. If we assume that the outcomes in patients who drop out are fully reflected in
analyses of CYBOCS scores in the meta-analysis (i.e. analyses were predominantly intention to treat), then
clomipramine, rather than SSRIs, is more likely to be the most cost-effective pharmacotherapy at lower
willingness-to pay-thresholds (Figure 23) and continues to be more cost-effective than strategies including
CBT even at higher willingness-to-pay thresholds.
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FIGURE 21 Cost-effectiveness acceptability curve: children and adolescents – primary analysis. CLO, clomipramine;
SER, sertraline.
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FIGURE 22 Cost-effectiveness acceptability frontier: children and adolescents – primary analysis. CLO, clomipramine;
SER, sertraline.
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As with the adult RCTs, the initial cost of psychological therapies is difficult to estimate because the number of
contact hours differed greatly across RCTs (see Table 55). The impact of this on NHS costs of initial therapy
was much greater than the range of daily doses used in pharmacotherapy trials. Therefore, if we assume that
all psychological and pharmacological therapies have a cost at the upper end of the range evaluated in RCTs,
pharmacotherapies become relatively cheaper and more cost-effective (Figure 24). Although psychological
therapy (specifically CBT and sertraline) was still estimated to be cost-effective at higher willingness-to-pay
thresholds, SSRIs remain the most cost-effective option at the £20,000-per-QALY threshold.
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FIGURE 23 Cost-effectiveness acceptability curve: children and adolescents. Effectiveness in patients who drop out.
CLO, clomipramine; SER, sertraline.
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FIGURE 24 Cost-effectiveness acceptability curve: children and adolescents. Maximum cost of initial therapy.
CLO, clomipramine; SER, sertraline.
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Assumptions about the sustainability of treatment effects observed in RCTs with short follow-up periods
(e.g. 12 weeks) are influential on the cost-effectiveness results. Our primary analysis assumes that some of
the benefits of more effective therapies (i.e. the psychological therapies, particularly CBT) are sustained
beyond the end of the trial, although they gradually diminish as patients who had an initial response
relapse. If we were to assume that all differences in intervention costs and benefits are limited to the
within-trial period, then SSRIs are predominantly likely to be most cost-effective (Figure 25).
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FIGURE 25 Cost-effectiveness acceptability curve: children and adolescents. Costs and benefits limited to the
within-trial period. CLO, clomipramine; SER, sertraline.
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Chapter 8 Discussion
Principal findings
In this NMA, we compared the effect of pharmacological and psychological interventions for the management
of OCD in all age groups. As far as we know, this is the first time that all available interventions for OCD
have been compared in a single analysis using mixed evidence (direct and indirect). Previous meta-analyses
on this issue had examined only the direct evidence between different interventions and most are now
outdated.120,262–264 More recent meta-analyses comparing the full range of treatment options in depression and
anxiety disorders did not focus specifically on OCD and also used the direct comparisons.265,266 Overall,
we included 86 studies reported in 85 papers (64 in adults and 22 in children and adolescents) involving 8611
randomised patients (7306 adults and 1305 children and adolescents). In the total sample, 23 different
interventions were tested in 194 arms. Interventions with the most studies were, in adults, clomipramine
(n= 17), fluvoxamine (n= 16) and BT (n= 15) and, in children and adolescents, CBT (n= 9), fluoxetine (n= 4);
clomipramine (n= 4) and sertraline (n= 4).
Clinical effectiveness findings
Results in adults
In total, 54 studies were included in this analysis, involving 6652 randomised patients. All active
interventions, apart from venlafaxine and hypericum, had a greater effect than drug placebo on OCD
symptom reduction. It should be noted that venlafaxine has not been directly compared with placebo, and
the result is based on indirect evidence only.
Regarding the pharmacological interventions, SSRIs as a class had greater effects than placebo
(class effect MD –3.49, 95% CrI –5.12 to –1.81) with small differences between them confirming previous
meta-analyses using pairwise comparisons only.263 There was a trend for clomipramine to have a greater
effect than SSRIs, but the 95% CrI included the null value. Previous meta-analyses have pointed to a
possible superior effect of clomipramine over SSRIs.120,263 Using the full data set we confirmed this trend,
although this was not formally significant. Clomipramine studies, however, were more likely to report
per-protocol and not intention-to-treat analyses (see Table 14). In our sensitivity analysis, including studies
with low risk of bias in the domain ‘incomplete outcome assessment’, the effect of clomipramine was no
longer different from those of other SSRIs (see Table 22). Therefore, our analysis cannot confirm the
supposed superiority of clomipramine over other SSRIs.
Regarding the psychological interventions, all active psychotherapies had larger effects than drug placebo,
with BT and CT having the largest effects, with small differences between them. However, CBT had a
smaller effect than both BT and CT (MD –9.11, 95% CrI –13.18 to –4.97 and MD –7.99, 95% CrI –12.97
to –3.01, respectively). Regarding the comparison between psychological interventions and psychological
placebo, both BT and CT had greater effects (MD –10.33, 95% CrI–13.38 to –7.29 and MD –9.21, 95%
CrI –13.1 to –5.34, respectively) but the effect of CBT was not significantly different from psychological
placebo (MD –1.22, 95% CrI –5.54 to 3.03).
It is difficult to explain why patients randomised to BT or CT fared better than those receiving CBT.
It is worth noting that in the sensitivity analyses, excluding the studies with high overall attrition, all
three psychotherapies had similar effects. In addition, CT has mainly been compared with BT, whereas CBT
has been compared with other interventions in a more extensive network of trials. CBT has also been
compared directly with several drugs in the same trial. Therefore, the differential effect found for CBT in
the full data set should be interpreted with caution.
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Regarding the comparison between psychological and pharmacological interventions, both BT and CT had
larger effects than SSRIs and clomipramine. The difference in effect between drugs and CBT was smaller
and the 95% CrI included the null value for both SSRIs and clomipramine. In a recent meta-analysis using
direct data only, Cuijpers et al.265 examined the differential effect of pharmacotherapy and psychotherapy
in major depression, dysthymia, panic disorder, social anxiety disorder and OCD. A positive effect for
psychotherapy over medications was reported for OCD only. The same finding was reported in a recent
meta-analysis of head-to-head comparisons of behavioural psychotherapy versus medications.267 Our NMA
confirms this trend for BT and CT but not for CBT (which is a combination of the two therapies). However,
there are two points that need to be taken into account. First, as mentioned, CT has been compared
mainly with BT, and in the data used for the analysis, BT had very limited connections with drugs
(one direct comparison with clomipramine and one with fluvoxamine). CBT, however, has several direct
links with other drugs. Second, a major limitation of psychotherapy trials is that most patients in these
trials were on a stable dose of a medication, usually a SSRI. Very few trials excluded patients on
medications and these were mainly trials that compared psychological interventions with pharmacological
interventions in the same trial (most often these were trials including CBT arms). Therefore, trials that
have compared psychological interventions only (e.g. CT vs. BT) have essentially examined the effectiveness
of these therapies in patients taking stable doses of antidepressant medications. Although patients were
symptomatic and fulfilled the criteria for inclusion in the trials (for example a YBOCS score of ≥ 16), it is
not known whether or not the concurrent use of medications could have influenced the results at the end
of the study. There is some evidence that continuous use of medications beyond the 12 weeks of the
short-term trials may reduce symptoms further.268 It is also unknown whether or not the effect of a therapy
would be different if patients were off medications, because such trials have not been performed.
However, placebo-controlled studies that used antipsychotic augmentation of SSRIs in treatment-refractory
patients have shown very small effects for ‘SSRIs+ placebo’; this is against the hypothesis of a delayed
effect of SSRIs in symptomatic patients in particular. In any case, the generalisability of these results in
patients not taking a stable dose of medication should be made with caution.
Combinations of medications and psychotherapy showed greater effects than drug placebo. The
combination of clomipramine with BT was also better than psychological placebo and clomipramine as
monotherapy (although this evidence is based on a small number of patients). However, there was no
evidence that the combinations were better than psychotherapy as monotherapy. In this respect, we did
not confirm the results of a previous direct meta-analysis that the effects of psychotherapy and
pharmacotherapy are largely independent and have additive effects.266
One of the aims of the NMA is to rank the treatments relative to each other. We have produced ranking
tables and rankograms. We would like to emphasise, however, that ranks are based on the calculated MDs
and, in that sense, they are considered a supplementary analysis regarding treatment effectiveness. The
rankograms in Figure 8 show the substantial uncertainty surrounding our estimates. In general, we did not
achieve more than a 50% probability that any of the treatments were best (and this refers to BT). A more
conservative interpretation is that there is a 50% probability that BT is the best treatment but this also
means that there is a 50% probability that it is not. Detailed tables in Appendix 8 present all the
rank probabilities.
Results in children
A total of 17 studies were included in the analysis, involving 991 randomised patients. CBT and BT had
greater effects than drug placebo. Compared with psychological placebo, both psychotherapies, and in
particular CBT, showed a trend for a greater effect, but the 95% CrIs included the null value. These results are
in line with those reported in a recent direct meta-analysis for the effectiveness of CBT in paediatric OCD.269
Selective serotonin reuptake inhibitors as a class showed a trend for a greater effect than drug placebo,
but the 95% CrIs included the null value. Individual SSRIs (fluoxetine and sertraline, but in particular the
latter), however, reached marginal statistical significance. Regarding clomipramine, taking into account
both the direct and indirect evidence (i.e. the results of the NMA), the 95% CrIs included the null value.
DISCUSSION
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The results of the pairwise analysis were formally statistically significant, whereas the results of one of the
sensitivity analyses (excluding studies with completers analyses) showed a greater effect than drug placebo.
Taken together, these results confirm that there is a trend for clomipramine to have a greater effect than
drug placebo. There is one previous meta-analysis of SSRIs and clomipramine conducted in 2003,264 but
since then most recent trials have included psychological therapies, with the exception of one recent trial
that compared CBT both alone and in combination with sertraline.234 Considering all the evidence, both
direct and indirect, our findings point to a possible advantage of some SSRIs and possibly clomipramine in
children and adolescents compared with drug placebo, although we do not confirm any superiority for
clomipramine as previously reported.264
Compared with SSRIs as a class, both psychological therapies (BT and CBT) showed a trend for a greater
effect, although the 95% CrIs included the null value. Similar results were found for clomipramine. The
combination of sertraline with CBT was associated with the largest effect compared with drug placebo
and showed marginal statistical significance compared with sertraline alone, but compared with CBT as
monotherapy, the combination had similar effects.
Regarding ranking of treatments, taking into account the limitations mentioned in the discussion of the
adult subset, CBT either as monotherapy or combined with sertraline were the best treatments, followed
by BT. All sensitivity analyses gave results with similar trends.
Tolerability findings
There is less uncertainty regarding the results of tolerability in all age groups. In adults, clomipramine was
clearly less well tolerated. All other drugs and therapies were not significantly different from placebo.
There was no evidence that combination treatments fared worse than monotherapies, although the data
are limited for these comparisons. In children and adolescents, clomipramine also showed a trend for
worse tolerability. The same was observed for BT, although this result is based on a very limited number of
patients and should be interpreted with caution. SSRIs in children and adolescents showed very good
tolerability compared with placebo, and CBT had excellent acceptability either alone or in combination
with sertraline.
Cost-effectiveness findings
Main findings
The selection of the most cost-effective therapy for adults or children and adolescents with OCD is not
clear-cut. In both populations, the most effective therapies were also among the more expensive therapies;
there is a trade-off between the higher upfront costs of psychological therapies and the potential for them
to improve outcomes and reduce long-term costs of care.
In the primary economic evaluation in adults, psychological therapies, specifically CT and BT, had the highest
probability of being most cost-effective at the conventional NICE thresholds (£20,000 to £30,000 per QALY)
and above. Perhaps surprisingly, CBT had a low probability of being cost-effective in adults at all
cost-effectiveness thresholds. This was predominantly a result of the substantially lower estimated effect
size of CBT, compared with CT and BT, and the higher intensity and, therefore, higher cost of CBT evaluated
in RCTs. However, the difference in estimated effectiveness between CBT and other psychotherapies was very
sensitive to the inclusion of RCTs that used waitlist controls and in which, therefore, participants were
unblinded. At lower willingness-to-pay thresholds (< £10,000 per QALY), pharmacotherapy, particularly
clomipramine and venlafaxine, had a relatively high probability of being cost-effective. The cost-effectiveness
of venlafaxine is particularly sensitive to the low dropout rate estimated from just two trials, which might be
viewed as an anomaly. It should be noted that the dropout rate in these two trials (< 10%) is well below the
average dropout rate of venlafaxine trials in depression or other anxiety disorders (usually > 20%). The finding
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that clomipramine is more likely to be more cost-effective than SSRIs should be considered in conjunction with
the known toxicity and side-effect profile of clomipramine.
There is substantially less trial evidence in children and adolescents. Of the five interventions compared,
SSRIs had the highest probability of being most cost-effective at lower willingness-to-pay thresholds
(< £15,000 per QALY). At the conventional NICE thresholds (£20,000 to £30,000 per QALY) and above,
CBT or CBT combined with a SSRI were more likely to be cost-effective.
The results of the economic evaluation reflect considerable uncertainty from many different sources.
Although several thousand patients with OCD have participated in RCTs, the numbers randomised to
each intervention varied considerably and were often small. The economic model is dependent on the
validity of the NMA, which itself depends on the transitivity of interventions and methods between RCTs.
Furthermore, we have demonstrated that cost-effectiveness results are sensitive to assumptions about the
sustainability of treatment effects beyond the initial treatment period. Clinicians and policy-makers should
bear this uncertainty in mind when developing treatment guidelines and prioritising future research.
Comparisons with previous studies
It is not possible to directly compare our results with those of the previous cost-effectiveness models. In
developing NICE clinical guidelines for the treatment of OCD,118 researchers developed a crude model for
comparing the cost-per-responder of SSRIs, CBT and combination therapy. They concluded that CBT alone
is dominated by SSRIs and combination (CBT and SSRI) therapy and that combination therapy is likely to be
a cost-effective option. Other work underpinning the NICE appraisal of computerised CBT compared three
interventions (computer-guided BT, clinician-led BT or relaxation) and concluded that, subject to substantial
uncertainties, therapist-led CBT is cost-effective compared with relaxation, and that computerised CBT has
the potential to be cost-effective, depending on the licence fees for health-care commissioners.248 Our
work is different in that it draws on a network of evidence, stratifies analysis by adults and children and
adolescents and provides a probabilistic analysis of treatment class options at various thresholds of
willingness to pay for a QALY.
Main limitations
Main limitations: clinical effectiveness
(a) In our NMA, we excluded studies that had not used the YBOCS to avoid using standardised MDs
instead of the MDs. There were only a small number of older trials with small sample sizes that had
not used the YBOCS. This decision was made in light of the well-documented methodological270
and interpretational difficulties142 associated with the standardised MD.
(b) There were few studies (n= 5) that had used different fixed doses of the same drug in order to
investigate the possibility of a dose–response association. Owing to the limited data in the NMA,
we were unable to treat these dosing schemes as different nodes in the network and, therefore,
we merged these treatment groups into one.
(c) There is meta-epidemiological evidence that suggests that blinding is crucial to avoid bias for subjective
and semi-objective outcome measures.271 Blinding in psychotherapy trials is difficult owing to the nature
of intervention, but in the case of waitlist controls, it is impossible. Therefore, trials that have used waitlist
controls (e.g. most of the CBT trials in children and adolescent) are more prone to bias owing to a lack of
blinding and this may have resulted in overestimation of the effect of psychotherapies.272
(d) We did not run additional tests, such as loop-specific examinations of inconsistency or a node-splitting
approach, to examine inconsistency, as suggested by some authors.149 However, given the good fit we
have observed in all our analyses we think that this was not necessary.
(e) Given that most trials were of a short-term duration rarely exceeding 12 weeks, generalisation of the
results beyond this point should be made with caution.
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Main limitations: cost-effectiveness
There has been very little research on the cost-effectiveness of therapy for OCD. Our work addresses a
broader question than two previous cost-effectiveness models by estimating cost per QALY gained and
by comparing behavioural therapies and pharmacotherapies. We use a more comprehensive range of
evidence, based on a systematic review and a NMA of RCTs, to inform model estimates of effect size and
allowing a full probabilistic assessment of the relative cost-effectiveness of treatment strategies. We also
used rapid literature reviews to identify recent evidence on the life course of OCD symptoms91,97 and
utility scores.114
Any cost-effectiveness model is only as valid as the structural assumptions and evidence that underlie it.273
We conducted the analysis from a NHS perspective, although it would be preferable to broaden it to also
include Personal Social Services costs (the perspective recommended by NICE) and broader societal costs to
patients, carers, employers and others. We could not identify any relevant data on the NHS costs of routine
care of patients with OCD, and including costs to other sectors of society would have been even more
speculative. However, it seems likely that if these costs had been available, the therapies that are initially
expensive, but also effective (i.e. psychological therapies), would become more cost-effective, as reducing
symptoms will reduce the impacts of OCD on wider society. Our model assesses the cost-effectiveness of
initial therapy only in patients with moderate or severe OCD symptoms, whereas clinical guidelines need to
consider appropriate treatment options for milder symptoms and where initial therapy has failed. Without
individual patient data from RCTs, it is difficult to judge how the (cost-)effectiveness of therapy varies by
initial symptom severity or to appropriately account for potential correlations between parameters, such
as effectiveness and dropout rates, in probabilistic sensitivity analyses. Furthermore, RCTs often collect
little detail on previous or concurrent treatment used by trial participants. Therefore, for example, an
intervention described in a RCT as ‘CBT’ may in fact include patients who have failed or are still being
prescribed various types of pharmacotherapies. In fact, our review showed that most of the patients who
were included in RCTs of psychological interventions were also taking stable doses of medications.
We conducted our economic evaluation at the class level, combining different SSRIs and different
intensities of psychological therapies. In part, this decision reflects the similarity of effect sizes within drug
classes and also the scarcity of data for conducting sub-class analysis. However, there are important
economic implications at the sub-class level. For example, although the average cost of SSRIs used in the
model was higher than clomipramine, a number of SSRIs (e.g. fluoxetine, paroxetine, sertraline or
citalopram) are cheaper and potentially more cost-effective. However, this was not confirmed from our
sensitivity analysis, assuming that SSRI medication costs were equivalent to the cheapest SSRI rather than
the class average cost. Likewise, psychological therapy might be delivered with different intensity (e.g. brief
or stepped care) and in different formats (group/individual, face to face/telephone/computer) tailored to
individual patients which may have important implications for cost-effectiveness.
Our model is based on relatively weak evidence on costs and outcomes in several areas, particularly for
children and adolescents. The sustainability of treatment effects beyond the typical 12-week follow-up
period observed in trials is particularly important. We relied on longitudinal data on response and relapse
from cohort studies following relatively small numbers of patients over a 3- to 5-year period.91,97 Long-term
follow-up of trial participants, particularly those in trials comparing pharmacotherapy and psychological
therapy, are essential to inform the cost-effectiveness of treatment options. We linked symptoms scores
(YBOCS) to response rates (full, partial or none) in order to estimate utilities via a Markov model. This
indirect approach would not have been necessary if utility scores, for instance the EQ-5D,274 were collected
in RCTs or if robust mapping functions had been developed between the YBOCS and EQ-5D.275 The
estimation of patient outcomes was further complicated by the absence of information on utilities in
children and adolescents and the widely differing definitions of full and partial response used in the
OCD literature.
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Our conclusions are sensitive to structural assumptions about patients who drop out of therapy. One
example of this is the cost-effectiveness of venlafaxine at low willingness-to-pay thresholds in adults. The
prominence of venlafaxine in our results is surprising, given the low effect size estimated in the NMA and
the fact that venlafaxine is explicitly not recommended in NICE OCD clinical guidelines118 and is caused by
the low apparent dropout rate for venlafaxine estimated in two trials. If the majority of RCTs report
‘intention to treat’ analyses where dropouts are already included in the CYBOCS/YBOCS effect size
estimate, then our primary analysis effectively ‘double-weights’ poorer outcomes in patients who drop out,
thereby unfairly favouring interventions such as venlafaxine with low dropout rates. This underlines the
importance of considering the cost-effectiveness findings alongside other evidence on the toxicity and side
effects of interventions.
DISCUSSION
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Chapter 9 Conclusions
Conclusions: clinical effectiveness
The results of this review support a range of effective options, both pharmacological and psychological, for
the management of OCD in all age groups. Regarding the relative effectiveness of treatments, our review
highlighted the great uncertainty surrounding the published randomised evidence. Although specific
psychological interventions were found to have greater effects than medications, there are important
methodological limitations that need to be taken into account in future research before a final decision
can be made.
Relevance of the findings to national guidelines: clinical effectiveness
The NICE guideline118 recommends a ‘stepped care’ approach towards managing OCD in both adults and
young people. They recommend that those with mild symptoms should be offered low-intensity (< 10
sessions or group treatment) CBT including ERP. The evidence we found did not stratify the analyses in
accordance with the severity of the illness so we could not justify this approach from the empirical data,
although it might appear sensible from a clinical perspective.
For adults with moderate symptoms, the NICE guideline recommends either SSRIs or high-intensity CBT
(including ERP). Our review finds evidence to support both these interventions. As discussed above, there
was some indication that behavioural approaches were more effective than SSRIs but we cannot be certain
of this conclusion. However, the combination of SSRIs and BT or CBT seemed an acceptable treatment,
although we do not have sufficient evidence to suggest that the combination of medication and
psychotherapy is better than psychotherapy alone. This is also relevant to the recommendation that for
those with severe illness, the combination of SSRI and BT is used.
Our review supports the NICE decision to recommend SSRIs rather than clomipramine as the first-line
antidepressant. Although clomipramine had a slightly larger effect size, we did not have any convincing
statistical evidence to suggest that clomipramine is more effective. Given the increased tolerability of SSRIs,
our review supports the recommendation that these should be used as a first-line treatment.
In conclusion, the evidence broadly supports the approach of the NICE guideline. At present, the trial
evidence on effectiveness does not justify a stepped approach towards the recommendations, although, of
course, other considerations would also have informed the NICE guideline group. The evidence suggested
that behavioural interventions could be more effective than SSRI medication, but there is a great deal of
uncertainty and we cannot confidently make that recommendation on the basis of the current evidence of
clinical effectiveness.
Research implications: clinical effectiveness
l More RCTs are needed comparing medications with psychotherapies in a single trial.
l Issues of blinding in psychotherapy trials should be taken into account. The possibility of comparing
combinations of mixed arms of the following types: ‘drug+ psychological placebo’ and ‘drug
placebo+ psychotherapy’ should be better explored. In the reviewed literature, there was just one
study that combined CBT with drug placebo. More studies of this design are needed.
l The use of the waitlist as a control in psychotherapy trials should be re-examined and perhaps replaced
with psychological placebo.
l Psychotherapy trials should exclude patients taking concurrent medications during the period of
the trial.
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Conclusions: cost-effectiveness
Relevance of the findings to national guidelines: cost-effectiveness
In adults with OCD with moderate functional impairment, current NICE guidance recommends either a
course of a SSRI or more intensive CBT (including ERP) with > 10 therapist hours per patient, noting that
these treatments appear to be comparably efficacious. The findings of our cost-effectiveness model have
important implications for guidance.
(a) There is considerable uncertainty in the economic model; at current NICE thresholds (£20,000–30,000
per QALY), CrIs of all therapies overlap and, therefore, clinical guidance is necessarily a difficult
judgement based on the balance of probabilities of costs, outcomes and risks of side effects
and withdrawal.
(b) The choice of the most cost-effective psychological therapy depends, to a large extent, on the subset
of RCTs informing effect size estimates. If all RCTs are included, the considerably larger effect sizes of
CT and BT (compared with CBT) make them most likely to be cost-effective options at current NICE
thresholds. If trials with high risk of bias owing to ‘incomplete outcome assessment’ are excluded, no CT
trials remain and the difference in effect size between BT and CBT is much smaller (see Appendix 10).
Excluding trials that use waitlist controls also reduces the differences in effect size between these
psychological therapies.
(c) The choice of the most cost-effective pharmacological therapy also depends, to a large extent, on the
subset of RCTs informing effect size estimates. In our primary analysis, clomipramine and venlafaxine
are slightly more cost-effective than SSRIs because of somewhat greater effectiveness (clomipramine)
or a lower dropout rate (venlafaxine). In sensitivity analyses, excluding trials with high risk of bias
owing to ‘incomplete outcome assessment’ and assuming patients who drop out are incorporated in
the intention-to-treat effect size estimates, SSRIs become relatively more cost-effective.
(d) Therefore, current NICE recommendations [SSRI or intensive CBT (including ERP)] are not inconsistent
with the evidence synthesised in this report, particularly if the focus is placed on trials with complete
outcome assessment. Our analysis suggests that CBT might be slightly more efficacious that SSRIs but
is initially more expensive. There is a fine balance between the relative costs and effects of SSRIs and
CBT. Tailoring the format and intensity of CBT might make it more cost-effective.
(e) If a SSRI is used, the choice of drug has important economic implications. Our analysis suggests that
the within-class treatment effect is similar, but current prices vary substantially. NICE guidance does
not currently distinguish between higher and lower cost SSRIs, but given that prescribing is
recommended for extended periods (12 months and beyond), a focus on the cheaper SSRIs
(e.g. fluoxetine, paroxetine, sertraline and citalopram) seems prudent.
In children and adolescents with OCD with moderate to severe functional impairment, NICE guidance
recommends CBT (including ERP), involving family or carers and adapted to suit the developmental age of
the child. Group or individual CBT should be offered based on patient and family preferences.
(a) Based on the limited evidence available, our findings suggest that this is a reasonable initial treatment
strategy. Again, there is considerable uncertainty in the economic model, which makes it impossible to
definitively identify a single most cost-effective treatment strategy.
(b) CBT is among the most effective treatment options, and the higher initial costs of CBT compared with
SSRIs are counterbalanced by better outcomes and lower long-term costs of care at current NICE
willingness-to-pay thresholds. Given the risk of withdrawal and side effects in this young population,
a strategy of reserving SSRI and combined SSRI and CBT therapy to children and adolescents who have
not responded to a full trial of CBT and who have had a multidisciplinary review seems appropriate.
(c) As with adult patients, considering ways to tailor the format and intensity of CBT and, if SSRIs
are used, selecting less expensive drugs licensed in children (e.g. sertraline) may improve the
cost-effectiveness of care.
CONCLUSIONS
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Research implications: cost-effectiveness
There are a number of areas of further research that would help policy-makers draw firmer conclusions
about the most cost-effective interventions for OCD:
(a) Observational research, most feasibly retrospective cohort studies based on routinely collected and
electronically collated primary care records, could provide evidence, currently absent, on the costs of
NHS care for patients with a diagnosis of OCD, stratified by symptom severity.
(b) Cross-sectional surveys of patients with OCD and their families should be conducted to provide new
information on the wider societal cost of OCD and might also be used to provide additional evidence
on the quality-of-life (utility) impact of OCD. These studies are particularly needed in children and
adolescents, where there is no strong evidence currently.
(c) Existing RCT evidence could be further used in individual patient data meta-analyses to provide a fuller
picture about any association between symptom severity and (cost) effectiveness of pharmacological
and psychological therapies.
(d) Long-term follow-up (i.e. at 12, 24 and 36 months) of published and ongoing high-quality RCTs,
particularly those directly comparing psychological and pharmacological therapies, would be very
valuable in establishing whether or not the initial high cost of psychological therapies is justified by
sustained treatment effects.
(e) New RCTs are needed to evaluate different formats and intensities of psychological therapies in direct
comparison with pharmacotherapy and should include data on costs and quality of life (utilities) of
patients over the course of the trial follow-up.
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Appendix 1 Search strategy
The CCDANCTR-Studies Register was initially searched (September–December 2012) using the followingindex terms:
Condition = obsess* or compulsi*
AND
Intervention = (Citalopram or (Clomipramin* or Clorimipramin* or Chlomipramin* or Chlorimipramin*)
or Escitalopram or Fluoxetine or Fluvoxamine or Paroxetine or Sertraline or Venlafaxine or Duloxetine or
Mirtazapine or SSRI* or Serotonin or cognitive* or behavi* or exposure or “response prevention”)
The CCDANCTR-References Register was initially searched using a more sensitive set of free-text terms
(to identify additional untagged/uncoded reports of trials):
((obsess* or compulsi* or OCD) AND (Citalopram or (Clomipramin* or Clorimipramin* or Chlomipramin*
or Chlorimipramin*) or Escitalopram or Fluoxetine or Fluvoxamine or Paroxetine or Sertraline or Venlafaxine
or Duloxetine or Mirtazapine or SSRI* or (Serotonin and (uptake or reuptake or re-uptake)) or SNRI* or
CBT or cognitive* or behavioral or behavioural or exposure or ERP or “response prevention” or ((*therap*
or train* or treatment*) and (behavi* or expos*))))
As the number of studies retrieved in this initial search was not very large (643 studies), in order to
increase the sensitivity of the search we decided to repeat the search using the condition only, (obsess* or
compulsi*), without any other terms.
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Appendix 2 Table of excluded studies
TABLE 63 List of excluded studies
Number Reference Summary comment for exclusion
1 Aigner M, Demal U, Zitterl W, Bach M, Trappl E, Lenz G.
Behavioural group therapy for obsessive–compulsive
disorder. Verhaltenstherapie 2004;14:7–14
Controlled but not randomised
2 Akouchekian S, Jamshidian Z, Maracy MR, Almasi A,
Davarpanah Jazi AH. Religious cognitive behavioural
therapy in religious oriented obsessive compulsive
disorder. The 19th European Congress of Psychiatry,
Vienna, Austria, 12–15 March 2011
Duplicate: early congress abstract of the full paper
3 Akouchekian S, Jamshidian Z, Maracy MR, Almasi A,
Davarpanah Jazi AH. Effectiveness of religious
cognitive–behavioural therapy on religious oriented
obsessive compulsive disorder and its co-morbidity.
J Isfahan Med School 2011;28:1
Special subgroup of OCD patients with religious-
oriented symptoms (in Arabic)
4 Askin R, Turan M, Cilli AS, Kaya N. Clomipramine
versus sertraline in the treatment of obsessive
compulsive disorder. Bull Clin Psychopharmacol
1999;9:133–8
Usable data only for dichotomous outcome. No
variability measure for continuous outcome
5 van Balkom A, Haan ED, Oppen PV, Spinhoven P,
Hoogduin L, Dyck RV. Cognitive–behavioural Therapy
Versus the Combination with Fluvoxamine in the
Treatment of OCD. 150th Annual Meeting of the
American Psychiatric Association. San Diego,
California, USA, 17–22 May 1997
Duplicate reporting: early congress abstract of the
van Balkom et al. 1998 paper
6 Belloch A, Cabedo E, Carrió C, Fernández-Alvarez H,
García F, Larsson C. Group versus individual cognitive
treatment for obsessive–compulsive disorder:
changes in non-OCD symptoms and cognitions at
post-treatment and 1-year follow-up. Psychiatry Res
2011;187:174–9
Secondary analysis of Cabedo et al. 2010 paper,
which has also been excluded
7 Black DW, Monahan P, Gable J, Blum N, Clancy G,
Baker P. Hoarding and treatment response in 38
nondepressed subjects with obsessive–compulsive
disorder. J Clin Psychiatry 1998;59:420–5
Duplicate data, paroxetine vs. placebo already
included in Hollander et al. 2003.180 CBT arm not
randomised
8 Cabedo E, Belloch A, Carrio C, Larsson C, Fernández-
Alvarez H, García F. Group versus individual cognitive
treatment for obsessive–compulsive disorder: changes
in severity at post-treatment and 1-year follow-up.
Behav Cogn Psychother 2010;38:227–32
Control intervention not covered (comparison
between different forms of the same therapy)
9 Denys D, van Megen HJ, van der Wee N, Westenberg
HG. A double-blind switch study of paroxetine and
venlafaxine in obsessive–compulsive disorder. J Clin
Psychiatry 2004;65:37–43
Extension of the Denys et al. 2003167 study in
non-responders (treatment refractory population)
10 Dougherty DD, Jameson M, Deckersbach T, et al.
Open-label study of high (30mg) and moderate
(20mg) dose escitalopram for the treatment
of obsessive–compulsive disorder. Int Clin
Psychopharmacol 2009;24:306–11
Dose ranging study of the same drug: no
comparator
11 Eli Lilly. Fluoxetine Treatment for Obsessive Compulsive
Disorder in Children and Adolescents. Clinical Study
Register. ID No. 3032. URL: www.lillytrials.com/results/
prozac.pdf (accessed 5 February 2016)
Duplicate with Geller et al. 2001224
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TABLE 63 List of excluded studies (continued )
Number Reference Summary comment for exclusion
12 Fineberg NA, Hughes A, Gale TM, Roberts A. Group
cognitive behaviour therapy in obsessive–compulsive
disorder (OCD): a controlled study. Int J Psychiatry Clin
Pract 2005;9:257–63
This paper used systematic and not random
sampling
13 Franklin ME, Abramowitz JS, Bux DA Jr, Zoellner LA,
Feeny NC. Cognitive–behavioural therapy with
and without medication in the treatment of
obsessive–compulsive disorder. Prof Psychol Res Pract
2002;33:162–8
Observational study stratified by medication: not an
experimental study
14 Giasuddini NA, Nahar JS, Morshed NM, Balhara YP,
Sobhan MA. Efficacy of combination of fluoxetine and
cognitive behavioural therapy and fluoxetine alone for
the treatment of obsessive compulsive disorder.
Pak J Pharm Sci 2013;26:95–8
Uncertain if truly randomised (abstract does not
mention randomised, baseline scores of the scale
used almost marginally significantly different
between the two groups with p= 0.07), unable to
find if the symptom scale used (Dhaka University
Obsessive–Compulsive Scale) has been validated or
not – reference given unable to locate, this scale
has not been used again in research
15 GlaxoSmithKline. Paroxetine versus Placebo in the
Treatment of Obsessive–Compulsive Disorder.
Clinical Study Register. 1993. URL: www.
gsk-clinicalstudyregister.com/study/29060/116
(accessed 5 February 2016)
Early report of the Hollander et al. 2003180 data set
16 GlaxoSmithKline. A Double-Blind Study to Assess the
Efficacy and Tolerance of a Flexible Dose of Paroxetine
Compared with a Flexible Dose of Clomipramine and
Placebo in the Treatment of Obsessive Compulsive
Disorder. Clinical Study Register. Study No.
MY-1037/BRL-029060/1/CPMS-136. 1993.
URL: www.gsk-clinicalstudyregister.com/files2/2287.pdf
(accessed 5 February 2016)
Duplicate of Zohar and Judge 1996213
17 Goodman WK, Lydiard RB, Rubin A, Hackett E,
Wolkow R, Londborg PD. Safety of sertraline in
long-term OCD treatment: preliminary results of a
multicenter study. 152nd Annual Meeting of the
American Psychiatric Association, Washington, DC,
15–20 May 1999
Relapse prevention study
18 Goodman WK, Price LH, Delgado PL, Palumbo J,
Krystal JH, Nagy LM, et al. Specificity of serotonin
reuptake inhibitors in the treatment of
obsessive–compulsive disorder: comparison of
fluvoxamine and desipramine. Arch Gen Psychiatry
1990;47:577–85
See control intervention
19 Greist JH. Fluvoxamine in obsessive compulsive
disorder: a multicenter parallel design double-blind
placebo-controlled trial. Clin Neuropharm
1992;15(Suppl. 1):310B
Abstract report with no data given. This is one of
the two pivotal studies of fluvoxamine from Solvay
but only the second – Goodman et al. 1996177 –
has been published. Greist et al. 1995126 in a
meta-analysis has combined the two trials but
no data can be used either
20 Greist JH, Jefferson JW, Kobak KA, Chouinard G,
DuBoff E, Halaris A, et al. A 1 year double-blind
placebo-controlled fixed dose study of sertraline in the
treatment of obsessive–compulsive disorder. Int Clin
Psychopharmacol 1995;10:57–65
Duplicate of the CCSG 1991154
21 Hewlett WA, Vinogradov S, Agras WS. Clomipramine,
clonazepam, and clonidine treatment of
obsessive–compulsive disorder. J Clin Psychopharmacol
1992;12:420–30
Comparator not covered (clonazepam, clonidine)
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TABLE 63 List of excluded studies (continued )
Number Reference Summary comment for exclusion
22 Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH,
Lydiard B, et al. Multicenter double-blind comparison
of sertraline and desipramine for concurrent
obsessive–compulsive and major depressive disorders.
Arch Gen Psychiatry 2000;57:76–82
See diagnosis and control not covered
23 Hohagen F, Konig A, Rasche-Rauchle H, Hand I, Rey E,
Aldenhoff J, et al. Behaviour therapy and fluvoxamine
versus behaviour therapy and placebo: results of a
multicenter study. Sixth World Congress of Biological
Psychiatry, Nice, France, 22–27 June 1997
Duplicate: early congress abstract of the Hohagen
et al. 1998179 paper
24 Holland R, Vardy A, Bolt G. A comparison of
fluvoxamine (FL) and clomipramine (CLO) in the
treatment of obsessive compulsive disorder (OCD).
Clin Neuropharm 1992;15(Suppl. 1):311B
Abstract congress about tolerability including
previously published data from Solvay
25 Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C,
Linnoila M. Obsessive–compulsive disorder. A double-
blind trial of clomipramine and clorgyline. Arch Gen
Psychiatry 1983;40:605–12
Control intervention not covered
26 Jakubovski E, Diniz JB, Valerio C, Fossaluza V,
Belotto-Silva C, Gorenstein C, et al. Clinical predictors
of long-term outcome in obsessive–compulsive
disorder. Depress Anxiety 2013;30:763–72
Duplicate of Belotto-Silva et al. 2012:160 secondary
27 Jenike MA, Baer L, Summergrad P, Weilburg JB,
Holland A, Seymour R. Obsessive–compulsive disorder:
a double-blind, placebo-controlled trial of
clomipramine in 27 patients. Am J Psychiatry
1989;146:1328–30
Duplicate of CCSG 1991154
28 Jonsson H, Hougaard E, Bennedsen BE. Randomised
comparative study of group versus individual cognitive
behavioural therapy for obsessive compulsive disorder.
Acta Psychiatr Scand 2011;123:387–97
Control intervention not covered (comparison
between different forms of the same therapy)
29 Karabanow O. Double-blind controlled study in
phobias and obsessions. J Int Med Res
1977;5(Suppl. 5):42–8
Not exclusively OCD (phobias): unstandardised
diagnosis
30 Kearns C, Tone Y, Rush G, Lucey JV. Effectiveness of
group-based cognitive–behavioural therapy in patients
with obsessive–compulsive disorder. Psychiatrist
2010;34:6–9
Uncontrolled case series (not randomised)
31 Khan MN, Hotiana UA, Ahmad S. Escitalopram in the
treatment of obsessive–compulsive disorder: a double
blind placebo control trial. J Ayub Med Coll
Abbottabad 2007;19:58–63
First phase of the study open label uncontrolled
trial, second phase randomised responders only for
relapse prevention
32 Koran LM, Cain JW, Dominguez RA, Rush AJ,
Thiemann S. Are fluoxetine plasma levels related to
outcome in obsessive–compulsive disorder? Am J
Psychiatry 1996;153:1450–4
Duplicate of Tollefson et al., 1994127
33 Kudo Y. A placebo controlled double blind study in
obsessive compulsive disorder with fluvoxamine.
Eur Neuropsychopharmacol 1995;5:371–2
Early congress report of the Nakajima et al. 1996201
paper
34 Leonard HL, Swedo SE, Rapoport JL, Koby EV,
Lenane MC, Cheslow DL, et al. Treatment of
obsessive–compulsive disorder with clomipramine and
desipramine in children and adolescents. A double-
blind crossover comparison. Arch Gen Psychiatry
1989;46:1088–92
Comparator not covered
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TABLE 63 List of excluded studies (continued )
Number Reference Summary comment for exclusion
35 Ma JD, Wang CH, Li HF, Zhang XL, Zhang YL, Hou YH,
et al. Cognitive-coping therapy for obsessive–compulsive
disorder: a randomised controlled trial. J Psychiatr Res
2013;47:1785–90
Non-extractable data for non-resistant patients: this
study included patients who were treatment resistant
within the study but no separate data are given for
those who were non-resistant
36 Mallya GK, White K, Waternaux C, Quay S. Short and
long term treatment of obsessive compulsive disorder
with fluvoxamine. Ann Clin Psychiatry 1992;4:77–80
Duplicate data also reported in Goodman et al.
1996177
37 Marks IM, Lelliott P, Basoglu M, Noshirvani H,
Monteiro W, Cohen D, et al. Clomipramine,
self-exposure and therapist-aided exposure for
obsessive–compulsive rituals. Br J Psychiatry
1988;152:522–34
No extractable data for treatment comparisons
38 Marks IM, Stern RS, Mawson D, Cobb J, McDonald R.
Clomipramine and exposure for obsessive–compulsive
rituals. Br J Psychiatry 1980;136:1–25
No extractable data for treatment comparisons:
OCD diagnosis not standardised
39 Mavissakalian MR, Jones B, Olson S, Perel JM.
Clomipramine in obsessive–compulsive disorder: clinical
response and plasma levels. J Clin Psychopharmacol
1990;10:261–8
Duplicate with CCSG 1991154
40 Montgomery SA. Clomipramine in obsessional
neurosis: a placebo-controlled trial. Pharmacol Med
1980;1:189–92
Duplicate: crossover data at the point of cross-over,
also reported later in Montgomery et al. 1990
41 Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine,
paroxetine, and citalopram in the treatment of
obsessive–compulsive disorder: a single-blind study.
J Clin Psychopharmacol 1997;17:267–71
Dose-ranging study of the same drug: no
comparator
42 Mundo E, Maina G, Uslenghi C. Multicentre, double-
blind, comparison of fluvoxamine and clomipramine
in the treatment of obsessive–compulsive disorder.
Int Clin Psychopharmacol 2000;15:69–76
Early report of a subset of the data that also
reported in Mundo et al. 2001200 (14 out of the
40 centres)
43 Muroff J, Steketee G, Bratiotis C, Ross A. Group
cognitive and behavioural therapy and bibliotherapy
for hoarding: a pilot trial. Depress Anxiety
2012;29:597–604
Hoarding disorder not OCD
44 Nazari H, Momeni N, Jariani M, Tarrahi MJ.
Comparison of eye movement desensitization and
reprocessing with citalopram in treatment of obsessive
compulsive disorder. Int J Psychiatry Clin Pract
2011;15:270–4
Main intervention not covered: eye movement
desensitization and reprocessing
45 Olatunji BO, Rosenfield D, Tart CD, Cottraux J,
Powers MB, Smits JA. Behavioural versus cognitive
treatment of obsessive–compulsive disorder: an
examination of outcome and mediators of change.
J Consult Clin Psychol 2013;81:415–28
Reports same data with Cottraux et al. 2001,166 but
different method of analysis and treating missing
data (multilevel instead of last observation carried
forwards)
46 Omranifard V, Akuchakian S, Almasi A, Maraci MR.
Effect of religious cognitive–behavour therapy on
religious content obsessive compulsive disorder and
marital satisfaction [conference abstract]. Eur Psychiatry
2011;26(Suppl. 1):1742
Duplicate with the Akouchakian 2011 paper, which
has been excluded
47 Pigott TA, L’Heureux F, Rubenstein CS, Bernstein SE,
Hill JL, Murphy DL. A double-blind, placebo controlled
study of trazodone in patients with obsessive–compulsive
disorder. J Clin Psychopharmacol 1992;12:156–62
Intervention not included (trazodone)
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TABLE 63 List of excluded studies (continued )
Number Reference Summary comment for exclusion
48 Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL,
Tolliver TJ, et al. Controlled comparisons of
clomipramine and fluoxetine in the treatment of
obsessive–compulsive disorder. Behavioural and
biological results. Arch Gen Psychiatry 1990;47:926–32
Data not extractable at the point of cross-over
49 Rapoport J, Elkins R, Mikkelsen E. Clinical controlled
trial of chlorimipramine in adolescents with
obsessive–compulsive disorder. Psychopharmacol Bull
1980;16:61–3
Duplicate data - this is an early report of the
Flament et al. 1985222 study (this is reported and
cited in the later Flament study)
50 Richter P, Witheridge K, Daskalakis ZJ, Deluce J,
Nebitt R, Rector N, et al. Investigation of predictors of
drug response in obsessive compulsive disorder (OCD)
[conference abstract]. Eur Neuropsychopharmacol
2010;20:529
Congress abstract only: crossover of escitalopram
versus clomipramine but no usable data given
51 Rouillon F. A double-blind comparison of fluvoxamine
and clomipramine in OCD. 11th European College of
Neuropyschopharmacology Congress. Paris, France,
31 October–4 November 1998
Duplicate, early congress report of the Mundo et al.
2001200 study
52 Shareh H, Gharaie B, Vahid MKA. [Comparison
between metacognitive therapy, fluvoxamine and
combined therapy in the improvement of thought
control strategies and stop signal criteria in obsessive
compulsive disorder.] IJPCP 2011;17:199–207
Duplicate publication of Shareh et al. 2010206
53 Shareh H, Gharraee B, Vahid MKA. [Comparison of
metacognitive therapy, fluvoxamine and combined
treatment in improving metacognitive beliefs and
subjective distress of patients with obsessive–compulsive
disorder.] Adv Cog Sci 2011;12:45–59
Secondary analysis of Sharreh et al. 2010206
54 Shavitt R, Valerio C, Diniz JB, Fossaluza V,
Belotto-Silva C, Jakubovski J, et al. Clinical predictors
of treatment outcome in obsessive–compulsive
disorder: a 2-year follow-up [conference abstract].
Eur Neuropsychopharmacol 2011;21(Suppl. 3):530
Congress abstract: extension of the Belotto-Silva
et al. 2012160 dataset
55 Sibon I, Leyton M, Gravel P, Sookman D, Pinard G,
Diksic M, et al. CBT vs sertraline in OCD: effects on
brain regional serotonin synthesis index. ACNP,
Waikoloa, HI, 11–15 December 2005
Congress abstract, data not given for analysis,
unable to decide on inclusion criteria
56 Solyom L, Sookman D. A comparison of clomipramine
hydrochloride (Anafranil) and behaviour therapy
in the treatment of obsessive neurosis. J Int Med Res
1977;5(Suppl. 5):49–61
Not randomised
57 Stein DJ, Hollander E, Mullen LS, DeCaria CM,
Liebowitz MR. Comparison of clomipramine,
alprazolam and placebo in the treatment of obsessive
compulsive disorder. Hum Psychopharmacol
1992;7:389–95
Continuous data not extractable for treatment
comparisons
58 Stein DJ, Tonnior B, Andersen EW. Escitalopram in the
treatment of OCD. Proceedings of the 159th Annual
Meeting of the American Psychiatric Association,
Toronto, ON, 20–25 May 2006
Early congress abstract of the full Stein et al. 2007124
paper
59 Steketee G, Frost RO, Tolin DF, Rasmussen J,
Brown TA. Waitlist-controlled trial of cognitive
behaviour therapy for hoarding disorder. Depress
Anxiety 2010;27:476–84
Hoarding disorder not OCD
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TABLE 63 List of excluded studies (continued )
Number Reference Summary comment for exclusion
60 Tamimi Raed R, Mavissakalian Matig R, Jones B,
Olson S. Clomipramine versus fluvoxamine in
obsessive–compulsive disorder. Ann Clin Psychiatry
1991;3:275–9
Unblinded (open-label) controlled trial
61 Turner SM, Jacob RG, Beidel DC, Himmelhoch J.
Fluoxetine treatment of obsessive–compulsive disorder.
J Clin Psychopharmacol 1985;5:207–12
Uncontrolled study, only one fluoxetine arm
62 Vallejo J, Olivares J, Marcos T, Bulbena A,
Menchón JM. Clomipramine versus phenelzine in
obsessive–compulsive disorder. A controlled clinical
trial. Br J Psychiatry 1992;161:665–70
Comparator (phenelzine) not covered
63 van Balkom AJ, de Haan E, van Oppen P, Spinhoven P,
Hoogduin KA, van Dyck R. Cognitive and behavioural
therapies alone versus in combination with
fluvoxamine in the treatment of obsessive compulsive
disorder. J Nerv Ment Dis 1998;186:492–9
The usable comparison (CBT vs. BT for 16 weeks)
has been fully reported in Van Oppen et al. 1995209
study, therefore this reports is duplicate. Remaining
arms cannot be used owing to the complexity of the
design
64 Wheadon DE, Bushnell WD, Steiner MA. A fixed-dose
comparison of 20, 40 or 60mg paroxetine to placebo
in the treatment of obsessive–compulsive disorder.
The annual meeting of the American College of
Neuropsychopharmacology, Honolulu, HI, 1993
Early report of the Hollander et al. 2003180 data set
65 Wilhelm S, Steketee G, Fama JM, Buhlmann U,
Teachman BA, Golan E. Modular cognitive therapy for
obsessive–compulsive disorder: a wait-list controlled
trial. J Cogn Psychother 2009;23:294–305
Not random assignment (but ‘according to therapist
availability’)
66 Williams TI, Salkovskis P, White H, Turner S, Forrester E,
Allsopp M. Trialled cognitive behaviour therapy for
children with OCD: a randomised controlled trial. 32nd
Congress of the British Association for Behavioural and
Cognitive Psychotherapies (jointly with the European
Association of Behavioural and Cognitive Therapies),
Manchester, 7–11 September 2004
Duplicate: early congress abstract of the Williams
et al. 2010236 full paper
67 Wootton BM, Dear BF, Johnston L, Terides MD, Titov N.
Remote treatment of obsessive–compulsive disorder:
a randomised controlled trial. J Obsess Compuls Relat
Disord 2013;2:375–84
Main aim of the paper to compare different form of
same treatment
68 Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in
obsessive–compulsive disorder. Arch Gen Psychiatry
1996;53:653–4
This is a letter from a small pilot study that,
according to the authors, is double blind but the
results have not been published. The authors report
very general trends and the study is negative. It is
not possible to extract any information
CCSG, Clomipramine Collaborative Study Group.
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Appendix 3 Publications in waiting status
TABLE 64 List of publications in waiting status
Study Comment for waiting status
Bai X, Liu C, Li X. A comparative trial of paroxetine versus
clomipramine in treatment of obsessive–compulsive neurosis.
Pract Clin Med 2002;13:63–4
In Chinese
Huang SN, Ji QM, Xie SP. A clinical comparative study of
venlafaxine and paroxetine in the treatment of
obsessive–compulsive disorder. Shandong Arch Psychiatry
2003;16:129–30
In Chinese
Jianxun L, Hu X, Haiying D. Clinical controlled study
of paroxetine and clomipramine in treatment of
obsessive–compulsive disorder. Chin J Psychiatry
1998;31:215–17
In Chinese
Jing Ping, ZA. Controlled study of clomipramine and
amitriptyline for treating obsessive–compulsive disorder.
Chin J Neurol Psychiatry 1990;23:68–70
In Chinese
Lakatos A. Cognitive behaviour therapy of
obsessive–compulsive neurosis. Praxis der Klinischen
Verhaltensmedizin und Rehabilitation 1994;7:99–106
Unable to locate (article in German): small study (n= 28)
comparing BT with CBT – e-mailed author
Lei BS. A cross-over treatment of obsessive–compulsive
neurosis with imipramine and chlorimipramine. Chin J
Neurol Psychiatry 1986;19:275–8
In Chinese
Li X, Li Z, Li Z, Huang K, Sun L. Comparative study of
citalopram and clomipramine in treatment of
obsessive–compulsive disorder. J Clin Psychological Med
2005;15:354–5
In Chinese
Liu X, Liu J, Long J. Paroxetine combined with cognitive
behaviour therapy in treatment of obsessive–compulsive
disorder. Chin J Health Psychology 2005;13:86–7
In Chinese
Liu Y, Yao C, Xu M. A comparative study of fluoxetine and
sertraline in the treatment of obsessive–compulsive disorder.
Shandong Arch Psychiatry 2004;17:204–6
In Chinese
Marconi P, Pancheri P, Catapano F, Maj M. Fluvoxamine vs
clomipramine in obsessive–compulsive disorder. 10th World
Congress of Psychiatry, 23–28 August 1996, Madrid, Spain
Congress report, no further details, no usable data, no
further publication
Montgomery SA, Montgomery DB, Fineberg N. Early
response with clomipramine in obsessive compulsive
disorder a placebo controlled study. Prog Neuro-
Psychopharmacol Biol Psychiatry 1990;14:719–27
Uncertain if duplicate data with the Montgomery SA.
Clomipramine in obsessional neurosis: a placebo-
controlled trial. Pharmacological Med 1980;1:189–92
study: e-mailed authors
Qing Y, Denghua T, Xiaoyang G. Comparative study of
cognitive therapy on obsessional compulsive disorder.
Chin Mental Health J 2004;18:421–2
In Chinese
Rajagopalan R, Niveditha, Vijayakumar. A comparative study
of efficacy and tolerability of fluvoxamine and sertraline in
treatment of obsessive–compulsive disorder. Int J Pharm
Pharm Sci 2013;5(Suppl. 2):629–32
Another publication of the same study (the thesis of the
first author) reports slightly different and inconsistent
results, although it is the same study with the same
patient population – e-mailed authors
Saboory S, Mehryar H, Ghareeb A. Comparing the
effectiveness of cognitive–behavioural techniques,
clomipramine and their combination in treatment of
obsessive–compulsive disorder. Andeesheh Va Raftar
1998;4:25–34
In Arabic
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TABLE 64 List of publications in waiting status (continued )
Study Comment for waiting status
Shaomei L, Fenglia H. Combination of clomipramine with
exposure therapy in treatment of obsessive–compulsive
disorder. Chin Mental Health J 2001;15:239–40
In Chinese
Song R, Zheng Z, Chen M. Contrast study of the effects of
paroxetine and chlorimipramine on obsessive–compulsive
disorder. J Linyi Med Coll 2005;27:327–8
In Chinese
Todorov C, Brassard M, Fontaine R, Vezina M, Elie R.
Fluoxetine vs clomipramine in obsessive–compulsive disorder.
10th World Congress of Psychiatry, 23–28 August 1996,
Madrid, Spain
Congress: abstract – no further data
Ushijima S, Kamijima K, Asai M, Murasaki M, Nakajima T,
Kudo Y, et al. Clinical evaluation of sertraline hydrochloride,
a selective serotonin reuptake inhibitor in the treatment of
obsessive–compulsive disorder. Jpn J Neuropsychopharmacol
1997;19:603–23
In Japanese: unable to locate
Wang Y, Long J, Sun M. A comparative study of citalopram
and clomipramine in the treatment of obsessive–compulsive
disorder. J Clin Psychosomatic Dis 2005;11:17–18
In Chinese
Wu H, Luo Y, Chen C. Control study of fluvoxamine and
chlorimipramine in treatment of obsession. Nervous Dis
Mental Health 2005;5:101–2
In Chinese
Yargic LI, Enderer M, Imre H, Sen D, Yazici O. A randomised
single blind comparison of clomipramine and fluvoxamine in
OCD patients. Noropsikiyatri Arsivi 1995;32:70–5
In Turkish: unable to locate
Yu L, Jin W. Clinical comparing study of sertraline and
clomipramine in treatment of obsessive–compulsive disorder.
Med J Chin People Health 2006;18:169–71
In Chinese
Zhao JP. [A control study of clomipramine and amitriptyline
for treating obsessive–compulsive disorder.] Chin J Neurol
Psychiatry 1991;24:68–70
In Chinese
Zhu J, Zhang F, Zhou D. A comparative study of mirtazapine
and chlorimipramine in treatment of obsessive–compulsive
disorder. Shandong Arch Psychiatry 2005;18:84–5
In Chinese
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Appendix 4 Main data extraction: adult subset
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TABLE 65 Main data extraction for adult subset
Study
Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Albert et al.,
2002155
2 2001 VEN 8 YBOCS 26 26 25 4.81 1 25 18.36 7.11
Albert et al.,
2002155
2 2001 CLO 9 YBOCS 47 47 25.7 5.07 7 40 17.3 6.15
Ananth et al.,
1981156
2 1981 CLO 9 Severity
Quest
10 10 122 NA 1 9 43 NA
Ananth et al.,
1981156
2 1981 AMI 13 Severity
Quest
10 10 113 NA 2 8 76 NA
Anderson and
Rees, 2007157
2 2007 CBT 11 YBOCS 21 17 24 6.2 4 17 16.7 6.8
Anderson and
Rees, 2007157
2 2007 Waitlist 2 YBOCS 17 14 24.1 5.1 3 14 23.5 6.4
Andersson et al.,
2012158
2 2012 CBT 11 YBOCS 50 50 21.42 4.59 2 49 12.94 6.26
Andersson et al.,
2012158
2 2012 PsychPLA 25 YBOCS 51 51 20.8 4.04 0 51 18.88 4.18
Belloch et al.,
2008159
2 2008 BT 10 YBOCS 15 13 24.69 5.72 2 13 8.31 8.75
Belloch et al.,
2008159
2 2008 CT 12 YBOCS 18 16 26.4 4.98 2 16 6.8 3.55
Belotto-Silva
et al., 2012160
2 2012 FLX 3 YBOCS 88 88 25.82 5.1 33 88 20.29 8.05
Belotto-Silva
et al., 2012160
2 2012 CBT 11 YBOCS 70 70 25.97 5.48 18 70 19.97 8.48
Bergeron et al.,
2002161
2 2002 FLX 3 YBOCS 73 72 26.1 5.1 22 72 NA NA 72 9.7 7.7
Bergeron et al.,
2002161
2 2002 SER 6 YBOCS 77 76 25.3 5 22 76 NA NA 76 9.6 7.9
Bisserbe et al.,
1997162
2 1997 SER 6 YBOCS 86 86 27.86 NA 23 86 13.56 NA
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Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Bisserbe et al.,
1997162
2 1997 CLO 9 YBOCS 82 81 27.43 NA 35 81 15.72 NA
CCSG1, 1991154 2 1991 CLO 9 YBOCS 118 118 26.3 5.5 17 102 16.23 0.73
CCSG1, 1991154 2 1991 PLA 1 YBOCS 121 120 26 5.5 13 108 25.11 0.61
CCSG1, 1991154 2 1991 CLO 9 YBOCS 142 134 26.2 4.9 14 120 14.7 0.68
CCSG1, 1991154 2 1991 PLA 1 YBOCS 139 129 27.2 4.8 12 119 25.59 0.53
Chouinard et al.,
1990163
2 1990 SER 6 YBOCS 43 43 23.4 4.9 6 43 3.79 5.22
Chouinard et al.,
1990163
2 1990 PLA 1 YBOCS 44 44 22.6 6.1 4 44 1.48 5.22
Cordioli et al.,
2003164
2 2003 CBT 11 YBOCS 23 23 26.7 4.9 1 23 15.1 7.8
Cordioli et al.,
2003164
2 2003 Waitlist 2 YBOCS 24 24 24.7 5.2 1 24 23.2 5.5
Cottraux et al.,
1993165
3 1993 FLV 4 NA 20 13 NA 7 13 NA
Cottraux et al.,
1993165
3 1993 BT 10 NA 20 15 NA 5 15 NA
Cottraux et al.,
1993165
3 1993 BT+ FLV 15 NA 20 16 NA 4 16 NA
Cottraux et al.,
2001166
2 2001 BT 10 YBOCS 33 32 28.5 4.9 3 30 12.1 7.8
Cottraux et al.,
2001166
2 2001 CT 12 YBOCS 32 30 28.6 5.1 2 30 12.5 8.2
Denys et al.,
2003167
2 2003 PAR 5 YBOCS 75 72 25.3 5.6 9 72 17.5 8 72 7.8 5.4
Denys et al.,
2003167
2 2003 VEN 8 YBOCS 75 73 26.9 5 4 73 19.7 8.6 73 7.2 7.5
Emmelkamp and
Beens, 1991168
2 1991 CT 12 Maudsley
OCI
15 10 17.2 6.2 5 10 12.3 7.3
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TABLE 65 Main data extraction for adult subset (continued )
Study
Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Emmelkamp and
Beens, 1991168
2 1991 BT 10 Maudsley
OCI
15 11 16.3 5.7 4 11 13.7 5.8
Emmelkamp et al.,
1988169
2 1988 CT 12 Maudsley
OCI
10 9 15.6 2.9 1 9 11.3 1.7
Emmelkamp
et al., 1988169
2 1988 BT 10 Maudsley
OCI
10 9 15.6 4 1 9 12.6 5.4
Fals-Stewart
et al., 1993170
2 1993 BT 10 YBOCS 34 31 20.2 NA 3 31 12.1 NA
Fals-Stewart
et al., 1993170
2 1993 PsychPLA 25 YBOCS 32 32 19.9 NA 0 32 18.1 NA
Foa et al., 2005171 4 2005 BT 10 YBOCS 37 29 24.6 4.8 16 29 11 7.9
Foa et al., 2005171 4 2005 CLO 9 YBOCS 47 36 26.3 4.4 20 36 18.2 7.8
Foa et al., 2005171 4 2005 BT+CLO 18 YBOCS 33 31 25.4 4.6 14 31 10.5 8.2
Foa et al., 2005171 4 2005 PLA 1 YBOCS 32 26 25 4 12 26 22.2 6.4
Freeman et al.,
1994172
2 1994 FLV 4 YBOCS 34 34 26.2 NA 6 8.6 NA
Freeman et al.,
1994172
2 1994 CLO 9 YBOCS 32 30 25.5 NA 13 7.8 NA
Freeston et al.,
1997173
2 1997 CBT 11 YBOCS 15 15 25.1 5 3 15 12.2 9.6
Freeston et al.,
1997173
2 1997 Waitlist 2 YBOCS 14 14 21.2 6 0 14 22 6
GlaxoSmithKline,
2005174
3 1993 PLA 1 YBOCS 77 75 24.66 NA 20 75 4.61 0.87
GlaxoSmithKline,
2005174
3 1993 PAR 5 YBOCS 82 79 23.28 NA 28 79 5.61 0.84
GlaxoSmithKline,
2005174
3 1993 CLO 9 YBOCS 82 78 23.9 NA 28 78 7.73 0.84
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Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
GlaxoSmithKline,
2005175
2 1999 PAR 5 YBOCS 73 72 25.11 6.07 1 72 10.85 6.85 72 14.26 6.33
GlaxoSmithKline,
2005175
2 1999 CLO 9 YBOCS 73 69 24.07 5.74 4 69 10.88 6.86 69 13.19 6.48
Goodman et al.,
1989176
2 1989 PLA 1 YBOCS 23 21 25.6 6.6 6 21 28 7
Goodman et al.,
1989176
2 1989 FLV 4 YBOCS 23 21 25 6 2 21 19.4 7
Goodman et al.,
1996177
2 1996 PLA 1 YBOCS 80 78 24 NA 17 78 1.71 4.88
Goodman et al.,
1996177
2 1996 FLV 4 YBOCS 80 78 22.6 NA 23 78 3.95 6.28
Greist et al.,
1995126
2 1995 SER 6 YBOCS 241 240 23.8 5.3 65 240 5.57 6.19
Greist et al.,
1995126
2 1995 PLA 1 YBOCS 84 84 23.4 4.9 24 84 3.41 6.19
Greist et al.,
2002178
2 2002 BT 10 YBOCS 69 55 25.2 4.6 14 55 17.6 6.2
Greist et al.,
2002178
2 2002 PsychPLA 25 YBOCS 75 66 25.8 5.1 9 66 24.1 6.7
Hohagen et al.,
1998179
2 1998 BT+ PLA 21 YBOCS 30 25 28.4 3.8 NA 25 15.9 7.9
Hohagen et al.,
1998179
2 1998 BT+ FLV 15 YBOCS 30 24 27.9 2.9 NA 24 12.4 6.8
Hollander et al.,
2003181
2 2003 PLA 1 YBOCS 126 120 26.4 0.3 31 120 21 1 120 5.60 0.70
Hollander et al.,
2003181
2 2003 FLV 4 YBOCS 127 117 26.8 0.3 43 117 17.6 1.1 117 8.5 0.70
Hollander et al.,
2003181
4 2003 PLA 1 YBOCS 89 89 25.6 NA 15 89 3.33 NA
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TABLE 65 Main data extraction for adult subset (continued )
Study
Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Hollander et al.,
2003180
4 2003 PAR-20 5 YBOCS 88 88 25.9 NA 14 88 4.14 NA
Hollander et al.,
2003180
4 2003 PAR-40 5 YBOCS 86 86 25.4 NA 20 86 6.35 NA
Hollander et al.,
2003180
4 2003 PAR-60 5 YBOCS 85 85 25.3 NA 19 85 7.34 NA
Jaurrieta et al.,
2008182
2 2008 CBT 11 YBOCS 19 19 25.2 7.7 NA 19 17.8 8.4
Jaurrieta et al.,
2008182
2 2008 Waitlist 2 YBOCS 19 19 24.8 7.3 NA 19 24.6 8.9
Jenike et al.,
1990183
2 1990 SER 6 YBOCS 10 10 22.8 6 0 10 20.6 9.2
Jenike et al.,
1990183
2 1990 PLA 1 YBOCS 9 9 22.8 4.8 0 9 22.3 7.8
Jenike et al.,
1990184
2 1990 PLA 1 YBOCS 20 20 22.7 6.1 0 20 21.8 7.6
Jenike et al.,
1990184
2 1990 FLV 4 YBOCS 20 18 22.6 3.5 2 18 18.8 4
Jenike et al.,
1997185
2 1997 PLA 1 YBOCS 21 19 18.9 6.2 3 18 18.7 6.1
Jenike et al.,
1997185
2 1997 FLX 3 YBOCS 23 22 19 5.4 4 19 16.2 6.3
Jones and Menzies,
1998186
2 1998 CT 12 Maudsley
OCI
12 11 17.82 NA 1 11 14.27 NA
Jones and Menzies,
1998186
2 1998 Waitlist 2 Maudsley
OCI
11 10 17.6 NA 1 10 17.7 NA
Kamijima et al.,
2004187
2 2004 PLA 1 YBOCS 96 94 23.4 4.72 NA 94 20.3 7.38
Kamijima et al.,
2004187
2 2004 PAR 5 YBOCS 95 94 24.3 4.4 NA 94 15.8 8.09
Khodarahimi,
2009188
2 2009 Waitlist 2 YBOCS 20 20 36.4 2.26 0 20 36.45 2.24
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Study
Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Khodarahimi,
2009188
2 2009 BT 10 YBOCS 20 20 37.2 1.91 0 20 5.58 2.39
Kobak et al.,
2005189
2 2005 PLA 1 YBOCS 30 30 23.47 5.54 9 30 19.87 7.46
Kobak et al.,
2005189
2 2005 HYP 13 YBOCS 30 30 23.17 3.81 8 30 19.75 7.46
Koran et al.,
1996190
2 1996 FLV 4 YBOCS 37 34 25.5 5.97 8 34 17.8 7.7
Koran et al.,
1996190
2 1996 CLO 9 YBOCS 42 39 24.3 5.95 15 39 17 8.55
Kronig et al.,
1999191
2 1999 SER 6 YBOCS 86 86 25.21 3.79 25 85 8.5 10.50
Kronig et al.,
1999191
2 1999 PLA 1 YBOCS 81 81 25.05 4.09 25 79 4.14 10.50
Lindsay et al.,
1997192
2 1997 BT 10 YBOCS 9 9 28.7 4.56 0 9 11 3.81
Lindsay et al.,
1997192
2 1997 PsychPLA 25 YBOCS 9 9 24.44 6.98 0 9 25.89 5.8
López-Ibor et al.,
1996193
2 1996 FLX 3 YBOCS 30 30 27.6 5.2 5 30 30 7.5 9.29
López-Ibor et al.,
1996193
2 1996 CLO 9 YBOCS 25 24 25.6 6.09 3 24 24 8.9 7.13
Mavissakalian
et al., 1985194
2 1985 CLO 9 OCNS NA 7 74.5 4.74 NA 7 48 6.94
Mavissakalian
et al., 1985194
2 1985 PLA 1 OCNS NA 5 80 6.55 NA 5 69 8.51
McLean et al.,
2001195
2 2001 CT 12 YBOCS 49 33 21.9 5.8 18 31 16.1 6.7
McLean et al.,
2001195
2 2001 BT 10 YBOCS 44 40 21.8 4.6 12 32 13.2 7.2
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TABLE 65 Main data extraction for adult subset (continued )
Study
Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Milanfranchi
et al., 1997196
2 1997 CLO 9 YBOCS 13 13 27.5 6.8 1 12 16.5 11
Milanfranchi
et al., 1997196
2 1997 FLV 4 YBOCS 13 13 29.7 5.5 0 13 18.4 9.2
Montgomery
et al., 1993197
4 1993 PLA 1 YBOCS 57 56 23.25 6.86 15 56 20.04 NA 56 3.7 5.98
Montgomery
et al., 1993197
4 1993 FLX-20 3 YBOCS 53 52 23.79 4.91 14 53 18.66 NA 52 5.13 6.41
Montgomery
et al., 1993197
4 1993 FLX-40 3 YBOCS 52 52 25.52 5.59 13 52 19.06 NA 52 4.76 6.89
Montgomery
et al., 1993197
4 1993 FLX-60 3 YBOCS 55 54 22.98 7.18 14 54 17.71 NA 54 6.07 6.92
Montgomery
et al., 2001198
4 2001 CIT-20 7 YBOCS 102 102 25.1 3.9 16 102 8.4 7.3
Montgomery
et al., 2001198
4 2001 CIT-40 7 YBOCS 98 98 26 3.7 15 98 8.9 7.00
Montgomery
et al., 2001198
4 2001 CIT-60 7 YBOCS 100 100 25.9 4.5 15 100 10.4 6.90
Montgomery
et al., 2001198
4 2001 PLA 1 YBOCS 101 101 25.4 3.9 17 101 5.6 6.90
Mundo et al.,
1997199
3 1997 FLV 4 YBOCS 10 10 25.4 6.5 0 10 16.2 8.9
Mundo et al.,
1997199
3 1997 PAR 5 YBOCS 9 9 30.5 3.9 0 9 21.6 7.6
Mundo et al.,
1997199
3 1997 CIT 7 YBOCS 11 11 29.3 3.9 0 11 19.8 10.1
Mundo et al.,
2001200
2 2001 CLO 9 YBOCS 112 112 25.4 6.1 26 112 13.4 NA
Mundo et al.,
2001200
2 2001 FLV 4 YBOCS 115 115 26.5 5.6 19 115 14.3 NA
Nakajima et al.,
1996201
2 1996 FLV 4 YBOCS 61 61 24.7 4.8 NA 61 NA NA 61 7.1 7.03
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Study
Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Nakajima et al.,
1996201
2 1996 PLA 1 YBOCS 33 33 26.2 6.1 NA 33 NA NA 33 1.9 7.20
Nakatani et al.,
2005202
3 2005 PsychPLA 25 YBOCS 9 8 30.5 3.7 1 8 28.4 5.5
Nakatani et al.,
2005202
3 2005 FLV 4 YBOCS 11 10 28.4 3.8 1 10 20.2 9.4
Nakatani et al.,
2005202
3 2005 BT 10 YBOCS 11 10 29.9 3.1 1 10 12.9 4.9
O’Connor et al.,
1999203
4 1999 SRI 14 YBOCS 6 5 21 2.9 1 5 12 4.5
O’Connor et al.,
1999203
4 1999 Waitlist 2 YBOCS 6 6 19.3 4.5 0 6 17.5 4
O’Connor et al.,
1999203
4 1999 CBT 11 YBOCS 7 6 23.5 4 1 6 13.3 8.6
O’Connor et al.,
1999203
4 1999 CBT+ SRI 20 YBOCS 10 9 23.8 5.4 1 9 17.8 4.7
O’Connor et al.,
2006204
2 2006 PLA 1 YBOCS 10 10 27.3 4.3 NA 10 25.4 3.5
O’Connor et al.,
2006204
2 2006 FLV 4 YBOCS 11 11 28.3 3.9 NA 11 24 4.7
Perse et al.,
1987205
2 1987 PLA 1 Maudsley
OCI
10 8 NA NA 2 NA NA
Perse et al.,
1987205
2 1987 FLV 4 Maudsley
OCI
10 8 NA NA 2 NA NA
Shareh et al.,
2010206
3 2010 FLV 4 YBOCS 7 6 25.83 5.77 1 6 16.66 3.2
Shareh et al.,
2010206
3 2010 CBT 11 YBOCS 7 7 29 6.73 0 7 7 2.38
Shareh et al.,
2010206
3 2010 FLV+CBT 16 YBOCS 7 6 26.16 7.98 1 6 8.5 2.42
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TABLE 65 Main data extraction for adult subset (continued )
Study
Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Sousa et al.,
2006207
2 2006 SER 6 YBOCS 28 25 26.12 NA 3 25 18.76 NA
Sousa et al.,
2006207
2 2006 CBT 11 YBOCS 28 25 25.08 NA 3 25 14.28 NA
Stein et al.,
2007124
4 2007 PLA 1 YBOCS 115 113 27.7 4.2 18 113 8.46 0.76
Stein et al.,
2007124
4 2007 PAR 5 YBOCS 119 116 27.3 4 29 116 11.67 0.78
Stein et al.,
2007124
4 2007 ESCIT-10 19 YBOCS 116 112 26.6 3.7 24 112 11.43 0.78
Stein et al.,
2007124
4 2007 ESCIT-20 19 YBOCS 116 114 26.6 3.9 21 114 12.14 0.77
Thoren et al.,
1980208
2 1980 CLO 9 OCD
symptom
scale
NA 8 4.38 1.22 NA 8 2.94 1.15
Thoren et al.,
1980208
2 1980 PLA 1 OCD
symptom
scale
NA 8 3.94 1.24 NA 8 3.69 1.46
Tollefson et al.,
1994127
4 1994 PLA 1 YBOCS 89 89 24.3 5.7 13 76 23.6 7.5 89 0.8 5.66
Tollefson et al.,
1994127
4 1994 FLX-20 3 YBOCS 87 87 23.6 5.7 12 75 18.9 8.3
Tollefson et al.,
1994127
4 1994 FLX-40 3 YBOCS 89 89 23.5 5.6 22 67 18.1 7.9
Tollefson et al.,
1994127
4 1994 FLX-60 3 YBOCS 90 90 24.4 5.1 22 68 16.8 7.8
Van Oppen et al.,
1995209
2 1995 CT 12 YBOCS 35 28 28.7 5.3 7 28 13.4 9.4
Van Oppen et al.,
1995209
2 1995 BT 10 YBOCS 36 29 31.4 5 7 29 17.9 9
Volavka et al.,
1985210
2 1985 CLO 9 SRONS 11 8 61.5 13.6 3 8 41.9 13.9
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Number
of arms Year Intervention
Coding of
intervention Scale used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Volavka et al.,
1985210
2 1985 IMI 13 SRONS 12 8 80.7 11.5 4 8 63.6 20.5
Whittal et al.,
2005211
2 2005 CT 12 YBOCS 41 34 23.5 4.3 11 30 10.6 7.1
Whittal et al.,
2005211
2 2005 BT 10 YBOCS 42 37 21.66 5.9 13 29 10.41 7.6
Whittal et al.,
2010212
2 2010 CT 12 YBOCS 40 40 18.03 6.29 3 37 6.43 4.77
Whittal et al.,
2010212
2 2010 PsychPLA 25 YBOCS 33 33 17.73 7.73 3 30 9.1 6.48
Zohar and Judge,
1996213
3 1996 PLA 1 YBOCS 100 99 NA NA 40 99 4.2 7.2
Zohar and Judge,
1996213
3 1996 PAR 5 YBOCS 205 201 NA NA 53 201 6.4 7.1
Zohar and Judge,
1996213
3 1996 CLO 9 YBOCS 101 99 NA NA 36 99 7 6.8
AMI, amitriptyline; BL_m, mean YBOCS (or other scale) at baseline; BLn, number at baseline; BL_sd, SD of YBOCS at baseline; CCSG, Clomipramine Collaborative Study Group;
CGE_m, mean change in YBOCS from baseline; CGEn, number of patients with data for score changes; CGE_sd, SD of change; CIT, citalopram; CLO, clomipramine; Dr_n, total dropouts;
ESCIT, escitalopram; FLV, fluvoxamine; FLX, fluoxetine; FU_mean, mean YBOCS at the end of study; FU_n, number at the end of study; FU_sd, SD of YBOCS (of other scale) at the end of
study; HYP, hypericum; IMI, imipramine; NA, not available; OCI, Obssessive–Compulsive Inventory; OCNS, Obsessive–Compulsive Neurotic Scale; OCR, Obssessive–Compulsive Rating scale;
PAR, paroxetine; PLA, placebo; PsychPLA, psychological placebo; SER, sertraline; SRI, serotonin reuptake inhibitor; SRONS, Self-Rating Obsessional Neurotic Scale; VEN, venlafaxine.
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TABLE 66 Main data extraction for children and adolescents subset
Study
Number
of arms Year Intervention
Coding of
intervention
Scale
used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Alaghband-Rad and
Hakimshooshtary, 2009215
2 2009 FLX 3 CYBOCS 15 15 26.66 NA NA NA 15 NA
Alaghband-Rad and
Hakimshooshtary, 2009215
2 2009 CIT 7 CYBOCS 14 14 28 NA NA NA 16.9 NA
Asbahr et al., 2005216 2 2005 SER 6 CYBOCS 20 19 27 6.65 1 19 NA NA
Asbahr et al., 2005216 2 2005 CBT 11 CYBOCS 20 20 26.3 4.9 0 20 NA NA
Barrett et al., 2004217 2 2004 CBT 11 CYBOCS 24 22 23.64 4.3 NA 22 8.36 6.93
Barrett et al., 2004217 2 2004 Waitlist 2 CYBOCS 24 24 22.95 5.49 NA 24 24.04 4.14
Bolton and Perrin, 2008218 2 2008 BT 10 CYBOCS 10 10 24 4.78 2 10 13.9 10.74
Bolton and Perrin, 2008218 2 2008 Waitlist 2 CYBOCS 10 10 22 8.25 0 10 21.1 5.9
Bolton et al., 2011219 2 2011 Waitlist 2 CYBOCS 24 24 24,2 5 3 24 23.3 8.3
Bolton et al., 2011219 2 2011 CBT 11 CYBOCS 36 36 22.3 5 2 36 9.5 8
de Haan et al., 1998220 2 1998 CLO 9 CYBOCS 10 10 23.8 7.2 0 10 17.6 11.8
de Haan et al., 1998220 2 1998 BT 10 CYBOCS 13 12 21.5 5.9 1 12 9.1 9.1
DeVeaugh-Geiss
et al., 1992221
2 1992 CLO 9 CYBOCS 31 31 27.1 NA 4 31 17.1 NA
DeVeaugh-Geiss
et al., 1992221
2 1992 PLA 1 CYBOCS 29 29 28.4 NA 2 29 26 NA
Flament et al., 1985222 2 1985 CLO 9 OCR
scale
NA NA NA NA NA NA 9.1 3.6
Flament et al., 1985222 2 1985 PLA 1 OCR
scale
NA NA NA NA NA NA 12.1 4
Freeman et al., 2008223 2 2008 CBT 11 CYBOCS 22 22 22.95 3.84 6 22 14.45 8.16
Freeman et al., 2008223 2 2008 PsychPLA 25 CYBOCS 20 20 21.7 4.52 5 20 17.1 7.57
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Study
Number
of arms Year Intervention
Coding of
intervention
Scale
used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
Geller et al., 2001224 2 2001 PLA 1 CYBOCS 32 32 26.3 4.6 12 32 5.2 7.4
Geller et al., 2001224 2 2001 FLX 3 CYBOCS 71 71 24.5 5.1 22 71 9.5 9.2
GlaxoSmithKline, 2001225 2 2001 PAR 5 CYBOCS 100 98 24.4 4.95 35 98
GlaxoSmithKline, 2001225 2 2001 PLA 1 CYBOCS 107 105 25.3 5.05 27 105
Liebowitz et al., 2002226 2 2002 PLA 1 CYBOCS 22 22 23.82 5.77 4 22 18.55 11.44
Liebowitz et al., 2002226 2 2002 FLX 3 CYBOCS 21 21 22.5 4.16 1 21 14.71 8.73
March et al., 1990227 2 1990 CLO 9 YBOCS 8 8 24.5 3.6 2 8 19.3 8.6
March et al., 1990227 2 1990 PLA 1 YBOCS 8 8 27.4 3.4 0 8 25.6 2.4
March et al., 1998228 2 1998 SER 6 CYBOCS 92 92 23.4 NA 18 92 6.8 0.87
March et al., 1998228 2 1998 PLA 1 CYBOCS 95 95 22.2 NA 13 95 3.4 0.82
Neziroglu et al., 2000229 2 2000 FLV 4 CYBOCS 5 5 22.8 4.21 0 5 19.2 3.56
Neziroglu et al., 2000229 2 2000 BT+ FLV 15 CYBOCS 5 5 28 6.2 0 5 16.4 5.18
Piacentini et al., 2011230 2 2011 CBT 11 CYBOCS 49 49 24.7 0.71 8 49 13.3 1.33
Piacentini et al., 2011230 2 2011 PsychPLA 25 CYBOCS 22 22 25.3 0.97 5 22 17.2 2.14
Riddle et al., 1992231 2 1992 PLA 1 CYBOCS 6 6 20.2 7.7 1 6 14.8 7
Riddle et al., 1992231 2 1992 FLX 3 CYBOCS 7 7 24.3 4.2 1 7 13.6 5.7
Riddle et al., 2001232 2 2001 PLA 1 CYBOCS 63 63 24.2 4.8 27 63 20.9 8.5
Riddle et al., 2001232 2 2001 FLV 4 CYBOCS 57 57 24.2 4.4 19 57 18.2 8.6
Storch et al., 2011233 2 2011 CBT 11 CYBOCS 16 16 25.38 3.81 2 16 11.13 10.53
Storch et al., 2011233 2 2011 Waitlist 2 CYBOCS 15 15 21.27 2.74 0 15 18.53 8.11
Storch et al., 2013234 2 2013 SER+CBT 17 CYBOCS 14 14 23.64 4.48 6 14 15.43 9.72
Storch et al., 2013234 2 2013 CBT+ PLA 22 CYBOCS 16 16 25.06 4.01 3 16 15.56 6.62
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TABLE 66 Main data extraction for children and adolescents subset (continued )
Study
Number
of arms Year Intervention
Coding of
intervention
Scale
used
Original N
randomised BLn BL_m BL_sd Dr_n FU_n FU_mean FU_sd CGEn CGE_m CGE_sd
The Pediatric OCD
Treatment Study, 2004236
4 2004 SER 6 CYBOCS 28 28 23.5 4.7 2 28 16.5 9.1
The Pediatric OCD
Treatment Study, 2004236
4 2004 CBT 11 CYBOCS 28 28 26 4.6 3 28 14 9.5
The Pediatric OCD
Treatment Study, 2004236
4 2004 SER+CBT 17 CYBOCS 28 28 23.8 3 3 28 11.2 8.6
The Pediatric OCD
Treatment Study, 2004236
4 2004 PLA 1 CYBOCS 28 28 25.2 3.3 7 28 21.5 5.4
Williams et al., 2010235 2 2010 CBT 11 CYBOCS 11 11 23.09 1.22 1 11 12.09 2.25
Williams et al., 2010235 2 2010 Waitlist 2 CYBOCS 10 10 21.05 1.84 1 10 19.6 2.03
BL_m, mean CYBOCS (or other scale) at baseline; BLn, number at baseline; BL_sd, SD of CYBOCS at baseline; CGE_m, mean change in YBOCS from baseline; CGEn, number of patients
with data for score changes; CGE_sd, SD of change; CIT, citalopram; CLO, clomipramine; Dr_n, total dropouts; FLV, fluvoxamine; FLX, fluoxetine; FU_mean, mean CYBOCS at the end of
study; FU_n, number at the end of study; FU_sd, SD of CYBOCS (of other scale) at the end of study; NA, not available; PAR, paroxetine; PLA, placebo; PsychPLA, psychological placebo;
SER, sertraline.
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TABLE 67 Additional extraction: adult subset
Study Settinga Intervention
Average or mean
dose at the end (mg)
SD of mean
dose (mg)
Minimum dose
during the study (mg)
Maximum
dose during
the study (mg)
Number of
sessions
Duration of
session (hours)
Albert et al., 2002155 1 VEN 265 52.5 225 350
Albert et al., 2002155 1 CLO 168 28.9 150 225
Ananth et al. 1981156 3 CLO 133.3 NA 75 300
Ananth et al. 1981156 3 AMI 197.4 NA 75 300
Anderson and Rees, 2007157 1 CBT 10 1
Anderson and Rees, 2007157 1 Waitlist Waitlist Waitlist
Anderson and Rees, 2007157 1 CBT 10 NA
Anderson and Rees, 2007157 1 PsychPLA PsychPLA PsychPLA
Belloch et al., 2008159 1 BT 20 1
Belloch et al., 2008159 1 CT 18 1
Belotto-Silva et al., 2012160 1 FLX 80 Fixed
Belotto-Silva et al., 2012160 1 CBT 12 2
Bergeron et al., 2002161 1 FLX 56.7 23 20 80
Bergeron et al., 2002161 1 SER 139.5 58.5 50 200
Bisserbe et al., 1997162 1 SER 136 NA 50 200
Bisserbe et al., 1997162 1 CLO 110 NA 50 200
CCSG1, 1991154 1 CLO 234.5 NA 100 300
CCSG1, 1991154 1 PLA PLA
CCSG2, 1991154 1 CLO 218.8 NA 100 300
CCSG2, 1991154 1 PLA PLA
Chouinard et al., 1990163 1 SER 185 NA 50 200
Chouinard et al., 1990163 1 PLA PLA PLA PLA PLA
Cordiolo et al., 2003164 1 CBT 12 2
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Study Settinga Intervention
Average or mean
dose at the end (mg)
SD of mean
dose (mg)
Minimum dose
during the study (mg)
Maximum
dose during
the study (mg)
Number of
sessions
Duration of
session (hours)
Cordiolo et al., 2003164 1 Waitlist Waitlist Waitlist
Cottraux et al., 1993165 1 FLV 282 NA NA 300
Cottraux et al., 1993165 1 BT 25 NA
Cottraux et al., 1993165 1 BT+ FLV 282 NA NA 300 25 NA
Cottraux et al., 2001166 1 BT 20 1
Cottraux et al., 2001166 1 CT 20 1
Denys et al., 2003167 1 PAR 60 Fixed 60
Denys et al., 2003167 1 VEN 300 Fixed 300
Emmelkamp and Beens,
1991168
1 CT 31 NA
Emmelkamp and Beens,
1991168
1 BT 31 1.5
Emmelkamp et al., 1988169 1 CT 10 1
Emmelkamp et al., 1988169 1 BT 10 1
Fals-Stewart et al., 1993170 1 BT 24 1
Fals-Stewart et al., 1993170 1 PsychPLA
Foa et al., 2005171 1 BT 15 2
Foa et al., 2005171 1 CLO 235 34 250
Foa et al., 2005171 1 BT+CLO 194 48 250 15 2
Foa et al., 2005171 1 PLA PLA
Freeman et al., 1994172 1 FLV 200 NA 150 250
Freeman et al., 1994172 1 CLO 200 NA 150 250
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TABLE 67 Additional extraction: adult subset (continued )
Study Settinga Intervention
Average or mean
dose at the end (mg)
SD of mean
dose (mg)
Minimum dose
during the study (mg)
Maximum
dose during
the study (mg)
Number of
sessions
Duration of
session (hours)
Freeston et al., 1997173 1 CBT 40 1.5
Freeston et al., 1997173 1 Waitlist Waitlist Waitlist
GlaxoSmithKline, 2005174 1 PLA PLA PLA PLA PLA
GlaxoSmithKline, 2005174 1 PAR NA NA 60
GlaxoSmithKline, 2005174 1 CLO NA NA 250
GlaxoSmithKline, 2005175 9 PAR NA NA 50
GlaxoSmithKline, 2005175 9 CLO NA NA 275
Goodman et al., 1989176 1 PLA PLA
Goodman et al., 1989176 1 FLV 255 60 300
Goodman et al., 1996177 1 PLA PLA
Goodman et al., 1996177 1 FLV 245 NA 100 300
Greist et al., 1995126 1 SER 50/100/200 Fixed
Greist et al., 1995126 1 PLA PLA
Greist et al., 2002178 1 BT 11 1
Greist et al., 2002178 1 PsychPLA PsychPLA PsychPLA
Hohagen et al., 1998179 2 BT+ PLA PLA PLA PLA PLA
Hohagen et al., 1998179 2 BT+ FLV 288.1 NA 300
Hollander et al., 2003181 1 PLA PLA
Hollander et al., 2003181 1 FLV 271 NA 100 300
Hollander et al., 2003180 1 PLA PLA PLA PLA PLA
Hollander et al., 2003180 1 PAR-20 20 Fixed Fixed Fixed
Hollander et al., 2003180 1 PAR-40 40 Fixed Fixed Fixed
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Study Settinga Intervention
Average or mean
dose at the end (mg)
SD of mean
dose (mg)
Minimum dose
during the study (mg)
Maximum
dose during
the study (mg)
Number of
sessions
Duration of
session (hours)
Hollander et al., 2003180 1 PAR-60 60 Fixed Fixed Fixed
Jaurrieta et al., 2008182 1 CBT 20 0.75 hours
(45 minutes)
Jaurrieta et al., 2008182 1 Waitlist Waitlist Waitlist
Jenike et al., 1990183 9 SER 200 Fixed 200
Jenike et al., 1990183 9 PLA PLA PLA
Jenike et al., 1990184 1 PLA PLA
Jenike et al., 1990184 1 FLV 294 23.6 100 300
Jenike et al., 1997185 1 PLA PLA PLA PLA PLA
Jenike et al., 1997185 1 FLX 77.9 6.3 80
Jones and Menzies, 1998186 1 CT 8 1
Jones and Menzies, 1998186 1 Waitlist
Kamijima et al., 2004187 9 PLA PLA PLA PLA PLA
Kamijima et al., 2004187 9 PAR 45 5 40 50
Khodarahimi, 2009188 1 Waitlist Waitlist Waitlist
Khodarahimi, 2009188 1 BT 12 1.5
Kobak et al., 2005189 1 PLA PLA
Kobak et al., 2005189 1 HYP 1663.64 303.22 600 1800
Koran et al., 1996190 1 FLV 255 NA 100 300
Koran et al., 1996190 1 CLO 201 NA 100 250
Kronig et al., 1999191 1 SER 165 55 50 200
Kronig et al., 1999191 1 PLA PLA PLA PLA PLA
Lindsay et al., 1997192 1 BT 15 1
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TABLE 67 Additional extraction: adult subset (continued )
Study Settinga Intervention
Average or mean
dose at the end (mg)
SD of mean
dose (mg)
Minimum dose
during the study (mg)
Maximum
dose during
the study (mg)
Number of
sessions
Duration of
session (hours)
Lindsay et al., 1997192 1 PsychPLA PsychPLA PsychPLA
López-Ibor et al., 1996193 9 FLX 40 Fixed 40
López-Ibor et al., 1996193 9 CLO 150 Fixed 150
Mavissakalian et al., 1985194 1 CLO 228.5 NA 100 300
Mavissakalian et al., 1985194 1 PLA PLA
McLean et al., 2001195 1 CT 12 2.5
McLean et al., 2001195 1 BT 12 2.5
Milanfranchi et al., 1997196 1 CLO 300 0 300
Milanfranchi et al., 1997196 1 FLV 300 0 300
Montgomery et al., 1993197 9 PLA PLA
Montgomery et al., 1993197 9 FLX-20 20 Fixed
Montgomery et al., 1993197 9 FLX-40 40 Fixed
Montgomery et al., 1993197 9 FLX-60 60 Fixed
Montgomery et al., 2001198 9 CIT-20 20 Fixed
Montgomery et al., 2001198 9 CIT-40 40 Fixed
Montgomery et al., 2001198 9 CIT-60 60 Fixed
Montgomery et al., 2001198 9 PLA PLA
Mundo et al., 1997199 2 FLV 290 31 150 300
Mundo et al., 1997199 2 PAR 53.3 10 20 60
Mundo et al., 1997199 2 CIT 50.9 10.4 20 60
Mundo et al., 2001200 9 CLO NA NA 150 300
Mundo et al., 2001200 9 FLV NA NA 150 300
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Study Settinga Intervention
Average or mean
dose at the end (mg)
SD of mean
dose (mg)
Minimum dose
during the study (mg)
Maximum
dose during
the study (mg)
Number of
sessions
Duration of
session (hours)
Nakajima et al., 1996201 9 FLV 193.5 64 NA 150–300
Nakajima et al., 1996201 9 PLA PLA PLA PLA PLA
Nakatani et al., 2005202 1 PsychPLA
Nakatani et al., 2005202 1 FLV 190 21 150 200
Nakatani et al., 2005202 1 BT 12 0.75 hours
(45 minutes)
O’Connor et al., 1999203 1 SRI NA NA NA NA
O’Connor et al., 1999203 1 Waitlist
O’Connor et al., 1999203 1 CBT 20 1
O’Connor et al., 1999203 1 CBT+ SRI NA NA NA NA 20 1
O’Connor et al., 2006204 1 PLA PLA
O’Connor et al., 2006204 1 FLV NA NA 100 300
Perse et al., 1987205 1 PLA PLA
Perse et al., 1987205 1 FLV Not reported NA 300
Shareh et al., 2010206 1 FLV NA NA 50 300
Shareh et al., 2010206 1 CBT 10 1
Shareh et al., 2010206 1 FLV+CBT NA NA 50 300 10 1
Sousa et al., 2006207 1 SER 100 Fixed
Sousa et al., 2006207 1 CBT 12 2
Stein et al., 2007124 1 PLA PLA PLA PLA PLA
Stein et al., 2007124 1 PAR 40 Fixed Fixed Fixed
Stein et al., 2007124 1 ESCIT-10 10 Fixed Fixed Fixed
Stein et al., 2007124 1 ESCIT-20 20 Fixed Fixed Fixed
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TABLE 67 Additional extraction: adult subset (continued )
Study Settinga Intervention
Average or mean
dose at the end (mg)
SD of mean
dose (mg)
Minimum dose
during the study (mg)
Maximum
dose during
the study (mg)
Number of
sessions
Duration of
session (hours)
Thoren et al., 1980208 2 CLO 150 Fixed 150
Thoren et al., 1980208 2 PLA PLA
Tollefson et al., 1994127 1 PLA PLA
Tollefson et al., 1994127 1 FLX-20 20 Fixed
Tollefson et al., 1994127 1 FLX-40 40 Fixed
Tollefson et al., 1994127 1 FLX-60 60 Fixed
Van Oppen et al., 1995209 1 CT 16 0.75 hours
(45 minutes)
Van Oppen et al., 1995209 1 BT 16 0.75 hours
(45 minutes)
Volavka et al., 1985210 1 CLO 275 53.5 300
Volavka et al., 1985210 1 IMI 262.5 74.4 300
Whittal et al., 2005211 1 CT 12 1
Whittal et al., 2005211 1 BT 12 1
Whittal et al., 2010212 1 CT 12 1
Whittal et al., 2010212 1 PsychPLA PsychPLA PsychPLA
Zohar and Judge, 1996213 9 PLA PLA
Zohar and Judge, 1996213 9 PAR 49.3 13.7 20 60
Zohar and Judge, 1996213 9 CLO 204.5 65.1 50 250
AMI, amitriptyline; CCSG, Clomipramine Collaborative Study Group; CIT, citalopram; CLO, clomipramine; ESCIT, escitalopram; FLV, fluvoxamine; FLX, fluoxetine; HYP, hypericum;
IMI, imipramine; NA, not available; PAR, paroxetine; PLA, placebo; PsychPLA, psychological placebo; SER, sertraline; SRI, serotonin reuptake inhibitor; VEN, venlafaxine.
a 1= outpatients, 2= inpatients, 3=mixed, 9= unclear.
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TABLE 68 Additional extraction: children and adolescents subset
Study Settinga Intervention
Average or mean
dose at the end (mg)
SD of mean
dose (mg)
Minimum dose
during the study (mg)
Maximum
dose during
the study (mg)
Number of
sessions
Duration of
session (hours)
Alaghband-Rad and
Hakimshooshtary, 2009215
1 FLX 20 Fixed
Alaghband-Rad and
Hakimshooshtary, 2009215
1 CIT 20 Fixed
Asbahr et al., 2005216 1 SER 137.5 57.1 25 200
Asbahr et al., 2005216 1 CBT 12 1.5
Barrett et al., 2004217 1 CBT 14 1.5
Barrett et al., 2004217 1 PsychPLA Waitlist Waitlist
Bolton and Perrin, 2008218 1 BT 10 1 to 1.5
Bolton and Perrin, 2008218 1 PsychPLA Waitlist Waitlist
Bolton et al., 2011219 1 PsychPLA Waitlist Waitlist
Bolton et al., 2011219 1 CBT 12 1
de Haan et al., 1998220 1 CLO 2.5mg/kg 0.63 NA 3mg/kg
de Haan et al., 1998220 1 BT
DeVeaugh-Geiss et al.,
1992221
1 CLO NA NA 75 200
DeVeaugh-Geiss et al.,
1992221
1 PLA PLA
Flament et al., 1985222 1 CLO 141 30 100 200
Flament et al., 1985222 1 PLA PLA
Freeman et al., 2008223 1 CBT 12 1
Freeman et al., 2008223 1 PsychPLA 12 1
Geller et al., 2001224 1 PLA PLA
Geller et al., 2001224 1 FLX 24.6 NA 20 60
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TABLE 68 Additional extraction: children and adolescents subset (continued )
Study Settinga Intervention
Average or mean
dose at the end (mg)
SD of mean
dose (mg)
Minimum dose
during the study (mg)
Maximum
dose during
the study (mg)
Number of
sessions
Duration of
session (hours)
GlaxoSmithKline, 2001225 1 PAR NA NA 20 50
GlaxoSmithKline, 2001225 1 PLA PLA PLA PLA PLA
Liebowitz et al., 2002226 9 PLA PLA
Liebowitz et al., 2002226 9 FLX 64.8 18.9 20 80
March et al., 1990227 1 CLO 190 NA 200
March et al., 1990227 1 PLA PLA
March et al., 1998228 1 SER 167 NA 200
March et al., 1998228 1 PLA 180
Neziroglu et al., 2000229 9 FLV 200 Fixed 200
Neziroglu et al., 2000229 9 BT+ FLV 200 Fixed 200 20 1.5
Piacentini et al., 2011230 1 CBT 12 1.5
Piacentini et al., 2011230 1 PsychPLA 12 1.5
Riddle et al., 1992231 1 PLA PLA
Riddle et al., 1992231 1 FLX 20 Fixed
Riddle et al., 2001232 9 PLA PLA
Riddle et al., 2001232 9 FLV 165 50 50 200
Storch et al., 2011233 1 CBT 12 1–1.5 hours
Storch et al., 2011233 1 PsychPLA Waitlist Waitlist
Storch et al., 2013234 1 SER+CBT 164.3 NA 200 14 1
Storch et al., 2013234 1 CBT+ PLA 14 1
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Appendix 7 Quality assessment of trials
TABLE 69 Quality assessment: randomisation – allocation section
Study
Sequence
generation
Sequence generation
comment
Allocation
concealment
Allocation concealment
comment
Alaghband-Rad and
Hakimshooshtary,
2009215
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc. (‘consenting
subjects were randomly assigned
to start with either’)
Unclear No description
Albert et al., 2002155 Unclear Description includes only ‘random’,
‘randomly generated’, ‘randomised’
Unclear No description
Ananth et al.
1981156
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Anderson and Rees
2007157
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Andersson et al.,
2012158
Low risk Computer-based randomisation Unclear No description
Asbahr et al.,
2005216
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Barrett et al.,
2004217
Low risk Block randomisation Unclear No description
Belloch et al.,
2008159
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Belotto-Silva et al.,
2012160
Low risk Minimisation using computer
program
Low risk Allocation for each group was
determined without the
knowledge of the professionals
responsible for screening and
recruitment of patients
Bergeron et al.,
2002161
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc. (‘patients were
randomised to 24 weeks of
double-blind treatment with
flexible doses of . . .’)
Unclear No description
Bisserbe et al.,
1997162
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
continued
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TABLE 69 Quality assessment: randomisation – allocation section (continued )
Study
Sequence
generation
Sequence generation
comment
Allocation
concealment
Allocation concealment
comment
Bolton and Perrin,
2008218
Low risk Participants were randomly
assigned to ERP or a waitlist
control condition by use of
random number tables. A
colleague independent of the trial
selected a random sequence of
20 numbers including 10 even
and 10 odd numbers, and then
made each kind represent 1 of
the 2 conditions on a database
containing 20 separate pages,
the assignment sequence being
unknown to the trial team.
Assignment of the nth case was
made after informed consent
to participate in the trial by
accessing the relevant separate
page of the assignment database
Low risk Participants were randomly
assigned to ERP or a waitlist
control condition by use of
random number tables. A
colleague independent of the
trial selected a random
sequence of 20 numbers
including 10 even and 10 odd,
and then made each kind
represent one of the two
conditions on a database
containing 20 separate pages,
the assignment sequence being
unknown to the trial team.
Assignment of the nth case was
made after informed consent to
participate in the trial by
accessing the relevant separate
page of the assignment
database
Bolton et al.,
2011219
Low risk Randomisation was carried out
independently of the study team
using sampling without
replacement in blocks of six.
The randomisation was stratified
depending on whether or not the
participant was receiving current
stable medication for OCD
Low risk Assignment of the next
recruited participant was placed
in a sealed envelope and held
by an independent
administrator, and this
information was provided to the
research assessor in written
form or by telephone following
consent to enter the trial
CCSG1, 1991154 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
CCSG2, 1991154 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Chouinard et al.,
1990163
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Cordioli et al.,
2003164
Low risk Computer-based randomisation Low risk The random allocation was
done by a researcher not
involved in the clinical trial
Cottraux et al.,
1993165
Unclear Description only includes
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Cottraux et al.,
2001166
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
de Haan et al.,
1998220
Unclear Description only includes
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Denys et al., 2003167 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
DeVeaugh-Geiss
et al., 1992221
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
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TABLE 69 Quality assessment: randomisation – allocation section (continued )
Study
Sequence
generation
Sequence generation
comment
Allocation
concealment
Allocation concealment
comment
Emmelkamp and
Beens 1991168
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Emmelkamp et al.,
1988169
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Fals-Stewart et al.,
1993170
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Flament et al.,
1985222
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Foa et al., 2005171 Low risk Block randomisation Unclear No description
Freeman et al.,
1994172
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Freeman et al.,
2008223
Unclear Description only includes
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Freeston et al.,
1997173
Unclear The authors describe the process
but they do not present how they
got the random numbers.
Therefore unclear
Unclear No description
Geller et al., 2001224 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Unclear No description
GlaxoSmithKline,
2005174
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
GlaxoSmithKline,
2005175
Unclear Description only includes
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
GlaxoSmithKline,
2001225
Low risk Stratified by age randomisation Unclear No description
Goodman et al.,
1989176
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Goodman et al.,
1996177
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Greist et al., 1995126 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Greist et al., 2002178 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Hohagen et al.,
1998179
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Unclear No description
Hollander et al.,
2003181
Unclear Description only includes
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
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TABLE 69 Quality assessment: randomisation – allocation section (continued )
Study
Sequence
generation
Sequence generation
comment
Allocation
concealment
Allocation concealment
comment
Hollander et al.,
2003180
Low risk A computer-based randomisation Low risk Central randomisation by
SmithKline Beecham plc
Jaurrieta et al.,
2008182
Low risk Tables of random numbers Low risk The random allocation was
performed by a researcher not
involved in the clinical trial
Jenike et al., 1990183 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Jenike et al., 1990184 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Jenike et al., 1997185 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Unclear No description
Jones and Menzies,
1998186
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Kamijima et al.,
2004187
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Khodarahimi,
2009188
Low risk Description includes block
randomisation in groups of three
Unclear No description
Kobak et al.,
2005189
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Koran et al., 1996190 Low risk Patients were randomly assigned
to double-blind treatment with
fluvoxamine or clomipramine in
approximately equal numbers in
accordance with a randomisation
schedule
Unclear No description
Kronig et al.,
1999191
Low risk Randomly assigned via computer-
generated codes
Unclear No description
Liebowitz 2002226 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Unclear No description
Lindsay et al.,
1997192
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
López-Ibor et al.,
1996193
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
March 1990227 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
March 1998228 Low risk Computer-generated
randomisation algorithm
Unclear No description
Mavissakalian et al.,
1985194
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
McLean et al.,
2001195
Low risk Block randomisation Unclear No description
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TABLE 69 Quality assessment: randomisation – allocation section (continued )
Study
Sequence
generation
Sequence generation
comment
Allocation
concealment
Allocation concealment
comment
Milanfranchi et al.,
1997196
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Unclear No description
Montgomery et al.,
1993197
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Unclear No description
Montgomery et al.,
2001198
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Mundo et al.,
1997199
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Mundo et al.,
2001200
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Unclear No description
Nakajima et al.,
1996201
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Unclear No description
Nakatani et al.,
2005202
Unclear Description only includes
‘random’, ‘randomly generated’,
‘randomised’
Low risk Central randomisation:
A study coordinator who
did not know any further
information of the subjects
randomly assigned them to
one of three treatment
conditions
Neziroglu et al.,
2000229
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
O’Connor et al.,
1999203
High risk Three clients had definite
preferences (at least initially)
regarding whether they preferred
medication or non-medication.
This choice was respected, so
allocation to groups was not
entirely random
Unclear No description
O’Connor et al.,
2006204
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Low risk Pharmacy-controlled
randomisation:
The code was controlled
through random allocation
by the hospital pharmacy
who revealed the code
only at the end of
follow-up
Perse et al., 1987205 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Piacentini et al.,
2011230
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
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TABLE 69 Quality assessment: randomisation – allocation section (continued )
Study
Sequence
generation
Sequence generation
comment
Allocation
concealment
Allocation concealment
comment
Riddle et al., 1992231 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Low risk Pharmacy-controlled
randomisation
Riddle et al., 2001232 Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Shareh et al.,
2010206
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc. (‘21 patients
who met all the conditions to
participate in the study were
randomly assigned to one of the
three’)
Unclear No description
Sousa et al., 2006207 Low risk Computer-generated random
numbers
Unclear No description
Stein et al., 2007124 Low risk A computer-generated
randomisation list
Low risk Sealed opaque envelopes
Storch et al.,
2011233
Low risk Computer-based randomisation Unclear No description
Storch et al.,
2013234
Low risk A computer-based randomisation Unclear No description
The Pediatric OCD
Treatment Study,
2004236
Low risk Patients were randomly assigned
(within site) to treatment using a
computer-generated randomised
permuted blocking procedure
using a block size of four
Low risk Concealment methods followed
standard recommendations
Thoren et al.,
1980208
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Tollefson et al.,
1994127
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’, etc.
Unclear No description
Van Oppen et al.,
1995209
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Volavka et al.,
1985210
Low risk Computer-generated random
numbers were used in blocks
Low risk Central randomisation by the
manufacturer of the drug
Whittal et al.,
2005211
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Whittal et al.,
2010212
Unclear Description includes only
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
Williams et al.,
2010235
Low risk Tables of random numbers Low risk Only the trial administrator was
aware which participants were
in which group
Zohar and Judge
1996213
Unclear Description only includes
‘random’, ‘randomly generated’,
‘randomised’
Unclear No description
CCSG, Clomipramine Collaborative Study Group.
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TABLE 70 Quality assessment: blinding section
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Alaghband-Rad and
Hakimshooshtary,
2009215
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear The CYBOCS was
administrated by an
experienced clinician (MS)
Albert et al., 2002155 High risk Open-label treatment,
as in the outcome
assessment the authors
report that the patients
were instructed not to
reveal their current
treatment to evaluators
High risk Open label treatment for
clinicians; the term single
blind was used to refer to
independent evaluators
Low risk Independent evaluators and
patients were also instructed not
to reveal their current treatment
Ananth et al. 1981156 Low risk Identical pills and
description includes
‘double blind’
Low risk Identical pills and
description includes
‘double blind’
Unclear No description
Anderson and Rees
2007157
High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Unclear No description
Andersson et al.,
2012158
High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk The assessors were blinded to
treatment allocation at the
post-treatment interview and
were instructed to guess to
which treatment condition
the participant had been
randomised in order to control
for blinding integrity
Asbahr et al., 2005216 High risk No description of blindness
regarding the drug and
not possible to blind the
psychological intervention
High risk No description of
blindness regarding the
drug and not possible to
blind the psychological
intervention
Low risk Two independent evaluators who
were blinded to treatment
assignment, performed all
clinician-rated instruments.
Subjects were not assessed by
their own therapist and were
asked not to reveal any
information about their treatment
to the independent evaluators
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Barrett et al., 2004217 High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Unclear No description
Belloch et al., 2008159 High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk The evaluator was blind to the
treatment received by patients
Belotto-Silva et al.,
2012160
High risk Psychological intervention
in group format compared
with drug
High risk The principal CBT
therapist was the main
author of the manuscript
Low risk Follow-up assessments
administered by a rater who was
blind to the patient treatment
condition
Bergeron et al.,
2002161
Unclear Description includes only
‘double blind’
Unclear Description only includes
‘double blind’
Unclear Efficacy assessments were
conducted exclusively by
psychiatrists with expertise
in treatment research. Rater
training on the primary
outcome measures was
conducted at an
investigator meeting. As
often as possible the same
rater completed all of the
ratings of a given patient
Bisserbe et al., 1997162 Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Bolton and Perrin,
2008218
High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
High risk The rater undertaking the
CYBOCS assessment was not
involved in the treatment of the
case, but no attempt was made
to achieve blindness of rater to
condition because of the great
difficulty associated with
preserving it in this intensive
treatment condition, especially in
children
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Bolton et al., 2011219 High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk CYBOCS and ADIS–C/P
assessments were made by
trained independent evaluators
in the research team, masters’ or
doctoral-level psychologists, kept
blinded to the randomisation
status
CCSG1, 1991154 Low risk Identical capsules Low risk Identical capsules and
states double blind
Unclear No description
CCSG2, 1991154 Low risk Identical capsules Low risk Identical capsules and
states double blind
Unclear No description
Chouinard et al.,
1990163
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Cordioli et al., 2003164 High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk Patients of both groups were
rated by three independent
raters, blinded for patient group
allocation
Cottraux et al., 1993165 Unclear Stated as double blind
(expect FLV+ BT group
which is single blind)
Unclear Stated as double blind
(expect FLV+ BT group
which is single blind)
Unclear No description
Cottraux et al., 2001166 High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk The evaluator was independent
and did not take part in the
treatment. He or she had no
information about the treatment
under way
de Haan et al., 1998220 High risk Abstract says that open
clomipramine was used
and BT not possible to
blind
High risk Abstract says that open
clomipramine was used
and BT not possible to
blind
Unclear No description
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Denys et al., 2003167 Low risk The study drugs were
packaged so that the units
were identical, and each
subject received the
appropriate dosage
Low risk The study drugs were
packaged so that the
units were identical, and
each subject received the
appropriate dosage
Low risk Two trained investigators, blind
to the patient’s assigned
condition, completed the scales
at baseline and on each visit
DeVeaugh-Geiss et al.,
1992221
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Emmelkamp and
Beens 1991168
High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk In addition, an independent
assessor, a clinical psychologist
who was blind with respect to
the treatment condition rated
the patients at assessment II
(pretest) and after the first
(assessment III) and second
(assessment V) treatment block
Emmelkamp et al.,
1988169
High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk In addition, an independent
assessor, a clinical psychologist
who was blind with respect to
the treatment condition, rated
the patients at pre- and post-test
Fals-Stewart et al.,
1993170
High risk Psychological interventions
not possible to blind
High risk Psychological interventions
not possible to blind
Unclear No description
Flament et al., 1985222 Low risk Identical pills and
description includes
‘double blind’
Low risk Identical pills and
description includes
‘double blind’
Low risk Two independent psychiatrists
blinded to the patients’
treatment
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Foa et al., 2005171 Unclear Description includes only
double blind for
medication and placebo.
Blinding not possible for
psychological intervention
Low risk Independent evaluators,
who remained blind to
treatment assignment,
conducted the
assessments. Psychiatrists
were blind to patients’
medication assignment
and therapy status. The
therapists who provided
exposure and ritual
prevention were blind to
patients’medication status.
Patients were reminded
not to discuss their
treatment in order to
maintain the blinding
Low risk Independent evaluators, who
remained blind to treatment
assignment, conducted the
assessments. Psychiatrists were
blind to patients’ medication
assignment and therapy status.
The therapists who provided
exposure and ritual prevention
were blind to patients’
medication status. Patients were
reminded not to discuss their
treatment in order to maintain
the blinding
Freeman et al., 1994172 Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Freeman et al., 2008223 High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk Trained independent evaluators
(i.e. child clinical psychologists
and child psychiatrists) who were
blind
Freeston et al., 1997173 High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
High risk The rater was aware of
treatment status
Geller et al., 2001224 Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
GlaxoSmithKline,
2005174
Unclear Description only includes
‘double blind’
Unclear Description only includes
‘double blind’
Unclear Description includes only ‘double
blind’
GlaxoSmithKline,
2005175
Unclear Description only includes
‘double blind’
Unclear Description only includes
‘double blind’
Unclear Description includes only ‘double
blind’
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
GlaxoSmithKline,
2001225
Low risk Both double-blind
medications (i.e.
paroxetine and placebo)
were in the form of white,
oval, film-coated tablets
for oral administration
once daily. They were
identical in size, shape and
colour
Low risk Both double-blind
medications (i.e.
paroxetine and placebo)
were in the form of
white, oval, film-coated
tablets for oral
administration once daily.
They were identical in
size, shape and colour
Unclear No description
Goodman et al.,
1989176
Low risk ‘Identical appearing
tablets’ and double blind
Low risk ‘Identical appearing
tablets’ and double blind
Low risk Experienced raters blind to drug
assignment assessed symptoms
of OCD
Goodman et al.,
1996177
Unclear Description only includes
‘double blind’
Unclear Description only includes
‘double blind’
Unclear No description
Greist et al., 1995126 Unclear Description only includes
‘double blind’
Unclear Description only includes
‘double blind’
Unclear No description
Greist et al., 2002178 High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
High risk Self-rated YBOCS by patients
Hohagen et al.,
1998179
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Low risk The YBOCS was used weekly by
an independent rater to rate
patients’ symptoms
Hollander et al.,
2003181
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Hollander et al.,
2003180
Low risk Description includes
‘double blind’ and
‘identical tablets and
identical coded bottles’
Low risk Description includes
‘double blind’ and
‘identical tablets and
identical coded bottles’
Unclear No description
Jaurrieta et al., 2008182 High risk Psychological interventions
not possible to blind
High risk Psychological interventions
not possible to blind
Unclear Vague description unable to
decide if high risk or not;
therefore, unclear
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Jenike et al., 1990183 Low risk Identically appearing
placebo capsules
Low risk Identically appearing
placebo capsules
Unclear No description
Jenike et al., 1990184 Low risk Identical appearing
placebo capsules
Low risk Identical appearing
placebo capsules
Low risk The authors give details on the
rigorous procedure they
followed about measuring
YBOCS (giving intraclass
correlation coefficients) and they
state that:
the raters were provided
with standardized
instructions and the same
rater assessed each
individual patient
throughout the course of
the study
Jenike et al., 1997185 Unclear No description Unclear No description Unclear No description
Jones and Menzies,
1998186
High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
High risk Self-rated instruments
Kamijima et al.,
2004187
Unclear Description includes only
‘double blind’
Unclear Description only includes
‘double blind’
Unclear No description
Khodarahimi, 2009188 High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Unclear No description
Kobak et al., 2005189 Low risk The authors describe
‘matched’ placebo
Low risk The authors describe
‘matched’ placebo
Unclear No description
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Kobak et al., 2005189 Low risk Blinding was accomplished
by having all study patients
take the same number of
capsules daily and
medications supplied in
identical capsules for oral
administration
Low risk Blinding was
accomplished by having
all study patients take the
same number of capsules
daily and medications
supplied in identical
capsules for oral
administration
Unclear No description
Kronig et al., 1999191 Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Liebowitz et al.,
2002226
Unclear Study is only described as
‘placebo-controlled’
Unclear Study is only described as
‘placebo-controlled’
Low risk Independent evaluators assessing
symptoms were blind to
treatment assignment
Lindsay et al., 1997192 High risk Psychological interventions
not possible to blind
High risk Psychological interventions
not possible to blind
Unclear No description
López-Ibor et al.,
1996193
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
March et al., 1990227 Low risk Identical pills and
description includes
‘double blind’
Low risk Identical pills and
description includes
‘double blind’
Unclear No description
March et al., 1998228 Low risk Identical blisters Low risk Identical blisters Unclear No description
Mavissakalian et al.,
1985194
Unclear Description only includes
‘double blind’
Unclear Description only includes
‘double blind’
Unclear No description
McLean et al., 2001195 High risk Psychological interventions
not possible to blind
High risk Psychological interventions
not possible to blind
Unclear No description
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Milanfranchi et al.,
1997196
Low risk Description includes
‘double blind’ and also the
authors note how the two
drugs were similar (‘the
drugs were administered in
capsules containing either
50mg of FLV or 50mg of
CLO; the clomipramine
dose was distributed in
two comfits of 25mg in
the same capsule’)
Low risk Description includes
‘double blind’ and also
the authors note how the
two drugs were similar
(‘the drugs were
administered in capsules
containing either 50mg
of FLV or 50mg of CLO;
the clomipramine dose
was distributed in two
comfits of 25mg in the
same capsule’)
Unclear No description
Montgomery et al.,
1993197
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Montgomery et al.,
2001198
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Mundo et al., 1997199 High risk Mentioned that patients
were not blinded for
medication
High risk The authors report that
this is a single blind
study, with the blinding
referring to independent
raters, therefore we
can assume that the
health-care providers
were not blinded
Low risk The ratings were all made under
blind conditions
Mundo et al., 2001200 Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Nakajima et al.,
1996201
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear No description
Nakatani et al.,
2005202
High risk No description but due to
the nature of intervention
this is high risk
Unclear No description Low risk Clinical ratings were
undertaken blindly at
baseline, week 4, 8
and 12 by 4 clinically
experienced psychiatrists
continued
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Neziroglu et al.,
2000229
High risk Psychological intervention
was added to one of the
groups and, therefore,
blinding was not possible
High risk Psychological intervention
was added to one of the
groups and, therefore,
blinding was not possible
Unclear No description
O’Connor et al.,
1999203
High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk The same clinician carried out all
ratings post treatment and was
blind to treatment-group
membership
O’Connor et al.,
2006204
Low risk Paper discusses how
placebos were similar
(‘The active and inactive
medication was given in
identical tablet form of
50mg units and were
identical in appearance’)
Low risk Paper discusses how
placebos were similar
(‘The active and inactive
medication was given in
identical tablet form of
50mg units and were
identical in appearance’)
Low risk An independent assessor
administered the YBOCS at
pre-, mid- and post-treatment
and follow-ups
Perse et al., 1987205 Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Low risk Each of the three physician
investigators made independent
blind clinical ratings
Piacentini et al.,
2011230
High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Low risk Trained evaluators blinded to
treatment condition conducted
assessments with families
Riddle et al., 1992231 Low risk Paper discusses how
placebos were similar
(‘placebo capsules were
prepared by filling identical
opaque jackets with
lactose powder’)
Low risk Paper discusses how
placebos were similar
(‘placebo capsules were
prepared by filling
identical opaque jackets
with lactose powder’)
Unclear No description
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Riddle et al., 2001232 Low risk Description includes
‘double blind’ and
‘identical placebo capsule’
Low risk Description includes
‘double blind’ and
‘identical placebo
capsule’
Low risk The authors give details on the
rigorous procedure they
followed about measuring
CYBOCS
Shareh et al., 2010206 High risk No description but owing
to the nature of
intervention this is high risk
High risk No description of
blindness in the paper,
therefore high risk
Unclear No description
Sousa et al., 2006207 High risk Psychological intervention
was added to one of the
groups and, therefore,
blinding was not possible
High risk Psychological intervention
was added to one of the
groups and, therefore,
blinding was not possible
Low risk Two psychiatrists blind to the
type of treatment were used as
independent evaluators
Stein et al., 2007124 Low risk Double blind and identical
appearance of study
medications
Low risk Double blind and
identical appearance of
study medications
Low risk The authors give details on the
rigorous procedure they
followed about measuring
YBOCS (‘Only those investigators
who had actively participated in
rater training sessions prior to
inclusion of patients into the
study were allowed to rate
patients. Rater training was
undertaken to increase
inter-rater reliability, and was
chaired by an experienced
psychiatrist’). Patient ratings
were assessed by the same
investigator at each visit,
whenever possible
continued
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Storch et al., 2011233 High risk Psychological interventions
not possible to blind
High risk Psychological interventions
not possible to blind
Low risk Independent evaluators blinded
to treatment
Storch et al., 2013234 Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Low risk Independent evaluators trained
by the authors in the
administration of scales
Thoren et al., 1980208 Low risk Identical pills and
description includes
‘double blind’
Low risk Identical pills and
description includes
‘double blind’
Unclear No description
Tollefson et al.,
1994127
Unclear No description Unclear ‘Patients were examined
by the treating clinicians
who were blinded to the
study medication’ but no
further information
Unclear No description
Van Oppen et al.,
1995209
High risk Psychological interventions
not possible to blind
High risk Psychological
interventions not possible
to blind
Unclear No description
Volavka et al., 1985210 Low risk Identical capsules Low risk Identical capsules and
double blind
Unclear No description
The Pediatric OCD
Treatment Study,
2004236
Unclear Except in emergencies,
participants and clinicians
remained masked in the
pills-only conditions.
However, it is not possible
to blind the psychological
intervention
Unclear Except in emergencies,
participants and clinicians
remained masked in the
pills-only conditions.
However, it is not
possible to blind the
psychological intervention
Low risk Independent evaluators
Whittal et al., 2005211 High risk Psychological interventions
not possible to blind
High risk Psychological interventions
not possible to blind
Low risk The assessors were blind to
treatment type. With few
exceptions, the same assessor
was used at pre- and post-
treatment, and follow-up
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TABLE 70 Quality assessment: blinding section (continued )
Study
Blinding of
participants
Blinding of participants
comment
Blinding of those
delivering the
intervention
Blinding of those
delivering comment
Blinding of the
outcome assessor
Blinding of outcome assessors
comment
Whittal et al., 2010212 High risk Psychological interventions
not possible to blind
High risk Psychological interventions
not possible to blind
Unclear No description
Williams et al., 2010235 High risk Psychological interventions
not possible to blind
High risk Psychological interventions
not possible to blind
Low risk Assessors were blind to the
allocation of the participants,
and the participants were
instructed not to reveal whether
or not they had received
treatment
Zohar and Judge
1996213
Unclear Description includes only
‘double blind’
Unclear Description includes only
‘double blind’
Unclear Description includes only ‘double
blind’
ADIS–C/P, Anxiety Disorders Interview Schedule for DSM-IV, child and parent versions; CCSG, Clomipramine Collaborative Study Group; CLO, clomipramine; FLU, fluvoxamine.
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TABLE 71 Quality assessment: outcome reporting/other biases
Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Alaghband-Rad and
Hakimshooshtary, 2009215
High risk No description of how the
handled missing data,
no ITT analysis. Overall
attrition 17%; no further
details
High risk SDs not given for
CYBOCS
High risk No data for number of
children screened initially,
excluded because not
eligible. Standard of
reporting not high despite
this being a relatively
recent trial
Albert et al., 2002155 High risk Missing data not
imputed, completers
analysis. Differential
attrition almost reached
15%
High risk Data for completers only,
even though they
reported that they have
also carried out LOCF as
well, they only present
the results for the
visitwise analysis
High risk Differential attrition ≈15%
Ananth et al. 1981156 High risk Completers analysis Low risk Low risk Not any other
Anderson and Rees,
2007157
Low risk Completers analysis
reported in detail
although the authors
have also used ITT but
only giving F-statistics and
p-values
High risk The results of the ITT
analysis are not given in
full; therefore, only the
completers analysis can
be included
Low risk Not any other
Andersson et al., 2012158 Low risk One dropout only and
therefore they performed
completers analysis.
Unlikely that this may
have influenced their
results, and also they
examined blinding
integrity. Therefore, could
be low risk
Low risk Low risk Not any other
Asbahr et al., 2005216 Low risk The authors reported that
they did not use ITT
because only one patient
dropped out. Could be
low risk for this reason
High risk No detailed measures for
CYBOCS for follow-up
measurements, only
F-tests and figures
Low risk Not any other
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Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Barrett et al., 2004217 Unclear It is not clear from the
description whether this is
a completers or ITT
analysis
High risk Dropouts not per arm Low risk Not any other
Belloch et al., 2008159 High risk Completers analysis Low risk Low risk Not any other
Belotto-Silva et al.,
2012160
Low risk Missing data have been
imputed using
appropriate methods
(‘Intention-to-treat and
last-observation-carried-
forward analyses were
conducted in order to
make conservative
estimates of symptom
severity for individuals
whose outcome measures
were missing’). Dropout
rates were 25.7% in the
CBT (n= 18) and 37.5%
in the SSRI group (n= 33).
Overall attrition > 20%
and some evidence of
differential attrition but
reasons for dropouts
given and judgement is
that there is no serious
risk for differential bias.
Overall, low risk
Low risk Low risk Not any other serious risk
(see comment for
differential attrition in
column 3 – Incomplete
outcome comment – of
this table)
Bergeron et al., 2002161 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). However,
overall attrition rate high
(> 30%) without
differential attrition
Low risk High risk Overall attrition high
(> 30%)
continued
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TABLE 71 Quality assessment: outcome reporting/other biases (continued )
Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Bisserbe et al., 1997162 Low risk The authors report that
they used ITT and ‘last
efficacy assessment’ for
those who dropped out
High risk SDs not given High risk High attrition 35% and
evidence of differential
attrition > 15% (27% vs.
43%)
Bolton and Perrin, 2008218 Low risk ITT analysis and LOCF as
stated in the methods
section
Low risk Low risk Not any other
Bolton et al., 2011219 Low risk ITT analysis and LOCF as
stated in the methods
section
Low risk Low risk Not any other
CCSG1, 1991154 Unclear In the methods section
they do not mention how
they handled missing
data. In the results,
although they mention
that in the efficacy
analysis that all patients
and not just the
completers have been
used, it is not clear from
figures and tables that
this is the case
High risk In the results, although
they mention that in the
efficacy analysis all
patients and not just the
completers have been
used, it is not clear from
figures and tables that
this is the case. Therefore,
evidence for selective
reporting
High risk They report deviations from
the protocol:
Because the physicians’
and patients’ global
ratings did not satisfy
the statistical
assumptions for logistic
regression, i.e., the
analysis that had been
intended, these scores
were analysed by the
Wilcoxon rank-sum test
CCSG2, 1991154 Unclear In the methods section
they do not mention how
they handled missing
data. In the results,
although they mention
that in the efficacy
analysis all patients and
not just the completers
have been used it is not
clear from figures and
tables that this is the case
High risk In the results, although
they mention that in the
efficacy analysis all
patients and not just the
completers have been
used it is not clear from
figures and tables that
this is the case. Therefore,
evidence for selective
reporting
High risk They report deviations from
the protocol:
Because the physicians’
and patients’ global
ratings did not satisfy
the statistical
assumptions for logistic
regression, i.e., the
analysis that had been
intended, these scores
were analysed by the
Wilcoxon rank-sum test
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Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Chouinard et al., 1990163 Low risk The authors report that
‘no patients were
excluded from analysis’
and LOCF was used to
handle missing data – low
attrition
High risk SDs not given Low risk Not any other
Cordioli et al., 2003164 Low risk ITT analysis and LOCF as
stated in the methods
section. Overall attrition
low
Low risk Low risk Not any other
Cottraux et al., 1993165 High risk No description of how the
handled missing data,
completers and no ITT
analysis. High attrition
rate: 45%
Low risk High risk Very high attrition (45%).
Not standardised scale of
overall OCD symptoms
Cottraux et al., 2001166 High risk Completers analysis
reported although the
authors point out that
they have also used ITT
with LOCF
High risk Completers analysis only
reported. Regarding the
results of the ITT, there
were no differences
Low risk Not any other
de Haan et al., 1998220 Low risk Although this is
completers analysis, just
one dropout so possibly
no effect
Low risk Low risk Not any other
Denys et al., 2003167 Low risk ITT analysis and LOCF as
stated in the methods
section
Low risk Low risk Not any other
DeVeaugh-Geiss et al.,
1992221
Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Low
attrition and no evidence
of differential attrition
High risk SDs not given Low risk Not any other
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TABLE 71 Quality assessment: outcome reporting/other biases (continued )
Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Emmelkamp and Beens
1991168
High risk There were dropouts but
the authors focused only
on the completers
analysis
Low risk High risk Dropout rate 8/31= 26%
Emmelkamp et al.,
1988169
High risk Two dropped out but the
authors conducted
completers analysis
Low risk Low risk Not any other
Fals-Stewart et al.,
1993170
High risk Completers analysis High risk SDs not reported Low risk Not any other
Flament et al., 1985222 Unclear Crossover trial High risk Not sufficient data for
baseline and first
crossover
Low risk Not any other
Foa et al., 2005171 Low risk Linear mixed-effects
model to account for
missing data
Low risk High risk Overall attrition high (29%)
and evidence of > 15%
differential attrition
between placebo and
BT+CLO groups
Freeman et al., 1994172 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Overall
attrition high (26%) and
some evidence for
differential attrition
(17% vs. 34%)
High risk SDs not given High risk Overall attrition high (26%)
and evidence for
differential attrition > 15%
(17% FLV vs. 34% CLO)
Freeman et al., 2008223 Low risk ITT analysis and LOCF as
stated in the methods
section. Overall attrition
moderate 26% but no
evidence of differential
attrition
Low risk High risk Overall attrition > 25%
(= 26%); no differential
attrition however
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Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Freeston et al., 1997173 Low risk ITT analysis although not
exactly sure which
method they have used
for missing data, possibly
LOCF though
Low risk Low risk Not any other
Geller et al., 2001224 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Overall
attrition high (33%); no
evidence of differential
attrition
Low risk High risk Overall attrition high
(> 33%)
GlaxoSmithKline, 2005174 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Overall
high attrition (32%), but
no evidence of differential
attrition > 15%
Low risk High risk No publication: high
attrition of 32%
GlaxoSmithKline, 2005175 Unclear Report describes ITT as
the method of the
analysis but from the
table it is not clear
Low risk High risk No publication: company
report
GlaxoSmithKline, 2001225 High risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Overall
high attrition (31%) but
no evidence of differential
attrition > 15%
Low risk High risk No publication: high
attrition of 31%
Goodman et al., 1989176 Low risk ‘Dropouts were subjected
to endpoint analysis’
Low risk High risk Differential attrition
(8% vs. 26%) but in favour
of active treatment rather
than placebo
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TABLE 71 Quality assessment: outcome reporting/other biases (continued )
Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Goodman et al., 1996177 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Overall
attrition moderate (23%),
but no evidence for
differential attrition
High risk Absolute values for
YBOCS at follow-up not
given for the ITT
population, only figures
and change values
Low risk Not any other
Greist et al., 1995126 Unclear Tables for end-point
analysis report N for all
patients randomised, but
there is no discussion of
how the missing data
were handled or if they
used ITT, although it
seems that this is ITT
analysis
Low risk High risk High attrition of 27%
overall with no evidence of
differential attrition
Greist et al., 2002178 Low risk LOCF and ITT Low risk Low risk Not any other
Hohagen et al., 1998179 Unclear No discussion of dropouts Low risk High risk The authors state that
owing to significant
imbalance in the two
groups at baseline, they
dropped the outliers in
both therefore reducing
the sample for analysis to
25 and 24, respectively
Hollander et al., 2003181 Low risk Missing data have been
imputed using
appropriate methods
(LOCF, ITT). Overall
attrition 31%, but no
evidence of differential
attrition (> 15% between
treatments)
High risk SEs given instead of SDs,
high attrition
Low risk Not any other
Hollander et al., 2003180 Low risk ITT analysis and LOCF as
stated in the methods
section
High risk SDs not given Low risk Not any other
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Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Jaurrieta et al., 2008182 Low risk ITT analysis and LOCF as
stated in the methods
section. Overall attrition
< 25% (= 21%)
High risk Dropouts not per arm Low risk Not any other
Jenike et al., 1990183 Low risk No dropouts Low risk Low risk Not any other
Jenike et al., 1990184 High risk No description of how the
handled missing data,
completers and no ITT
analysis. Low attrition rate
(45%)
High risk Baseline data only for
completers
Low risk Not any other
Jenike et al., 1997185 Low risk No methods for imputing
but the authors note that
‘All analyses were
conducted for both
patients who completed
the study and all patients
in intent-to-treat analyses.
In all cases, the pattern of
results was identical
across both analyses’.
Therefore, one can
assume low risk
Low risk Unclear ITT analysis not reported
but they mention that
results were similar with
completers
Jones and Menzies,
1998186
Unclear No discussion of
dropouts, possibly no
dropouts
Low risk Low risk Not any other
Kamijima et al., 2004187 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF)
High risk No description of
dropouts per arm
reported
Low risk Not any other
Khodarahimi, 2009188 High risk No discussion of dropouts Low risk Low risk Not any other
Kobak et al., 2005189 Low risk ITT and LOCF Low risk Low risk Not any other
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TABLE 71 Quality assessment: outcome reporting/other biases (continued )
Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Kobak et al., 2005189 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Overall
attrition however high
(29%) and some evidence
for differential attrition
Low risk High risk Differential attrition despite
missing data handling
(21% FLV vs. 36% CLO)
Kronig et al., 1999191 Low risk The authors report LOCF High risk No detailed follow-up
data, figures only and
F-tests and p-values
High risk High attrition (30%) but no
evidence of differential
attrition
Liebowitz et al., 2002226 Low risk Missing data have been
imputed using
appropriate methods.
Low overall attrition
(12%) and low
differential attrition
Low risk Low risk Not any other serious risk
Lindsay et al., 1997192 Unclear The authors do not
discuss any dropouts but
it is unclear if this was a
completers analysis or
there were no dropouts
Unclear No discussion of
dropouts, therefore
unable to decide if
completers or not
Low risk Not any other
López-Ibor et al., 1996193 Low risk ITT and LOCF Low risk Low risk Not any other
March et al., 1990227 Low risk There were two dropouts
and the authors say that
they did an ITT analysis by
using the mean treatment
score of the treatment
group
Low risk Low risk Not any other
March et al., 1998228 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Low
attrition of 16% and no
evidence of differential
attrition
High risk SDs not given Low risk Not any other
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Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Mavissakalian et al.,
1985194
High risk Completers analysis High risk Original number
randomised not reported
Low risk Not any other
McLean et al., 2001195 High risk Completers analysis Low risk Low risk Not any other
Milanfranchi et al.,
1997196
High risk One dropout only but no
LOCF
Low risk Low risk Not any other
Montgomery et al.,
1993197
Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Overall
attrition high (25%), no
evidence of differential
attrition
Low risk Low risk Not any other
Montgomery et al.,
2001198
Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Low
attrition and no evidence
of differential attrition
Low risk Low risk Not any other
Mundo et al., 1997199 Low risk No dropouts, therefore
no need to handle
missing data
Low risk Low risk Not any other
Mundo et al., 2001200 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Attrition
20%
High risk SDs not given for follow-
up
Low risk Not any other
Nakajima et al., 1996201 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF)
Low risk Low risk Not any other
Nakatani et al., 2005202 High risk No description of how
missing data were
handled, completers and
no ITT analysis
Low risk Low risk Not any other
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TABLE 71 Quality assessment: outcome reporting/other biases (continued )
Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Neziroglu et al., 2000229 Low risk No dropouts according to
the authors
Low risk Low risk Not any other
O’Connor et al., 1999203 High risk Completers analysis High risk No baseline data for
dropouts, only for
completers
Low risk Not any other
O’Connor et al., 2006204 High risk No description of how the
handled missing data,
completers and no ITT
analysis
Low risk Low risk Not any other
Perse et al., 1987205 High risk Missing data not imputed,
completers analysis
High risk Not full reporting of
means and SDs
Low risk Not any other
Piacentini et al., 2011230 Low risk ITT analysis and LOCF as
stated in the methods
section. Moderate
attrition and no evidence
of differential attrition
Low risk Low risk Not any other
Riddle et al., 1992231 Low risk Missing data have been
imputed using
appropriate methods
(‘Intention-to-treat’ and
‘the 4-week data for
those two subjects were
carried over to week 8’)
Low risk Low risk Very small sample size,
initial protocol for crossover
not feasible in the end, but
no evidence for risk for the
first 8 weeks of analysis
included in this
meta-analysis
Riddle et al., 2001232 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Overall
attrition high (38%) but
no evidence for
differential attrition
Low risk High risk Very high attrition (38%)
Shareh et al., 2010206 High risk No description of how the
handled missing data,
completers and no ITT
analysis
Low risk High risk No standard reporting
despite this being a recent
trial, no flow chart,
potentially high risk
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Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Sousa et al., 2006207 Low risk No dropouts with at least
one baseline evaluation,
therefore it can be
considered that there are
no missing data
High risk SDs not given Low risk Not any other
Stein et al., 2007124 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF)
Low risk Low risk Not any other
Storch et al., 2011233 Low risk ITT analysis and LOCF as
stated in the methods
section
Low risk Low risk Not any other
Storch et al., 2013234 Low risk Missing data have been
imputed using
appropriate methods
[random-effects models in
SAS (SAS Institute Inc.,
Cary, NC, USA) with MLE
instead of LOCF, which is
more conservative].
Overall high attrition
(30%) and evidence of
differential attrition
(> 15%)
Low risk High risk High attrition (30%) and
evidence of differential
attrition (> 15%) between
some of the arms
The Pediatric OCD
Treatment Study, 2004236
Low risk Missing data have been
imputed using
appropriate methods (ITT
and LOCF)
Low risk Low risk Not any other
Thoren et al., 1980208 High risk Completers analysis High risk No details for dropouts Low risk Not any other
Tollefson et al., 1994127 Low risk They have used
appropriate methods
(LOCF and ITT) but see
reporting issues
High risk SDs not given for ITT
analysis, therefore only
completers analysis can
be used
High risk Reporting should be better,
reliance on secondary
outcomes
Van Oppen et al., 1995209 High risk Completers analysis High risk Baseline data only for
completers
Low risk Not any other
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TABLE 71 Quality assessment: outcome reporting/other biases (continued )
Study ID
(author and year)
Incomplete
outcome data
Incomplete outcome
comment
Selective outcome
reporting
Selective outcome
comment
Any other potential
threats to validity Any other comment
Volavka et al., 1985210 High risk Completers analysis Low risk Low risk Not any other
Whittal et al., 2005211 High risk Completers analysis Low risk Low risk Not any other
Whittal et al., 2010212 High risk Completers analysis Low risk Low risk Not any other
Williams et al., 2010235 Low risk ITT analysis and LOCF as
stated in the methods
section. Moderate
attrition and no evidence
of differential attrition
High risk SEs given instead of SDs Low risk Not any other
Zohar and Judge, 1996213 Low risk Missing data have been
imputed using
appropriate methods
(ITT and LOCF). Overall
high attrition (30%), but
no evidence of differential
attrition > 15%
Low risk High risk High attrition (30%)
CCSG, Clomipramine Collaborative Study Group; CLO, clomipramine; FLU, fluvoxamine; ITT, intention to treat; LOCF, last observation carried forward; MLE, maximum likelihood estimation;
SE, standard error.
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TABLE 72 Quality assessment: analysis section
Study
Imputation for
missing data Imputation method ITT analysis
Alaghband-Rad and Hakimshooshtary, 2009215 No No
Albert et al., 2002155 No No
Ananth et al. 1981156 No No
Anderson and Rees, 2007157 Unclear No description given Unclear
Andersson et al., 2012158 No No
Asbahr et al., 2005216 No No
Barrett et al., 2004217 Unclear Unclear Unclear
Belloch et al., 2008159 No No
Belotto-Silva et al., 2012160 Yes LOCF Yes
Bergeron et al., 2002161 Yes LOCF Yes
Bisserbe et al., 1997162 Yes LOCF Yes
Bolton and Perrin, 2008218 Yes LOCF Yes
Bolton et al., 2011219 Yes LOCF Yes
CCSG1, 1991154 Unclear Unclear Unclear
CCSG2, 1991154 Unclear Unclear Unclear
Chouinard et al., 1990163 Yes LOCF Yes
Cordioli et al., 2003164 Yes LOCF Yes
Cottraux et al., 1993165 No No
Cottraux et al., 2001166 No No
de Haan et al., 1998220 No No
Denys et al., 2003167 Yes LOCF Yes
DeVeaugh-Geiss et al., 1992221 Yes LOCF Yes
Emmelkamp and Beens 1991168 No No
Emmelkamp et al., 1988169 No No
Fals-Stewart et al., 1993170 No No
Flament et al., 1985222 Unclear Unclear Unclear
Foa et al., 2005171 Yes Linear mixed-effects
models
Yes
Freeman et al., 1994172 Yes LOCF Yes
Freeman et al., 2008223 Yes LOCF Yes
Freeston et al., 1997173 Yes Unclear Yes
Geller et al., 2001224 Yes LOCF Yes
GlaxoSmithKline, 2005174 Yes LOCF Yes
GlaxoSmithKline, 2005175 Unclear Unclear Unclear
GlaxoSmithKline, 2001225 Yes LOCF Yes
Goodman et al., 1989176 Yes LOCF Yes
Goodman et al., 1996177 Yes LOCF Yes
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TABLE 72 Quality assessment: analysis section (continued )
Study
Imputation for
missing data Imputation method ITT analysis
Greist et al., 1995126 Unclear Unclear Unclear
Greist et al., 2002178 Yes LOCF Yes
Hohagen et al., 1998179 Unclear Unclear No
Hollander et al., 2003180 Yes LOCF Yes
Hollander et al., 2003181 Yes LOCF Yes
Jaurrieta et al., 2008182 Yes LOCF Yes
Jenike et al., 1990183 NA NA NA
Jenike et al., 1990184 No No
Jenike et al., 1997185 No No
Jones and Menzies, 1998186 Unclear Unclear Unclear
Kamijima et al., 2004187 Yes LOCF Yes
Khodarahimi, 2009188 No Unclear Unclear
Kobak et al., 2005189 Yes LOCF Yes
Koran et al., 1996190 Yes LOCF Yes
Kronig et al., 1999191 Yes LOCF Yes
Liebowitz et al., 2002226 Yes LOCF Yes
Lindsay et al., 1997192 Unclear Unclear Unclear
López-Ibor et al., 1996193 Yes LOCF Yes
March et al., 1990227 Yes Other Yes
March et al., 1998228 Yes LOCF Yes
Mavissakalian et al., 1985194 No No
McLean et al., 2001195 No No
Milanfranchi et al., 1997196 No No
Montgomery et al., 1993197 Yes LOCF Yes
Montgomery et al., 2001198 Yes LOCF Yes
Mundo et al., 1997199 No Yes
Mundo et al., 2001200 Yes LOCF Yes
Nakajima et al., 1996201 Yes LOCF Yes
Nakatani et al., 2005202 No No
Neziroglu et al., 2000229 NA NA Yes
O’Connor et al., 1999203 No No
O’Connor et al., 2006204 No No
Perse et al., 1987205 No No
Piacentini et al., 2011230 Yes LOCF Yes
Riddle et al., 1992231 Yes LOCF Yes
Riddle et al., 2001232 Yes LOCF Yes
Shareh et al., 2010206 No No
Sousa et al., 2006207 NA NA NA
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TABLE 72 Quality assessment: analysis section (continued )
Study
Imputation for
missing data Imputation method ITT analysis
Stein et al., 2007124 Yes LOCF Yes
Storch et al., 2011233 Yes LOCF Yes
Storch et al., 2013234 Yes MLE Yes
The Pediatric OCD Treatment Study, 2004236 Yes LOCF Yes
Thoren et al., 1980208 No No
Tollefson et al., 1994127 No No
Van Oppen et al., 1995209 No No
Volavka et al., 1985210 No No
Whittal et al., 2005211 No No
Whittal et al., 2010212 No No
Williams et al., 2010235 Yes LOCF Yes
Zohar and Judge, 1996213 Yes LOCF Yes
CCSG, Clomipramine Collaborative Study Group; ITT, intention to treat; LOCF, last observation carried forward;
MLE, maximum likelihood estimation; NA, not applicable.
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Appendix 8 Detailed results of network
meta-analysis
Adult subset: clinical effectiveness (Yale–Brown
Obsessive–Compulsive Scale)
Network geometry
CBT
CBTFLV
BTCLO
BT
WL
VEN
SSRI
PSYPL
PL
HYP
CT
CLO
FIGURE 26 Network plot for class effects (the plot for individual effects is included in the main report).
BTCLO, BT+ clomipramine; CBTFLV, CBT+ fluvoxamine; CLO, clomipramine; HYP, hypericum; PL, placebo;
PSYPL, psychological placebo; VEN, venlafaxine; WL, waitlist.
TABLE 73 Model fit: consistency model
Model fit
Dbar Dhat DIC pD
mu.sd 2.773 2.773 2.773 4.24 × 10–12
sd1 386.1 382.1 390.2 4.046
y 370.1 259.4 480.8 110.7
total 759 644.2 873.7 114.7
Mean SD MC_error val2.5pc Median val97.5pc Start Sample
sdev 3.128 0.3794 0.002615 2.462 3.102 3.95 50,001 100,000
totresdev 104.6 14.35 0.06465 78.34 103.9 134.6 50,001 100,000
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TABLE 74 Model fit: inconsistency model
Model fit
Dbar Dhat DIC pD
mu.sd 2.773 2.773 2.773 5.16 × 10–12
sd1 386.1 382.1 390.2 4.054
y 370.8 262.6 479.1 108.3
total 759.8 647.4 872.1 112.3
Mean SD MC_error val2.5pc Median val97.5pc Start Sample
sdev 1.78 0.3462 0.003119 1.18 1.755 2.534 60,001 120,000
totresdev 105.8 14.46 0.06664 79.48 105.2 135.8 60,001 120,000
Data synthesis: consistency model (network meta-analysis)
Key: intervention (class)
1. Placebo (1).
2. Waitlist (2).
3. Fluoxetine (3).
4. Fluvoxamine (3).
5. Paroxetine (3).
6. Sertraline (3).
7. Citalopram (3).
8. Venlafaxine (4).
9. Clomipramine (5).
10. BT (6).
11. CBT (7).
12. CT (8).
13. Hypericum (9).
14. Fluvoxamine+CBT (10).
15. BT+ clomipramine (11).
16. Escitalopram (3).
17. Psychological placebo (12).
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TABLE 75 Data synthesis: adults – class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[1,2] 5.62 2.378 0.02451 0.9106 5.635 10.26 50,001 100,000
class.mean.diff[1,3] –3.493 0.8465 0.0126 –5.116 –3.503 –1.814 50,001 100,000
class.mean.diff[1,4] –3.217 2.577 0.01525 –8.262 –3.225 1.885 50,001 100,000
class.mean.diff[1,5] –4.724 1.078 0.009793 –6.851 –4.728 –2.601 50,001 100,000
class.mean.diff[1,6] –14.48 2.131 0.02531 –18.61 –14.51 –10.23 50,001 100,000
class.mean.diff[1,7] –5.374 1.898 0.02087 –9.098 –5.377 –1.632 50,001 100,000
class.mean.diff[1,8] –13.36 2.59 0.02797 –18.4 –13.39 –8.21 50,001 100,000
class.mean.diff[1,9] –0.1555 3.716 0.01768 –7.456 –0.1629 7.124 50,001 100,000
class.mean.diff[1,10] –7.521 3.222 0.02186 –13.89 –7.517 –1.173 50,001 100,000
class.mean.diff[1,11] –12.97 3.165 0.01717 –19.18 –12.97 –6.738 50,001 100,000
class.mean.diff[1,12] –4.147 2.324 0.02623 –8.649 –4.171 0.4895 50,001 100,000
class.mean.diff[2,3] –9.114 2.349 0.02079 –13.67 –9.133 –4.459 50,001 100,000
class.mean.diff[2,4] –8.838 3.395 0.02372 –15.47 –8.856 –2.141 50,001 100,000
class.mean.diff[2,5] –10.34 2.462 0.02028 –15.14 –10.36 –5.475 50,001 100,000
class.mean.diff[2,6] –20.1 2.272 0.01427 –24.52 –20.13 –15.55 50,001 100,000
class.mean.diff[2,7] –10.99 1.715 0.008719 –14.31 –11.01 –7.601 50,001 100,000
class.mean.diff[2,8] –18.98 2.694 0.01744 –24.21 –19 –13.62 50,001 100,000
class.mean.diff[2,9] –5.776 4.413 0.0298 –14.44 –5.784 2.911 50,001 100,000
class.mean.diff[2,10] –13.14 3.501 0.01671 –19.98 –13.15 –6.262 50,001 100,000
class.mean.diff[2,11] –18.59 3.719 0.02054 –25.88 –18.6 –11.23 50,001 100,000
class.mean.diff[2,12] –9.768 2.455 0.01473 –14.51 –9.796 –4.857 50,001 100,000
class.mean.diff[3,4] 0.2759 2.553 0.01126 –4.731 0.2721 5.325 50,001 100,000
class.mean.diff[3,5] –1.231 1.109 0.00638 –3.408 –1.231 0.9418 50,001 100,000
class.mean.diff[3,6] –10.99 2.129 0.02277 –15.14 –11.01 –6.752 50,001 100,000
class.mean.diff[3,7] –1.88 1.85 0.01643 –5.517 –1.878 1.763 50,001 100,000
class.mean.diff[3,8] –9.866 2.587 0.02559 –14.91 –9.878 –4.739 50,001 100,000
class.mean.diff[3,9] 3.338 3.815 0.02117 –4.134 3.339 10.82 50,001 100,000
class.mean.diff[3,10] –4.028 3.19 0.01734 –10.36 –4.016 2.212 50,001 100,000
class.mean.diff[3,11] –9.476 3.211 0.01784 –15.78 –9.473 –3.137 50,001 100,000
class.mean.diff[3,12] –0.6541 2.312 0.02379 –5.139 –0.6794 3.949 50,001 100,000
class.mean.diff[4,5] –1.507 2.519 0.01091 –6.501 –1.502 3.436 50,001 100,000
class.mean.diff[4,6] –11.26 3.229 0.02526 –17.57 –11.29 –4.862 50,001 100,000
class.mean.diff[4,7] –2.156 3.074 0.0198 –8.191 –2.164 3.879 50,001 100,000
class.mean.diff[4,8] –10.14 3.547 0.02778 –17.08 –10.16 –3.114 50,001 100,000
class.mean.diff[4,9] 3.062 4.517 0.02292 –5.836 3.084 11.9 50,001 100,000
class.mean.diff[4,10] –4.304 4.033 0.02118 –12.26 –4.292 3.584 50,001 100,000
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TABLE 75 Data synthesis: adults – class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[4,11] –9.752 3.988 0.01997 –17.62 –9.746 –1.905 50,001 100,000
class.mean.diff[4,12] –0.93 3.354 0.02612 –7.449 –0.9471 5.711 50,001 100,000
class.mean.diff[5,6] –9.756 2.191 0.02149 –14.02 –9.771 –5.404 50,001 100,000
class.mean.diff[5,7] –0.6494 2.008 0.016 –4.604 –0.642 3.293 50,001 100,000
class.mean.diff[5,8] –8.635 2.638 0.02443 –13.79 –8.651 –3.385 50,001 100,000
class.mean.diff[5,9] 4.569 3.876 0.02024 –3.072 4.582 12.15 50,001 100,000
class.mean.diff[5,10] –2.797 3.291 0.01753 –9.323 –2.794 3.677 50,001 100,000
class.mean.diff[5,11] –8.245 3.177 0.01566 –14.48 –8.238 –1.984 50,001 100,000
class.mean.diff[5,12] 0.577 2.384 0.02248 –4.048 0.559 5.333 50,001 100,000
class.mean.diff[6,7] 9.106 2.089 0.01435 4.97 9.109 13.18 50,001 100,000
class.mean.diff[6,8] 1.12 1.561 0.008178 –1.955 1.122 4.192 50,001 100,000
class.mean.diff[6,9] 14.32 4.282 0.03056 5.879 14.34 22.7 50,001 100,000
class.mean.diff[6,10] 6.959 3.54 0.0212 –0.04063 6.976 13.87 50,001 100,000
class.mean.diff[6,11] 1.511 3.379 0.01985 –5.158 1.517 8.135 50,001 100,000
class.mean.diff[6,12] 10.33 1.547 0.006452 7.289 10.33 13.38 50,001 100,000
class.mean.diff[7,8] –7.986 2.532 0.01758 –12.97 –7.981 –3.008 50,001 100,000
class.mean.diff[7,9] 5.218 4.167 0.02699 –2.976 5.23 13.37 50,001 100,000
class.mean.diff[7,10] –2.147 3.121 0.01332 –8.307 –2.136 3.987 50,001 100,000
class.mean.diff[7,11] –7.596 3.495 0.01823 –14.46 –7.606 –0.7485 50,001 100,000
class.mean.diff[7,12] 1.226 2.173 0.01469 –3.029 1.22 5.541 50,001 100,000
class.mean.diff[8,9] 13.2 4.535 0.03276 4.261 13.19 22.11 50,001 100,000
class.mean.diff[8,10] 5.838 3.814 0.02375 –1.666 5.839 13.33 50,001 100,000
class.mean.diff[8,11] 0.3902 3.698 0.02294 –6.854 0.3933 7.678 50,001 100,000
class.mean.diff[8,12] 9.212 1.973 0.009613 5.341 9.213 13.1 50,001 100,000
class.mean.diff[9,10] –7.366 4.933 0.02833 –17.08 –7.357 2.351 50,001 100,000
class.mean.diff[9,11] –12.81 4.871 0.02431 –22.35 –12.81 –3.281 50,001 100,000
class.mean.diff[9,12] –3.992 4.379 0.03134 –12.55 –3.996 4.653 50,001 100,000
class.mean.diff[10,11] –5.448 4.415 0.02175 –14.08 –5.445 3.286 50,001 100,000
class.mean.diff[10,12] 3.374 3.619 0.02194 –3.661 3.354 10.53 50,001 100,000
class.mean.diff[11,12] 8.822 3.563 0.02118 1.849 8.797 15.84 50,001 100,000
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TABLE 76 Data synthesis: adults – individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[1,2] 5.62 2.378 0.02451 0.9106 5.635 10.26 50,001 100,000
treat.mean.diff[1,3] –3.463 0.9264 0.01216 –5.268 –3.478 –1.584 50,001 100,000
treat.mean.diff[1,4] –3.604 0.8429 0.01194 –5.292 –3.594 –1.947 50,001 100,000
treat.mean.diff[1,5] –3.416 0.878 0.01195 –5.105 –3.431 –1.611 50,001 100,000
treat.mean.diff[1,6] –3.498 0.9257 0.0124 –5.304 –3.506 –1.628 50,001 100,000
treat.mean.diff[1,7] –3.488 1.065 0.01272 –5.622 –3.498 –1.309 50,001 100,000
treat.mean.diff[1,8] –3.217 2.577 0.01525 –8.262 –3.225 1.885 50,001 100,000
treat.mean.diff[1,9] –4.724 1.078 0.009793 –6.851 –4.728 –2.601 50,001 100,000
treat.mean.diff[1,10] –14.48 2.131 0.02531 –18.61 –14.51 –10.23 50,001 100,000
treat.mean.diff[1,11] –5.374 1.898 0.02087 –9.098 –5.377 –1.632 50,001 100,000
treat.mean.diff[1,12] –13.36 2.59 0.02797 –18.4 –13.39 –8.21 50,001 100,000
treat.mean.diff[1,13] –0.1555 3.716 0.01768 –7.456 –0.1629 7.124 50,001 100,000
treat.mean.diff[1,14] –7.521 3.222 0.02186 –13.89 –7.517 –1.173 50,001 100,000
treat.mean.diff[1,15] –12.97 3.165 0.01717 –19.18 –12.97 –6.738 50,001 100,000
treat.mean.diff[1,16] –3.483 1.088 0.01272 –5.611 –3.498 –1.234 50,001 100,000
treat.mean.diff[1,17] –4.147 2.324 0.02623 –8.649 –4.171 0.4895 50,001 100,000
treat.mean.diff[2,3] –9.083 2.36 0.02061 –13.68 –9.102 –4.405 50,001 100,000
treat.mean.diff[2,4] –9.225 2.329 0.02016 –13.77 –9.237 –4.628 50,001 100,000
treat.mean.diff[2,5] –9.036 2.384 0.02101 –13.68 –9.06 –4.306 50,001 100,000
treat.mean.diff[2,6] –9.118 2.358 0.02042 –13.73 –9.134 –4.45 50,001 100,000
treat.mean.diff[2,7] –9.108 2.451 0.0212 –13.89 –9.127 –4.253 50,001 100,000
treat.mean.diff[2,8] –8.838 3.395 0.02372 –15.47 –8.856 –2.141 50,001 100,000
treat.mean.diff[2,9] –10.34 2.462 0.02028 –15.14 –10.36 –5.475 50,001 100,000
treat.mean.diff[2,10] –20.1 2.272 0.01427 –24.52 –20.13 –15.55 50,001 100,000
treat.mean.diff[2,11] –10.99 1.715 0.008719 –14.31 –11.01 –7.601 50,001 100,000
treat.mean.diff[2,12] –18.98 2.694 0.01744 –24.21 –19 –13.62 50,001 100,000
treat.mean.diff[2,13] –5.776 4.413 0.0298 –14.44 –5.784 2.911 50,001 100,000
treat.mean.diff[2,14] –13.14 3.501 0.01671 –19.98 –13.15 –6.262 50,001 100,000
treat.mean.diff[2,15] –18.59 3.719 0.02054 –25.88 –18.6 –11.23 50,001 100,000
treat.mean.diff[2,16] –9.103 2.457 0.02115 –13.9 –9.118 –4.223 50,001 100,000
treat.mean.diff[2,17] –9.768 2.455 0.01473 –14.51 –9.796 –4.857 50,001 100,000
treat.mean.diff[3,4] –0.1412 0.8752 0.004168 –2.196 –0.04312 1.62 50,001 100,000
treat.mean.diff[3,5] 0.04729 0.8874 0.003442 –1.843 0.009691 2.033 50,001 100,000
treat.mean.diff[3,6] –0.03457 0.8854 0.00315 –2.019 –0.00726 1.857 50,001 100,000
treat.mean.diff[3,7] –0.02461 1.042 0.004036 –2.315 –0.00442 2.256 50,001 100,000
treat.mean.diff[3,8] 0.2457 2.602 0.01119 –4.871 0.2425 5.377 50,001 100,000
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TABLE 76 Data synthesis: adults – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[3,9] –1.261 1.182 0.006338 –3.63 –1.254 1.055 50,001 100,000
treat.mean.diff[3,10] –11.02 2.155 0.0226 –15.23 –11.04 –6.742 50,001 100,000
treat.mean.diff[3,11] –1.911 1.853 0.01622 –5.549 –1.902 1.728 50,001 100,000
treat.mean.diff[3,12] –9.896 2.606 0.02546 –14.98 –9.912 –4.757 50,001 100,000
treat.mean.diff[3,13] 3.308 3.832 0.02092 –4.217 3.312 10.81 50,001 100,000
treat.mean.diff[3,14] –4.058 3.21 0.01732 –10.43 –4.039 2.225 50,001 100,000
treat.mean.diff[3,15] –9.506 3.231 0.01754 –15.86 –9.5 –3.137 50,001 100,000
treat.mean.diff[3,16] –0.01967 1.048 0.003805 –2.314 –0.0041 2.276 50,001 100,000
treat.mean.diff[3,17] –0.6843 2.33 0.02355 –5.218 –0.7018 3.94 50,001 100,000
treat.mean.diff[4,5] 0.1885 0.8269 0.004488 –1.409 0.06661 2.146 50,001 100,000
treat.mean.diff[4,6] 0.1066 0.8689 0.003919 –1.676 0.02994 2.116 50,001 100,000
treat.mean.diff[4,7] 0.1166 0.9929 0.004682 –1.94 0.03256 2.417 50,001 100,000
treat.mean.diff[4,8] 0.3869 2.571 0.0118 –4.653 0.377 5.462 50,001 100,000
treat.mean.diff[4,9] –1.12 1.083 0.005907 –3.24 –1.131 1.036 50,001 100,000
treat.mean.diff[4,10] –10.88 2.099 0.02222 –14.96 –10.91 –6.69 50,001 100,000
treat.mean.diff[4,11] –1.769 1.831 0.01591 –5.365 –1.776 1.866 50,001 100,000
treat.mean.diff[4,12] –9.755 2.557 0.0251 –14.73 –9.778 –4.697 50,001 100,000
treat.mean.diff[4,13] 3.449 3.816 0.02111 –4.032 3.454 10.95 50,001 100,000
treat.mean.diff[4,14] –3.917 3.147 0.01687 –10.14 –3.912 2.281 50,001 100,000
treat.mean.diff[4,15] –9.365 3.198 0.01756 –15.62 –9.371 –3.02 50,001 100,000
treat.mean.diff[4,16] 0.1215 1.012 0.004475 –1.937 0.02962 2.493 50,001 100,000
treat.mean.diff[4,17] –0.5431 2.283 0.02332 –4.964 –0.566 4.005 50,001 100,000
treat.mean.diff[5,6] –0.08186 0.8859 0.003587 –2.096 –0.0227 1.769 50,001 100,000
treat.mean.diff[5,7] –0.0719 0.9897 0.004086 –2.309 –0.01626 2.029 50,001 100,000
treat.mean.diff[5,8] 0.1984 2.501 0.01046 –4.704 0.1935 5.125 50,001 100,000
treat.mean.diff[5,9] –1.309 1.101 0.005826 –3.508 –1.304 0.848 50,001 100,000
treat.mean.diff[5,10] –11.06 2.156 0.023 –15.27 –11.08 –6.784 50,001 100,000
treat.mean.diff[5,11] –1.958 1.898 0.0166 –5.704 –1.955 1.762 50,001 100,000
treat.mean.diff[5,12] –9.944 2.61 0.02578 –15.06 –9.961 –4.784 50,001 100,000
treat.mean.diff[5,13] 3.26 3.821 0.02081 –4.243 3.263 10.76 50,001 100,000
treat.mean.diff[5,14] –4.105 3.218 0.0176 –10.49 –4.092 2.212 50,001 100,000
treat.mean.diff[5,15] –9.554 3.214 0.01765 –15.88 –9.547 –3.232 50,001 100,000
treat.mean.diff[5,16] –0.06696 0.9761 0.003684 –2.261 –0.01811 2.024 50,001 100,000
treat.mean.diff[5,17] –0.7316 2.342 0.02399 –5.301 –0.7494 3.927 50,001 100,000
treat.mean.diff[6,7] 0.009959 1.039 0.003995 –2.271 0.001729 2.285 50,001 100,000
treat.mean.diff[6,8] 0.2803 2.596 0.01146 –4.789 0.2729 5.417 50,001 100,000
treat.mean.diff[6,9] –1.227 1.173 0.006392 –3.552 –1.224 1.095 50,001 100,000
treat.mean.diff[6,10] –10.98 2.153 0.02246 –15.16 –11.01 –6.708 50,001 100,000
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TABLE 76 Data synthesis: adults – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[6,11] –1.876 1.859 0.01605 –5.532 –1.881 1.798 50,001 100,000
treat.mean.diff[6,12] –9.862 2.604 0.0253 –14.93 –9.871 –4.706 50,001 100,000
treat.mean.diff[6,13] 3.342 3.835 0.02118 –4.181 3.344 10.86 50,001 100,000
treat.mean.diff[6,14] –4.023 3.209 0.01722 –10.39 –4.009 2.274 50,001 100,000
treat.mean.diff[6,15] –9.472 3.23 0.01747 –15.82 –9.468 –3.113 50,001 100,000
treat.mean.diff[6,16] 0.0149 1.044 0.003616 –2.26 0.001961 2.338 50,001 100,000
treat.mean.diff[6,17] –0.6497 2.333 0.02343 –5.19 –0.6678 3.987 50,001 100,000
treat.mean.diff[7,8] 0.2703 2.644 0.01148 –4.932 0.262 5.48 50,001 100,000
treat.mean.diff[7,9] –1.237 1.304 0.007012 –3.847 –1.229 1.338 50,001 100,000
treat.mean.diff[7,10] –10.99 2.24 0.0231 –15.36 –11.01 –6.56 50,001 100,000
treat.mean.diff[7,11] –1.886 1.982 0.01693 –5.806 –1.884 2.029 50,001 100,000
treat.mean.diff[7,12] –9.872 2.677 0.02598 –15.12 –9.893 –4.573 50,001 100,000
treat.mean.diff[7,13] 3.332 3.87 0.02124 –4.254 3.332 10.93 50,001 100,000
treat.mean.diff[7,14] –4.033 3.265 0.01785 –10.52 –4.013 2.361 50,001 100,000
treat.mean.diff[7,15] –9.482 3.281 0.01792 –15.91 –9.484 –3.001 50,001 100,000
treat.mean.diff[7,16] 0.004941 1.13 0.003898 –2.469 –3.77 × 10–4 2.509 50,001 100,000
treat.mean.diff[7,17] –0.6597 2.418 0.02409 –5.361 –0.6761 4.163 50,001 100,000
treat.mean.diff[8,9] –1.507 2.519 0.01091 –6.501 –1.502 3.436 50,001 100,000
treat.mean.diff[8,10] –11.26 3.229 0.02526 –17.57 –11.29 –4.862 50,001 100,000
treat.mean.diff[8,11] –2.156 3.074 0.0198 –8.191 –2.164 3.879 50,001 100,000
treat.mean.diff[8,12] –10.14 3.547 0.02778 –17.08 –10.16 –3.114 50,001 100,000
treat.mean.diff[8,13] 3.062 4.517 0.02292 –5.836 3.084 11.9 50,001 100,000
treat.mean.diff[8,14] –4.304 4.033 0.02118 –12.26 –4.292 3.584 50,001 100,000
treat.mean.diff[8,15] –9.752 3.988 0.01997 –17.62 –9.746 –1.905 50,001 100,000
treat.mean.diff[8,16] –0.2654 2.646 0.0116 –5.501 –0.2571 4.944 50,001 100,000
treat.mean.diff[8,17] –0.93 3.354 0.02612 –7.449 –0.9471 5.711 50,001 100,000
treat.mean.diff[9,10] –9.756 2.191 0.02149 –14.02 –9.771 –5.404 50,001 100,000
treat.mean.diff[9,11] –0.6494 2.008 0.016 –4.604 –0.642 3.293 50,001 100,000
treat.mean.diff[9,12] –8.635 2.638 0.02443 –13.79 –8.651 –3.385 50,001 100,000
treat.mean.diff[9,13] 4.569 3.876 0.02024 –3.072 4.582 12.15 50,001 100,000
treat.mean.diff[9,14] –2.797 3.291 0.01753 –9.323 –2.794 3.677 50,001 100,000
treat.mean.diff[9,15] –8.245 3.177 0.01566 –14.48 –8.238 –1.984 50,001 100,000
treat.mean.diff[9,16] 1.242 1.316 0.006932 –1.352 1.236 3.89 50,001 100,000
treat.mean.diff[9,17] 0.577 2.384 0.02248 –4.048 0.559 5.333 50,001 100,000
treat.mean.diff[10,11] 9.106 2.089 0.01435 4.97 9.109 13.18 50,001 100,000
treat.mean.diff[10,12] 1.12 1.561 0.008178 –1.955 1.122 4.192 50,001 100,000
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TABLE 76 Data synthesis: adults – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[10,13] 14.32 4.282 0.03056 5.879 14.34 22.7 50,001 100,000
treat.mean.diff[10,14] 6.959 3.54 0.0212 –0.04063 6.976 13.87 50,001 100,000
treat.mean.diff[10,15] 1.511 3.379 0.01985 –5.158 1.517 8.135 50,001 100,000
treat.mean.diff[10,16] 11 2.241 0.02308 6.548 11.01 15.4 50,001 100,000
treat.mean.diff[10,17] 10.33 1.547 0.006452 7.289 10.33 13.38 50,001 100,000
treat.mean.diff[11,12] –7.986 2.532 0.01758 –12.97 –7.981 –3.008 50,001 100,000
treat.mean.diff[11,13] 5.218 4.167 0.02699 –2.976 5.23 13.37 50,001 100,000
treat.mean.diff[11,14] –2.147 3.121 0.01332 –8.307 –2.136 3.987 50,001 100,000
treat.mean.diff[11,15] –7.596 3.495 0.01823 –14.46 –7.606 –0.7485 50,001 100,000
treat.mean.diff[11,16] 1.891 1.985 0.0168 –2.03 1.891 5.813 50,001 100,000
treat.mean.diff[11,17] 1.226 2.173 0.01469 –3.029 1.22 5.541 50,001 100,000
treat.mean.diff[12,13] 13.2 4.535 0.03276 4.261 13.19 22.11 50,001 100,000
treat.mean.diff[12,14] 5.838 3.814 0.02375 –1.666 5.839 13.33 50,001 100,000
treat.mean.diff[12,15] 0.3902 3.698 0.02294 –6.854 0.3933 7.678 50,001 100,000
treat.mean.diff[12,16] 9.877 2.678 0.02587 4.591 9.889 15.14 50,001 100,000
treat.mean.diff[12,17] 9.212 1.973 0.009613 5.341 9.213 13.1 50,001 100,000
treat.mean.diff[13,14] –7.366 4.933 0.02833 –17.08 –7.357 2.351 50,001 100,000
treat.mean.diff[13,15] –12.81 4.871 0.02431 –22.35 –12.81 –3.281 50,001 100,000
treat.mean.diff[13,16] –3.327 3.874 0.02134 –10.94 –3.331 4.227 50,001 100,000
treat.mean.diff[13,17] –3.992 4.379 0.03134 –12.55 –3.996 4.653 50,001 100,000
treat.mean.diff[14,15] –5.448 4.415 0.02175 –14.08 –5.445 3.286 50,001 100,000
treat.mean.diff[14,16] 4.038 3.274 0.01775 –2.386 4.023 10.51 50,001 100,000
treat.mean.diff[14,17] 3.374 3.619 0.02194 –3.661 3.354 10.53 50,001 100,000
treat.mean.diff[15,16] 9.487 3.285 0.01803 3.003 9.481 15.93 50,001 100,000
treat.mean.diff[15,17] 8.822 3.563 0.02118 1.849 8.797 15.84 50,001 100,000
treat.mean.diff[16,17] –0.6646 2.418 0.0241 –5.384 –0.6767 4.141 50,001 100,000
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TABLE 77 Data synthesis: adults – inconsistency model (pairwise comparison)
d Mean SD MC_error val2.5pc Median val97.5pc Start Sample
d[1,3] –2.656 1.064 0.006615 –4.722 –2.666 –0.5367 60,001 120,000
d[1,4] –3.577 0.9644 0.005258 –5.513 –3.566 –1.704 60,001 120,000
d[1,5] –2.839 0.8353 0.004452 –4.48 –2.844 –1.174 60,001 120,000
d[1,6] –2.85 1.188 0.006132 –5.182 –2.854 –0.503 60,001 120,000
d[1,7] –3.653 1.32 0.008286 –6.255 –3.651 –1.056 60,001 120,000
d[1,9] –6.278 0.9656 0.004634 –8.154 –6.291 –4.34 60,001 120,000
d[1,10] –11.76 2.598 0.0167 –16.87 –11.77 –6.617 60,001 120,000
d[1,13] –0.0795 2.658 0.01658 –5.297 –0.08029 5.112 60,001 120,000
d[1,15] –12.25 2.599 0.01664 –17.29 –12.26 –7.094 60,001 120,000
d[1,16] –3.281 1.563 0.008429 –6.38 –3.275 –0.1997 60,001 120,000
d[2,10] –30.86 1.945 0.00709 –34.72 –30.86 –27 60,001 120,000
d[2,11] –7.392 1.452 0.0107 –10.25 –7.395 –4.542 60,001 120,000
d[3,6] 0.1054 2.22 0.009702 –4.27 0.106 4.466 60,001 120,000
d[3,9] –1.422 2.862 0.0203 –7.063 –1.414 4.208 60,001 120,000
d[3,11] –0.3179 2.244 0.01055 –4.766 –0.3078 4.083 60,001 120,000
d[4,5] 5.399 4.21 0.0448 –2.866 5.41 13.59 60,001 120,000
d[4,7] 3.603 4.507 0.05032 –5.237 3.594 12.44 60,001 120,000
d[4,9] –0.1027 1.331 0.007964 –2.735 –0.1039 2.515 60,001 120,000
d[4,10] –7.277 3.785 0.05031 –14.74 –7.247 0.05766 60,001 120,000
d[4,11] –9.656 2.408 0.01619 –14.4 –9.656 –4.914 60,001 120,000
d[4,14] –8.149 2.426 0.0168 –12.92 –8.147 –3.367 60,001 120,000
d[4,17] 8.227 3.961 0.05129 0.4291 8.253 15.93 60,001 120,000
d[5,7] Not estimable
d[5,8] 0.6068 2.106 0.008706 –3.561 0.6089 4.744 60,001 120,000
d[5,9] 1.06 2.109 0.009106 –3.096 1.06 5.213 60,001 120,000
d[5,16] Not estimable
d[6,9] 2.581 2.123 0.009151 –1.611 2.584 6.762 60,001 120,000
d[6,11] –3.44 2.711 0.01678 –8.768 –3.438 1.924 60,001 120,000
d[8,9] –1.071 2.502 0.0164 –5.988 –1.08 3.865 60,001 120,000
d[9,10] Not estimable
d[9,15] Not estimable
d[10,12] –0.3039 1.246 0.008738 –2.747 –0.3015 2.147 60,001 120,000
d[10,15] Not estimable
d[10,17] 8.424 1.437 0.008111 5.641 8.405 11.31 60,001 120,000
d[11,14] Not estimable
d[11,17] 5.937 2.105 0.01018 1.741 5.942 10.06 60,001 120,000
d[12,17] 2.673 2.301 0.01049 –1.86 2.686 7.185 60,001 120,000
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TABLE 78 Data synthesis: adults – median ranks (class effects)
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 10.37 0.6439 0.003308 9 10 11 50,001 100,000
rk.class[2] 11.89 0.3477 0.001867 11 12 12 50,001 100,000
rk.class[3] 7.882 1.128 0.007899 5 8 10 50,001 100,000
rk.class[4] 7.852 2 0.009506 4 8 11 50,001 100,000
rk.class[5] 6.353 1.27 0.007864 4 6 9 50,001 100,000
rk.class[6] 1.585 0.6645 0.002948 1 1 3 50,001 100,000
rk.class[7] 5.892 1.42 0.008825 4 6 9 50,001 100,000
rk.class[8] 2.294 0.8118 0.004527 1 2 4 50,001 100,000
rk.class[9] 9.666 2.042 0.01036 4 10 12 50,001 100,000
rk.class[10] 4.733 1.776 0.007904 2 4 9 50,001 100,000
rk.class[11] 2.369 1.104 0.00559 1 3 4 50,001 100,000
rk.class[12] 7.116 1.826 0.01607 4 7 10 50,001 100,000
TABLE 79 Data synthesis: adults – median ranks (individual effects)
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 15.36 0.6554 0.00344 14 15 16 50,001 100,000
rk[2] 16.89 0.3588 0.00192 16 17 17 50,001 100,000
rk[3] 10.46 2.306 0.01013 6 11 14 50,001 100,000
rk[4] 10.03 2.199 0.01102 6 10 14 50,001 100,000
rk[5] 10.61 2.204 0.01088 6 11 14 50,001 100,000
rk[6] 10.35 2.314 0.009603 6 10 14 50,001 100,000
rk[7] 10.35 2.498 0.01192 5 10 14 50,001 100,000
rk[8] 10.56 4.078 0.01757 4 12 16 50,001 100,000
rk[9] 7.078 2.24 0.01174 4 7 13 50,001 100,000
rk[10] 1.585 0.6645 0.002947 1 1 3 50,001 100,000
rk[11] 6.683 2.744 0.01967 4 6 14 50,001 100,000
rk[12] 2.295 0.8165 0.004561 1 2 4 50,001 100,000
rk[13] 13.71 3.736 0.01859 4 15 17 50,001 100,000
rk[14] 5.252 2.984 0.01282 2 4 14 50,001 100,000
rk[15] 2.38 1.168 0.005787 1 3 4 50,001 100,000
rk[16] 10.35 2.504 0.01141 5 10 14 50,001 100,000
rk[17] 9.053 3.823 0.03553 4 8 15 50,001 100,000
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Children and adolescent/clinical effectiveness (CYBOCS)
Network geometry
CBTPL
CBTSER
CLO
PL
PSYPL
SSRI
WL
BT
BTFLV
CBT
FIGURE 27 Network plot for class effects (the plot for individual effects is included in the main report). BTFLV,
BT+ fluvoxamine; CBTPL, CBT+placebo; CBTSER, CBT+ sertraline; CLO, clomipramine; PL, placebo; PSYPL,
psychological placebo; WL, waitlist.
TABLE 80 Model fit: children and adolescents – consistency model
Model fit
Dbar Dhat DIC pD
mu.sd 2.773 2.773 2.773 4.24 × 10–12
sd1 139.7 135.2 144.2 4.505
y 156.2 110.9 201.6 45.36
total 298.7 248.8 348.5 49.87
Mean SD MC_error val2.5pc Median val97.5pc Start Sample
sdev 2.083 1.352 0.0313 0.1306 1.888 5.233 50,001 100,000
totresdev 35.04 7.992 0.07331 20.81 34.58 52.19 50,001 100,000
TABLE 81 Model fit: children and adolescents – inconsistency model
Model fit
Dbar Dhat DIC pD
mu.sd 2.773 2.773 2.773 6.30 × 10–12
sd1 139.7 135.2 144.2 4.504
y 558.8 108.9 1009 449.9
total 701.2 246.8 1156 454.4
Mean SD MC_error val2.5pc Median val97.5pc Start Sample
sdev 2.062 1.506 0.02984 0.07666 1.809 5.782 70,000 140,001
totresdev 34.27 7.881 0.0579 20.53 33.71 51.36 70,000 140,001
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Data synthesis: consistency model (network meta-analysis)
Key
Treatment Treatment ID Class ID
Placebo 1 1
Waitlist 2 2
Psychological placebo 3 3
Fluoxetine 4 4
Fluvoxamine 5 4
Sertraline 6 4
Clomipramine 7 5
BT 8 6
CBT 9 7
BT+ fluvoxamine 10 8
CBT+ sertraline 11 9
CBT+ placebo 12 10
TABLE 82 Data synthesis: children and adolescents – class effects
Intervention code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[1,2] 3.10E+ 00 3.212 0.05846 –3.792 3.275 9.03 50,001 100,000
class.mean.diff[1,3] –5.374 3.736 0.05499 –12.9 –5.318 2.011 50,001 100,000
class.mean.diff[1,4] –3.577 2.379 0.01829 –8.57 –3.586 1.515 50,001 100,000
class.mean.diff[1,5] –5.645 3.004 0.03301 –11.36 –5.736 0.6411 50,001 100,000
class.mean.diff[1,6] –8.467 4.206 0.06413 –16.98 –8.355 –0.3873 50,001 100,000
class.mean.diff[1,7] –8.664 2.798 0.04855 –14.38 –8.643 –3.139 50,001 100,000
class.mean.diff[1,8] –6.123 4.247 0.04411 –14.49 –6.139 2.453 50,001 100,000
class.mean.diff[1,9] –10.3 2.899 0.03269 –16.16 –10.27 –4.582 50,001 100,000
class.mean.diff[1,10] –10.22 4.864 0.0634 –19.84 –10.19 –0.6097 50,001 100,000
class.mean.diff[2,3] –8.474 3.04 0.03171 –14.15 –8.61 –2.028 50,001 100,000
class.mean.diff[2,4] –6.678 3.848 0.05634 –13.96 –6.843 1.556 50,001 100,000
class.mean.diff[2,5] –8.745 4.027 0.06251 –16.1 –9.018 –0.08619 50,001 100,000
class.mean.diff[2,6] –11.57 3.843 0.04655 –19.04 –11.63 –3.788 50,001 100,000
class.mean.diff[2,7] –11.77 1.782 0.02223 –14.91 –11.91 –7.83 50,001 100,000
class.mean.diff[2,8] –9.223 5.273 0.07134 –19.09 –9.409 1.857 50,001 100,000
class.mean.diff[2,9] –13.41 3.719 0.05122 –20.39 –13.52 –5.562 50,001 100,000
class.mean.diff[2,10] –13.32 5.388 0.07379 –23.62 –13.42 –2.244 50,001 100,000
class.mean.diff[3,4] 1.796 4.285 0.05382 –6.692 1.727 10.48 50,001 100,000
class.mean.diff[3,5] –0.2708 4.495 0.05865 –8.874 –0.3962 9.083 50,001 100,000
class.mean.diff[3,6] –3.093 4.648 0.05348 –12.43 –3.028 6.046 50,001 100,000
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TABLE 82 Data synthesis: children and adolescents – class effects (continued )
Intervention code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[3,7] –3.291 2.472 0.02408 –8.218 –3.284 1.637 50,001 100,000
class.mean.diff[3,8] –0.7488 5.572 0.06654 –11.55 –0.7911 10.54 50,001 100,000
class.mean.diff[3,9] –4.931 4.171 0.05001 –13.15 –4.954 3.422 50,001 100,000
class.mean.diff[3,10] –4.842 5.686 0.07099 –16.03 –4.884 6.517 50,001 100,000
class.mean.diff[4,5] –2.067 3.803 0.03652 –9.524 –2.189 5.901 50,001 100,000
class.mean.diff[4,6] –4.889 4.752 0.06341 –14.6 –4.8 4.28 50,001 100,000
class.mean.diff[4,7] –5.087 3.497 0.04683 –12.33 –5.027 1.864 50,001 100,000
class.mean.diff[4,8] –2.545 4.413 0.04026 –11.24 –2.6 6.461 50,001 100,000
class.mean.diff[4,9] –6.727 3.563 0.03146 –14.02 –6.7 0.4664 50,001 100,000
class.mean.diff[4,10] –6.638 5.296 0.06311 –17.16 –6.637 3.873 50,001 100,000
class.mean.diff[5,6] –2.822 4.143 0.0641 –11.37 –2.708 4.944 50,001 100,000
class.mean.diff[5,7] –3.02 3.772 0.05265 –10.9 –2.876 4.19 50,001 100,000
class.mean.diff[5,8] –0.478 5.187 0.05526 –11.06 –0.4075 9.66 50,001 100,000
class.mean.diff[5,9] –4.66 4.054 0.04384 –13.04 –4.557 3.127 50,001 100,000
class.mean.diff[5,10] –4.571 5.637 0.07232 –15.96 –4.49 6.375 50,001 100,000
class.mean.diff[6,7] –0.1977 3.979 0.04858 –7.957 –0.2628 7.793 50,001 100,000
class.mean.diff[6,8] 2.344 5.954 0.07583 –9.139 2.32 14.35 50,001 100,000
class.mean.diff[6,9] –1.838 4.766 0.06176 –11.08 –1.904 7.805 50,001 100,000
class.mean.diff[6,10] –1.749 6.167 0.08015 –13.74 –1.834 10.65 50,001 100,000
class.mean.diff[7,8] 2.542 5.002 0.06231 –7.198 2.474 12.75 50,001 100,000
class.mean.diff[7,9] –1.64 3.354 0.04181 –8.257 –1.633 5.06 50,001 100,000
class.mean.diff[7,10] –1.551 5.131 0.06601 –11.68 –1.547 8.672 50,001 100,000
class.mean.diff[8,9] –4.182 5.044 0.05016 –14.35 –4.165 5.715 50,001 100,000
class.mean.diff[8,10] –4.093 6.354 0.06923 –16.77 –4.056 8.517 50,001 100,000
class.mean.diff[9,10] 0.08868 3.909 0.04742 –7.601 0.1137 7.812 50,001 100,000
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TABLE 83 Data synthesis: children and adolescents – individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[1,2] 3.101 3.212 0.05846 –3.792 3.275 9.03 50,001 100,000
treat.mean.diff[1,3] –5.374 3.736 0.05499 –12.9 –5.318 2.011 50,001 100,000
treat.mean.diff[1,4] –3.58 1.693 0.01926 –7.014 –3.588 –0.08378 50,001 100,000
treat.mean.diff[1,5] –3.273 2.073 0.02171 –7.39 –3.334 1.127 50,001 100,000
treat.mean.diff[1,6] –3.903 1.69 0.01729 –7.466 –3.845 –0.5958 50,001 100,000
treat.mean.diff[1,7] –5.645 3.004 0.03301 –11.36 –5.736 0.6411 50,001 100,000
treat.mean.diff[1,8] –8.467 4.206 0.06413 –16.98 –8.355 –0.3873 50,001 100,000
treat.mean.diff[1,9] –8.664 2.798 0.04855 –14.38 –8.643 –3.139 50,001 100,000
treat.mean.diff[1,10] –6.123 4.247 0.04411 –14.49 –6.139 2.453 50,001 100,000
treat.mean.diff[1,11] –10.3 2.899 0.03269 –16.16 –10.27 –4.582 50,001 100,000
treat.mean.diff[1,12] –10.22 4.864 0.0634 –19.84 –10.19 –0.6097 50,001 100,000
treat.mean.diff[2,3] –8.474 3.04 0.03171 –14.15 –8.61 –2.028 50,001 100,000
treat.mean.diff[2,4] –6.68 3.558 0.06036 –13.32 –6.846 0.9085 50,001 100,000
treat.mean.diff[2,5] –6.373 3.71 0.05793 –13.18 –6.567 1.58 50,001 100,000
treat.mean.diff[2,6] –7.004 3.324 0.05219 –13.24 –7.145 0.04082 50,001 100,000
treat.mean.diff[2,7] –8.745 4.027 0.06251 –16.1 –9.018 –0.08619 50,001 100,000
treat.mean.diff[2,8] –11.57 3.843 0.04655 –19.04 –11.63 –3.788 50,001 100,000
treat.mean.diff[2,9] –11.77 1.782 0.02223 –14.91 –11.91 –7.83 50,001 100,000
treat.mean.diff[2,10] –9.223 5.273 0.07134 –19.09 –9.409 1.857 50,001 100,000
treat.mean.diff[2,11] –13.41 3.719 0.05122 –20.39 –13.52 –5.562 50,001 100,000
treat.mean.diff[2,12] –13.32 5.388 0.07379 –23.62 –13.42 –2.244 50,001 100,000
treat.mean.diff[3,4] 1.794 4.023 0.05669 –5.995 1.719 10.03 50,001 100,000
treat.mean.diff[3,5] 2.101 4.162 0.05531 –6.055 2.018 10.64 50,001 100,000
treat.mean.diff[3,6] 1.47 3.83 0.05047 –6.121 1.457 9.187 50,001 100,000
treat.mean.diff[3,7] –0.2708 4.495 0.05865 –8.874 –0.3962 9.083 50,001 100,000
treat.mean.diff[3,8] –3.093 4.648 0.05348 –12.43 –3.028 6.046 50,001 100,000
treat.mean.diff[3,9] –3.291 2.472 0.02408 –8.218 –3.284 1.637 50,001 100,000
treat.mean.diff[3,10] –0.7488 5.572 0.06654 –11.55 –0.7911 10.54 50,001 100,000
treat.mean.diff[3,11] –4.931 4.171 0.05001 –13.15 –4.954 3.422 50,001 100,000
treat.mean.diff[3,12] –4.842 5.686 0.07099 –16.03 –4.884 6.517 50,001 100,000
treat.mean.diff[4,5] 0.307 2.246 0.01943 –4.344 0.1259 5.191 50,001 100,000
treat.mean.diff[4,6] –0.3238 1.993 0.01728 –4.802 –0.129 3.582 50,001 100,000
treat.mean.diff[4,7] –2.065 3.406 0.03578 –8.647 –2.177 5.01 50,001 100,000
treat.mean.diff[4,8] –4.887 4.487 0.06599 –14.04 –4.789 3.696 50,001 100,000
treat.mean.diff[4,9] –5.085 3.17 0.05022 –11.62 –5.016 1.052 50,001 100,000
treat.mean.diff[4,10] –2.543 4.315 0.04213 –11.05 –2.564 6.081 50,001 100,000
treat.mean.diff[4,11] –6.725 3.245 0.03557 –13.33 –6.666 –0.326 50,001 100,000
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TABLE 83 Data synthesis: children and adolescents – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[4,12] –6.636 5.077 0.06581 –16.73 –6.632 3.319 50,001 100,000
treat.mean.diff[5,6] –0.6308 2.251 0.01714 –5.809 –0.3063 3.693 50,001 100,000
treat.mean.diff[5,7] –2.372 3.627 0.03927 –9.412 –2.481 5.184 50,001 100,000
treat.mean.diff[5,8] –5.194 4.632 0.06495 –14.65 –5.112 3.752 50,001 100,000
treat.mean.diff[5,9] –5.392 3.358 0.04913 –12.33 –5.295 1.14 50,001 100,000
treat.mean.diff[5,10] –2.85 3.731 0.03711 –10.18 –2.877 4.587 50,001 100,000
treat.mean.diff[5,11] –7.032 3.437 0.03377 –14.08 –6.998 –0.2872 50,001 100,000
treat.mean.diff[5,12] –6.943 5.199 0.06297 –17.36 –6.922 3.356 50,001 100,000
treat.mean.diff[6,7] –1.741 3.389 0.03599 –8.13 –1.877 5.471 50,001 100,000
treat.mean.diff[6,8] –4.563 4.383 0.06104 –13.39 –4.497 3.961 50,001 100,000
treat.mean.diff[6,9] –4.761 2.92 0.043 –10.69 –4.737 1.034 50,001 100,000
treat.mean.diff[6,10] –2.22E+ 00 4.337 0.04293 –10.64 –2.267 6.639 50,001 100,000
treat.mean.diff[6,11] –6.401 2.992 0.02854 –12.35 –6.394 –0.4037 50,001 100,000
treat.mean.diff[6,12] –6.312 4.927 0.06145 –16.05 –6.315 3.455 50,001 100,000
treat.mean.diff[7,8] –2.822 4.143 0.0641 –11.37 –2.708 4.944 50,001 100,000
treat.mean.diff[7,9] –3.02 3.772 0.05265 –10.9 –2.876 4.19 50,001 100,000
treat.mean.diff[7,10] –0.478 5.187 0.05526 –11.06 –0.4075 9.66 50,001 100,000
treat.mean.diff[7,11] –4.66 4.054 0.04384 –13.04 –4.557 3.127 50,001 100,000
treat.mean.diff[7,12] –4.571 5.637 0.07232 –15.96 –4.49 6.375 50,001 100,000
treat.mean.diff[8,9] –0.1977 3.979 0.04858 –7.957 –0.2628 7.793 50,001 100,000
treat.mean.diff[8,10] 2.344 5.954 0.07583 –9.139 2.32 14.35 50,001 100,000
treat.mean.diff[8,11] –1.838 4.766 0.06176 –11.08 –1.904 7.805 50,001 100,000
treat.mean.diff[8,12] –1.749 6.167 0.08015 –13.74 –1.834 10.65 50,001 100,000
treat.mean.diff[9,10] 2.542 5.002 0.06231 –7.198 2.474 12.75 50,001 100,000
treat.mean.diff[9,11] –1.64 3.354 0.04181 –8.257 –1.633 5.06 50,001 100,000
treat.mean.diff[9,12] –1.551 5.131 0.06601 –11.68 –1.547 8.672 50,001 100,000
treat.mean.diff[10,11] –4.182 5.044 0.05016 –14.35 –4.165 5.715 50,001 100,000
treat.mean.diff[10,12] –4.093 6.354 0.06923 –16.77 –4.056 8.517 50,001 100,000
treat.mean.diff[11,12] 0.08868 3.909 0.04742 –7.601 0.1137 7.812 50,001 100,000
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TABLE 84 Data synthesis: children and adolescents – inconsistency model (pairwise comparison)
d Mean SD MC_error val2.5pc Median val97.5pc Start Sample
d[1,4] –3.525 2.099 0.0166 –7.589 –3.553 0.8077 70,000 140,001
d[1,5] –2.687 2.984 0.01831 –8.731 –2.705 3.354 70,000 140,001
d[1,6] –3.989 2.122 0.01392 –8.452 –3.963 0.2112 70,000 140,001
d[1,7] –7.623 3.303 0.02624 –14.21 –7.667 –0.9719 70,000 140,001
d[1,9] –7.299 3.282 0.02647 –13.95 –7.278 –0.8807 70,000 140,001
d[1,11] –10.12 3.166 0.02212 –16.58 –10.09 –3.844 70,000 140,001
d[2,8] –7.051 4.672 0.05982 –16.17 –7.073 2.047 70,000 140,001
d[2,9] –12.34 1.828 0.01991 –15.6 –12.47 –8.35 70,000 140,001
d[3,9] –3.206 2.514 0.02367 –8.194 –3.214 1.915 70,000 140,001
d[5,10] –2.811 3.829 0.04023 –10.26 –2.79 4.759 70,000 140,001
d[6,9] Not estimable
d[6,11] Not estimable
d[7,8] –8.57 5.227 0.07107 –18.81 –8.609 1.701 70,000 140,001
d[9,11] Not estimable
d[11,12] 0.1554 3.988 0.04839 –7.703 0.1543 7.952 70,000 140,001
TABLE 85 Data synthesis: children and adolescents – median ranks (class effects)
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 8.879 0.7007 0.007675 7 9 10 50,001 100,000
rk.class[2] 9.707 0.7274 0.009997 7 10 10 50,001 100,000
rk.class[3] 5.887 1.851 0.02335 2 6 9 50,001 100,000
rk.class[4] 6.933 1.447 0.0142 3 7 9 50,001 100,000
rk.class[5] 5.574 1.831 0.02318 2 6 9 50,001 100,000
rk.class[6] 3.808 2.143 0.03 1 4 8 50,001 100,000
rk.class[7] 3.44 1.435 0.01966 1 3 6 50,001 100,000
rk.class[8] 5.212 2.385 0.02745 1 5 10 50,001 100,000
rk.class[9] 2.555 1.41 0.01666 1 2 6 50,001 100,000
rk.class[10] 3.005 2.204 0.0301 1 2 8 50,001 100,000
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TABLE 86 Data synthesis: children and adolescents – median ranks (individual effects)
Mean Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 10.84 0.7791 0.008764 9 11 12 50,001 100,000
rk[2] 11.64 0.9671 0.01322 8 12 12 50,001 100,000
rk[3] 6.508 2.503 0.03344 2 6 11 50,001 100,000
rk[4] 7.963 1.701 0.02002 4 8 11 50,001 100,000
rk[5] 8.28 1.734 0.01771 4 9 11 50,001 100,000
rk[6] 7.667 1.621 0.01517 4 8 10 50,001 100,000
rk[7] 6.065 2.39 0.02953 2 6 11 50,001 100,000
rk[8] 4.057 2.571 0.03552 1 4 10 50,001 100,000
rk[9] 3.519 1.598 0.02183 1 3 7 50,001 100,000
rk[10] 5.701 2.976 0.03297 1 6 12 50,001 100,000
rk[11] 2.587 1.512 0.01737 1 2 6 50,001 100,000
rk[12] 3.171 2.57 0.03467 1 2 10 50,001 100,000
Adults/acceptability (total dropouts)
Network geometry
CBT
CBTFLV
CLO
CT
HYP
IMI
PL
PSYPL
SSRI
VEN
WL
AMI
BT
BTCLO
BTFLV
FIGURE 28 Network plot for class effects (the plot for individual effects is included in the main report).
AMI, amitriptyline; BTCLO, BT+ clomipramine; BTFLV, BT+ fluvoxamine; CBTFLV, CBT+ fluvoxamine;
CLO, clomipramine; HYP, hypericum; IMI, imipramine; PL, placebo; PSYPL, psychological placebo; VEN, venlafaxine;
WL, waitlist.
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Model fit
TABLE 87 Model fit: adults – consistency model
Model fit
Dbar Dhat DIC pD
r 537.2 464.1 610.3 73.1
total 537.2 464.1 610.3 73.1
Mean SD MC_error val2.5pc Median val97.5pc Start Sample
sd 0.1379 0.08448 0.002286 0.008152 0.1295 0.3204 100,001 200,000
totresdev 118.2 12.81 0.1327 94.43 117.7 144.7 100,001 200,000
TABLE 88 Model fit: adults – inconsistency model
Model fit
Dbar Dhat DIC pD
r 539.3 452.5 626 86.73
total 539.3 452.5 626 86.73
Mean SD MC_error val2.5pc Median val97.5pc Start Sample
SD 0.1304 0.08595 0.001213 0.007238 0.1197 0.3231 100,001 200,000
totresdev 120.3 13.96 0.1046 94.57 119.7 149.3 100,001 200,000
Data synthesis: consistency model (network meta-analysis)
Key: intervention (class)
1. Placebo (1).
2. Waitlist (11).
3. Fluoxetine (3).
4. Fluvoxamine (3).
5. Paroxetine (3).
6. Sertraline (3).
7. Citalopram (3).
8. Venlafaxine (2).
9. Clomipramine (4).
10. BT (5).
11. CBT (6).
12. CT (7).
13. Amitriptyline (10).
14. BT+ fluvoxamine (13).
15. CBT+ fluvoxamine (9).
16. BT+ clomipramine (8).
17. Escitalopram (3).
18. Psychological placebo (12).
19. Hypericum (14).
20. Imipramine (15).
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TABLE 89 Data synthesis: adults – class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[1,2] 0.4546 0.2824 0.006189 0.1095 0.3921 1.148 100,001 200,000
OR.D[1,3] 1.087 0.1338 0.002307 0.8511 1.081 1.363 100,001 200,000
OR.D[1,4] 1.539 0.2175 0.004003 1.163 1.521 2.015 100,001 200,000
OR.D[1,5] 1.105 0.411 0.01157 0.5177 1.041 2.085 100,001 200,000
OR.D[1,6] 0.8339 0.3076 0.007419 0.4018 0.7748 1.595 100,001 200,000
OR.D[1,7] 1.103 0.4937 0.01353 0.4341 1.009 2.301 100,001 200,000
OR.D[1,8] 1.383 0.6327 0.01068 0.5262 1.267 2.931 100,001 200,000
OR.D[1,9] 11.39 59.29 1.302 0.04345 2.128 74.15 100,001 200,000
OR.D[1,10] 31.64 294 8.646 0.2991 4.513 138.6 100,001 200,000
OR.D[1,11] 0.5054 0.3846 0.01051 0.09958 0.402 1.502 100,001 200,000
OR.D[1,12] 0.5986 0.3323 0.008996 0.1878 0.5216 1.451 100,001 200,000
OR.D[1,13] 0.7691 0.6121 0.01333 0.1304 0.6073 2.353 100,001 200,000
OR.D[1,14] 1.018 0.6868 0.01217 0.2476 0.8517 2.729 100,001 200,000
OR.D[1,15] 3.486 4.934 0.1183 0.2908 1.965 16.07 100,001 200,000
OR.D[2,3] 3.437 2.555 0.0562 0.9351 2.754 9.894 100,001 200,000
OR.D[2,4] 4.848 3.603 0.0798 1.342 3.893 14.07 100,001 200,000
OR.D[2,5] 3.479 2.973 0.06704 0.7327 2.697 10.99 100,001 200,000
OR.D[2,6] 2.647 2.323 0.05077 0.5758 1.969 8.62 100,001 200,000
OR.D[2,7] 3.461 3.038 0.0705 0.655 2.641 11.18 100,001 200,000
OR.D[2,8] 4.347 3.974 0.07893 0.82 3.254 14.34 100,001 200,000
OR.D[2,9] 35.55 169.6 4.153 0.09668 5.559 245.3 100,001 200,000
OR.D[2,10] 88.25 763.8 19.5 0.6283 11.4 457.7 100,001 200,000
OR.D[2,11] 1.642 2.047 0.05398 0.1755 1.02 6.745 100,001 200,000
OR.D[2,12] 1.875 1.793 0.04252 0.3112 1.352 6.566 100,001 200,000
OR.D[2,13] 2.416 2.889 0.05796 0.2337 1.567 9.449 100,001 200,000
OR.D[2,14] 3.21 4.582 0.06746 0.4138 2.186 11.82 100,001 200,000
OR.D[2,15] 10.94 21.64 0.5357 0.6329 5.165 55.38 100,001 200,000
OR.D[3,4] 1.429 0.2256 0.003166 1.049 1.409 1.92 100,001 200,000
OR.D[3,5] 1.025 0.3859 0.0103 0.4757 0.9626 1.96 100,001 200,000
OR.D[3,6] 0.7713 0.2807 0.006354 0.3736 0.7205 1.458 100,001 200,000
OR.D[3,7] 1.022 0.4608 0.01212 0.398 0.9287 2.164 100,001 200,000
OR.D[3,8] 1.285 0.5984 0.009415 0.482 1.171 2.763 100,001 200,000
OR.D[3,9] 10.52 57.29 1.231 0.04033 1.96 68.64 100,001 200,000
OR.D[3,10] 28.96 266.4 7.609 0.281 4.165 130.1 100,001 200,000
OR.D[3,11] 0.4677 0.3561 0.009647 0.09169 0.3746 1.387 100,001 200,000
OR.D[3,12] 0.5544 0.3075 0.008097 0.1734 0.4835 1.343 100,001 200,000
continued
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TABLE 89 Data synthesis: adults – class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[3,13] 0.7128 0.5665 0.01217 0.1194 0.5624 2.177 100,001 200,000
OR.D[3,14] 0.9489 0.6533 0.01133 0.2263 0.7891 2.598 100,001 200,000
OR.D[3,15] 3.239 4.603 0.1088 0.2702 1.82 15.01 100,001 200,000
OR.D[4,5] 0.725 0.2687 0.007152 0.3367 0.6836 1.365 100,001 200,000
OR.D[4,6] 0.5495 0.2096 0.00475 0.2521 0.5112 1.066 100,001 200,000
OR.D[4,7] 0.7238 0.3236 0.008512 0.279 0.6648 1.517 100,001 200,000
OR.D[4,8] 0.9061 0.4111 0.006424 0.3459 0.8282 1.912 100,001 200,000
OR.D[4,9] 7.599 40.91 0.893 0.02825 1.385 49.55 100,001 200,000
OR.D[4,10] 21.27 209 6.016 0.2031 2.94 90.76 100,001 200,000
OR.D[4,11] 0.3326 0.2554 0.006912 0.06458 0.2654 1.007 100,001 200,000
OR.D[4,12] 0.3925 0.2165 0.005704 0.1237 0.3411 0.9491 100,001 200,000
OR.D[4,13] 0.5061 0.4044 0.008782 0.08497 0.3978 1.579 100,001 200,000
OR.D[4,14] 0.6731 0.4673 0.008039 0.1572 0.5572 1.846 100,001 200,000
OR.D[4,15] 2.256 3.113 0.07227 0.1957 1.294 10.07 100,001 200,000
OR.D[5,6] 0.8443 0.4219 0.01039 0.3086 0.7506 1.904 100,001 200,000
OR.D[5,7] 1.002 0.2496 0.00467 0.598 0.9733 1.573 100,001 200,000
OR.D[5,8] 1.362 0.693 0.01231 0.4607 1.223 3.091 100,001 200,000
OR.D[5,9] 11.3 70.18 1.397 0.04308 2.05 77.11 100,001 200,000
OR.D[5,10] 31.6 283.5 8.307 0.2778 4.329 133.7 100,001 200,000
OR.D[5,11] 0.5049 0.4307 0.01168 0.0914 0.3873 1.65 100,001 200,000
OR.D[5,12] 0.5443 0.2164 0.004716 0.2302 0.506 1.06 100,001 200,000
OR.D[5,13] 0.7347 0.5717 0.01167 0.1261 0.5881 2.234 100,001 200,000
OR.D[5,14] 1.048 0.8506 0.01773 0.1978 0.8174 3.252 100,001 200,000
OR.D[5,15] 3.483 5.141 0.1092 0.2599 1.923 16.52 100,001 200,000
OR.D[6,7] 1.467 0.8041 0.01971 0.4573 1.292 3.472 100,001 200,000
OR.D[6,8] 1.862 1.1 0.0206 0.5442 1.614 4.707 100,001 200,000
OR.D[6,9] 14.49 73.24 1.588 0.05081 2.72 96.33 100,001 200,000
OR.D[6,10] 40.64 335.9 10.24 0.3673 5.493 195.3 100,001 200,000
OR.D[6,11] 0.614 0.4048 0.01061 0.1467 0.526 1.641 100,001 200,000
OR.D[6,12] 0.7916 0.4931 0.01244 0.2065 0.6677 2.035 100,001 200,000
OR.D[6,13] 1.037 0.94 0.02044 0.1448 0.7629 3.418 100,001 200,000
OR.D[6,14] 1.372 1.075 0.01909 0.2664 1.09 4.156 100,001 200,000
OR.D[6,15] 4.731 7.86 0.2071 0.3283 2.57 21.78 100,001 200,000
OR.D[7,8] 1.442 0.8391 0.01591 0.4264 1.251 3.555 100,001 200,000
OR.D[7,9] 11.77 72.72 1.422 0.04379 2.1 80.25 100,001 200,000
OR.D[7,10] 32.96 305.2 8.652 0.2665 4.467 145.6 100,001 200,000
OR.D[7,11] 0.527 0.4687 0.0128 0.09104 0.3952 1.767 100,001 200,000
OR.D[7,12] 0.5707 0.2543 0.005342 0.2155 0.525 1.178 100,001 200,000
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TABLE 89 Data synthesis: adults – class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[7,13] 0.7775 0.6611 0.01371 0.1214 0.601 2.464 100,001 200,000
OR.D[7,14] 1.107 0.9609 0.02076 0.1875 0.847 3.562 100,001 200,000
OR.D[7,15] 3.674 5.679 0.1201 0.2566 1.99 17.86 100,001 200,000
OR.D[8,9] 9.921 60.43 1.178 0.03375 1.735 65.2 100,001 200,000
OR.D[8,10] 28.5 317.4 7.988 0.2241 3.573 120 100,001 200,000
OR.D[8,11] 0.4387 0.4185 0.009987 0.06539 0.3156 1.566 100,001 200,000
OR.D[8,12] 0.5026 0.3446 0.006854 0.1265 0.4141 1.405 100,001 200,000
OR.D[8,13] 0.6512 0.6021 0.01046 0.09153 0.4819 2.245 100,001 200,000
OR.D[8,14] 0.894 0.7887 0.01299 0.1541 0.671 2.934 100,001 200,000
OR.D[8,15] 2.957 4.606 0.08921 0.1993 1.574 14.18 100,001 200,000
OR.D[9,10] 59.82 684.1 14.32 0.02385 2.139 291.7 100,001 200,000
OR.D[9,11] 2.12 27.16 0.6386 0.004269 0.1896 11.94 100,001 200,000
OR.D[9,12] 2.971 52.54 1.085 0.006906 0.2424 12.3 100,001 200,000
OR.D[9,13] 3.417 53.45 1.251 0.005859 0.2718 16.1 100,001 200,000
OR.D[9,14] 4.489 62.3 1.452 0.009721 0.3928 23.35 100,001 200,000
OR.D[9,15] 10.21 84.75 1.67 0.01887 1.002 74.09 100,001 200,000
OR.D[10,11] 0.3217 1.189 0.02484 0.002413 0.08551 1.913 100,001 200,000
OR.D[10,12] 0.3608 1.521 0.02863 0.003334 0.117 2.003 100,001 200,000
OR.D[10,13] 0.4583 2.107 0.03533 0.003304 0.1371 2.633 100,001 200,000
OR.D[10,14] 0.6583 3.664 0.05761 0.005043 0.1925 3.699 100,001 200,000
OR.D[10,15] 1.952 8.639 0.1464 0.009582 0.4587 12.83 100,001 200,000
OR.D[11,12] 1.834 1.712 0.04359 0.254 1.325 6.453 100,001 200,000
OR.D[11,13] 2.458 3.08 0.07976 0.2077 1.47 10.96 100,001 200,000
OR.D[11,14] 3.319 4.124 0.09609 0.354 2.132 13.53 100,001 200,000
OR.D[11,15] 11.59 22.71 0.5601 0.4562 4.985 64.95 100,001 200,000
OR.D[12,13] 1.557 1.423 0.02744 0.2142 1.16 5.396 100,001 200,000
OR.D[12,14] 2.248 2.206 0.0467 0.3217 1.628 7.927 100,001 200,000
OR.D[12,15] 7.492 12.33 0.255 0.4661 3.715 38.18 100,001 200,000
OR.D[13,14] 2.288 3.079 0.05419 0.2268 1.417 9.682 100,001 200,000
OR.D[13,15] 7.571 17.92 0.3625 0.3497 3.417 38.12 100,001 200,000
OR.D[14,15] 5.008 9.252 0.2034 0.2605 2.337 26.58 100,001 200,000
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TABLE 90 Data synthesis: adults – individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[1,2] 0.5054 0.3846 0.01051 0.09958 0.402 1.502 100,001 200,000
OR[1,3] 1.146 0.1657 0.00323 0.8801 1.125 1.539 100,001 200,000
OR[1,4] 1.101 0.1416 0.00298 0.852 1.092 1.409 100,001 200,000
OR[1,5] 1.099 0.1324 0.002389 0.8648 1.09 1.385 100,001 200,000
OR[1,6] 1.042 0.1368 0.002443 0.785 1.039 1.326 100,001 200,000
OR[1,7] 1.063 0.1678 0.002733 0.7366 1.059 1.413 100,001 200,000
OR[1,8] 0.4546 0.2824 0.006189 0.1095 0.3921 1.148 100,001 200,000
OR[1,9] 1.539 0.2175 0.004003 1.163 1.521 2.015 100,001 200,000
OR[1,10] 1.105 0.411 0.01157 0.5177 1.041 2.085 100,001 200,000
OR[1,11] 0.8339 0.3076 0.007419 0.4018 0.7748 1.595 100,001 200,000
OR[1,12] 1.103 0.4937 0.01353 0.4341 1.009 2.301 100,001 200,000
OR[1,13] 31.64 294 8.646 0.2991 4.513 138.6 100,001 200,000
OR[1,14] 0.7691 0.6121 0.01333 0.1304 0.6073 2.353 100,001 200,000
OR[1,15] 11.39 59.29 1.302 0.04345 2.128 74.15 100,001 200,000
OR[1,16] 1.383 0.6327 0.01068 0.5262 1.267 2.931 100,001 200,000
OR[1,17] 1.091 0.1666 0.002681 0.7961 1.081 1.461 100,001 200,000
OR[1,18] 0.5986 0.3323 0.008996 0.1878 0.5216 1.451 100,001 200,000
OR[1,19] 1.018 0.6868 0.01217 0.2476 0.8517 2.729 100,001 200,000
OR[1,20] 3.486 4.934 0.1183 0.2908 1.965 16.07 100,001 200,000
OR[2,3] 3.64 2.864 0.07925 0.7702 2.818 11.32 100,001 200,000
OR[2,4] 3.521 2.808 0.07836 0.7258 2.7 10.95 100,001 200,000
OR[2,5] 3.52 2.818 0.07883 0.7285 2.702 11.11 100,001 200,000
OR[2,6] 3.337 2.688 0.07447 0.6859 2.541 10.6 100,001 200,000
OR[2,7] 3.41 2.764 0.07634 0.6762 2.605 10.82 100,001 200,000
OR[2,8] 1.476 1.646 0.03985 0.1483 0.9807 5.698 100,001 200,000
OR[2,9] 4.933 3.982 0.1111 0.9928 3.768 15.49 100,001 200,000
OR[2,10] 3.423 2.827 0.07772 0.6061 2.582 10.94 100,001 200,000
OR[2,11] 2.409 1.719 0.04724 0.6094 1.901 6.815 100,001 200,000
OR[2,12] 3.364 2.856 0.07542 0.566 2.531 10.98 100,001 200,000
OR[2,13] 85.96 665.7 19.86 0.5226 11.69 414.6 100,001 200,000
OR[2,14] 2.458 3.08 0.07976 0.2077 1.47 10.96 100,001 200,000
OR[2,15] 32.47 174.6 3.61 0.08373 5.275 234.4 100,001 200,000
OR[2,16] 4.379 4.156 0.09986 0.6387 3.168 15.29 100,001 200,000
OR[2,17] 3.487 2.807 0.07781 0.7085 2.674 11.01 100,001 200,000
OR[2,18] 1.834 1.712 0.04359 0.254 1.325 6.453 100,001 200,000
OR[2,19] 3.319 4.124 0.09609 0.354 2.132 13.53 100,001 200,000
OR[2,20] 11.59 22.71 0.5601 0.4562 4.985 64.95 100,001 200,000
OR[3,4] 0.9715 0.1316 0.002139 0.6796 0.9855 1.246 100,001 200,000
OR[3,5] 0.9703 0.1269 0.00171 0.6966 0.9837 1.235 100,001 200,000
OR[3,6] 0.9206 0.1304 0.002143 0.6268 0.9486 1.143 100,001 200,000
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TABLE 90 Data synthesis: adults – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[3,7] 0.9392 0.1547 0.002319 0.5827 0.9685 1.229 100,001 200,000
OR[3,8] 0.4023 0.2532 0.00544 0.09534 0.3422 1.015 100,001 200,000
OR[3,9] 1.362 0.2279 0.00366 0.9379 1.35 1.853 100,001 200,000
OR[3,10] 0.9754 0.3665 0.009627 0.4438 0.9183 1.871 100,001 200,000
OR[3,11] 0.7303 0.2527 0.005679 0.36 0.6864 1.332 100,001 200,000
OR[3,12] 0.973 0.4383 0.01139 0.3734 0.8857 2.06 100,001 200,000
OR[3,13] 27.29 237.7 7.204 0.2683 3.99 123.8 100,001 200,000
OR[3,14] 0.6805 0.5435 0.01177 0.111 0.5364 2.114 100,001 200,000
OR[3,15] 10.01 53.13 1.166 0.03831 1.855 65.45 100,001 200,000
OR[3,16] 1.224 0.5745 0.00902 0.4514 1.117 2.648 100,001 200,000
OR[3,17] 0.962 0.1468 0.001912 0.6432 0.9805 1.264 100,001 200,000
OR[3,18] 0.5276 0.2913 0.007611 0.1619 0.4604 1.291 100,001 200,000
OR[3,19] 0.9042 0.6268 0.01106 0.2144 0.7482 2.495 100,001 200,000
OR[3,20] 3.092 4.437 0.1049 0.2544 1.739 14.15 100,001 200,000
OR[4,5] 1.008 0.1307 0.001907 0.7557 1 1.317 100,001 200,000
OR[4,6] 0.9556 0.1308 0.002129 0.6772 0.9749 1.219 100,001 200,000
OR[4,7] 0.9742 0.1561 0.002078 0.6388 0.9871 1.315 100,001 200,000
OR[4,8] 0.4177 0.2622 0.005638 0.09918 0.3575 1.062 100,001 200,000
OR[4,9] 1.412 0.2153 0.00355 1.037 1.393 1.884 100,001 200,000
OR[4,10] 1.01 0.3718 0.009983 0.4754 0.9506 1.922 100,001 200,000
OR[4,11] 0.7633 0.2812 0.006348 0.3663 0.7095 1.458 100,001 200,000
OR[4,12] 1.008 0.4471 0.0118 0.3998 0.9185 2.137 100,001 200,000
OR[4,13] 28.57 260.8 7.54 0.2757 4.066 128.8 100,001 200,000
OR[4,14] 0.7001 0.5479 0.01173 0.1206 0.555 2.117 100,001 200,000
OR[4,15] 10.38 55.63 1.208 0.03995 1.935 66.97 100,001 200,000
OR[4,16] 1.268 0.5865 0.009184 0.4781 1.158 2.714 100,001 200,000
OR[4,17] 0.999 0.1534 0.001928 0.6945 0.9973 1.354 100,001 200,000
OR[4,18] 0.5467 0.3009 0.007949 0.1747 0.4782 1.328 100,001 200,000
OR[4,19] 0.9389 0.6505 0.01133 0.2231 0.7757 2.577 100,001 200,000
OR[4,20] 3.182 4.486 0.1031 0.2699 1.79 14.34 100,001 200,000
OR[5,6] 0.9554 0.1262 0.001717 0.6835 0.9739 1.212 100,001 200,000
OR[5,7] 0.974 0.1515 0.001814 0.6456 0.987 1.296 100,001 200,000
OR[5,8] 0.4147 0.2534 0.005529 0.1012 0.3593 1.029 100,001 200,000
OR[5,9] 1.412 0.2086 0.003072 1.046 1.397 1.868 100,001 200,000
OR[5,10] 1.013 0.3773 0.01014 0.4664 0.9546 1.92 100,001 200,000
OR[5,11] 0.7637 0.2809 0.006426 0.3654 0.7111 1.456 100,001 200,000
OR[5,12] 1.011 0.4524 0.01199 0.3923 0.9218 2.121 100,001 200,000
OR[5,13] 28.58 259.1 7.517 0.2763 4.13 128.4 100,001 200,000
OR[5,14] 0.704 0.5564 0.01195 0.1189 0.5555 2.131 100,001 200,000
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TABLE 90 Data synthesis: adults – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[5,15] 10.44 56.56 1.22 0.03955 1.935 68.25 100,001 200,000
OR[5,16] 1.269 0.5876 0.009358 0.4772 1.162 2.725 100,001 200,000
OR[5,17] 0.9973 0.1375 0.001376 0.7274 0.9967 1.314 100,001 200,000
OR[5,18] 0.548 0.3014 0.007975 0.1702 0.4789 1.329 100,001 200,000
OR[5,19] 0.9384 0.6472 0.01124 0.2231 0.7797 2.568 100,001 200,000
OR[5,20] 3.203 4.561 0.109 0.2661 1.807 15.02 100,001 200,000
OR[6,7] 1.029 0.1702 0.002173 0.7202 1.007 1.453 100,001 200,000
OR[6,8] 0.4412 0.276 0.005935 0.104 0.3794 1.118 100,001 200,000
OR[6,9] 1.495 0.2482 0.003963 1.081 1.469 2.061 100,001 200,000
OR[6,10] 1.073 0.4116 0.01112 0.4918 1.001 2.077 100,001 200,000
OR[6,11] 0.8072 0.2982 0.006886 0.386 0.7514 1.533 100,001 200,000
OR[6,12] 1.071 0.4889 0.01292 0.412 0.9697 2.306 100,001 200,000
OR[6,13] 30.42 280.2 8.141 0.2922 4.339 135.4 100,001 200,000
OR[6,14] 0.7473 0.5986 0.01322 0.1243 0.5863 2.329 100,001 200,000
OR[6,15] 10.95 59.74 1.273 0.04193 2.042 72.71 100,001 200,000
OR[6,16] 1.344 0.6319 0.01025 0.4972 1.223 2.886 100,001 200,000
OR[6,17] 1.057 0.179 0.002455 0.7688 1.017 1.504 100,001 200,000
OR[6,18] 0.5804 0.3238 0.008627 0.1792 0.5024 1.394 100,001 200,000
OR[6,19] 0.9924 0.6832 0.01197 0.2337 0.8286 2.725 100,001 200,000
OR[6,20] 3.385 4.835 0.1141 0.2827 1.911 15.34 100,001 200,000
OR[7,8] 0.4375 0.2814 0.006025 0.1004 0.3746 1.148 100,001 200,000
OR[7,9] 1.48 0.3017 0.004631 1.012 1.439 2.205 100,001 200,000
OR[7,10] 1.062 0.4309 0.01126 0.4743 0.9828 2.105 100,001 200,000
OR[7,11] 0.7997 0.3172 0.007052 0.3729 0.7357 1.593 100,001 200,000
OR[7,12] 1.059 0.5044 0.01298 0.3995 0.9528 2.318 100,001 200,000
OR[7,13] 29.9 277.2 7.74 0.287 4.276 134.2 100,001 200,000
OR[7,14] 0.7391 0.6056 0.01274 0.1215 0.5756 2.286 100,001 200,000
OR[7,15] 10.8 56.9 1.236 0.04037 2.015 71.57 100,001 200,000
OR[7,16] 1.329 0.6467 0.0102 0.4849 1.199 2.929 100,001 200,000
OR[7,17] 1.044 0.2045 0.002524 0.7223 1.007 1.576 100,001 200,000
OR[7,18] 0.5749 0.3338 0.008727 0.1733 0.4948 1.418 100,001 200,000
OR[7,19] 0.9805 0.688 0.01158 0.229 0.8131 2.729 100,001 200,000
OR[7,20] 3.351 4.772 0.1112 0.2727 1.868 15.43 100,001 200,000
OR[8,9] 4.848 3.603 0.0798 1.342 3.893 14.07 100,001 200,000
OR[8,10] 3.479 2.973 0.06704 0.7327 2.697 10.99 100,001 200,000
OR[8,11] 2.647 2.323 0.05077 0.5758 1.969 8.62 100,001 200,000
OR[8,12] 3.461 3.038 0.0705 0.655 2.641 11.18 100,001 200,000
OR[8,13] 88.25 763.8 19.5 0.6283 11.4 457.7 100,001 200,000
OR[8,14] 2.416 2.889 0.05796 0.2337 1.567 9.449 100,001 200,000
OR[8,15] 35.55 169.6 4.153 0.09668 5.559 245.3 100,001 200,000
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TABLE 90 Data synthesis: adults – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[8,16] 4.347 3.974 0.07893 0.82 3.254 14.34 100,001 200,000
OR[8,17] 3.446 2.587 0.05629 0.9096 2.768 9.988 100,001 200,000
OR[8,18] 1.875 1.793 0.04252 0.3112 1.352 6.566 100,001 200,000
OR[8,19] 3.21 4.582 0.06746 0.4138 2.186 11.82 100,001 200,000
OR[8,20] 10.94 21.64 0.5357 0.6329 5.165 55.38 100,001 200,000
OR[9,10] 0.725 0.2687 0.007152 0.3367 0.6836 1.365 100,001 200,000
OR[9,11] 0.5495 0.2096 0.00475 0.2521 0.5112 1.066 100,001 200,000
OR[9,12] 0.7238 0.3236 0.008512 0.279 0.6648 1.517 100,001 200,000
OR[9,13] 21.27 209 6.016 0.2031 2.94 90.76 100,001 200,000
OR[9,14] 0.5061 0.4044 0.008782 0.08497 0.3978 1.579 100,001 200,000
OR[9,15] 7.599 40.91 0.893 0.02825 1.385 49.55 100,001 200,000
OR[9,16] 0.9061 0.4111 0.006424 0.3459 0.8282 1.912 100,001 200,000
OR[9,17] 0.719 0.1298 0.001756 0.4905 0.7096 1.006 100,001 200,000
OR[9,18] 0.3925 0.2165 0.005704 0.1237 0.3411 0.9491 100,001 200,000
OR[9,19] 0.6731 0.4673 0.008039 0.1572 0.5572 1.846 100,001 200,000
OR[9,20] 2.256 3.113 0.07227 0.1957 1.294 10.07 100,001 200,000
OR[10,11] 0.8443 0.4219 0.01039 0.3086 0.7506 1.904 100,001 200,000
OR[10,12] 1.002 0.2496 0.00467 0.598 0.9733 1.573 100,001 200,000
OR[10,13] 31.6 283.5 8.307 0.2778 4.329 133.7 100,001 200,000
OR[10,14] 0.7347 0.5717 0.01167 0.1261 0.5881 2.234 100,001 200,000
OR[10,15] 11.3 70.18 1.397 0.04308 2.05 77.11 100,001 200,000
OR[10,16] 1.362 0.693 0.01231 0.4607 1.223 3.091 100,001 200,000
OR[10,17] 1.115 0.4284 0.01116 0.4918 1.038 2.147 100,001 200,000
OR[10,18] 0.5443 0.2164 0.004716 0.2302 0.506 1.06 100,001 200,000
OR[10,19] 1.048 0.8506 0.01773 0.1978 0.8174 3.252 100,001 200,000
OR[10,20] 3.483 5.141 0.1092 0.2599 1.923 16.52 100,001 200,000
OR[11,12] 1.467 0.8041 0.01971 0.4573 1.292 3.472 100,001 200,000
OR[11,13] 40.64 335.9 10.24 0.3673 5.493 195.3 100,001 200,000
OR[11,14] 1.037 0.94 0.02044 0.1448 0.7629 3.418 100,001 200,000
OR[11,15] 14.49 73.24 1.588 0.05081 2.72 96.33 100,001 200,000
OR[11,16] 1.862 1.1 0.0206 0.5442 1.614 4.707 100,001 200,000
OR[11,17] 1.468 0.5409 0.01177 0.6645 1.389 2.759 100,001 200,000
OR[11,18] 0.7916 0.4931 0.01244 0.2065 0.6677 2.035 100,001 200,000
OR[11,19] 1.372 1.075 0.01909 0.2664 1.09 4.156 100,001 200,000
OR[11,20] 4.731 7.86 0.2071 0.3283 2.57 21.78 100,001 200,000
OR[12,13] 32.96 305.2 8.652 0.2665 4.467 145.6 100,001 200,000
OR[12,14] 0.7775 0.6611 0.01371 0.1214 0.601 2.464 100,001 200,000
OR[12,15] 11.77 72.72 1.422 0.04379 2.1 80.25 100,001 200,000
OR[12,16] 1.442 0.8391 0.01591 0.4264 1.251 3.555 100,001 200,000
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TABLE 90 Data synthesis: adults – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[12,17] 1.178 0.5401 0.01398 0.4475 1.076 2.559 100,001 200,000
OR[12,18] 0.5707 0.2543 0.005342 0.2155 0.525 1.178 100,001 200,000
OR[12,19] 1.107 0.9609 0.02076 0.1875 0.847 3.562 100,001 200,000
OR[12,20] 3.674 5.679 0.1201 0.2566 1.99 17.86 100,001 200,000
OR[13,14] 0.4583 2.107 0.03533 0.003304 0.1371 2.633 100,001 200,000
OR[13,15] 5.556 28.5 0.6176 0.003429 0.4675 41.93 100,001 200,000
OR[13,16] 0.8363 3.329 0.06118 0.008335 0.2799 4.463 100,001 200,000
OR[13,17] 0.676 2.681 0.05176 0.007658 0.2391 3.617 100,001 200,000
OR[13,18] 0.3608 1.521 0.02863 0.003334 0.117 2.003 100,001 200,000
OR[13,19] 0.6583 3.664 0.05761 0.005043 0.1925 3.699 100,001 200,000
OR[13,20] 1.952 8.639 0.1464 0.009582 0.4587 12.83 100,001 200,000
OR[14,15] 23.43 123.1 2.653 0.06213 3.679 170.7 100,001 200,000
OR[14,16] 3.005 3.138 0.05922 0.4455 2.075 10.93 100,001 200,000
OR[14,17] 2.437 2.294 0.04934 0.4563 1.778 8.501 100,001 200,000
OR[14,18] 1.247 1.316 0.02774 0.1854 0.8621 4.669 100,001 200,000
OR[14,19] 2.288 3.079 0.05419 0.2268 1.417 9.682 100,001 200,000
OR[14,20] 7.571 17.92 0.3625 0.3497 3.417 38.12 100,001 200,000
OR[15,16] 7.697 133.4 3.041 0.01534 0.5764 29.64 100,001 200,000
OR[15,17] 4.798 59.05 1.332 0.01439 0.509 25.01 100,001 200,000
OR[15,18] 2.971 52.54 1.085 0.006906 0.2424 12.3 100,001 200,000
OR[15,19] 4.489 62.3 1.452 0.009721 0.3928 23.35 100,001 200,000
OR[15,20] 10.21 84.75 1.67 0.01887 1.002 74.09 100,001 200,000
OR[16,17] 0.9526 0.4623 0.007213 0.3544 0.8549 2.11 100,001 200,000
OR[16,18] 0.5026 0.3446 0.006854 0.1265 0.4141 1.405 100,001 200,000
OR[16,19] 0.894 0.7887 0.01299 0.1541 0.671 2.934 100,001 200,000
OR[16,20] 2.957 4.606 0.08921 0.1993 1.574 14.18 100,001 200,000
OR[17,18] 0.557 0.3131 0.008084 0.1705 0.4845 1.358 100,001 200,000
OR[17,19] 0.9535 0.6646 0.01152 0.2234 0.7871 2.615 100,001 200,000
OR[17,20] 3.27 4.723 0.1144 0.267 1.825 15.75 100,001 200,000
OR[18,19] 2.248 2.206 0.0467 0.3217 1.628 7.927 100,001 200,000
OR[18,20] 7.492 12.33 0.255 0.4661 3.715 38.18 100,001 200,000
OR[19,20] 5.008 9.252 0.2034 0.2605 2.337 26.58 100,001 200,000
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TABLE 91 Data synthesis: adults – inconsistency model (pairwise comparison)
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
or[1,3] 1.293 0.3195 0.003551 0.7902 1.251 2.035 100,001 200,000
or[1,4] 1.422 0.3342 0.00321 0.8762 1.385 2.177 100,001 200,000
or[1,5] 1.097 0.1883 0.001546 0.7836 1.078 1.521 100,001 200,000
or[1,6] 1.009 0.2379 0.001747 0.6274 0.9797 1.549 100,001 200,000
or[1,7] 0.9585 0.3273 0.003297 0.4869 0.9016 1.751 100,001 200,000
or[1,9] 1.267 0.2235 0.001783 0.8794 1.25 1.756 100,001 200,000
or[1,10] 1.406 0.6698 0.005369 0.5194 1.274 3.08 100,001 200,000
or[1,16] 1.371 0.683 0.006053 0.4762 1.23 3.049 100,001 200,000
or[1,17] 1.147 0.3434 0.002527 0.6416 1.092 1.971 100,001 200,000
or[1,19] 1.009 0.6816 0.007816 0.2523 0.8358 2.8 100,001 200,000
or[2,11] 3.016 2.536 0.04166 0.6695 2.329 9.441 100,001 200,000
or[2,12] 7.359 77.39 1.501 0.0235 0.9059 37.32 100,001 200,000
or[3,6] 0.9992 0.4135 0.003322 0.4231 0.9231 1.998 100,001 200,000
or[3,9] 0.9222 0.9469 0.01388 0.1094 0.6574 3.308 100,001 200,000
or[3,11] 0.6126 0.2452 0.001872 0.2643 0.5702 1.209 100,001 200,000
or[4,9] 2.063 0.5714 0.005245 1.177 1.986 3.404 100,001 200,000
or[4,10] 0.8249 0.602 0.007823 0.1737 0.6654 2.401 100,001 200,000
or[4,11] 0.1916 2.693 0.0376 3.22 × 10–29 3.71 × 10–08 0.9807 100,001 200,000
or[4,14] 0.6066 0.5124 0.005516 0.093 0.4648 1.954 100,001 200,000
or[4,15] 9.598 112.2 1.093 0.0197 1.011 55.18 100,001 200,000
or[4,18] 2.525 7.221 0.08789 0.02603 0.9102 14.75 100,001 200,000
or[5,8] 0.4725 0.3376 0.003374 0.09511 0.3896 1.333 100,001 200,000
or[5,9] 24.61 164.5 2.297 0.6354 5.26 137.3 100,001 200,000
or[5,17] Not estimable
or[6,9] 2.218 0.8519 0.00654 1.009 2.069 4.304 100,001 200,000
or[6,11] 1.593 2.08 0.02623 0.1562 1.01 6.675 100,001 200,000
or[8,9] 34.05 274.8 3.707 0.8065 6.109 186.5 100,001 200,000
or[9,10] Not estimable
or[9,13] 37.43 957.5 15.96 0.1695 2.827 106.7 100,001 200,000
or[9,16] Not estimable
or[9,20] 2.254 3.057 0.0391 0.1999 1.345 9.741 100,001 200,000
or[10,12] 1.115 0.296 0.003279 0.6476 1.079 1.802 100,001 200,000
or[10,14] Not estimable
or[10,16] Not estimable
or[10,18] 0.4653 0.2291 0.002258 0.1581 0.4214 1.031 100,001 200,000
or[11,15] Not estimable
or[11,18] 0.02907 0.4428 0.00551 5.48 × 10–34 1.47 × 10–10 0.2107 100,001 200,000
or[12,18] 1.886 2.371 0.02685 0.2005 1.216 7.628 100,001 200,000
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TABLE 92 Data synthesis: adults – median ranks (class effects)
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 8.085 1.946 0.05168 4 8 12 100,001 200,000
rk.class[2] 3.071 2.329 0.0511 1 2 10 100,001 200,000
rk.class[3] 9.087 1.926 0.0441 5 9 12 100,001 200,000
rk.class[4] 12.04 1.439 0.03463 9 12 14 100,001 200,000
rk.class[5] 8.67 2.485 0.0615 4 9 13 100,001 200,000
rk.class[6] 6.351 2.659 0.0627 2 6 12 100,001 200,000
rk.class[7] 8.397 2.913 0.07246 3 8 14 100,001 200,000
rk.class[8] 10.04 3.093 0.0506 3 11 14 100,001 200,000
rk.class[9] 10.27 5.291 0.1756 1 13 15 100,001 200,000
rk.class[10] 12.73 3.762 0.09555 2 14 15 100,001 200,000
rk.class[11] 3.386 2.829 0.07809 1 2 12 100,001 200,000
rk.class[12] 4.019 2.365 0.05665 1 4 10 100,001 200,000
rk.class[13] 5.306 3.719 0.08131 1 4 14 100,001 200,000
rk.class[14] 7.223 3.919 0.07868 1 7 14 100,001 200,000
rk.class[15] 11.32 3.987 0.08988 2 13 15 100,001 200,000
TABLE 93 Data synthesis: adults – median ranks (individual effects)
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 9.484 2.829 0.06994 5 9 16 100,001 200,000
rk[2] 3.757 3.831 0.1029 1 2 17 100,001 200,000
rk[3] 12.69 2.82 0.04927 7 13 18 100,001 200,000
rk[4] 11.83 2.771 0.04972 6 12 17 100,001 200,000
rk[5] 11.82 2.792 0.05045 6 12 17 100,001 200,000
rk[6] 10.51 2.987 0.05807 5 10 16 100,001 200,000
rk[7] 10.99 3.276 0.05719 5 11 17 100,001 200,000
rk[8] 3.245 2.897 0.05979 1 2 13 100,001 200,000
rk[9] 16.92 1.568 0.03531 13 17 19 100,001 200,000
rk[10] 10.95 4.431 0.1165 4 10 18 100,001 200,000
rk[11] 7.263 4.037 0.09317 2 6 17 100,001 200,000
rk[12] 10.55 4.908 0.1263 3 9 19 100,001 200,000
rk[13] 16.92 5.446 0.1358 2 19 20 100,001 200,000
rk[14] 6.362 5.435 0.1197 1 4 19 100,001 200,000
rk[15] 13.53 7.524 0.2471 1 18 20 100,001 200,000
rk[16] 13.23 5.061 0.08111 4 15 19 100,001 200,000
rk[17] 11.53 3.142 0.05114 5 12 17 100,001 200,000
rk[18] 4.438 3.362 0.08106 1 4 15 100,001 200,000
rk[19] 8.965 5.926 0.1137 1 7 19 100,001 200,000
rk[20] 15.02 5.952 0.1315 2 18 20 100,001 200,000
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Children and adolescents/acceptability (total dropouts)
Network geometry
CBTSER
CBTPL
CBT
BT
WL
SSRI
PSYPL
PL
CLO
FIGURE 29 Network plot for class effects (the plot for individual effects is included in the main report).
CBTPL, CBT+placebo; CBTSER, CBT+ sertraline; CLO, clomipramine; PL, placebo; PSYPL, psychological placebo; WL, waitlist.
Model fit
TABLE 94 Model fit: children and adolescents – consistency model
Model fit
Dbar Dhat DIC pD
r 147.2 116.9 177.5 30.29
total 147.2 116.9 177.5 30.29
Mean SD MC_error val2.5pc Median val97.5pc Start Sample
sd 0.5147 0.3715 0.006303 0.02217 0.4515 1.403 100,001 200,000
totresdev 37.05 8.216 0.06423 22.75 36.44 54.83 100,001 200,000
TABLE 95 Model fit: children and adolescent – inconsistency model
Model fit
Dbar Dhat DIC pD
r 149.1 115.7 182.6 33.43
total 149.1 115.7 182.6 33.43
Mean SD MC_error val2.5pc Median val97.5pc Start Sample
sd 0.8612 0.6323 0.01195 0.04502 0.7421 2.443 70,001 140,000
totresdev 38.99 8.76 0.07706 23.62 38.36 57.84 70,001 140,000
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Data synthesis: consistency model (network meta-analysis)
Key: intervention (class)
1. Placebo (1).
2. Waitlist (2).
3. Psychological placebo (3).
4. Fluoxetine (4).
5. Fluvoxamine (4).
6. Paroxetine (4).
7. Sertraline (4).
8. Clomipramine (5).
9. BT (6).
10. CBT (7).
11. Sertraline+CBT (8).
12. CBT+ placebo (9).
TABLE 96 Data synthesis: children and adolescent – class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[1,2] 0.9559 1.936 0.01895 0.05486 0.5295 4.328 100,001 200,000
OR.D[1,3] 1.033 2.564 0.01631 0.0683 0.5781 4.439 100,001 200,000
OR.D[1,4] 6.742 851.4 1.95 0.227 0.872 2.997 100,001 200,000
OR.D[1,5] 5.094 8.9 0.08637 0.5404 3.061 21.69 100,001 200,000
OR.D[1,6] 107.2 1453 24.67 0.4076 7.645 423.7 100,001 200,000
OR.D[1,7] 0.6919 0.8371 0.008558 0.09176 0.4952 2.415 100,001 200,000
OR.D[1,8] 0.8625 9.133 0.02526 0.07651 0.5374 3.148 100,001 200,000
OR.D[1,9] 0.5534 13.27 0.03814 0.008114 0.1486 2.26 100,001 200,000
OR.D[2,3] 2.018 8.554 0.03339 0.1509 1.081 8.872 100,001 200,000
OR.D[2,4] 17.42 2021 4.562 0.1446 1.628 20.15 100,001 200,000
OR.D[2,5] 18.19 156.2 0.6924 0.4662 5.804 95.46 100,001 200,000
OR.D[2,6] 280.2 4183 76.79 0.8716 14.28 785.2 100,001 200,000
OR.D[2,7] 1.323 1.526 0.0146 0.2087 0.9368 4.786 100,001 200,000
OR.D[2,8] 3.04 106.5 0.2573 0.08032 0.9982 13.51 100,001 200,000
OR.D[2,9] 2.462 174.6 0.4081 0.01024 0.2817 7.587 100,001 200,000
OR.D[3,4] 11.87 1088 2.437 0.1354 1.491 16.49 100,001 200,000
OR.D[3,5] 17.02 193.3 0.6174 0.4127 5.315 85.68 100,001 200,000
OR.D[3,6] 258.7 3404 54.9 0.5696 13.49 922 100,001 200,000
OR.D[3,7] 1.087 1.212 0.006656 0.2347 0.8582 3.236 100,001 200,000
OR.D[3,8] 2.277 15.15 0.05515 0.07783 0.9071 11.15 100,001 200,000
OR.D[3,9] 1.817 122.3 0.2775 0.009615 0.257 6.481 100,001 200,000
OR.D[4,5] 76.63 12,040 26.87 0.4338 3.553 38.72 100,001 200,000
OR.D[4,6] 554.3 89,330 205.4 0.374 8.929 635.8 100,001 200,000
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TABLE 96 Data synthesis: children and adolescent – class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[4,7] 10.86 2349 5.272 0.07641 0.5772 4.21 100,001 200,000
OR.D[4,8] 15.5 3969 8.915 0.06728 0.6203 5.557 100,001 200,000
OR.D[4,9] 9.836 2643 5.916 0.007736 0.1714 3.576 100,001 200,000
OR.D[5,6] 31.56 471.1 7.974 0.1311 2.483 114.1 100,001 200,000
OR.D[5,7] 0.315 0.9211 0.006088 0.01411 0.163 1.498 100,001 200,000
OR.D[5,8] 0.5014 23.49 0.0536 0.01133 0.172 2.019 100,001 200,000
OR.D[5,9] 0.3448 22.67 0.06146 0.001491 0.04777 1.189 100,001 200,000
OR.D[6,7] 0.2088 3.232 0.009925 0.001165 0.06527 1.222 100,001 200,000
OR.D[6,8] 0.543 86.68 0.195 9.79 × 10–04 0.06738 1.925 100,001 200,000
OR.D[6,9] 0.6371 137.2 0.42 1.67 × 10–04 0.01871 1.026 100,001 200,000
OR.D[7,8] 2.104 52.45 0.124 0.1312 1.076 8.83 100,001 200,000
OR.D[7,9] 1.357 36.53 0.1004 0.01429 0.3014 5.617 100,001 200,000
OR.D[8,9] 0.5331 6.051 0.01487 0.0303 0.284 2.25 100,001 200,000
TABLE 97 Data synthesis: children and adolescent – individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[1,2] 0.9559 1.936 0.01895 0.05486 0.5295 4.328 100,001 200,000
OR[1,3] 1.033 2.564 0.01631 0.0683 0.5781 4.439 100,001 200,000
OR[1,4] 0.794 0.4219 0.0038 0.2479 0.7371 1.685 100,001 200,000
OR[1,5] 0.8868 1.63 0.005053 0.2456 0.7863 2.068 100,001 200,000
OR[1,6] 1.33 1.974 0.006881 0.3738 1.118 3.416 100,001 200,000
OR[1,7] 0.9712 0.6798 0.004586 0.3211 0.8925 2.069 100,001 200,000
OR[1,8] 5.094 8.9 0.08637 0.5404 3.061 21.69 100,001 200,000
OR[1,9] 107.2 1453 24.67 0.4076 7.645 423.7 100,001 200,000
OR[1,10] 0.6919 0.8371 0.008558 0.09176 0.4952 2.415 100,001 200,000
OR[1,11] 0.8625 9.133 0.02526 0.07651 0.5374 3.148 100,001 200,000
OR[1,12] 0.5534 13.27 0.03814 0.008114 0.1486 2.26 100,001 200,000
OR[2,3] 2.018 8.554 0.03339 0.1509 1.081 8.872 100,001 200,000
OR[2,4] 3.042 18.91 0.1008 0.1342 1.361 14.35 100,001 200,000
OR[2,5] 3.507 39.05 0.1307 0.1436 1.457 16.19 100,001 200,000
OR[2,6] 5.1 30.22 0.1806 0.2113 2.137 24.52 100,001 200,000
OR[2,7] 3.307 10.22 0.07605 0.1953 1.669 15.4 100,001 200,000
OR[2,8] 18.19 156.2 0.6924 0.4662 5.804 95.46 100,001 200,000
OR[2,9] 280.2 4183 76.79 0.8716 14.28 785.2 100,001 200,000
OR[2,10] 1.323 1.526 0.0146 0.2087 0.9368 4.786 100,001 200,000
OR[2,11] 3.04 106.5 0.2573 0.08032 0.9982 13.51 100,001 200,000
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TABLE 97 Data synthesis: children and adolescent – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[2,12] 2.462 174.6 0.4081 0.01024 0.2817 7.587 100,001 200,000
OR[3,4] 2.608 11.99 0.06187 0.1282 1.249 11.67 100,001 200,000
OR[3,5] 3.004 34.47 0.1066 0.1356 1.335 13.25 100,001 200,000
OR[3,6] 4.512 42.92 0.1743 0.1992 1.953 20.02 100,001 200,000
OR[3,7] 2.829 9.741 0.05322 0.1882 1.533 12.37 100,001 200,000
OR[3,8] 17.02 193.3 0.6174 0.4127 5.315 85.68 100,001 200,000
OR[3,9] 258.7 3404 54.9 0.5696 13.49 922 100,001 200,000
OR[3,10] 1.087 1.212 0.006656 0.2347 0.8582 3.236 100,001 200,000
OR[3,11] 2.277 15.15 0.05515 0.07783 0.9071 11.15 100,001 200,000
OR[3,12] 1.817 122.3 0.2775 0.009615 0.257 6.481 100,001 200,000
OR[4,5] 1.35 3.422 0.01122 0.3257 1.03 3.962 100,001 200,000
OR[4,6] 2.156 10.46 0.03006 0.5414 1.398 7.302 100,001 200,000
OR[4,7] 1.495 2.231 0.01093 0.4176 1.127 4.38 100,001 200,000
OR[4,8] 8.423 26.44 0.1767 0.6242 4.257 39.7 100,001 200,000
OR[4,9] 181.7 3674 42.78 0.5159 10.75 682.9 100,001 200,000
OR[4,10] 1.104 2.866 0.01676 0.1108 0.6883 4.419 100,001 200,000
OR[4,11] 1.452 21.8 0.05584 0.09549 0.7402 5.771 100,001 200,000
OR[4,12] 1.014 51.89 0.1321 0.01033 0.2054 3.781 100,001 200,000
OR[5,6] 2.072 13.12 0.03253 0.4542 1.306 6.815 100,001 200,000
OR[5,7] 1.471 19.68 0.04918 0.3417 1.074 4.143 100,001 200,000
OR[5,8] 8.204 37.83 0.179 0.5597 3.976 37.72 100,001 200,000
OR[5,9] 1076 402,800 920.1 0.4583 10.06 630.1 100,001 200,000
OR[5,10] 1.17 37.78 0.09073 0.09699 0.6418 4.208 100,001 200,000
OR[5,11] 1.425 23.22 0.0606 0.08489 0.6927 5.429 100,001 200,000
OR[5,12] 3.115 968.3 2.163 0.009302 0.1932 3.573 100,001 200,000
OR[6,7] 0.9465 3.136 0.008293 0.1962 0.8573 2.296 100,001 200,000
OR[6,8] 6.161 239.5 0.5562 0.3643 2.717 26.15 100,001 200,000
OR[6,9] 142.6 12,870 38.12 0.3133 6.805 423.3 100,001 200,000
OR[6,10] 0.7211 2.777 0.01193 0.06349 0.4408 2.793 100,001 200,000
OR[6,11] 0.9726 17.57 0.05602 0.05624 0.4719 3.725 100,001 200,000
OR[6,12] 0.8511 65.25 0.1538 0.006448 0.1303 2.479 100,001 200,000
OR[7,8] 6.738 28.23 0.1415 0.5278 3.444 31.11 100,001 200,000
OR[7,9] 136.3 3712 24.62 0.4528 8.661 528.2 100,001 200,000
OR[7,10] 0.7998 1.026 0.008957 0.1085 0.5644 2.844 100,001 200,000
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TABLE 97 Data synthesis: children and adolescent – individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[7,11] 1.013 8.437 0.0233 0.09035 0.6052 3.916 100,001 200,000
OR[7,12] 0.769 46.44 0.1119 0.00959 0.1673 2.794 100,001 200,000
OR[8,9] 31.56 471.1 7.974 0.1311 2.483 114.1 100,001 200,000
OR[8,10] 0.315 0.9211 0.006088 0.01411 0.163 1.498 100,001 200,000
OR[8,11] 0.5014 23.49 0.0536 0.01133 0.172 2.019 100,001 200,000
OR[8,12] 0.3448 22.67 0.06146 0.001491 0.04777 1.189 100,001 200,000
OR[9,10] 0.2088 3.232 0.009925 0.001165 0.06527 1.222 100,001 200,000
OR[9,11] 0.543 86.68 0.195 9.79 × 10–4 0.06738 1.925 100,001 200,000
OR[9,12] 0.6371 137.2 0.42 1.67 × 10–4 0.01871 1.026 100,001 200,000
OR[10,11] 2.104 52.45 0.124 0.1312 1.076 8.83 100,001 200,000
OR[10,12] 1.357 36.53 0.1004 0.01429 0.3014 5.617 100,001 200,000
OR[11,12] 0.5331 6.051 0.01487 0.0303 0.284 2.25 100,001 200,000
TABLE 98 Data synthesis: children and adolescent – inconsistency model (pairwise comparison)
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
or[1,4] 0.8024 4.62 0.01388 0.0948 0.5591 2.567 70,001 140,000
or[1,5] 4.409 395.2 1.456 0.06265 0.6615 6.949 70,001 140,000
or[1,6] 17.57 1645 4.528 0.1618 1.59 16.65 70,001 140,000
or[1,7] 1.265 19.6 0.06121 0.1058 0.807 3.784 70,001 140,000
or[1,8] 10.7 484.8 1.345 0.415 3.437 41.35 70,001 140,000
or[1,10] 4.49 505.5 1.392 0.02441 0.441 5.079 70,001 140,000
or[1,11] 2.774 246.6 0.6614 0.02385 0.4328 4.915 70,001 140,000
or[2,9] 78,230 1.39E+ 07 60,100 0.2729 12.92 9205 70,001 140,000
or[2,10] 1.948 9.336 0.03735 0.1654 1.04 7.907 70,001 140,000
or[3,10] 1.549 12.69 0.04082 0.1434 0.8612 5.475 70,001 140,000
or[7,10] 4.438 634.4 1.722 2.25 × 10–4 0.1758 10.21 70,001 140,000
or[7,11] Not estimable
or[8,9] 6840 643,600 2588 0.06813 4.448 2504 70,001 140,000
or[10,11] Not estimable
or[11,12] 16.02 3927 10.53 0.01717 0.2818 4.169 70,001 140,000
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TABLE 99 Data synthesis: children and adolescents – median ranks (class effects)
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 5.769 1.498 0.0213 2 6 8 100,001 200,000
rk.class[2] 4.003 2.107 0.02918 1 4 8 100,001 200,000
rk.class[3] 4.27 2.069 0.02356 1 4 8 100,001 200,000
rk.class[4] 5.184 1.858 0.01989 1 5 8 100,001 200,000
rk.class[5] 7.725 1.361 0.01701 3 8 9 100,001 200,000
rk.class[6] 8.35 1.377 0.0248 4 9 9 100,001 200,000
rk.class[7] 3.678 1.502 0.01782 1 4 7 100,001 200,000
rk.class[8] 4.059 1.958 0.02073 1 4 8 100,001 200,000
rk.class[9] 1.961 1.752 0.01679 1 1 7 100,001 200,000
TABLE 100 Data synthesis: children and adolescents – median ranks (individual effects)
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 7.652 1.96 0.02736 3 8 11 100,001 200,000
rk[2] 4.993 3.158 0.04543 1 4 11 100,001 200,000
rk[3] 5.321 3.121 0.0377 1 5 11 100,001 200,000
rk[4] 5.741 2.404 0.02741 1 6 10 100,001 200,000
rk[5] 6.099 2.48 0.02415 1 6 11 100,001 200,000
rk[6] 8.067 2.388 0.02601 3 9 12 100,001 200,000
rk[7] 6.873 2.174 0.02246 2 7 11 100,001 200,000
rk[8] 10.43 1.945 0.02452 4 11 12 100,001 200,000
rk[9] 11.11 2.012 0.03567 4 12 12 100,001 200,000
rk[10] 4.467 2.351 0.0305 1 4 10 100,001 200,000
rk[11] 4.97 2.906 0.02952 1 4 11 100,001 200,000
rk[12] 2.283 2.458 0.02273 1 1 10 100,001 200,000
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Complete data for rank probabilities by type of intervention
TABLE 101 Data used to draw the absolute rankograms that appear in the main text of the report
Adults
Rank (YBOCS: 17 treatments; dropouts: 20 treatments)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Sum
YBOCS Placebo 0 0 0 0 0 0 0 0 0 1.00×10–5 5.00×10–5 5.50×10–4 0.00586 0.07351 0.4772 0.4383 0.00453 1
Dropout Placebo 0.00 0.00 0.00 0.02 0.04 0.08 0.12 0.14 0.14 0.13 0.10 0.08 0.06 0.04 0.03 0.02 0.01 0.00 0.00 0.00 1
YBOCS Waitlist 0 0 0 0 0 1.00×10–5 3.00×10–5 1.00×10–5 2.00×10–5 0 1.00×10–5 4.00×10–5 1.30×10–4 0.00135 0.0063 0.09427 0.8978 1
Dropout Waitlist 0.29 0.21 0.15 0.10 0.06 0.04 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 1
YBOCS Fluoxetine 0 0 8.00×10–5 0.00223 0.01146 0.03125 0.06575 0.1076 0.1323 0.1413 0.146 0.1426 0.1258 0.07633 0.01688 3.30×10–4 0 1
Dropout Fluoxetine 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.04 0.06 0.08 0.10 0.13 0.13 0.13 0.12 0.09 0.05 0.02 0.01 0.00 1
YBOCS Fluvoxamine 0 0 0 0.00166 0.01125 0.0377 0.08082 0.1311 0.1591 0.1571 0.1451 0.1246 0.09534 0.04741 0.00875 2.00×10–5 0 1
Dropout Fluvoxamine 0.00 0.00 0.00 0.00 0.01 0.02 0.04 0.06 0.08 0.11 0.13 0.13 0.13 0.11 0.09 0.06 0.03 0.01 0.00 0.00 1
YBOCS Paroxetine 0 0 1.00×10–5 0.00139 0.00764 0.02466 0.05581 0.09689 0.1297 0.1461 0.1559 0.1563 0.1355 0.07485 0.01502 1.20×10–4 0 1
Dropout Paroxetine 0.00 0.00 0.00 0.00 0.01 0.02 0.04 0.06 0.09 0.11 0.12 0.13 0.13 0.11 0.09 0.06 0.03 0.01 0.00 0.00 1
YBOCS Sertraline 0 0 6.00×10–5 0.00275 0.01315 0.03431 0.06953 0.1118 0.137 0.1448 0.1448 0.1386 0.116 0.07135 0.01556 2.60×10–4 0 1
Dropout Sertraline 0.00 0.00 0.00 0.01 0.03 0.05 0.07 0.10 0.11 0.12 0.12 0.11 0.09 0.07 0.05 0.03 0.01 0.00 0.00 0.00 1
YBOCS Citalopram 0 1.00×10–5 2.10×10–4 0.00634 0.02091 0.04177 0.07302 0.1076 0.125 0.129 0.132 0.133 0.1248 0.08273 0.02196 0.00169 7.00×10–5 1
Dropout Citalopram 0.00 0.00 0.01 0.01 0.03 0.05 0.06 0.08 0.10 0.11 0.11 0.11 0.10 0.09 0.07 0.05 0.03 0.01 0.00 0.00 1
YBOCS Venlafaxine 2.00×10–4 5.90×10–4 0.00452 0.05998 0.09522 0.08724 0.08047 0.06269 0.03474 0.03017 0.03238 0.0416 0.07623 0.199 0.1285 0.06263 0.00382 1
Dropout Venlafaxine 0.28 0.25 0.16 0.11 0.07 0.04 0.03 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 1
YBOCS Clomipramine 0 0 8.60×10–4 0.06048 0.1751 0.2376 0.2215 0.1153 0.05586 0.03749 0.02873 0.02559 0.02463 0.01445 0.00242 1.00×10–5 0 1
Dropout Clomipramine 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.04 0.08 0.17 0.28 0.26 0.11 0.02 1
YBOCS BT 5.11×10–1 0.3972 0.08817 0.00367 3.00×10–5 0 0 0 0 0 0 0 0 0 0 0 0 1
Dropout BT 0.00 0.00 0.01 0.03 0.06 0.10 0.11 0.09 0.06 0.04 0.04 0.04 0.05 0.08 0.09 0.08 0.07 0.04 0.02 0.00 1
YBOCS CBT 0 6.00×10–5 0.00445 0.1258 0.33 0.1982 0.1035 0.05264 0.03062 0.02482 0.02428 0.03059 0.03744 0.02797 0.00867 9.80×10–4 0 1
Dropout CBT 0.00 0.03 0.09 0.15 0.16 0.14 0.10 0.07 0.05 0.03 0.03 0.02 0.02 0.02 0.03 0.03 0.02 0.01 0.00 0.00 1
YBOCS CT 0.1726 0.4096 0.3718 0.04326 0.0021 3.70×10–4 1.00×10–4 7.00×10–5 2.00×10–5 2.00×10–5 1.00×10–5 1.00×10–5 2.00×10–5 0 0 0 0 1
Dropout CT 0.00 0.01 0.02 0.06 0.09 0.11 0.10 0.07 0.05 0.04 0.03 0.03 0.04 0.05 0.07 0.08 0.08 0.05 0.03 0.00 1
YBOCS Hypericum 3.10×10–4 7.10×10–4 0.00299 0.02795 0.03718 0.03148 0.02984 0.02298 0.0172 0.01398 0.01413 0.01878 0.03187 0.08821 0.196 0.3728 0.09357 1
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TABLE 101 Data used to draw the absolute rankograms that appear in the main text of the report (continued )
Adults
Rank (YBOCS: 17 treatments; dropouts: 20 treatments)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Sum
Dropout Hypericum 0.04 0.07 0.10 0.10 0.09 0.08 0.06 0.04 0.03 0.02 0.02 0.02 0.02 0.03 0.04 0.05 0.06 0.07 0.05 0.01 1
YBOCS CBT+ fluvoxamine 0.0151 0.02434 0.09851 0.5006 0.1236 0.06653 0.03564 0.01945 0.01279 0.01009 0.0107 0.01376 0.02199 0.02712 0.01438 0.00538 1.10×10–4 1
Dropout CBT+ fluvoxamine 0.12 0.05 0.04 0.03 0.03 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.09 0.20 0.27 1
YBOCS BT+ clomipramine 0.3009 0.1674 0.4262 0.08548 0.01209 0.00361 0.00154 6.30×10–4 3.60×10–4 3.40×10–4 3.00×10–4 4.20×10–4 3.40×10–4 3.10×10–4 1.10×10–4 1.00×10–5 0 1
Dropout BT+ clomipramine 0.00 0.01 0.02 0.03 0.05 0.05 0.05 0.05 0.04 0.03 0.03 0.03 0.03 0.04 0.07 0.10 0.14 0.14 0.08 0.02 1
YBOCS Escitalopram 0 2.00×10–5 2.40×10–4 0.00669 0.02092 0.04178 0.07282 0.1064 0.1263 0.1309 0.1329 0.1308 0.1215 0.08387 0.02289 0.00203 2.00×10–5 1
Dropout Escitalopram 0.00 0.00 0.00 0.01 0.02 0.03 0.05 0.07 0.09 0.10 0.12 0.11 0.11 0.10 0.08 0.06 0.03 0.01 0.00 0.00 1
YBOCS Psychological
placebo
0 0 0.00195 0.07178 0.1394 0.1635 0.1096 0.06475 0.03905 0.03389 0.03261 0.04278 0.08253 0.1316 0.06533 0.02116 5.00×10–5 1
Dropout Psychological
placebo
0.09 0.19 0.21 0.17 0.12 0.06 0.04 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 1
Dropout Amitriptyline 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.07 0.20 0.49 1
Dropout BT+ fluvoxamine 0.13 0.14 0.14 0.12 0.09 0.06 0.04 0.03 0.02 0.01 0.01 0.01 0.02 0.02 0.03 0.03 0.03 0.04 0.02 0.01 1
Dropout Imipramine 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.04 0.06 0.15 0.27 0.17 1
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Children and adolescents
Rank (CYBOCS: 12 treatments; dropouts: 12 treatments)
1 2 3 4 5 6 7 8 9 10 11 12 Sum
CYBOCS Placebo 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.04 0.14 0.69 0.12 1.00
Dropout Placebo 0.00 0.01 0.02 0.04 0.08 0.12 0.16 0.20 0.20 0.14 0.03 0.00 1.00
CYBOCS Waitlist 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.04 0.10 0.82 1.00
Dropout Waitlist 0.12 0.16 0.14 0.11 0.10 0.06 0.05 0.05 0.06 0.10 0.04 0.00 1.00
CYBOCS Psychological placebo 0.02 0.03 0.06 0.11 0.17 0.16 0.12 0.08 0.08 0.11 0.05 0.00 1.00
Dropout Psychological placebo 0.08 0.14 0.14 0.13 0.10 0.06 0.05 0.06 0.07 0.09 0.05 0.02 1.00
CYBOCS Fluoxetine 0.00 0.00 0.01 0.02 0.05 0.10 0.17 0.23 0.22 0.17 0.02 0.00 1.00
Dropout Fluoxetine 0.03 0.07 0.10 0.11 0.13 0.16 0.14 0.10 0.08 0.05 0.01 0.00 1.00
CYBOCS Fluvoxamine 0.00 0.00 0.01 0.02 0.04 0.08 0.14 0.21 0.24 0.21 0.04 0.01 1.00
Dropout Fluvoxamine 0.03 0.06 0.09 0.10 0.12 0.15 0.14 0.12 0.09 0.06 0.02 0.01 1.00
Dropout Paroxetine 0.01 0.02 0.03 0.04 0.06 0.09 0.11 0.13 0.16 0.22 0.10 0.03 1.00
CYBOCS Sertraline 0.00 0.00 0.01 0.02 0.06 0.12 0.21 0.25 0.20 0.11 0.01 0.00 1.00
Dropout Sertraline 0.01 0.02 0.05 0.07 0.11 0.16 0.17 0.16 0.13 0.09 0.03 0.00 1.00
CYBOCS Clomipramine 0.02 0.04 0.08 0.12 0.17 0.18 0.13 0.08 0.07 0.08 0.02 0.01 1.00
Dropout Clomipramine 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.05 0.10 0.51 0.23 1.00
CYBOCS BT 0.19 0.14 0.15 0.15 0.13 0.08 0.05 0.03 0.03 0.03 0.01 0.00 1.00
Dropout BT 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.04 0.16 0.69 1.00
CYBOCS CBT 0.09 0.17 0.26 0.24 0.13 0.06 0.02 0.01 0.01 0.00 0.00 0.00 1.00
Dropout CBT 0.04 0.15 0.23 0.19 0.11 0.07 0.06 0.06 0.05 0.03 0.01 0.00 1.00
CYBOCS CBT+ sertraline 0.24 0.35 0.19 0.11 0.06 0.03 0.01 0.00 0.00 0.00 0.00 0.00 1.00
Dropout CBT+ sertraline 0.03 0.25 0.12 0.12 0.12 0.07 0.06 0.05 0.06 0.07 0.03 0.01 1.00
CYBOCS CBT+ placebo 0.36 0.18 0.12 0.10 0.07 0.05 0.03 0.02 0.02 0.02 0.01 0.01 1.00
Dropout CBT+ placebo 0.66 0.10 0.06 0.05 0.03 0.02 0.02 0.02 0.02 0.02 0.01 0.01 1.00
CYBOCS BT+ fluvoxamine 0.08 0.08 0.11 0.11 0.12 0.13 0.10 0.06 0.07 0.08 0.04 0.03 1.00
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WinBUGs code
# Code adapted from Program 5(a) 
#http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015Ap
ril2014.pdf 
 
model{ 
for (i in 1:complete){ #loop through studies reporting SD 
 for(z in 1:na[i]){ 
  sd1[i,z]<-sd[i,z] 
#calculate the mean and precision of the reported SDs 
  sd1[i,z]~dnorm(mu.sd[out[i]],prec.sd[out[i]])  
  } } 
 
for (i in complete+1:ns){#loop through remaining studies (not report SD) 
 for (z in 1:na[i]){ 
  sd1[i,z]~dnorm(mu.sd[out[i]],prec.sd[out[i]]) 
#SD is equal to estimated SD only for studies that did not report uncertainty 
   sd[i,z]<- cut(sd1[i,z])  
  } } 
 
 for (i in 1:ns){ #loop through all studies converting SDs to SEs 
  for (z in 1:na[i]){ 
   se[i,z]<-sd[i,z]/sqrt(n[i,z]) 
   prec[i,z]<-pow(se[i,z],-2) 
  }  } 
 
#TSD code 
for(i in 1:ns){ # LOOP THROUGH STUDIES 
 w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm 
 delta[i,1] <- 0 # treatment effect is zero for control arm 
 mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines 
 for (k in 1:na[i]) { # LOOP THROUGH ARMS 
   y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # normal likelihood 
   theta[i,k] <- mu[i] + delta[i,k] # model for linear 
predictor 
   dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-
theta[i,k])*prec[i,k]  
  } 
   
resdev[i] <- sum(dev[i,1:na[i]]) # summed deviance contribution  
 
for (k in 2:na[i]) { # LOOP THROUGH ARMS 
  delta[i,k] ~ dnorm(md[i,k],taud[i,k]) # trial-specific LOR 
distributions 
  md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of treat effect 
distributions (with multi-arm trial correction) 
  taud[i,k] <- tau *2*(k-1)/k # precision of treat effects 
distributions  
  w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment for 
multi-arm  
  sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for 
multi-arm  
  } 
 } 
  
totresdev <- sum(resdev[1:complete]) #Total Residual Deviance 
d[1]<-0 # treatment effect is zero for reference treatment 
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D[1]<-0 
  
for (i in 1:n.j1){ #vague prior for trt effects only 1 treatment per 
"class" 
 d[j1[i]]~dnorm(0,.0001) 
 D[class[j1[i]]]<-d[j1[i]] 
} 
  
for (i in 1:n.jclass){ #trt effects when multiple treatments form a 'class' 
 d[jclass[i]]~dnorm(D[class[jclass[i]]],Prec3[class[jclass[i]]]) 
} 
 
 
D[3]~dnorm(0, 0.0001) #vague prior for 'class' effect 
 
Prec3[3]<- 1/(SD3*SD3) 
SD3~dunif(0,10) 
 
 
 # vague priors for treatment effects 
 sdev ~ dunif(0,10) # vague prior for between-trial SD. 
 tau <- pow(sdev,-2) # between-trial precision = (1/between-trial 
variance) 
 
for (i  in 1:2){ 
 mu.sd[i]~dnorm(0,.0001)I(0,) 
 } 
 for (i  in 1:2){ 
  prec.sd[i]~dgamma(.01,.01) 
  } 
  
# Ranking and probabilities for treatment and class level effects 
for(k in 1:nt){ 
 rk[k]<-rank(d[],k) 
 best[k]<-equals(rk[k],1) 
  for (h in 1:nt){  prob[h,k]<-equals(rk[k],h)}  } 
 
for (q in 1:nclass){ 
 rk.class[q]<-rank(D[],q) 
 best.class[q]<-equals(rk.class[q],1)  
  for (x in 1:nclass){   
   prob.class[x,q]<-equals(rk.class[x],q) 
} }  
  
 # all MDs for each treatment level comparison 
for (c in 1:(nt-1)) {  
 for (k in (c+1):nt) { 
  treat.mean.diff[c,k] <- (d[k]-d[c])  } } 
  
# all MDs for each class level comparison 
for (f in 1:(nclass-1)) {  
 for (q in (f+1):nclass) { 
  class.mean.diff[f,q] <- (D[q]-D[f])  } } 
  
} 
 
*************************************************************************** 
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 #Random effects model for multi-arm trials. Binomial link 
 
model{ #  
for(i in 1:ns){  
 w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm  
 delta[i,1] <- 0 # treatment effect is zero for control arm  
 mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines  
 
 for (k in 1:na[i]) { # LOOP THROUGH ARMS  
 r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood  
 logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor  
 rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators  
 dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) #Deviance contribution  
 + (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))  
 }  
 
 resdev[i] <- sum(dev[i,1:na[i]]) # summed res.dev contribution per trial 
 
 for (k in 2:na[i]) { # LOOP THROUGH ARMS  
 delta[i,k] ~ dnorm(md[i,k],taud[i,k]) # trial-specific LOR distributions  
 md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of LOR distributions  
 taud[i,k] <- tau *2*(k-1)/k # precision of LOR distributions  
 w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment for multi-arm 
RCTs  
 sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials  
 }  
 }  
 
totresdev <- sum(resdev[]) #Total Residual Deviance  
d[1] <- 0 # treatment effect is zero for reference treatment  
D[1]<-0 
 
 
for (i in 1:n.j1){ 
 d[j1[i]]~dnorm(0,.0001) 
 D[class[j1[i]]]<-d[j1[i]]   } 
 
 
for (i in 1:n.jclass){ 
 d[jclass[i]]~dnorm(D[class[jclass[i]]],Prec3[class[jclass[i]]])   } 
 
 
D[3]~dnorm(0, 0.0001) 
Prec3[3]<- 1/(SD3*SD3) 
SD3~dunif(0,10) 
sd ~ dunif(0,5) # vague prior for between-trialSD 
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance)  
 
 
# Ranking and probabilities for treatment and class level effects 
for(k in 1:20){ 
 rk[k]<-rank(d[],k) 
 best[k]<-equals(rk[k],1) 
  for (h in 1:20){  prob[h,k]<-equals(rk[k],h)}  } 
for (q in 1:15){ 
 rk.class[q]<-rank(D[],q) 
 best.class[q]<-equals(rk.class[q],1)  
  for (x in 1:15){   
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   prob.class[x,q]<-equals(rk.class[x],q) 
} } 
 
 
#Pairwise ORs for treatment level analysis 
for (f in 1:14) 
          {  for (q in (f+1):15)   
                {  lor.D[f,q] <- D[q] - D[f] 
                  OR.D[f,q]<-exp(lor.D[f,q]) 
                 }} 
            
#Pairwise ORs for class level analyis 
for (c in 1:19)  { 
for (k in (c+1):20) { 
     lor[c,k] <- d[k] - d[c] 
     OR[c,k]<-exp(lor[c,k])}   } 
 
   }}}
 
DOI: 10.3310/hta20430 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 43
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Skapinakis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
267
Appendix 9 Detailed results of the sensitivity
analyses
Adults
Adults: clinical effectiveness (YBOCS) – sensitivity analysis 1
(low overall attrition)
See Table 21 for a summary.
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TABLE 102 Raw data used
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Albert et al., 2002155 18.36 25 7.11 17.3 40 6.15 NA NA NA NA NA NA 2 2 8 9 NA NA
Anderson and Rees, 2007157 23.5 14 6.4 16.7 17 6.8 NA NA NA NA NA NA 2 2 2 11 NA NA
Andersson et al., 2012158 12.94 49 6.26 18.88 51 4.18 NA NA NA NA NA NA 2 2 11 17 NA NA
Belloch et al., 2008159 8.31 13 8.75 6.8 16 3.55 NA NA NA NA NA NA 2 2 10 12 NA NA
CCSG1, 1991154 25.11 108 6.34 16.23 102 7.37 NA NA NA NA NA NA 2 2 1 9 NA NA
CCSG2, 1991154 25.59 119 5.78 14.7 120 7.45 NA NA NA NA NA NA 2 2 1 9 NA NA
Chouinard et al., 1990163 –1.48 44 NA –3.79 43 NA NA NA NA NA NA NA 2 1 1 6 NA NA
Cordioli et al., 2003164 23.2 24 5.5 15.1 23 7.8 NA NA NA NA NA NA 2 2 2 11 NA NA
Cottraux et al., 2001166 –12.1 30 7.8 –12.5 30 8.2 NA NA NA NA NA NA 2 1 10 12 NA NA
Denys et al., 2003167 –7.8 72 5.4 –7.2 73 7.5 NA NA NA NA NA NA 2 1 5 8 NA NA
Fals-Stewart et al., 1993170 –8.1 31 NA –1.8 32 NA NA NA NA NA NA NA 2 1 10 17 NA NA
GlaxoSmithKline, 2005175 –14.26 72 6.33 –13.19 69 6.48 NA NA NA NA NA NA 2 1 5 9 NA NA
Greist et al., 2002178 17.6 55 6.2 24.1 66 6.7 NA NA NA NA NA NA 2 2 10 17 NA NA
Hollander et al., 2003181 –3.33 89 NA –4.14 88 NA –6.35 86 NA –7.34 85 NA 4 1 1 5 5 5
Jaurrieta et al., 2008182 24.6 19 8.9 17.8 19 8.4 NA NA NA NA NA NA 2 2 2 11 NA NA
Jenike et al., 1990183 22.3 9 7.8 20.6 10 9.2 NA NA NA NA NA NA 2 2 1 6 NA NA
Jenike et al., 1990184 21.8 20 7.6 18.8 18 4 NA NA NA NA NA NA 2 2 1 4 NA NA
Jenike et al., 1997185 18.7 18 6.1 16.2 19 6.3 NA NA NA NA NA NA 2 2 1 3 NA NA
Kamijima et al., 2004187 20.3 94 7.38 15.8 94 8.09 NA NA NA NA NA NA 2 2 1 5 NA NA
Lindsay et al., 1997192 11 9 3.81 25.89 9 5.8 NA NA NA NA NA NA 2 2 10 17 NA NA
López-Ibor et al., 1996193 –7.5 30 9.29 –8.9 24 7.13 NA NA NA NA NA NA 2 1 3 9 NA NA
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Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Milanfranchi et al., 1997196 18.4 13 9.2 16.5 12 11 NA NA NA NA NA NA 2 2 4 9 NA NA
Montgomery et al., 2001198 –5.6 101 6.9 –8.4 102 7.3 –8.9 98 7 –10.4 100 6.9 4 1 1 7 7 7
Mundo et al., 1997199 16.2 10 8.9 21.6 9 7.6 19.8 11 10.1 NA NA NA 3 2 4 5 7 NA
Mundo et al., 2001200 –12.2 115 NA –12 112 NA NA NA NA NA NA NA 2 1 4 9 NA NA
Nakatani et al., 2005202 20.2 10 9.4 12.9 10 4.9 28.4 8 5.5 NA NA NA 3 2 4 10 17 NA
O’Connor et al., 1999203 17.5 6 4 13.3 6 8.6 NA NA NA NA NA NA 2 2 2 11 NA NA
Shareh et al., 2010206 16.66 6 3.2 7 7 2.38 8.5 6 2.42 NA NA NA 3 2 4 11 14 NA
Sousa et al., 2006207 –7.36 25 NA –10.8 25 NA NA NA NA NA NA NA 2 1 6 11 NA NA
Stein et al., 2007124 –8.46 113 8.08 –11.67 116 8.40 –11.43 112 8.25 –12.14 114 8.22 4 1 1 5 16 16
Tollefson et al., 1994127 –0.8 89 5.66 –5.44 266 7.88 NA NA NA NA NA NA 2 1 1 3 NA NA
Van Oppen et al., 1995209 17.9 29 9 13.4 28 9.4 NA NA NA NA NA NA 2 2 10 12 NA NA
Whittal et al., 2010212 6.43 37 4.77 9.1 30 6.48 NA NA NA NA NA NA 2 2 12 17 NA NA
CCSG, Clomipramine Collaborative Study Group; NA, not applicable.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine,
9= clomipramine, 10= BT, 11=CBT, 12=CT, 13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo; t[i,2], type of treatment
[i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4]; y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline
(negative) for arm [1]; y[i,2], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean YBOCS scores at end of study
(positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total
number of patients for arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of patients for arm [4]; sd[i,1], SD of mean total
score or change from baseline for arm [1]; sd[i,2], SD of mean total score or change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3];
sd[i,4], SD of mean total score or change from baseline for arm [4].
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Key: intervention (class)
1. Placebo (1).
2. Waitlist (2).
3. Fluoxetine(3).
4. Fluvoxamine(3).
5. Paroxetine (3).
6. Sertraline (3).
7. Citalopram (3).
8. Venlafaxine (4).
9. Clomipramine(5).
10. BT (6).
11. CBT (7).
12. CT (8).
13. CBT+ fluvoxamine (9).
14. Escitalopram (3).
15. Psychological placebo (10).
TABLE 103 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[1,2] –3.317 2.875 0.03854 –8.983 –3.324 2.38 50,001 100,000
class.mean.diff[1,3] –4.091 1.005 0.0165 –6.066 –4.092 –2.061 50,001 100,000
class.mean.diff[1,4] –4.319 2.234 0.01698 –8.719 –4.321 0.1204 50,001 100,000
class.mean.diff[1,5] –6.419 1.284 0.01173 –8.932 –6.435 –3.852 50,001 100,000
class.mean.diff[1,6] –11.04 2.971 0.0506 –16.84 –11.04 –5.186 50,001 100,000
class.mean.diff[1,7] –10.13 2.241 0.03435 –14.52 –10.15 –5.687 50,001 100,000
class.mean.diff[1,8] –10.63 3.282 0.05325 –17.08 –10.62 –4.16 50,001 100,000
class.mean.diff[1,9] –10.31 2.939 0.0301 –16.14 –10.31 –4.521 50,001 100,000
class.mean.diff[1,10] –2.851 2.811 0.04821 –8.334 –2.868 2.771 50,001 100,000
class.mean.diff[2,3] –0.7743 2.771 0.03045 –6.23 –0.776 4.688 50,001 100,000
class.mean.diff[2,4] –1.002 3.487 0.03399 –7.916 –0.9951 5.826 50,001 100,000
class.mean.diff[2,5] –3.102 2.984 0.03305 –9.001 –3.116 2.781 50,001 100,000
class.mean.diff[2,6] –7.725 3.195 0.0332 –13.98 –7.734 –1.385 50,001 100,000
class.mean.diff[2,7] –6.816 1.816 0.01158 –10.38 –6.819 –3.22 50,001 100,000
class.mean.diff[2,8] –7.31 3.461 0.03576 –14.15 –7.299 –0.5329 50,001 100,000
class.mean.diff[2,9] –6.996 3.24 0.01976 –13.41 –6.997 –0.6501 50,001 100,000
class.mean.diff[2,10] 0.466 2.969 0.03005 –5.327 0.4427 6.392 50,001 100,000
class.mean.diff[3,4] –0.2282 2.198 0.011 –4.59 –0.2308 4.143 50,001 100,000
class.mean.diff[3,5] –2.328 1.324 0.009057 –4.944 –2.333 0.2878 50,001 100,000
class.mean.diff[3,6] –6.951 2.883 0.04368 –12.63 –6.943 –1.295 50,001 100,000
class.mean.diff[3,7] –6.042 2.109 0.02551 –10.19 –6.048 –1.89 50,001 100,000
class.mean.diff[3,8] –6.535 3.202 0.04661 –12.84 –6.513 –0.2369 50,001 100,000
class.mean.diff[3,9] –6.222 2.844 0.02163 –11.91 –6.212 –0.651 50,001 100,000
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TABLE 103 Class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[3,10] 1.24 2.713 0.04085 –4.066 1.227 6.595 50,001 100,000
class.mean.diff[4,5] –2.1 2.15 0.01099 –6.334 –2.103 2.167 50,001 100,000
class.mean.diff[4,6] –6.723 3.562 0.04667 –13.7 –6.73 0.3361 50,001 100,000
class.mean.diff[4,7] –5.814 2.977 0.02942 –11.63 –5.837 0.1271 50,001 100,000
class.mean.diff[4,8] –6.307 3.83 0.04946 –13.81 –6.314 1.295 50,001 100,000
class.mean.diff[4,9] –5.994 3.524 0.02539 –12.98 –5.999 0.9386 50,001 100,000
class.mean.diff[4,10] 1.468 3.43 0.04404 –5.222 1.436 8.318 50,001 100,000
class.mean.diff[5,6] –4.623 3.072 0.04576 –10.65 –4.629 1.457 50,001 100,000
class.mean.diff[5,7] –3.714 2.374 0.02835 –8.372 –3.718 0.9799 50,001 100,000
class.mean.diff[5,8] –4.207 3.377 0.04856 –10.86 –4.196 2.451 50,001 100,000
class.mean.diff[5,9] –3.894 3.039 0.02453 –9.925 –3.889 2.079 50,001 100,000
class.mean.diff[5,10] 3.568 2.914 0.04304 –2.132 3.547 9.364 50,001 100,000
class.mean.diff[6,7] 0.909 2.631 0.02946 –4.294 0.9241 6.055 50,001 100,000
class.mean.diff[6,8] 0.4155 1.699 0.01145 –2.946 0.4231 3.735 50,001 100,000
class.mean.diff[6,9] 0.7288 3.549 0.03566 –6.29 0.7441 7.672 50,001 100,000
class.mean.diff[6,10] 8.191 1.441 0.007783 5.408 8.173 11.1 50,001 100,000
class.mean.diff[7,8] –0.4935 2.951 0.0326 –6.361 –0.4901 5.267 50,001 100,000
class.mean.diff[7,9] –0.1802 2.679 0.01381 –5.513 –0.1689 5.036 50,001 100,000
class.mean.diff[7,10] 7.282 2.346 0.02592 2.708 7.252 12 50,001 100,000
class.mean.diff[8,9] 0.3133 3.799 0.03858 –7.207 0.3088 7.792 50,001 100,000
class.mean.diff[8,10] 7.776 1.919 0.0128 4.082 7.744 11.64 50,001 100,000
class.mean.diff[9,10] 7.462 3.377 0.03274 0.9321 7.425 14.23 50,001 100,000
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TABLE 104 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[1,2] –3.317 2.875 0.03854 –8.983 –3.324 2.38 50,001 100,000
treat.mean.diff[1,3] –4.103 1.11 0.01554 –6.307 –4.106 –1.837 50,001 100,000
treat.mean.diff[1,4] –4.259 1.141 0.0184 –6.642 –4.224 –1.997 50,001 100,000
treat.mean.diff[1,5] –4.096 0.9845 0.01555 –6.032 –4.098 –2.095 50,001 100,000
treat.mean.diff[1,6] –4.048 1.193 0.01704 –6.413 –4.065 –1.62 50,001 100,000
treat.mean.diff[1,7] –4.009 1.149 0.01604 –6.247 –4.031 –1.633 50,001 100,000
treat.mean.diff[1,8] –4.319 2.234 0.01698 –8.719 –4.321 0.1204 50,001 100,000
treat.mean.diff[1,9] –6.419 1.284 0.01173 –8.932 –6.435 –3.852 50,001 100,000
treat.mean.diff[1,10] –11.04 2.971 0.0506 –16.84 –11.04 –5.186 50,001 100,000
treat.mean.diff[1,11] –10.13 2.241 0.03435 –14.52 –10.15 –5.687 50,001 100,000
treat.mean.diff[1,12] –10.63 3.282 0.05325 –17.08 –10.62 –4.16 50,001 100,000
treat.mean.diff[1,13] –10.31 2.939 0.0301 –16.14 –10.31 –4.521 50,001 100,000
treat.mean.diff[1,14] –4.031 1.169 0.01598 –6.304 –4.05 –1.609 50,001 100,000
treat.mean.diff[1,15] –2.851 2.811 0.04821 –8.334 –2.868 2.771 50,001 100,000
treat.mean.diff[2,3] –0.7862 2.858 0.0316 –6.418 –0.7947 4.886 50,001 100,000
treat.mean.diff[2,4] –0.9422 2.714 0.02867 –6.295 –0.9318 4.388 50,001 100,000
treat.mean.diff[2,5] –0.7796 2.819 0.03121 –6.333 –0.7792 4.795 50,001 100,000
treat.mean.diff[2,6] –0.7312 2.776 0.02917 –6.191 –0.7352 4.749 50,001 100,000
treat.mean.diff[2,7] –0.6924 2.87 0.03127 –6.315 –0.6962 4.98 50,001 100,000
treat.mean.diff[2,8] –1.002 3.487 0.03399 –7.916 –0.9951 5.826 50,001 100,000
treat.mean.diff[2,9] –3.102 2.984 0.03305 –9.001 –3.116 2.781 50,001 100,000
treat.mean.diff[2,10] –7.725 3.195 0.0332 –13.98 –7.734 –1.385 50,001 100,000
treat.mean.diff[2,11] –6.816 1.816 0.01158 –10.38 –6.819 –3.22 50,001 100,000
treat.mean.diff[2,12] –7.31 3.461 0.03576 –14.15 –7.299 –0.5329 50,001 100,000
treat.mean.diff[2,13] –6.996 3.24 0.01976 –13.41 –6.997 –0.6501 50,001 100,000
treat.mean.diff[2,14] –0.7137 2.869 0.03115 –6.355 –0.721 4.963 50,001 100,000
treat.mean.diff[2,15] 0.466 2.969 0.03005 –5.327 0.4427 6.392 50,001 100,000
treat.mean.diff[3,4] –0.156 1.103 0.007438 –2.735 –0.04447 2.038 50,001 100,000
treat.mean.diff[3,5] 0.006609 1.008 0.004452 –2.178 0.001402 2.213 50,001 100,000
treat.mean.diff[3,6] 0.05504 1.172 0.005662 –2.451 0.01024 2.699 50,001 100,000
treat.mean.diff[3,7] 0.09385 1.146 0.005167 –2.324 0.02365 2.704 50,001 100,000
treat.mean.diff[3,8] –0.2163 2.266 0.01135 –4.703 –0.2168 4.258 50,001 100,000
treat.mean.diff[3,9] –2.316 1.4 0.008942 –5.099 –2.322 0.4748 50,001 100,000
treat.mean.diff[3,10] –6.939 2.965 0.04455 –12.8 –6.929 –1.119 50,001 100,000
treat.mean.diff[3,11] –6.03 2.224 0.02668 –10.45 –6.035 –1.652 50,001 100,000
treat.mean.diff[3,12] –6.524 3.276 0.04749 –13 –6.5 –0.07921 50,001 100,000
treat.mean.diff[3,13] –6.21 2.931 0.02268 –12.05 –6.2 –0.4791 50,001 100,000
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TABLE 104 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[3,14] 0.0725 1.149 0.004902 –2.351 0.01609 2.679 50,001 100,000
treat.mean.diff[3,15] 1.252 2.802 0.04176 –4.238 1.242 6.796 50,001 100,000
treat.mean.diff[4,5] 0.1626 0.9883 0.007063 –1.784 0.05258 2.498 50,001 100,000
treat.mean.diff[4,6] 0.211 1.126 0.006667 –1.972 0.06478 2.911 50,001 100,000
treat.mean.diff[4,7] 0.2498 1.135 0.00808 –1.907 0.082 2.999 50,001 100,000
treat.mean.diff[4,8] –0.06028 2.248 0.01251 –4.467 –0.07289 4.436 50,001 100,000
treat.mean.diff[4,9] –2.16 1.354 0.01034 –4.79 –2.18 0.5713 50,001 100,000
treat.mean.diff[4,10] –6.783 2.794 0.04167 –12.26 –6.785 –1.267 50,001 100,000
treat.mean.diff[4,11] –5.874 2.03 0.02349 –9.855 –5.887 –1.842 50,001 100,000
treat.mean.diff[4,12] –6.368 3.122 0.04471 –12.5 –6.361 –0.2322 50,001 100,000
treat.mean.diff[4,13] –6.054 2.75 0.01995 –11.5 –6.054 –0.6226 50,001 100,000
treat.mean.diff[4,14] 0.2285 1.147 0.007522 –1.963 0.06855 3.003 50,001 100,000
treat.mean.diff[4,15] 1.408 2.624 0.0388 –3.693 1.395 6.616 50,001 100,000
treat.mean.diff[5,6] 0.04843 1.075 0.005323 –2.252 0.01349 2.452 50,001 100,000
treat.mean.diff[5,7] 0.08724 1.032 0.004494 –2.071 0.02513 2.433 50,001 100,000
treat.mean.diff[5,8] –0.2229 2.108 0.009994 –4.415 –0.2219 3.938 50,001 100,000
treat.mean.diff[5,9] –2.323 1.29 0.008259 –4.891 –2.327 0.2327 50,001 100,000
treat.mean.diff[5,10] –6.946 2.924 0.04461 –12.71 –6.928 –1.22 50,001 100,000
treat.mean.diff[5,11] –6.037 2.17 0.02639 –10.31 –6.04 –1.745 50,001 100,000
treat.mean.diff[5,12] –6.53 3.238 0.04748 –12.91 –6.51 –0.1723 50,001 100,000
treat.mean.diff[5,13] –6.217 2.888 0.02244 –11.99 –6.207 –0.5708 50,001 100,000
treat.mean.diff[5,14] 0.06589 0.9877 0.003986 –1.993 0.01554 2.29 50,001 100,000
treat.mean.diff[5,15] 1.246 2.755 0.04179 –4.146 1.231 6.695 50,001 100,000
treat.mean.diff[6,7] 0.03881 1.182 0.005654 –2.523 0.008911 2.675 50,001 100,000
treat.mean.diff[6,8] –0.2713 2.316 0.01176 –4.882 –0.2655 4.303 50,001 100,000
treat.mean.diff[6,9] –2.371 1.494 0.009976 –5.379 –2.368 0.5962 50,001 100,000
treat.mean.diff[6,10] –6.994 2.914 0.0427 –12.72 –6.991 –1.266 50,001 100,000
treat.mean.diff[6,11] –6.085 2.115 0.02415 –10.27 –6.088 –1.935 50,001 100,000
treat.mean.diff[6,12] –6.579 3.23 0.04573 –12.97 –6.57 –0.2254 50,001 100,000
treat.mean.diff[6,13] –6.265 2.887 0.02079 –12.02 –6.243 –0.6345 50,001 100,000
treat.mean.diff[6,14] 0.01746 1.187 0.005286 –2.536 0.001934 2.635 50,001 100,000
treat.mean.diff[6,15] 1.197 2.741 0.03985 –4.157 1.18 6.626 50,001 100,000
treat.mean.diff[7,8] –0.3101 2.3 0.01147 –4.911 –0.3019 4.232 50,001 100,000
treat.mean.diff[7,9] –2.41 1.48 0.009452 –5.408 –2.4 0.4917 50,001 100,000
treat.mean.diff[7,10] –7.033 2.977 0.04466 –12.92 –7.021 –1.186 50,001 100,000
treat.mean.diff[7,11] –6.124 2.235 0.02647 –10.56 –6.122 –1.743 50,001 100,000
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TABLE 104 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[7,12] –6.617 3.285 0.04754 –13.1 –6.593 –0.1509 50,001 100,000
treat.mean.diff[7,13] –6.304 2.939 0.02248 –12.17 –6.28 –0.5407 50,001 100,000
treat.mean.diff[7,14] –0.02135 1.154 0.004668 –2.562 –0.00565 2.516 50,001 100,000
treat.mean.diff[7,15] 1.158 2.811 0.04188 –4.36 1.148 6.676 50,001 100,000
treat.mean.diff[8,9] –2.1 2.15 0.01099 –6.334 –2.103 2.167 50,001 100,000
treat.mean.diff[8,10] –6.723 3.562 0.04667 –13.7 –6.73 0.3361 50,001 100,000
treat.mean.diff[8,11] –5.814 2.977 0.02942 –11.63 –5.837 0.1271 50,001 100,000
treat.mean.diff[8,12] –6.307 3.83 0.04946 –13.81 –6.314 1.295 50,001 100,000
treat.mean.diff[8,13] –5.994 3.524 0.02539 –12.98 –5.999 0.9386 50,001 100,000
treat.mean.diff[8,14] 0.2888 2.288 0.01111 –4.217 0.2814 4.854 50,001 100,000
treat.mean.diff[8,15] 1.468 3.43 0.04404 –5.222 1.436 8.318 50,001 100,000
treat.mean.diff[9,10] –4.623 3.072 0.04576 –10.65 –4.629 1.457 50,001 100,000
treat.mean.diff[9,11] –3.714 2.374 0.02835 –8.372 –3.718 0.9799 50,001 100,000
treat.mean.diff[9,12] –4.207 3.377 0.04856 –10.86 –4.196 2.451 50,001 100,000
treat.mean.diff[9,13] –3.894 3.039 0.02453 –9.925 –3.889 2.079 50,001 100,000
treat.mean.diff[9,14] 2.389 1.476 0.009127 –0.5044 2.379 5.359 50,001 100,000
treat.mean.diff[9,15] 3.568 2.914 0.04304 –2.132 3.547 9.364 50,001 100,000
treat.mean.diff[10,11] 0.909 2.631 0.02946 –4.294 0.9241 6.055 50,001 100,000
treat.mean.diff[10,12] 0.4155 1.699 0.01145 –2.946 0.4231 3.735 50,001 100,000
treat.mean.diff[10,13] 0.7288 3.549 0.03566 –6.29 0.7441 7.672 50,001 100,000
treat.mean.diff[10,14] 7.012 2.978 0.04446 1.171 6.995 12.9 50,001 100,000
treat.mean.diff[10,15] 8.191 1.441 0.007783 5.408 8.173 11.1 50,001 100,000
treat.mean.diff[11,12] –0.4935 2.951 0.0326 –6.361 –0.4901 5.267 50,001 100,000
treat.mean.diff[11,13] –0.1802 2.679 0.01381 –5.513 –0.1689 5.036 50,001 100,000
treat.mean.diff[11,14] 6.103 2.241 0.02636 1.693 6.095 10.55 50,001 100,000
treat.mean.diff[11,15] 7.282 2.346 0.02592 2.708 7.252 12 50,001 100,000
treat.mean.diff[12,13] 0.3133 3.799 0.03858 –7.207 0.3088 7.792 50,001 100,000
treat.mean.diff[12,14] 6.596 3.285 0.04743 0.1353 6.576 13.06 50,001 100,000
treat.mean.diff[12,15] 7.776 1.919 0.0128 4.082 7.744 11.64 50,001 100,000
treat.mean.diff[13,14] 6.283 2.939 0.02256 0.5358 6.257 12.18 50,001 100,000
treat.mean.diff[13,15] 7.462 3.377 0.03274 0.9321 7.425 14.23 50,001 100,000
treat.mean.diff[14,15] 1.18 2.812 0.04166 –4.332 1.171 6.716 50,001 100,000
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Median ranks
TABLE 105 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[2] 7.601 1.575 0.01425 5 8 10 50,001 100,000
rk.class[3] 7.167 1.017 0.01022 5 7 9 50,001 100,000
rk.class[4] 6.893 1.61 0.01281 3 7 9 50,001 100,000
rk.class[5] 5.127 1.116 0.01217 2 5 7 50,001 100,000
rk.class[6] 2.287 1.195 0.0116 1 2 5 50,001 100,000
rk.class[7] 2.823 1.135 0.008796 1 3 5 50,001 100,000
rk.class[8] 2.695 1.437 0.0147 1 2 6 50,001 100,000
rk.class[9] 2.778 1.518 0.009753 1 3 6 50,001 100,000
rk.class[10] 7.933 1.469 0.02014 5 8 10 50,001 100,000
TABLE 106 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 14.69 0.6014 0.007856 13 15 15 50,001 100,000
rk[2] 10.65 3.606 0.03481 5 12 15 50,001 100,000
rk[3] 9.634 2.297 0.01488 6 10 14 50,001 100,000
rk[4] 9.255 2.115 0.01239 6 9 13 50,001 100,000
rk[5] 9.658 2.098 0.0142 6 10 13 50,001 100,000
rk[6] 9.753 2.28 0.01095 6 10 14 50,001 100,000
rk[7] 9.853 2.321 0.01454 6 10 14 50,001 100,000
rk[8] 9.188 3.559 0.02113 3 9 14 50,001 100,000
rk[9] 5.38 1.585 0.01406 3 5 10 50,001 100,000
rk[10] 2.335 1.398 0.01375 1 2 5 50,001 100,000
rk[11] 2.844 1.207 0.009126 1 3 5 50,001 100,000
rk[12] 2.807 1.829 0.0191 1 2 7 50,001 100,000
rk[13] 2.86 1.799 0.0103 1 3 7 50,001 100,000
rk[14] 9.787 2.316 0.01366 6 10 14 50,001 100,000
rk[15] 11.31 3.409 0.04808 5 13 15 50,001 100,000
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Adults: clinical effectiveness (Yale–Brown Obsessive–Compulsive Scale) – sensitivity analysis 2
(incomplete outcome data)
See Table 22 for a summary.
TABLE 107 Raw data used
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Anderson and Rees, 2007157 23.5 14 6.4 16.7 17 6.8 NA NA NA NA NA NA 2 2 2 11 NA NA
Andersson et al., 2012158 12.94 49 6.26 18.88 51 4.18 NA NA NA NA NA NA 2 2 11 15 NA NA
Belotto-Silva et al., 2012160 20.29 88 8.05 19.97 70 8.48 NA NA NA NA NA NA 2 2 3 11 NA NA
Bergeron et al., 2002161 –9.7 72 7.7 –9.6 76 7.9 NA NA NA NA NA NA 2 1 3 6 NA NA
Bisserbe et al., 1997162 –14.3 86 NA –11.71 81 NA NA NA NA NA NA NA 2 1 6 9 NA NA
Chouinard et al., 1990163 –1.48 44 NA –3.79 43 NA NA NA NA NA NA NA 2 1 1 6 NA NA
Cordioli et al., 2003164 23.2 24 5.5 15.1 23 7.8 NA NA NA NA NA NA 2 2 2 11 NA NA
Denys et al., 2003167 –7.8 72 5.4 –7.2 73 7.5 NA NA NA NA NA NA 2 1 5 8 NA NA
Foa et al., 2005171 22.2 26 6.4 18.2 36 7.8 11 29 7.9 10.5 31 8.2 4 2 1 9 10 13
Freeman et al., 1994172 –8.6 28 NA –7.8 19 NA NA NA NA NA NA NA 2 1 4 9 NA NA
Freeston et al., 1997173 22 14 6 12.2 15 9.6 NA NA NA NA NA NA 2 2 2 11 NA NA
GlaxoSmithKline, 2005174 –4.61 75 7.53 –5.61 79 7.47 –7.73 78 7.42 NA NA NA 3 1 1 5 9 NA
Goodman et al., 1989176 28 21 7 19.4 21 7 NA NA NA NA NA NA 2 2 1 4 NA NA
Goodman et al., 1996177 –1.71 78 4.88 –3.95 78 6.28 NA NA NA NA NA NA 2 1 1 4 NA NA
Greist et al., 2002178 17.6 55 6.2 24.1 66 6.7 NA NA NA NA NA NA 2 2 10 15 NA NA
Hollander et al., 2003180 –5.6 120 7.67 –8.5 117 7.57 NA NA NA NA NA NA 2 1 1 4 NA NA
Hollander et al., 2003181 –3.33 89 NA –4.14 88 NA –6.35 86 NA –7.34 85 NA 4 1 1 5 5 5
Jaurrieta et al., 2008182 24.6 19 8.9 17.8 19 8.4 NA NA NA NA NA NA 2 2 2 11 NA NA
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TABLE 107 Raw data used (continued )
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Jenike et al., 1990183 22.3 9 7.8 20.6 10 9.2 NA NA NA NA NA NA 2 2 1 6 NA NA
Jenike et al., 1997185 18.7 18 6.1 16.2 19 6.3 NA NA NA NA NA NA 2 2 1 3 NA NA
Kamijima et al., 2004187 20.3 94 7.38 15.8 94 8.09 NA NA NA NA NA NA 2 2 1 5 NA NA
Kobak et al.,189 19.87 30 7.46 19.75 30 7.46 NA NA NA NA NA NA 2 2 1 12 NA NA
Koran et al., 1996190 17.8 34 7.7 17 39 8.55 NA NA NA NA NA NA 2 2 4 9 NA NA
Kronig et al., 1999191 –4.14 79 NA –8.5 85 NA NA NA NA NA NA NA 2 1 1 6 NA NA
López-Ibor et al., 1996193 –7.5 30 9.29 –8.9 24 7.13 NA NA NA NA NA NA 2 1 3 9 NA NA
Montgomery et al., 1993197 –3.7 56 5.98 –5.13 52 6.41 –4.76 52 6.89 –6.07 54 6.92 4 1 1 3 3 3
Montgomery et al., 2001198 –5.6 101 6.9 –8.4 102 7.3 –8.9 98 7 –10.4 100 6.9 4 1 1 7 7 7
Mundo et al., 1997199 16.2 10 8.9 21.6 9 7.6 19.8 11 10.1 NA NA NA 3 2 4 5 7 NA
Mundo et al., 2001200 –12.2 115 NA –12 112 NA NA NA NA NA NA NA 2 1 4 9 NA NA
Nakajima et al., 1996201 –1.9 33 7.2 –7.1 60 7.03 NA NA NA NA NA NA 2 1 1 4 NA NA
Sousa et al., 2006207 –7.36 25 NA –10.8 25 NA NA NA NA NA NA NA 2 1 6 11 NA NA
Stein et al., 2007124 –8.46 113 8.08 –11.67 116 8.40 –11.43 112 8.25 –12.14 114 8.22 4 1 1 5 14 14
Tollefson et al., 1994127 –0.8 89 5.66 –5.44 266 7.88 NA NA NA NA NA NA 2 1 1 3 NA NA
Zohar and Judge, 1996213 –4.2 99 7.2 –6.4 201 7.1 –7 99 6.8 NA NA NA 3 1 1 5 9 NA
NA, not applicable.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine,
9= clomipramine, 10= BT, 11=CBT, 12=CT, 13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo; t[i,2], type of treatment
[i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4]; y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline
(negative) for arm [1]; y[i,2], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean YBOCS scores at end of study
(positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total
number of patients for arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of patients for arm [4]; sd[i,1], SD of mean total
score or change from baseline for arm [1]; sd[i,2], SD of mean total score or change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3];
sd[i,4], SD of mean total score or change from baseline for arm [4].
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Key: intervention (class)
1. Placebo (1).
2. Waitlist (2).
3. Fluoxetine (3).
4. Fluvoxamine (3).
5. Paroxetine (3).
6. Sertraline (3).
7. Citalopram (3).
8. Venlafaxine (4).
9. Clomipramine (5).
10. BT (6).
11. CBT (7).
12. Hypericum (8).
13. BT+ clomipramine (9).
14. Escitalopram (3).
15. Psychological placebo (10).
TABLE 108 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[1,2] 2.063 1.806 0.03318 –1.509 2.067 5.611 50,001 100,000
class.mean.diff[1,3] –3.332 0.4591 0.006652 –4.25 –3.329 –2.456 50,001 100,000
class.mean.diff[1,4] –2.458 1.533 0.01317 –5.492 –2.461 0.5665 50,001 100,000
class.mean.diff[1,5] –3.156 0.6228 0.008235 –4.392 –3.151 –1.95 50,001 100,000
class.mean.diff[1,6] –8.7 1.541 0.02275 –11.78 –8.686 –5.747 50,001 100,000
class.mean.diff[1,7] –5.758 1.254 0.02213 –8.232 –5.744 –3.314 50,001 100,000
class.mean.diff[1,8] –0.103 2.164 0.02634 –4.344 –0.1013 4.112 50,001 100,000
class.mean.diff[1,9] –10.67 1.916 0.02438 –14.42 –10.68 –6.9 50,001 100,000
class.mean.diff[1,10] –0.9254 1.563 0.02449 –4.097 –0.8947 2.087 50,001 100,000
class.mean.diff[2,3] –5.395 1.808 0.03138 –8.945 –5.391 –1.829 50,001 100,000
class.mean.diff[2,4] –4.52 2.351 0.03469 –9.157 –4.511 0.08525 50,001 100,000
class.mean.diff[2,5] –5.219 1.856 0.0317 –8.904 –5.21 –1.566 50,001 100,000
class.mean.diff[2,6] –10.76 2.04 0.0285 –14.87 –10.74 –6.858 50,001 100,000
class.mean.diff[2,7] –7.821 1.32 0.01947 –10.41 –7.816 –5.23 50,001 100,000
class.mean.diff[2,8] –2.166 2.825 0.04148 –7.694 –2.138 3.396 50,001 100,000
class.mean.diff[2,9] –12.73 2.55 0.03768 –17.77 –12.72 –7.707 50,001 100,000
class.mean.diff[2,10] –2.988 1.838 0.02496 –6.636 –2.964 0.5565 50,001 100,000
class.mean.diff[3,4] 0.8747 1.533 0.0124 –2.121 0.8695 3.917 50,001 100,000
class.mean.diff[3,5] 0.1763 0.6482 0.005658 –1.104 0.1775 1.444 50,001 100,000
class.mean.diff[3,6] –5.368 1.564 0.02109 –8.483 –5.36 –2.357 50,001 100,000
class.mean.diff[3,7] –2.425 1.253 0.02014 –4.891 –2.417 0.03083 50,001 100,000
class.mean.diff[3,8] 3.229 2.214 0.02709 –1.126 3.233 7.557 50,001 100,000
class.mean.diff[3,9] –7.339 1.948 0.02407 –11.16 –7.34 –3.519 50,001 100,000
class.mean.diff[3,10] 2.407 1.569 0.02221 –0.7641 2.435 5.452 50,001 100,000
class.mean.diff[4,5] –0.6984 1.605 0.01404 –3.883 –0.6939 2.453 50,001 100,000
class.mean.diff[4,6] –6.242 2.159 0.02455 –10.57 –6.21 –2.064 50,001 100,000
class.mean.diff[4,7] –3.3 1.947 0.0237 –7.165 –3.296 0.5222 50,001 100,000
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TABLE 108 Class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[4,8] 2.354 2.654 0.03049 –2.853 2.366 7.492 50,001 100,000
class.mean.diff[4,9] –8.214 2.448 0.02614 –13.03 –8.188 –3.395 50,001 100,000
class.mean.diff[4,10] 1.532 2.161 0.02547 –2.839 1.562 5.704 50,001 100,000
class.mean.diff[5,6] –5.544 1.569 0.02063 –8.669 –5.542 –2.494 50,001 100,000
class.mean.diff[5,7] –2.602 1.326 0.02093 –5.179 –2.603 0.01789 50,001 100,000
class.mean.diff[5,8] 3.053 2.244 0.0267 –1.368 3.063 7.418 50,001 100,000
class.mean.diff[5,9] –7.516 1.923 0.02344 –11.28 –7.513 –3.713 50,001 100,000
class.mean.diff[5,10] 2.231 1.604 0.02237 –0.9882 2.245 5.346 50,001 100,000
class.mean.diff[6,7] 2.942 1.563 0.01848 –0.05385 2.929 6.044 50,001 100,000
class.mean.diff[6,8] 8.597 2.65 0.03238 3.396 8.619 13.8 50,001 100,000
class.mean.diff[6,9] –1.971 2.152 0.02598 –6.188 –1.968 2.292 50,001 100,000
class.mean.diff[6,10] 7.775 1.342 0.01406 5.142 7.772 10.43 50,001 100,000
class.mean.diff[7,8] 5.655 2.499 0.03332 0.7631 5.664 10.58 50,001 100,000
class.mean.diff[7,9] –4.914 2.18 0.02919 –9.214 –4.906 –0.6075 50,001 100,000
class.mean.diff[7,10] 4.832 1.278 0.01355 2.256 4.847 7.284 50,001 100,000
class.mean.diff[8,9] –10.57 2.89 0.03667 –16.23 –10.58 –4.859 50,001 100,000
class.mean.diff[8,10] –0.8223 2.675 0.0347 –6.086 –0.8262 4.44 50,001 100,000
class.mean.diff[9,10] 9.746 2.279 0.02926 5.261 9.76 14.22 50,001 100,000
TABLE 109 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[1,2] 2.063 1.806 0.03318 –1.509 2.067 5.611 50,001 100,000
treat.mean.diff[1,3] –3.374 0.4854 0.007081 –4.367 –3.369 –2.426 50,001 100,000
treat.mean.diff[1,4] –3.44 0.4873 0.007192 –4.479 –3.422 –2.535 50,001 100,000
treat.mean.diff[1,5] –3.038 0.4909 0.007551 –3.924 –3.067 –1.993 50,001 100,000
treat.mean.diff[1,6] –3.486 0.5394 0.007976 –4.662 –3.455 –2.499 50,001 100,000
treat.mean.diff[1,7] –3.366 0.5748 0.006907 –4.579 –3.357 –2.24 50,001 100,000
treat.mean.diff[1,8] –2.458 1.533 0.01317 –5.492 –2.461 0.5665 50,001 100,000
treat.mean.diff[1,9] –3.156 0.6228 0.008235 –4.392 –3.151 –1.95 50,001 100,000
treat.mean.diff[1,10] –8.7 1.541 0.02275 –11.78 –8.686 –5.747 50,001 100,000
treat.mean.diff[1,11] –5.758 1.254 0.02213 –8.232 –5.744 –3.314 50,001 100,000
treat.mean.diff[1,12] –0.103 2.164 0.02634 –4.344 –0.1013 4.112 50,001 100,000
treat.mean.diff[1,13] –10.67 1.916 0.02438 –14.42 –10.68 –6.9 50,001 100,000
treat.mean.diff[1,14] –3.289 0.583 0.007209 –4.447 –3.3 –2.07 50,001 100,000
treat.mean.diff[1,15] –0.9254 1.563 0.02449 –4.097 –0.8947 2.087 50,001 100,000
treat.mean.diff[2,3] –5.437 1.783 0.03076 –8.956 –5.432 –1.929 50,001 100,000
treat.mean.diff[2,4] –5.503 1.822 0.03167 –9.106 –5.493 –1.918 50,001 100,000
treat.mean.diff[2,5] –5.101 1.841 0.03199 –8.726 –5.093 –1.483 50,001 100,000
treat.mean.diff[2,6] –5.549 1.804 0.03141 –9.099 –5.545 –2 50,001 100,000
treat.mean.diff[2,7] –5.429 1.854 0.03184 –9.071 –5.426 –1.759 50,001 100,000
treat.mean.diff[2,8] –4.52 2.351 0.03469 –9.157 –4.511 0.08525 50,001 100,000
treat.mean.diff[2,9] –5.219 1.856 0.0317 –8.904 –5.21 –1.566 50,001 100,000
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TABLE 109 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[2,10] –10.76 2.04 0.0285 –14.87 –10.74 –6.858 50,001 100,000
treat.mean.diff[2,11] –7.821 1.32 0.01947 –10.41 –7.816 –5.23 50,001 100,000
treat.mean.diff[2,12] –2.166 2.825 0.04148 –7.694 –2.138 3.396 50,001 100,000
treat.mean.diff[2,13] –12.73 2.55 0.03768 –17.77 –12.72 –7.707 50,001 100,000
treat.mean.diff[2,14] –5.352 1.854 0.0316 –8.987 –5.35 –1.699 50,001 100,000
treat.mean.diff[2,15] –2.988 1.838 0.02496 –6.636 –2.964 0.5565 50,001 100,000
treat.mean.diff[3,4] –0.06626 0.535 0.004969 –1.276 –0.02218 1.039 50,001 100,000
treat.mean.diff[3,5] 0.3363 0.5731 0.006438 –0.5877 0.1992 1.711 50,001 100,000
treat.mean.diff[3,6] –0.1113 0.5238 0.004289 –1.318 –0.04389 0.9157 50,001 100,000
treat.mean.diff[3,7] 0.007895 0.6048 0.004594 –1.315 0.001216 1.316 50,001 100,000
treat.mean.diff[3,8] 0.9167 1.561 0.01295 –2.149 0.9082 3.996 50,001 100,000
treat.mean.diff[3,9] 0.2183 0.682 0.006852 –1.122 0.2135 1.565 50,001 100,000
treat.mean.diff[3,10] –5.326 1.561 0.02122 –8.441 –5.316 –2.31 50,001 100,000
treat.mean.diff[3,11] –2.383 1.218 0.01932 –4.777 –2.374 0.0129 50,001 100,000
treat.mean.diff[3,12] 3.271 2.216 0.02696 –1.086 3.276 7.605 50,001 100,000
treat.mean.diff[3,13] –7.297 1.954 0.02443 –11.13 –7.303 –3.467 50,001 100,000
treat.mean.diff[3,14] 0.08549 0.6104 0.004855 –1.127 0.02296 1.507 50,001 100,000
treat.mean.diff[3,15] 2.449 1.553 0.02204 –0.6869 2.479 5.475 50,001 100,000
treat.mean.diff[4,5] 0.4026 0.5837 0.006677 –0.4634 0.2551 1.823 50,001 100,000
treat.mean.diff[4,6] –0.04508 0.5522 0.004903 –1.264 –0.01395 1.109 50,001 100,000
treat.mean.diff[4,7] 0.07415 0.6022 0.004913 –1.168 0.02271 1.449 50,001 100,000
treat.mean.diff[4,8] 0.9829 1.567 0.01313 –2.052 0.9648 4.119 50,001 100,000
treat.mean.diff[4,9] 0.2846 0.632 0.006125 –0.9381 0.274 1.548 50,001 100,000
treat.mean.diff[4,10] –5.26 1.56 0.02093 –8.352 –5.257 –2.247 50,001 100,000
treat.mean.diff[4,11] –2.317 1.273 0.02044 –4.816 –2.322 0.2033 50,001 100,000
treat.mean.diff[4,12] 3.337 2.225 0.02755 –1.029 3.333 7.673 50,001 100,000
treat.mean.diff[4,13] –7.231 1.944 0.02369 –11.05 –7.235 –3.392 50,001 100,000
treat.mean.diff[4,14] 0.1518 0.6232 0.005332 –1.029 0.05458 1.642 50,001 100,000
treat.mean.diff[4,15] 2.515 1.571 0.02206 –0.6391 2.533 5.588 50,001 100,000
treat.mean.diff[5,6] –0.4477 0.638 0.007698 –2.005 –0.2799 0.4829 50,001 100,000
treat.mean.diff[5,7] –0.3284 0.632 0.006024 –1.869 –0.1792 0.7137 50,001 100,000
treat.mean.diff[5,8] 0.5804 1.459 0.0117 –2.292 0.5793 3.454 50,001 100,000
treat.mean.diff[5,9] –0.118 0.67 0.006758 –1.489 –0.101 1.153 50,001 100,000
treat.mean.diff[5,10] –5.662 1.586 0.02154 –8.832 –5.647 –2.628 50,001 100,000
treat.mean.diff[5,11] –2.72 1.301 0.02126 –5.327 –2.709 –0.195 50,001 100,000
treat.mean.diff[5,12] 2.935 2.222 0.02774 –1.443 2.948 7.263 50,001 100,000
treat.mean.diff[5,13] –7.634 1.961 0.02443 –11.48 –7.632 –3.774 50,001 100,000
treat.mean.diff[5,14] –0.2508 0.5732 0.004741 –1.606 –0.1365 0.7843 50,001 100,000
treat.mean.diff[5,15] 2.113 1.601 0.02298 –1.129 2.149 5.188 50,001 100,000
treat.mean.diff[6,7] 0.1192 0.6287 0.005016 –1.128 0.04269 1.588 50,001 100,000
treat.mean.diff[6,8] 1.028 1.588 0.01362 –2.061 1.012 4.194 50,001 100,000
treat.mean.diff[6,9] 0.3296 0.6914 0.006814 –1.012 0.3196 1.732 50,001 100,000
treat.mean.diff[6,10] –5.214 1.573 0.02119 –8.353 –5.202 –2.172 50,001 100,000
treat.mean.diff[6,11] –2.272 1.245 0.01989 –4.715 –2.262 0.1749 50,001 100,000
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
282
TABLE 109 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[6,12] 3.383 2.232 0.02709 –0.9925 3.391 7.727 50,001 100,000
treat.mean.diff[6,13] –7.186 1.961 0.02443 –11.03 –7.189 –3.335 50,001 100,000
treat.mean.diff[6,14] 0.1968 0.6542 0.005736 –0.9927 0.07337 1.795 50,001 100,000
treat.mean.diff[6,15] 2.56 1.568 0.02219 –0.6208 2.576 5.595 50,001 100,000
treat.mean.diff[7,8] 0.9088 1.587 0.01318 –2.186 0.898 4.079 50,001 100,000
treat.mean.diff[7,9] 0.2104 0.7561 0.006955 –1.273 0.2016 1.732 50,001 100,000
treat.mean.diff[7,10] –5.334 1.615 0.02169 –8.531 –5.319 –2.209 50,001 100,000
treat.mean.diff[7,11] –2.391 1.321 0.02061 –4.996 –2.384 0.1972 50,001 100,000
treat.mean.diff[7,12] 3.263 2.24 0.02707 –1.131 3.268 7.622 50,001 100,000
treat.mean.diff[7,13] –7.305 1.986 0.02454 –11.2 –7.309 –3.41 50,001 100,000
treat.mean.diff[7,14] 0.0776 0.6677 0.004748 –1.278 0.01998 1.616 50,001 100,000
treat.mean.diff[7,15] 2.441 1.624 0.02278 –0.8331 2.466 5.593 50,001 100,000
treat.mean.diff[8,9] –0.6984 1.605 0.01404 –3.883 –0.6939 2.453 50,001 100,000
treat.mean.diff[8,10] –6.242 2.159 0.02455 –10.57 –6.21 –2.064 50,001 100,000
treat.mean.diff[8,11] –3.3 1.947 0.0237 –7.165 –3.296 0.5222 50,001 100,000
treat.mean.diff[8,12] 2.354 2.654 0.03049 –2.853 2.366 7.492 50,001 100,000
treat.mean.diff[8,13] –8.214 2.448 0.02614 –13.03 –8.188 –3.395 50,001 100,000
treat.mean.diff[8,14] –0.8312 1.566 0.01265 –3.945 –0.8274 2.228 50,001 100,000
treat.mean.diff[8,15] 1.532 2.161 0.02547 –2.839 1.562 5.704 50,001 100,000
treat.mean.diff[9,10] –5.544 1.569 0.02063 –8.669 –5.542 –2.494 50,001 100,000
treat.mean.diff[9,11] –2.602 1.326 0.02093 –5.179 –2.603 0.01789 50,001 100,000
treat.mean.diff[9,12] 3.053 2.244 0.0267 –1.368 3.063 7.418 50,001 100,000
treat.mean.diff[9,13] –7.516 1.923 0.02344 –11.28 –7.513 –3.713 50,001 100,000
treat.mean.diff[9,14] –0.1328 0.7567 0.006481 –1.614 –0.1446 1.413 50,001 100,000
treat.mean.diff[9,15] 2.231 1.604 0.02237 –0.9882 2.245 5.346 50,001 100,000
treat.mean.diff[10,11] 2.942 1.563 0.01848 –0.05385 2.929 6.044 50,001 100,000
treat.mean.diff[10,12] 8.597 2.65 0.03238 3.396 8.619 13.8 50,001 100,000
treat.mean.diff[10,13] –1.971 2.152 0.02598 –6.188 –1.968 2.292 50,001 100,000
treat.mean.diff[10,14] 5.411 1.614 0.02145 2.293 5.403 8.617 50,001 100,000
treat.mean.diff[10,15] 7.775 1.342 0.01406 5.142 7.772 10.43 50,001 100,000
treat.mean.diff[11,12] 5.655 2.499 0.03332 0.7631 5.664 10.58 50,001 100,000
treat.mean.diff[11,13] –4.914 2.18 0.02919 –9.214 –4.906 –0.6075 50,001 100,000
treat.mean.diff[11,14] 2.469 1.322 0.02055 –0.08331 2.457 5.096 50,001 100,000
treat.mean.diff[11,15] 4.832 1.278 0.01355 2.256 4.847 7.284 50,001 100,000
treat.mean.diff[12,13] –10.57 2.89 0.03667 –16.23 –10.58 –4.859 50,001 100,000
treat.mean.diff[12,14] –3.186 2.244 0.02729 –7.572 –3.188 1.22 50,001 100,000
treat.mean.diff[12,15] –0.8223 2.675 0.0347 –6.086 –0.8262 4.44 50,001 100,000
treat.mean.diff[13,14] 7.383 1.987 0.02431 3.48 7.389 11.3 50,001 100,000
treat.mean.diff[13,15] 9.746 2.279 0.02926 5.261 9.76 14.22 50,001 100,000
treat.mean.diff[14,15] 2.363 1.623 0.02262 –0.9254 2.397 5.517 50,001 100,000
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Median ranks
TABLE 110 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 8.313 0.814 0.01061 7 8 10 50,001 100,000
rk.class[2] 9.576 0.7913 0.01062 7 10 10 50,001 100,000
rk.class[3] 4.78 0.8116 0.006447 4 5 6 50,001 100,000
rk.class[4] 5.846 1.456 0.01269 3 6 9 50,001 100,000
rk.class[5] 5.085 0.9136 0.007409 4 5 7 50,001 100,000
rk.class[6] 1.853 0.4327 0.003828 1 2 3 50,001 100,000
rk.class[7] 3.069 0.4784 0.004582 2 3 4 50,001 100,000
rk.class[8] 7.963 1.677 0.01967 4 8 10 50,001 100,000
rk.class[9] 1.191 0.4275 0.004097 1 1 2 50,001 100,000
rk.class[10] 7.323 1.297 0.01672 4 7 9 50,001 100,000
TABLE 111 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 13.31 0.814 0.0106 12 13 15 50,001 100,000
rk[2] 14.57 0.8591 0.01129 12 15 15 50,001 100,000
rk[3] 7.109 2.014 0.01435 4 7 11 50,001 100,000
rk[4] 6.782 1.983 0.01532 4 7 11 50,001 100,000
rk[5] 8.675 1.881 0.01767 5 9 12 50,001 100,000
rk[6] 6.617 2.041 0.01592 4 6 11 50,001 100,000
rk[7] 7.154 2.19 0.01599 4 7 11 50,001 100,000
rk[8] 9.42 3.3 0.02823 3 11 14 50,001 100,000
rk[9] 8.087 2.534 0.0223 4 9 12 50,001 100,000
rk[10] 1.856 0.4524 0.003938 1 2 3 50,001 100,000
rk[11] 3.219 1.074 0.01102 2 3 7 50,001 100,000
rk[12] 12.59 2.633 0.02894 4 13 15 50,001 100,000
rk[13] 1.192 0.4339 0.00412 1 1 2 50,001 100,000
rk[14] 7.441 2.19 0.01384 4 7 11 50,001 100,000
rk[15] 11.98 2.151 0.02675 4 12 14 50,001 100,000
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Adults: clinical effectiveness (Yale–Brown Obsessive–Compulsive Scale) – sensitivity analysis 3 (blinding)
See Table 23 for a summary.
TABLE 112 Raw data used
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Albert et al., 2002155 18.36 25 7.11 17.3 40 6.15 NA NA NA NA NA NA 2 2 8 9 NA NA
Andersson et al., 2012158 12.94 49 6.26 18.88 51 4.18 NA NA NA NA NA NA 2 2 11 15 NA NA
Belloch et al., 2008159 8.31 13 8.75 6.8 16 3.55 NA NA NA NA NA NA 2 2 10 12 NA NA
Belotto-Silva et al., 2012160 20.29 88 8.05 19.97 70 8.48 NA NA NA NA NA NA 2 2 3 11 NA NA
Cordioli et al., 2003164 23.2 24 5.5 15.1 23 7.8 NA NA NA NA NA NA 2 2 2 11 NA NA
Cottraux et al., 2001166 –12.1 30 7.8 –12.5 30 8.2 NA NA NA NA NA NA 2 1 10 12 NA NA
Denys et al., 2003167 –7.8 72 5.4 –7.2 73 7.5 NA NA NA NA NA NA 2 1 5 8 NA NA
Foa et al., 2005171 22.2 26 6.4 18.2 36 7.8 11 29 7.9 10.5 31 8.2 4 2 1 9 10 13
Goodman et al., 1989176 28 21 7 19.4 21 7 NA NA NA NA NA NA 2 2 1 4 NA NA
Jenike et al., 1990184 21.8 20 7.6 18.8 18 4 NA NA NA NA NA NA 2 2 1 4 NA NA
Mundo et al., 1997199 16.2 10 8.9 21.6 9 7.6 19.8 11 10.1 NA NA NA 3 2 4 5 7 NA
Nakatani et al., 2005202 20.2 10 9.4 12.9 10 4.9 28.4 8 5.5 NA NA NA 3 2 4 10 15 NA
O’Connor et al., 1999203 17.5 6 4 13.3 6 8.6 NA NA NA NA NA NA 2 2 2 11 NA NA
O’Connor et al., 2006204 25.4 10 3.5 24 11 4.7 NA NA NA NA NA NA 2 2 1 4 NA NA
Sousa et al., 2006207 –7.36 25 NA –10.8 25 NA NA NA NA NA NA NA 2 1 6 11 NA NA
Stein et al., 2007124 –8.46 113 8.08 –11.67 116 8.40 –11.43 112 8.25 –12.14 114 8.22 4 1 1 5 14 14
Whittal et al., 2005211 10.41 29 7.6 10.6 30 7.1 NA NA NA NA NA NA 2 2 10 12 NA NA
NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine,
9= clomipramine, 10= BT, 11=CBT, 12=CT, 13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo; t[i,2], type of treatment
[i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4]; y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline
(negative) for arm [1]; y[i,2], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean YBOCS scores at end of study
(positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total
number of patients for arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of patients for arm [4]; sd[i,1], SD of mean total
score or change from baseline for arm [1]; sd[i,2], SD of mean total score or change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3];
sd[i,4], SD of mean total score or change from baseline for arm [4].
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Key
1. Placebo (1).
2. Waitlist (2).
3. Fluoxetine (3).
4. Fluvoxamine (3).
5. Paroxetine (3).
6. Sertraline (3).
7. Citalopram (3).
8. Venlafaxine (4).
9. Clomipramine (5).
10. BT (6).
11. CBT (7).
12. CT (8).
13. BT+ clomipramine (9).
14. Escitalopram (3).
15. Psychological placebo (10).
TABLE 113 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[1,2] 3.235 2.714 0.06924 –2.16 3.238 8.44 50,001 100,000
class.mean.diff[1,3] –3.305 1.234 0.02794 –5.59 –3.349 –0.6521 50,001 100,000
class.mean.diff[1,4] –2.728 1.632 0.0314 –5.968 –2.7 0.4702 50,001 100,000
class.mean.diff[1,5] –4.046 1.674 0.03403 –7.303 –4.023 –0.73 50,001 100,000
class.mean.diff[1,6] –11.79 1.762 0.04753 –15.17 –11.81 –8.279 50,001 100,000
class.mean.diff[1,7] –4.112 1.842 0.04886 –7.631 –4.125 –0.3389 50,001 100,000
class.mean.diff[1,8] –12.23 2.231 0.05662 –16.66 –12.24 –7.796 50,001 100,000
class.mean.diff[1,9] –11.85 2.064 0.03817 –16.07 –11.85 –7.821 50,001 100,000
class.mean.diff[1,10] 2.328 1.991 0.0483 –1.486 2.28 6.364 50,001 100,000
class.mean.diff[2,3] –6.539 2.542 0.05609 –11.41 –6.547 –1.448 50,001 100,000
class.mean.diff[2,4] –5.963 2.911 0.06212 –11.5 –5.948 –0.1066 50,001 100,000
class.mean.diff[2,5] –7.28 2.983 0.06417 –12.95 –7.338 –1.344 50,001 100,000
class.mean.diff[2,6] –15.02 2.918 0.06588 –20.59 –15.07 –9.151 50,001 100,000
class.mean.diff[2,7] –7.347 1.969 0.04063 –11.07 –7.404 –3.352 50,001 100,000
class.mean.diff[2,8] –15.47 3.237 0.07454 –21.74 –15.48 –9.029 50,001 100,000
class.mean.diff[2,9] –15.09 3.247 0.06687 –21.38 –15.13 –8.626 50,001 100,000
class.mean.diff[2,10] –0.9071 2.429 0.04743 –5.577 –0.9553 4.094 50,001 100,000
class.mean.diff[3,4] 0.5765 1.669 0.02399 –2.802 0.5924 3.827 50,001 100,000
class.mean.diff[3,5] –0.7409 1.845 0.03034 –4.413 –0.7264 2.846 50,001 100,000
class.mean.diff[3,6] –8.486 1.902 0.04269 –12.2 –8.487 –4.694 50,001 100,000
class.mean.diff[3,7] –0.8074 1.611 0.03221 –3.942 –0.8267 2.399 50,001 100,000
class.mean.diff[3,8] –8.929 2.349 0.05339 –13.58 –8.912 –4.286 50,001 100,000
class.mean.diff[3,9] –8.55 2.272 0.03812 –13.14 –8.521 –4.061 50,001 100,000
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TABLE 113 Class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[3,10] 5.632 1.883 0.03501 1.957 5.593 9.45 50,001 100,000
class.mean.diff[4,5] –1.317 1.645 0.02532 –4.541 –1.319 1.944 50,001 100,000
class.mean.diff[4,6] –9.062 2.129 0.04457 –13.15 –9.064 –4.827 50,001 100,000
class.mean.diff[4,7] –1.384 2.151 0.03957 –5.588 –1.387 2.924 50,001 100,000
class.mean.diff[4,8] –9.506 2.52 0.0536 –14.52 –9.486 –4.519 50,001 100,000
class.mean.diff[4,9] –9.126 2.363 0.03643 –13.85 –9.098 –4.476 50,001 100,000
class.mean.diff[4,10] 5.056 2.304 0.0404 0.6046 5.021 9.779 50,001 100,000
class.mean.diff[5,6] –7.745 1.937 0.03849 –11.47 –7.768 –3.863 50,001 100,000
class.mean.diff[5,7] –0.06652 2.247 0.04401 –4.412 –0.07668 4.391 50,001 100,000
class.mean.diff[5,8] –8.188 2.369 0.04925 –12.86 –8.214 –3.489 50,001 100,000
class.mean.diff[5,9] –7.809 2.119 0.03235 –12.02 –7.798 –3.656 50,001 100,000
class.mean.diff[5,10] 6.373 2.334 0.04407 1.879 6.35 11.12 50,001 100,000
class.mean.diff[6,7] 7.678 2.142 0.04823 3.483 7.676 11.91 50,001 100,000
class.mean.diff[6,8] –0.4437 1.39 0.02557 –3.137 –0.472 2.314 50,001 100,000
class.mean.diff[6,9] –0.0644 2.231 0.04198 –4.457 –0.09329 4.256 50,001 100,000
class.mean.diff[6,10] 14.12 2.108 0.04427 10.07 14.1 18.22 50,001 100,000
class.mean.diff[7,8] –8.122 2.542 0.05765 –13.14 –8.119 –3.13 50,001 100,000
class.mean.diff[7,9] –7.743 2.583 0.04772 –12.93 –7.699 –2.677 50,001 100,000
class.mean.diff[7,10] 6.44 1.4 0.01987 3.792 6.404 9.349 50,001 100,000
class.mean.diff[8,9] 0.3793 2.612 0.05047 –4.818 0.3555 5.518 50,001 100,000
class.mean.diff[8,10] 14.56 2.518 0.05403 9.674 14.52 19.51 50,001 100,000
class.mean.diff[9,10] 14.18 2.643 0.04615 9.044 14.14 19.53 50,001 100,000
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TABLE 114 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[1,2] 3.235 2.714 0.06924 –2.16 3.238 8.44 50,001 100,000
treat.mean.diff[1,3] –3.416 1.611 0.03769 –6.618 –3.456 0.06601 50,001 100,000
treat.mean.diff[1,4] –3.849 1.018 0.02311 –5.988 –3.813 –1.948 50,001 100,000
treat.mean.diff[1,5] –3.203 1.103 0.02543 –5.291 –3.238 –0.8988 50,001 100,000
treat.mean.diff[1,6] –2.713 1.897 0.04831 –5.647 –3.041 2.035 50,001 100,000
treat.mean.diff[1,7] –3.272 1.64 0.03575 –6.501 –3.333 0.4173 50,001 100,000
treat.mean.diff[1,8] –2.728 1.632 0.0314 –5.968 –2.7 0.4702 50,001 100,000
treat.mean.diff[1,9] –4.046 1.674 0.03403 –7.303 –4.023 –0.73 50,001 100,000
treat.mean.diff[1,10] –11.79 1.762 0.04753 –15.17 –11.81 –8.279 50,001 100,000
treat.mean.diff[1,11] –4.112 1.842 0.04886 –7.631 –4.125 –0.3389 50,001 100,000
treat.mean.diff[1,12] –12.23 2.231 0.05662 –16.66 –12.24 –7.796 50,001 100,000
treat.mean.diff[1,13] –11.85 2.064 0.03817 –16.07 –11.85 –7.821 50,001 100,000
treat.mean.diff[1,14] –3.356 1.058 0.02341 –5.376 –3.374 –1.212 50,001 100,000
treat.mean.diff[1,15] 2.328 1.991 0.0483 –1.486 2.28 6.364 50,001 100,000
treat.mean.diff[2,3] –6.65 2.408 0.05065 –11.19 –6.696 –1.818 50,001 100,000
treat.mean.diff[2,4] –7.084 2.684 0.06565 –12.27 –7.059 –1.813 50,001 100,000
treat.mean.diff[2,5] –6.437 2.643 0.06003 –11.49 –6.466 –1.121 50,001 100,000
treat.mean.diff[2,6] –5.948 2.585 0.05411 –10.79 –5.974 –0.701 50,001 100,000
treat.mean.diff[2,7] –6.507 2.826 0.06123 –11.91 –6.538 –0.7908 50,001 100,000
treat.mean.diff[2,8] –5.963 2.911 0.06212 –11.5 –5.948 –0.1066 50,001 100,000
treat.mean.diff[2,9] –7.28 2.983 0.06417 –12.95 –7.338 –1.344 50,001 100,000
treat.mean.diff[2,10] –15.02 2.918 0.06588 –20.59 –15.07 –9.151 50,001 100,000
treat.mean.diff[2,11] –7.347 1.969 0.04063 –11.07 –7.404 –3.352 50,001 100,000
treat.mean.diff[2,12] –15.47 3.237 0.07454 –21.74 –15.48 –9.029 50,001 100,000
treat.mean.diff[2,13] –15.09 3.247 0.06687 –21.38 –15.13 –8.626 50,001 100,000
treat.mean.diff[2,14] –6.591 2.672 0.0623 –11.7 –6.581 –1.299 50,001 100,000
treat.mean.diff[2,15] –0.9071 2.429 0.04743 –5.577 –0.9553 4.094 50,001 100,000
treat.mean.diff[3,4] –0.4335 1.539 0.03259 –4.176 –0.1464 2.393 50,001 100,000
treat.mean.diff[3,5] 0.213 1.507 0.02551 –2.921 0.07384 3.508 50,001 100,000
treat.mean.diff[3,6] 0.7025 1.613 0.02607 –1.828 0.274 4.886 50,001 100,000
treat.mean.diff[3,7] 0.1434 1.802 0.02922 –3.65 0.03283 4.281 50,001 100,000
treat.mean.diff[3,8] 0.6875 1.981 0.032 –3.29 0.6776 4.713 50,001 100,000
treat.mean.diff[3,9] –0.6299 2.107 0.03662 –4.804 –0.6254 3.512 50,001 100,000
treat.mean.diff[3,10] –8.375 2.085 0.04425 –12.47 –8.381 –4.207 50,001 100,000
treat.mean.diff[3,11] –0.6964 1.413 0.025 –3.48 –0.6962 2.101 50,001 100,000
treat.mean.diff[3,12] –8.818 2.498 0.05483 –13.73 –8.806 –3.848 50,001 100,000
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TABLE 114 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[3,13] –8.439 2.477 0.04285 –13.47 –8.4 –3.502 50,001 100,000
treat.mean.diff[3,14] 0.05968 1.528 0.0269 –3.238 0.01872 3.303 50,001 100,000
treat.mean.diff[3,15] 5.743 1.812 0.02962 2.273 5.698 9.405 50,001 100,000
treat.mean.diff[4,5] 0.6465 1.14 0.02204 –1.226 0.3928 3.394 50,001 100,000
treat.mean.diff[4,6] 1.136 1.944 0.04714 –1.374 0.5156 6.365 50,001 100,000
treat.mean.diff[4,7] 0.5769 1.558 0.03087 –2.189 0.24 4.473 50,001 100,000
treat.mean.diff[4,8] 1.121 1.692 0.02782 –2.14 1.081 4.632 50,001 100,000
treat.mean.diff[4,9] –0.1964 1.813 0.03407 –3.689 –0.2383 3.494 50,001 100,000
treat.mean.diff[4,10] –7.941 1.858 0.04794 –11.5 –7.995 –4.206 50,001 100,000
treat.mean.diff[4,11] –0.2629 1.804 0.04362 –3.538 –0.3853 3.639 50,001 100,000
treat.mean.diff[4,12] –8.385 2.298 0.05613 –12.94 –8.403 –3.759 50,001 100,000
treat.mean.diff[4,13] –8.005 2.195 0.0387 –12.36 –7.983 –3.628 50,001 100,000
treat.mean.diff[4,14] 0.4932 1.107 0.02017 –1.358 0.2504 3.153 50,001 100,000
treat.mean.diff[4,15] 6.177 1.97 0.04435 2.515 6.081 10.36 50,001 100,000
treat.mean.diff[5,6] 0.4895 1.708 0.03427 –2.301 0.1156 5.021 50,001 100,000
treat.mean.diff[5,7] –0.06957 1.463 0.02327 –3.284 –0.02529 3.131 50,001 100,000
treat.mean.diff[5,8] 0.4744 1.39 0.01956 –2.333 0.4868 3.177 50,001 100,000
treat.mean.diff[5,9] –0.8429 1.7 0.02827 –4.188 –0.834 2.518 50,001 100,000
treat.mean.diff[5,10] –8.588 1.872 0.04338 –12.34 –8.598 –4.862 50,001 100,000
treat.mean.diff[5,11] –0.9094 1.761 0.0377 –4.336 –0.9386 2.646 50,001 100,000
treat.mean.diff[5,12] –9.031 2.325 0.05383 –13.77 –9.029 –4.414 50,001 100,000
treat.mean.diff[5,13] –8.652 2.21 0.03778 –13.1 –8.625 –4.289 50,001 100,000
treat.mean.diff[5,14] –0.1533 0.8776 0.01126 –2.036 –0.06866 1.617 50,001 100,000
treat.mean.diff[5,15] 5.53 1.963 0.03868 1.663 5.47 9.495 50,001 100,000
treat.mean.diff[6,7] –0.559 1.947 0.03412 –5.537 –0.1474 2.741 50,001 100,000
treat.mean.diff[6,8] –0.01503 2.163 0.04166 –4.997 0.178 3.768 50,001 100,000
treat.mean.diff[6,9] –1.332 2.291 0.04468 –6.485 –1.177 2.757 50,001 100,000
treat.mean.diff[6,10] –9.077 2.281 0.05002 –13.99 –8.955 –4.8 50,001 100,000
treat.mean.diff[6,11] –1.399 1.721 0.03463 –5.105 –1.283 1.726 50,001 100,000
treat.mean.diff[6,12] –9.521 2.677 0.0606 –15.06 –9.402 –4.468 50,001 100,000
treat.mean.diff[6,13] –9.141 2.662 0.05178 –14.85 –9.002 –4.184 50,001 100,000
treat.mean.diff[6,14] –0.6428 1.768 0.03724 –5.344 –0.2007 2.104 50,001 100,000
treat.mean.diff[6,15] 5.041 2.089 0.03947 0.7185 5.109 8.958 50,001 100,000
treat.mean.diff[7,8] 0.544 1.983 0.03284 –3.508 0.5492 4.486 50,001 100,000
treat.mean.diff[7,9] –0.7733 2.131 0.03768 –5.113 –0.7453 3.389 50,001 100,000
treat.mean.diff[7,10] –8.518 2.207 0.05009 –12.94 –8.523 –4.154 50,001 100,000
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TABLE 114 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[7,11] –0.8399 2.024 0.0397 –4.941 –0.8563 3.252 50,001 100,000
treat.mean.diff[7,12] –8.962 2.606 0.05965 –14.2 –8.937 –3.861 50,001 100,000
treat.mean.diff[7,13] –8.582 2.506 0.04391 –13.64 –8.573 –3.58 50,001 100,000
treat.mean.diff[7,14] –0.08376 1.496 0.02316 –3.474 –0.01512 3.063 50,001 100,000
treat.mean.diff[7,15] 5.6 2.232 0.04279 1.03 5.56 10.09 50,001 100,000
treat.mean.diff[8,9] –1.317 1.645 0.02532 –4.541 –1.319 1.944 50,001 100,000
treat.mean.diff[8,10] –9.062 2.129 0.04457 –13.15 –9.064 –4.827 50,001 100,000
treat.mean.diff[8,11] –1.384 2.151 0.03957 –5.588 –1.387 2.924 50,001 100,000
treat.mean.diff[8,12] –9.506 2.52 0.0536 –14.52 –9.486 –4.519 50,001 100,000
treat.mean.diff[8,13] –9.126 2.363 0.03643 –13.85 –9.098 –4.476 50,001 100,000
treat.mean.diff[8,14] –0.6278 1.588 0.0237 –3.819 –0.6289 2.551 50,001 100,000
treat.mean.diff[8,15] 5.056 2.304 0.0404 0.6046 5.021 9.779 50,001 100,000
treat.mean.diff[9,10] –7.745 1.937 0.03849 –11.47 –7.768 –3.863 50,001 100,000
treat.mean.diff[9,11] –0.06652 2.247 0.04401 –4.412 –0.07668 4.391 50,001 100,000
treat.mean.diff[9,12] –8.188 2.369 0.04925 –12.86 –8.214 –3.489 50,001 100,000
treat.mean.diff[9,13] –7.809 2.119 0.03235 –12.02 –7.798 –3.656 50,001 100,000
treat.mean.diff[9,14] 0.6896 1.772 0.02976 –2.805 0.6723 4.18 50,001 100,000
treat.mean.diff[9,15] 6.373 2.334 0.04407 1.879 6.35 11.12 50,001 100,000
treat.mean.diff[10,11] 7.678 2.142 0.04823 3.483 7.676 11.91 50,001 100,000
treat.mean.diff[10,12] –0.4437 1.39 0.02557 –3.137 –0.472 2.314 50,001 100,000
treat.mean.diff[10,13] –0.0644 2.231 0.04198 –4.457 –0.09329 4.256 50,001 100,000
treat.mean.diff[10,14] 8.434 1.879 0.04381 4.725 8.445 12.12 50,001 100,000
treat.mean.diff[10,15] 14.12 2.108 0.04427 10.07 14.1 18.22 50,001 100,000
treat.mean.diff[11,12] –8.122 2.542 0.05765 –13.14 –8.119 –3.13 50,001 100,000
treat.mean.diff[11,13] –7.743 2.583 0.04772 –12.93 –7.699 –2.677 50,001 100,000
treat.mean.diff[11,14] 0.7561 1.794 0.04019 –2.931 0.7941 4.193 50,001 100,000
treat.mean.diff[11,15] 6.44 1.4 0.01987 3.792 6.404 9.349 50,001 100,000
treat.mean.diff[12,13] 0.3793 2.612 0.05047 –4.818 0.3555 5.518 50,001 100,000
treat.mean.diff[12,14] 8.878 2.324 0.05373 4.27 8.853 13.55 50,001 100,000
treat.mean.diff[12,15] 14.56 2.518 0.05403 9.674 14.52 19.51 50,001 100,000
treat.mean.diff[13,14] 8.499 2.213 0.03778 4.126 8.485 12.94 50,001 100,000
treat.mean.diff[13,15] 14.18 2.643 0.04615 9.044 14.14 19.53 50,001 100,000
treat.mean.diff[14,15] 5.684 1.997 0.04124 1.801 5.616 9.757 50,001 100,000
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Median ranks
TABLE 115 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 8.137 0.6112 0.01187 7 8 10 50,001 100,000
rk.class[2] 9.508 0.7976 0.01363 8 10 10 50,001 100,000
rk.class[3] 5.739 0.9598 0.01586 4 6 7 50,001 100,000
rk.class[4] 6.292 1.061 0.01519 4 7 8 50,001 100,000
rk.class[5] 5.078 1.096 0.01975 4 5 7 50,001 100,000
rk.class[6] 2.151 0.6964 0.01172 1 2 3 50,001 100,000
rk.class[7] 5.029 1.128 0.02361 4 5 7 50,001 100,000
rk.class[8] 1.817 0.8127 0.01454 1 2 3 50,001 100,000
rk.class[9] 2.042 0.9115 0.01683 1 2 3 50,001 100,000
rk.class[10] 9.207 0.6445 0.009085 8 9 10 50,001 100,000
TABLE 116 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 13 0.8523 0.01843 11 13 15 50,001 100,000
rk[2] 14.45 1.038 0.01616 12 15 15 50,001 100,000
rk[3] 8.025 2.379 0.03519 4 8 12 50,001 100,000
rk[4] 7.033 2.123 0.042 4 7 11 50,001 100,000
rk[5] 8.577 1.988 0.02899 5 9 12 50,001 100,000
rk[6] 9.308 2.443 0.04107 5 10 13 50,001 100,000
rk[7] 8.341 2.554 0.04085 4 8 13 50,001 100,000
rk[8] 9.542 2.724 0.04309 4 10 13 50,001 100,000
rk[9] 6.822 2.859 0.05316 4 6 12 50,001 100,000
rk[10] 2.153 0.7003 0.01172 1 2 3 50,001 100,000
rk[11] 6.548 2.704 0.06183 4 5 12 50,001 100,000
rk[12] 1.82 0.8264 0.01462 1 2 3 50,001 100,000
rk[13] 2.047 0.9274 0.01687 1 2 3 50,001 100,000
rk[14] 8.16 2.132 0.03462 4 8 12 50,001 100,000
rk[15] 14.17 0.7426 0.01001 13 14 15 50,001 100,000
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Adults: clinical effectiveness (Yale–Brown Obsessive–Compulsive Scale) – sensitivity analysis 4 (post hoc),
excluding studies that have used a waitlist as control
This is a post-hoc analysis.
TABLE 117 Raw data used
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Albert et al., 2002155 18.36 25 7.11 17.3 40 6.15 NA NA NA NA NA NA 2 2 7 8 NA NA
Andersson et al., 2012158 12.94 49 6.26 18.88 51 4.18 NA NA NA NA NA NA 2 2 10 16 NA NA
Bisserbe et al., 1997162 –14.3 86 NA –11.71 81 NA NA NA NA NA NA NA 2 1 5 8 NA NA
Belloch et al., 2008159 8.31 13 8.75 6.8 16 3.55 NA NA NA NA NA NA 2 2 9 11 NA NA
Belotto-Silva et al., 2012160 20.29 88 8.05 19.97 70 8.48 NA NA NA NA NA NA 2 2 2 10 NA NA
Bergeron et al., 2002161 –9.7 72 7.7 –9.6 76 7.9 NA NA NA NA NA NA 2 1 2 5 NA NA
CCSG1, 1991154 25.11 108 6.34 16.23 102 7.37 NA NA NA NA NA NA 2 2 1 8 NA NA
CCSG2, 1991154 25.59 119 5.78 14.7 120 7.45 NA NA NA NA NA NA 2 2 1 8 NA NA
Chouinard et al., 1990163 –1.48 44 NA –3.79 43 NA NA NA NA NA NA NA 2 1 1 5 NA NA
Cottraux et al., 2001166 –12.1 30 7.8 –12.5 30 8.2 NA NA NA NA NA NA 2 1 9 11 NA NA
Denys et al., 2003167 –7.8 72 5.4 –7.2 73 7.5 NA NA NA NA NA NA 2 1 4 7 NA NA
Fals-Stewart et al., 1993170 –8.1 31 NA –1.8 32 NA NA NA NA NA NA NA 2 1 9 16 NA NA
Foa et al., 2005171 22.2 26 6.4 18.2 36 7.8 11 29 7.9 10.5 31 8.2 4 2 1 8 9 14
Freeman et al., 1994172 –8.6 28 NA –7.8 19 NA NA NA NA NA NA NA 2 1 3 8 NA NA
GlaxoSmithKline, 2005174 –4.61 75 7.53 –5.61 79 7.47 –7.73 78 7.42 NA NA NA 3 1 1 4 8 NA
GlaxoSmithKline, 2005175 –14.26 72 6.33 –13.19 69 6.48 NA NA NA NA NA NA 2 1 4 8 NA NA
Goodman et al., 1989176 28 21 7 19.4 21 7 NA NA NA NA NA NA 2 2 1 3 NA NA
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TABLE 117 Raw data used (continued )
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Goodman et al., 1996177 –1.71 78 4.88 –3.95 78 6.28 NA NA NA NA NA NA 2 1 1 3 NA NA
Greist et al., 1995126 –3.41 84 6.19 –5.57 240 6.19 NA NA NA NA NA NA 2 1 1 5 NA NA
Greist et al., 2002178 17.6 55 6.2 24.1 66 6.7 NA NA NA NA NA NA 2 2 9 16 NA NA
Hollander et al., 2003180 –5.6 120 7.67 –8.5 117 7.57 NA NA NA NA NA NA 2 1 1 3 NA NA
Hollander et al., 2003181 –3.33 89 NA –4.14 88 NA –6.35 86 NA –7.34 85 NA 4 1 1 4 4 4
Jenike et al., 1990183 22.3 9 7.8 20.6 10 9.2 NA NA NA NA NA NA 2 2 1 5 NA NA
Jenike et al., 1990184 21.8 20 7.6 18.8 18 4 NA NA NA NA NA NA 2 2 1 3 NA NA
Jenike et al., 1997185 18.7 18 6.1 16.2 19 6.3 NA NA NA NA NA NA 2 2 1 2 NA NA
Kamijima et al., 2004187 20.3 94 7.38 15.8 94 8.09 NA NA NA NA NA NA 2 2 1 4 NA NA
Kobak et al., 2005189 19.87 30 7.46 19.75 30 7.46 NA NA NA NA NA NA 2 2 1 12 NA NA
Koran et al., 1996190 17.8 34 7.7 17 39 8.55 NA NA NA NA NA NA 2 2 3 8 NA NA
Kronig et al., 1999191 –4.14 79 NA –8.5 85 NA NA NA NA NA NA NA 2 1 1 5 NA NA
Lindsay et al., 1997192 11 9 3.81 25.89 9 5.8 NA NA NA NA NA NA 2 2 9 16 NA NA
López-Ibor et al., 1996193 –7.5 30 9.29 –8.9 24 7.13 NA NA NA NA NA NA 2 1 2 8 NA NA
McLean et al., 2001195 16.1 31 6.7 13.2 32 7.2 NA NA NA NA NA NA 2 2 11 9 NA NA
Milanfranchi et al., 1997196 18.4 13 9.2 16.5 12 11 NA NA NA NA NA NA 2 2 3 8 NA NA
Montgomery et al., 1993197 –3.7 56 5.98 –5.13 52 6.41 –4.76 52 6.89 –6.07 54 6.92 4 1 1 2 2 2
Montgomery et al., 2001198 –5.6 101 6.9 –8.4 102 7.3 –8.9 98 7 –10.4 100 6.9 4 1 1 6 6 6
Mundo et al., 1997199 16.2 10 8.9 21.6 9 7.6 19.8 11 10.1 NA NA NA 3 2 3 4 6 NA
Mundo et al., 2001200 –12.2 115 NA –12 112 NA NA NA NA NA NA NA 2 1 3 8 NA NA
Nakajima et al., 1996201 –1.9 33 7.2 –7.1 60 7.03 NA NA NA NA NA NA 2 1 1 3 NA NA
Nakatani et al., 2005202 20.2 10 9.4 12.9 10 4.9 28.4 8 5.5 NA NA NA 3 2 3 9 16 NA
O’Connor et al., 2006203 25.4 10 3.5 24 11 4.7 NA NA NA NA NA NA 2 2 1 3 NA NA
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TABLE 117 Raw data used (continued )
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Shareh et al., 2010206 16.66 6 3.2 7 7 2.38 8.5 6 2.42 NA NA NA 3 2 3 10 13 NA
Sousa et al., 2006207 –7.36 25 NA –10.8 25 NA NA NA NA NA NA NA 2 1 5 10 NA NA
Stein et al., 2007124 –8.46 113 8.08 –11.67 116 8.40 –11.43 112 8.25 –12.14 114 8.22 4 1 1 4 15 15
Tollefson et al., 1994127 –0.8 89 5.66 –5.44 266 7.88 NA NA NA NA NA NA 2 1 1 2 NA NA
Van Oppen et al., 1995209 17.9 29 9 13.4 28 9.4 NA NA NA NA NA NA 2 2 9 11 NA NA
Whittal et al., 2005211 10.41 29 7.6 10.6 30 7.1 NA NA NA NA NA NA 2 2 9 11 NA NA
Whittal et al., 2010212 6.43 37 4.77 9.1 30 6.48 NA NA NA NA NA NA 2 2 11 16 NA NA
Zohar and Judge, 1996213 –4.2 99 7.2 –6.4 201 7.1 –7 99 6.8 NA NA NA 3 1 1 4 8 NA
CCSG, Clomipramine Collaborative Study Group; NA, not applicable.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine,
9= clomipramine, 10= BT, 11=CBT, 12=CT, 13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo; t[i,2], type of treatment
[i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4]; y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline
(negative) for arm [1]; y[i,2], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean YBOCS scores at end of study
(positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total
number of patients for arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of patients for arm [4]; sd[i,1], SD of mean total
score or change from baseline for arm [1]; sd[i,2], SD of mean total score or change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3];
sd[i,4], SD of mean total score or change from baseline for arm [4].
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Key
1. Placebo (1).
2. Fluoxetine (2).
3. Fluvoxamine (2).
4. Paroxetine (2).
5. Sertraline (2).
6. Citalopram (2).
7. Venlafaxine (3).
8. Clomipramine (4).
9. BT (5).
10. CBT (6).
11. CT (7).
12. Hypericum (8).
13. Fluvoxamine+CBT (9).
14. BT+ clomipramine (10).
15. Escitalopram (2).
16. Psychological placebo (11).
TABLE 118 Class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
D[2] –3.619 0.6562 0.008122 –4.889 –3.616 –2.341 72,201 140,000
D[3] –3.211 1.965 0.01096 –7.068 –3.222 0.6873 72,201 140,000
D[4] –4.665 0.8162 0.00625 –6.264 –4.668 –3.046 72,201 140,000
D[5] –10.41 1.854 0.02225 –14.04 –10.41 –6.774 72,201 140,000
D[6] –7.981 1.544 0.01264 –11.02 –7.982 –4.93 72,201 140,000
D[7] –9.452 2.179 0.02475 –13.76 –9.447 –5.195 72,201 140,000
D[8] –0.1281 2.957 0.01417 –5.932 –0.125 5.678 72,201 140,000
D[9] –8.808 2.5 0.01532 –13.75 –8.8 –3.879 72,201 140,000
D[10] –11.68 2.565 0.01434 –16.73 –11.68 –6.655 72,201 140,000
D[11] –1.896 1.923 0.02168 –5.621 –1.901 1.908 72,201 140,000
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TABLE 119 Individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
d[2] –3.668 0.7231 0.008129 –5.126 –3.655 –2.26 72,201 140,000
d[3] –3.658 0.6577 0.007807 –4.964 –3.648 –2.375 72,201 140,000
d[4] –3.513 0.6774 0.007931 –4.809 –3.528 –2.137 72,201 140,000
d[5] –3.684 0.717 0.007973 –5.141 –3.67 –2.296 72,201 140,000
d[6] –3.602 0.83 0.008281 –5.251 –3.606 –1.906 72,201 140,000
d[7] –3.211 1.965 0.01096 –7.068 –3.222 0.6873 72,201 140,000
d[8] –4.665 0.8162 0.00625 –6.264 –4.668 –3.046 72,201 140,000
d[9] –10.41 1.854 0.02225 –14.04 –10.41 –6.774 72,201 140,000
d[10] –7.981 1.544 0.01264 –11.02 –7.982 –4.93 72,201 140,000
d[11] –9.452 2.179 0.02475 –13.76 –9.447 –5.195 72,201 140,000
d[12] –0.1281 2.957 0.01417 –5.932 –0.125 5.678 72,201 140,000
d[13] –8.808 2.5 0.01532 –13.75 –8.8 –3.879 72,201 140,000
d[14] –11.68 2.565 0.01434 –16.73 –11.68 –6.655 72,201 140,000
d[15] –3.593 0.8384 0.008388 –5.247 –3.598 –1.861 72,201 140,000
d[16] –1.896 1.923 0.02168 –5.621 –1.901 1.908 72,201 140,000
Please note that these figures can be directly compared with those in Table 20 using the correct key for the treatment.
For example, the posterior MD for BT (treatment #9 in this table) is –10.41 (95% CrI –14.04 to –6.77) and this compares
with a MD of –14.48 (95% CrI –18.61 to –10.23) in Table 20.
Median ranks
TABLE 120 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 10.31 0.661 0.003972 9 10 11 72,201 140,000
rk.class[2] 7.593 0.8419 0.004448 6 8 9 72,201 140,000
rk.class[3] 7.828 1.488 0.007127 5 8 11 72,201 140,000
rk.class[4] 6.379 0.7793 0.003608 5 6 8 72,201 140,000
rk.class[5] 2.299 0.959 0.00593 1 2 4 72,201 140,000
rk.class[6] 4.237 1.006 0.004598 2 4 6 72,201 140,000
rk.class[7] 3.263 1.244 0.008831 1 3 5 72,201 140,000
rk.class[8] 9.763 1.565 0.007451 6 10 11 72,201 140,000
rk.class[9] 3.587 1.605 0.007865 1 4 7 72,201 140,000
rk.class[10] 1.861 1.25 0.005406 1 1 5 72,201 140,000
rk.class[11] 8.882 1.297 0.01203 6 9 11 72,201 140,000
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TABLE 121 Individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 15.31 0.6624 0.003989 14 15 16 72,201 140,000
rk[2] 9.917 2.111 0.007922 6 10 14 72,201 140,000
rk[3] 9.955 2.012 0.007881 6 10 14 72,201 140,000
rk[4] 10.49 1.975 0.007702 7 11 14 72,201 140,000
rk[5] 9.856 2.095 0.007831 6 10 14 72,201 140,000
rk[6] 10.12 2.242 0.008465 6 10 14 72,201 140,000
rk[7] 10.74 3.543 0.01511 5 12 16 72,201 140,000
rk[8] 6.998 1.73 0.007727 5 6 12 72,201 140,000
rk[9] 2.301 0.9668 0.006013 1 2 4 72,201 140,000
rk[10] 4.254 1.063 0.004597 2 4 6 72,201 140,000
rk[11] 3.288 1.35 0.00982 1 3 6 72,201 140,000
rk[12] 14.14 2.944 0.01332 6 15 16 72,201 140,000
rk[13] 3.684 1.935 0.008808 1 4 8 72,201 140,000
rk[14] 1.868 1.287 0.00547 1 1 5 72,201 140,000
rk[15] 10.14 2.236 0.008085 6 10 14 72,201 140,000
rk[16] 12.94 2.84 0.02645 6 14 16 72,201 140,000
Please note these figures can be directly compared with those in Table 20 using the correct key for the treatment.
For example, the posterior median rank for BT (treatment #9 in this table) is 2 (95% CrI 1 to 4) and this compares with a
median rank of 1 (95% CrI 1 to 3) in Table 20.
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Adults: acceptability (dropouts) – sensitivity analysis 1
(low overall attrition)
See Table 28 for a summary.
TABLE 122 Raw data used
Study r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] na[] t[,1] t[,2] t[,3] t[,4]
Ananth et al.
1981156
1 10 2 10 NA NA NA NA 2 9 13 NA NA
Anderson and Rees,
2007157
3 17 4 21 NA NA NA NA 2 2 11 NA NA
Andersson
et al., 2012158
2 50 0 51 NA NA NA NA 2 11 16 NA NA
Belloch et al.,
2008159
2 15 2 18 NA NA NA NA 2 10 12 NA NA
Belotto-Silva
et al., 2012160
33 88 18 70 NA NA NA NA 2 3 11 NA NA
CCSG1, 1991154 13 121 17 118 NA NA NA NA 2 1 9 NA NA
CCSG2, 1991154 12 139 14 142 NA NA NA NA 2 1 9 NA NA
Chouinard
et al., 1990163
4 44 6 43 NA NA NA NA 2 1 6 NA NA
Cordioli et al.,
2003164
1 24 1 23 NA NA NA NA 2 2 11 NA NA
Cottraux et al.,
2001166
3 33 2 32 NA NA NA NA 2 10 12 NA NA
Denys et al., 2003167 9 75 4 75 NA NA NA NA 2 5 8 NA NA
Emmelkamp
et al., 1988169
1 10 1 10 NA NA NA NA 2 10 12 NA NA
Fals-Stewart et al.,
1993170
3 34 0 32 NA NA NA NA 2 10 16 NA NA
Freeston et al.,
1997173
0 14 3 15 NA NA NA NA 2 2 11 NA NA
GlaxoSmithKline,
2005175
1 73 4 73 NA NA NA NA 2 5 9 NA NA
Goodman et al.,
1996177
17 80 23 80 NA NA NA NA 2 1 4 NA NA
Greist et al., 2002178 14 69 9 75 NA NA NA NA 2 10 16 NA NA
Hollander et al.,
2003180
31 126 43 127 NA NA NA NA 2 1 4 NA NA
Hollander et al.,
2003181
15 89 14 88 20 86 19 85 4 1 5 5 5
Jenike et al., 1990184 0 20 2 20 NA NA NA NA 2 1 4 NA NA
Jenike et al., 1997185 3 21 4 23 NA NA NA NA 2 1 3 NA NA
Jones and Menzies,
1998186
1 11 1 12 NA NA NA NA 2 2 12 NA NA
Kobak et al.,
2005189
9 30 8 30 NA NA NA NA 2 1 17 NA NA
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TABLE 122 Raw data used (continued )
Study r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] na[] t[,1] t[,2] t[,3] t[,4]
López-Ibor et al.,
1996193
5 30 3 25 NA NA NA NA 2 3 9 NA NA
McLean et al.,
2001195
12 44 18 49 NA NA NA NA 2 10 12 NA NA
Milanfranchi et al.,
1997196
0 13 1 13 NA NA NA NA 2 4 9 NA NA
Montgomery et al.,
1993197
15 57 14 53 13 52 14 55 4 1 3 3 3
Montgomery et al.,
2001198
17 101 15 100 15 98 16 102 4 1 7 7 7
Mundo et al.,
2001200
19 115 26 112 NA NA NA NA 2 4 9 NA NA
Nakatani et al.,
2005202
1 11 1 11 1 9 NA NA 3 4 10 16 NA
O’Connor et al.,
1999203
0 6 1 7 NA NA NA NA 2 2 11 NA NA
Perse et al., 1987205 2 10 2 10 NA NA NA NA 2 1 4 NA NA
Shareh et al.,
2010206
1 7 0 7 1 7 NA NA 3 4 11 14 NA
Sousa et al., 2006207 3 28 3 28 NA NA NA NA 2 6 11 NA NA
Stein et al., 2007124 16 115 29 119 24 116 21 116 4 1 5 15 15
Tollefson et al.,
1994127
13 89 12 87 22 89 22 90 4 1 3 3 3
Van Oppen et al.,
1995209
7 36 7 35 NA NA NA NA 2 10 12 NA NA
Volavka et al.,
1985210
3 11 4 12 NA NA NA NA 2 9 18 NA NA
Whittal et al.,
2005211
13 42 11 41 NA NA NA NA 2 10 12 NA NA
Whittal et al.,
2010212
3 40 3 33 NA NA NA NA 2 12 16 NA NA
CCSG, Clomipramine Collaborative Study Group; NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine,
5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine, 9= clomipramine, 10= BT, 11=CBT, 12=CT,
13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo;
t[i,2], type of treatment [i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4];
y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [1]; y[i,2], total
mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean
YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS
scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total number of patients for
arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of
patients for arm [4]; sd[i,1], SD of mean total score or change from baseline for arm [1]; sd[i,2], SD of mean total score or
change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3]; sd[i,4], SD of mean
total score or change from baseline for arm [4].
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Key: intervention
1. Placebo (1).
2. Waitlist (2).
3. Fluoxetine (3).
4. Fluvoxamine (3).
5. Paroxetine (3).
6. Sertraline (3).
7. Citalopram (3).
8. Venlafaxine (4).
9. Clomipramine (5).
10. BT (6).
11. CBT (7).
12. CT (8).
13. Amitriptyline (9).
14. CBT+ fluvoxamine (10).
15. Escitalopram (3).
16. Psychological placebo (11).
17. Hypericum (12).
18. Imipramine (13).
TABLE 123 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[1,2] 0.4606 0.3501 0.01443 0.08904 0.3605 1.427 60,001 120,000
OR.D[1,3] 1.302 0.5778 0.005701 0.9421 1.284 1.726 60,001 120,000
OR.D[1,4] 0.6364 0.4778 0.01466 0.1053 0.5162 1.844 60,001 120,000
OR.D[1,5] 1.639 0.389 0.0117 1.039 1.584 2.588 60,001 120,000
OR.D[1,6] 0.6941 0.7862 0.03535 0.04697 0.441 2.772 60,001 120,000
OR.D[1,7] 0.8902 0.3111 0.0109 0.4249 0.8389 1.623 60,001 120,000
OR.D[1,8] 0.6763 0.773 0.03433 0.05704 0.4481 2.699 60,001 120,000
OR.D[1,9] 21.37 93.67 2.768 0.2314 3.94 162.7 60,001 120,000
OR.D[1,10] 13.73 153.6 3.737 0.06158 1.936 79.68 60,001 120,000
OR.D[1,11] 0.371 0.4034 0.01803 0.02338 0.244 1.463 60,001 120,000
OR.D[1,12] 1.001 0.6832 0.01939 0.2341 0.825 2.914 60,001 120,000
OR.D[1,13] 3.569 4.944 0.1543 0.2675 2.05 15.9 60,001 120,000
OR.D[2,3] 4.455 4.03 0.1474 0.9014 3.545 14.27 60,001 120,000
OR.D[2,4] 2.197 2.781 0.08812 0.1703 1.383 9.484 60,001 120,000
OR.D[2,5] 5.704 5.164 0.2038 1.073 4.326 18.4 60,001 120,000
OR.D[2,6] 2.033 2.669 0.1063 0.1405 1.197 8.662 60,001 120,000
OR.D[2,7] 2.756 1.927 0.07397 0.7092 2.258 8.006 60,001 120,000
OR.D[2,8] 1.982 2.625 0.1042 0.1675 1.155 8.94 60,001 120,000
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TABLE 123 Class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[2,9] 63.9 294.6 7.505 0.4477 11.69 446.1 60,001 120,000
OR.D[2,10] 57.78 656.4 18.21 0.1507 5.399 223.4 60,001 120,000
OR.D[2,11] 1.086 1.332 0.05339 0.07371 0.6644 4.877 60,001 120,000
OR.D[2,12] 3.482 4.569 0.1517 0.4019 2.181 14.26 60,001 120,000
OR.D[2,13] 12.08 19.77 0.6272 0.5223 5.667 66.09 60,001 120,000
OR.D[3,4] 0.4951 0.3906 0.0112 0.08368 0.4031 1.472 60,001 120,000
OR.D[3,5] 1.287 0.4541 0.01003 0.7809 1.23 2.132 60,001 120,000
OR.D[3,6] 0.5391 0.6117 0.02709 0.0379 0.3446 2.155 60,001 120,000
OR.D[3,7] 0.6934 0.2743 0.007734 0.3377 0.6553 1.251 60,001 120,000
OR.D[3,8] 0.5248 0.6027 0.02624 0.04514 0.3496 2.17 60,001 120,000
OR.D[3,9] 16.58 71.88 2.044 0.1758 3.1 132.5 60,001 120,000
OR.D[3,10] 10.97 124.1 3.095 0.04991 1.508 62.93 60,001 120,000
OR.D[3,11] 0.2879 0.3122 0.01373 0.01926 0.1913 1.117 60,001 120,000
OR.D[3,12] 0.7896 0.567 0.01591 0.1776 0.6382 2.362 60,001 120,000
OR.D[3,13] 2.803 4.134 0.1232 0.2114 1.603 12.64 60,001 120,000
OR.D[4,5] 4.285 4.116 0.13 0.8094 3.101 15.29 60,001 120,000
OR.D[4,6] 1.825 2.953 0.1114 0.06651 0.8913 9.311 60,001 120,000
OR.D[4,7] 2.344 2.488 0.07862 0.3828 1.623 8.663 60,001 120,000
OR.D[4,8] 1.778 2.949 0.1098 0.06723 0.8737 9.341 60,001 120,000
OR.D[4,9] 54.1 250 7.15 0.3928 7.709 437.8 60,001 120,000
OR.D[4,10] 38.58 467.8 10.23 0.1029 3.557 226.3 60,001 120,000
OR.D[4,11] 0.9715 1.567 0.05868 0.03401 0.4878 4.693 60,001 120,000
OR.D[4,12] 2.707 3.643 0.1184 0.2615 1.635 12.61 60,001 120,000
OR.D[4,13] 9.49 19.25 0.6017 0.3936 4.032 53.97 60,001 120,000
OR.D[5,6] 0.4444 0.5035 0.02233 0.02804 0.2835 1.882 60,001 120,000
OR.D[5,7] 0.5686 0.2302 0.007678 0.239 0.5306 1.114 60,001 120,000
OR.D[5,8] 0.4333 0.5018 0.02191 0.03094 0.2805 1.759 60,001 120,000
OR.D[5,9] 13.6 61.38 1.756 0.1445 2.417 105.6 60,001 120,000
OR.D[5,10] 8.955 98.02 2.421 0.03736 1.17 54.48 60,001 120,000
OR.D[5,11] 0.2376 0.2609 0.01146 0.01275 0.1516 0.9647 60,001 120,000
OR.D[5,12] 0.6426 0.4697 0.01298 0.1333 0.5216 1.873 60,001 120,000
OR.D[5,13] 2.139 2.853 0.08707 0.1799 1.305 9.181 60,001 120,000
OR.D[6,7] 3.074 4.322 0.2128 0.3113 1.847 14.04 60,001 120,000
OR.D[6,8] 1.008 0.276 0.008877 0.5775 0.9644 1.685 60,001 120,000
OR.D[6,9] 55.97 262 7.207 0.3638 8.582 383.7 60,001 120,000
continued
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TABLE 123 Class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[6,10] 37.52 470.2 11.27 0.09105 4.489 194 60,001 120,000
OR.D[6,11] 0.5831 0.2309 0.007426 0.2459 0.5486 1.149 60,001 120,000
OR.D[6,12] 3.557 6.237 0.2474 0.1934 1.878 17.05 60,001 120,000
OR.D[6,13] 16.09 45.9 2.105 0.3054 4.402 121.9 60,001 120,000
OR.D[7,8] 0.7888 0.9077 0.03755 0.0783 0.5294 2.995 60,001 120,000
OR.D[7,9] 26.38 112.3 3.388 0.2515 4.747 189.2 60,001 120,000
OR.D[7,10] 17.54 206.1 4.953 0.07379 2.26 92.65 60,001 120,000
OR.D[7,11] 0.4352 0.478 0.02037 0.03298 0.2954 1.739 60,001 120,000
OR.D[7,12] 1.259 1.006 0.02827 0.2463 0.969 3.995 60,001 120,000
OR.D[7,13] 4.393 6.19 0.1776 0.2817 2.437 20.19 60,001 120,000
OR.D[8,9] 58.61 362.6 8.542 0.3793 9.009 409.6 60,001 120,000
OR.D[8,10] 40.73 655.4 14.48 0.09474 4.631 193 60,001 120,000
OR.D[8,11] 0.6139 0.2895 0.009711 0.235 0.5527 1.364 60,001 120,000
OR.D[8,12] 3.634 6.27 0.2406 0.2045 1.937 16.93 60,001 120,000
OR.D[8,13] 15.06 36.71 1.509 0.3086 4.474 119.3 60,001 120,000
OR.D[9,10] 5.53 39.52 0.9571 0.003667 0.4567 44.15 60,001 120,000
OR.D[9,11] 0.2245 0.5699 0.02051 0.001242 0.06062 1.593 60,001 120,000
OR.D[9,12] 0.7359 2.279 0.08093 0.005101 0.1999 4.611 60,001 120,000
OR.D[9,13] 2.564 9.984 0.3729 0.01042 0.4719 17.31 60,001 120,000
OR.D[10,11] 0.8251 3.825 0.1046 0.00282 0.1198 5.837 60,001 120,000
OR.D[10,12] 3.228 37.11 0.9332 0.01088 0.4266 14.55 60,001 120,000
OR.D[10,13] 11.66 192.3 3.894 0.01944 1.045 59.85 60,001 120,000
OR.D[11,12] 6.769 12 0.4891 0.3975 3.357 35.34 60,001 120,000
OR.D[11,13] 29.51 82.34 3.567 0.5747 7.942 243.2 60,001 120,000
OR.D[12,13] 5.49 10.53 0.3723 0.2458 2.469 32.39 60,001 120,000
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TABLE 124 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[1,2] 0.4606 0.3501 0.01443 0.08904 0.3605 1.427 60,001 120,000
OR[1,3] 1.338 0.23 0.007745 0.9537 1.316 1.874 60,001 120,000
OR[1,4] 1.325 0.2049 0.006246 0.9793 1.309 1.76 60,001 120,000
OR[1,5] 1.361 0.2378 0.006944 0.9756 1.336 1.901 60,001 120,000
OR[1,6] 1.31 0.2954 0.007809 0.8018 1.279 1.972 60,001 120,000
OR[1,7] 1.222 0.2357 0.006839 0.7468 1.224 1.672 60,001 120,000
OR[1,8] 0.6364 0.4778 0.01466 0.1053 0.5162 1.844 60,001 120,000
OR[1,9] 1.639 0.389 0.0117 1.039 1.584 2.588 60,001 120,000
OR[1,10] 0.6941 0.7862 0.03535 0.04697 0.441 2.772 60,001 120,000
OR[1,11] 0.8902 0.3111 0.0109 0.4249 0.8389 1.623 60,001 120,000
OR[1,12] 0.6763 0.773 0.03433 0.05704 0.4481 2.699 60,001 120,000
OR[1,13] 21.37 93.67 2.768 0.2314 3.94 162.7 60,001 120,000
OR[1,14] 13.73 153.6 3.737 0.06158 1.936 79.68 60,001 120,000
OR[1,15] 1.281 0.2332 0.006379 0.878 1.265 1.795 60,001 120,000
OR[1,16] 0.371 0.4034 0.01803 0.02338 0.244 1.463 60,001 120,000
OR[1,17] 1.001 0.6832 0.01939 0.2341 0.825 2.914 60,001 120,000
OR[1,18] 3.569 4.944 0.1543 0.2675 2.05 15.9 60,001 120,000
OR[2,3] 4.535 3.746 0.1472 0.9427 3.642 14.33 60,001 120,000
OR[2,4] 4.557 3.911 0.1555 0.9225 3.604 14.98 60,001 120,000
OR[2,5] 4.672 4.012 0.157 0.9489 3.659 15.04 60,001 120,000
OR[2,6] 4.503 4.001 0.1537 0.8925 3.537 15.34 60,001 120,000
OR[2,7] 4.175 3.561 0.1368 0.8044 3.323 13.4 60,001 120,000
OR[2,8] 2.197 2.781 0.08812 0.1703 1.383 9.484 60,001 120,000
OR[2,9] 5.704 5.164 0.2038 1.073 4.326 18.4 60,001 120,000
OR[2,10] 2.033 2.669 0.1063 0.1405 1.197 8.662 60,001 120,000
OR[2,11] 2.756 1.927 0.07397 0.7092 2.258 8.006 60,001 120,000
OR[2,12] 1.982 2.625 0.1042 0.1675 1.155 8.94 60,001 120,000
OR[2,13] 63.9 294.6 7.505 0.4477 11.69 446.1 60,001 120,000
OR[2,14] 57.78 656.4 18.21 0.1507 5.399 223.4 60,001 120,000
OR[2,15] 4.389 3.735 0.1444 0.8639 3.497 14.32 60,001 120,000
OR[2,16] 1.086 1.332 0.05339 0.07371 0.6644 4.877 60,001 120,000
OR[2,17] 3.482 4.569 0.1517 0.4019 2.181 14.26 60,001 120,000
OR[2,18] 12.08 19.77 0.6272 0.5223 5.667 66.09 60,001 120,000
OR[3,4] 1.007 0.1715 0.004519 0.6857 0.9984 1.409 60,001 120,000
OR[3,5] 1.034 0.195 0.005247 0.6817 1.006 1.522 60,001 120,000
OR[3,6] 0.9938 0.2267 0.005706 0.5629 0.993 1.539 60,001 120,000
OR[3,7] 0.9296 0.191 0.005216 0.4989 0.9628 1.292 60,001 120,000
OR[3,8] 0.481 0.3614 0.01066 0.08211 0.3942 1.418 60,001 120,000
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TABLE 124 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[3,9] 1.253 0.3481 0.01095 0.7396 1.207 2.032 60,001 120,000
OR[3,10] 0.5243 0.5968 0.02639 0.03664 0.3399 2.07 60,001 120,000
OR[3,11] 0.6685 0.2146 0.006749 0.3502 0.6374 1.17 60,001 120,000
OR[3,12] 0.5101 0.5863 0.02546 0.04024 0.343 2.073 60,001 120,000
OR[3,13] 16.42 72.74 2.059 0.1734 2.999 133.2 60,001 120,000
OR[3,14] 10.93 124.9 3.106 0.04764 1.444 64.07 60,001 120,000
OR[3,15] 0.9728 0.1811 0.004307 0.6006 0.9846 1.378 60,001 120,000
OR[3,16] 0.2794 0.3017 0.01329 0.01756 0.1876 1.066 60,001 120,000
OR[3,17] 0.7725 0.5588 0.01624 0.1732 0.6238 2.326 60,001 120,000
OR[3,18] 2.725 3.754 0.119 0.2046 1.568 12.24 60,001 120,000
OR[4,5] 1.04 0.1851 0.004175 0.7257 1.008 1.519 60,001 120,000
OR[4,6] 0.9987 0.2174 0.004848 0.5927 0.9933 1.526 60,001 120,000
OR[4,7] 0.9345 0.1836 0.004833 0.5292 0.964 1.312 60,001 120,000
OR[4,8] 0.4881 0.3765 0.01151 0.08158 0.3935 1.493 60,001 120,000
OR[4,9] 1.254 0.309 0.008943 0.7896 1.209 1.985 60,001 120,000
OR[4,10] 0.5274 0.5936 0.02646 0.03597 0.3396 2.098 60,001 120,000
OR[4,11] 0.6807 0.2425 0.008035 0.3265 0.6393 1.234 60,001 120,000
OR[4,12] 0.5136 0.582 0.02564 0.04066 0.3445 2.115 60,001 120,000
OR[4,13] 16.35 69.19 2.013 0.1728 3.009 132.8 60,001 120,000
OR[4,14] 10.72 118.9 2.998 0.04838 1.447 61.97 60,001 120,000
OR[4,15] 0.9791 0.1807 0.004128 0.637 0.9842 1.408 60,001 120,000
OR[4,16] 0.2818 0.3034 0.01341 0.01743 0.1898 1.093 60,001 120,000
OR[4,17] 0.7761 0.5589 0.0163 0.1644 0.6268 2.395 60,001 120,000
OR[4,18] 2.719 3.716 0.1167 0.2096 1.582 11.92 60,001 120,000
OR[5,6] 0.9767 0.2187 0.004774 0.5448 0.9825 1.484 60,001 120,000
OR[5,7] 0.9141 0.1865 0.004695 0.4873 0.9492 1.26 60,001 120,000
OR[5,8] 0.4677 0.3404 0.01036 0.0822 0.3879 1.358 60,001 120,000
OR[5,9] 1.231 0.3318 0.009517 0.7223 1.177 2.023 60,001 120,000
OR[5,10] 0.5186 0.5976 0.02638 0.03615 0.3292 2.094 60,001 120,000
OR[5,11] 0.6658 0.2411 0.007683 0.3142 0.6253 1.23 60,001 120,000
OR[5,12] 0.5051 0.5922 0.02574 0.04422 0.3302 2.083 60,001 120,000
OR[5,13] 16.03 71.8 1.987 0.1715 2.959 130.4 60,001 120,000
OR[5,14] 10.56 117.2 2.956 0.04809 1.426 61.86 60,001 120,000
OR[5,15] 0.953 0.1584 0.003553 0.6321 0.9693 1.296 60,001 120,000
OR[5,16] 0.2773 0.3066 0.01344 0.01786 0.1819 1.115 60,001 120,000
OR[5,17] 0.7562 0.5426 0.01551 0.1654 0.6113 2.296 60,001 120,000
OR[5,18] 2.693 3.755 0.1195 0.1985 1.542 12.09 60,001 120,000
OR[6,7] 0.9652 0.2306 0.005611 0.4897 0.9798 1.465 60,001 120,000
OR[6,8] 0.5048 0.3955 0.01208 0.08244 0.4028 1.552 60,001 120,000
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TABLE 124 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[6,9] 1.308 0.4288 0.01178 0.7103 1.236 2.365 60,001 120,000
OR[6,10] 0.5458 0.6266 0.02732 0.03707 0.3446 2.157 60,001 120,000
OR[6,11] 0.7041 0.2758 0.008852 0.3121 0.6567 1.343 60,001 120,000
OR[6,12] 0.5317 0.6163 0.02655 0.04695 0.3458 2.212 60,001 120,000
OR[6,13] 16.76 73.57 2.06 0.1745 3.127 128.8 60,001 120,000
OR[6,14] 10.93 122.7 3.062 0.05071 1.504 62.55 60,001 120,000
OR[6,15] 1.014 0.2603 0.005967 0.586 0.9945 1.63 60,001 120,000
OR[6,16] 0.2918 0.3188 0.01384 0.01922 0.1913 1.155 60,001 120,000
OR[6,17] 0.8007 0.5925 0.01636 0.1752 0.6381 2.444 60,001 120,000
OR[6,18] 2.841 3.933 0.1263 0.2084 1.595 12.91 60,001 120,000
OR[7,8] 0.5383 0.4246 0.01233 0.0867 0.4241 1.649 60,001 120,000
OR[7,9] 1.395 0.4565 0.0139 0.8077 1.295 2.6 60,001 120,000
OR[7,10] 0.5839 0.67 0.02938 0.0424 0.3661 2.397 60,001 120,000
OR[7,11] 0.7506 0.2931 0.009336 0.3527 0.6948 1.449 60,001 120,000
OR[7,12] 0.5688 0.6636 0.02858 0.0535 0.3705 2.348 60,001 120,000
OR[7,13] 17.57 76.02 2.141 0.1826 3.355 132.3 60,001 120,000
OR[7,14] 11.64 134.1 3.27 0.05443 1.656 65.3 60,001 120,000
OR[7,15] 1.079 0.2661 0.00615 0.7005 1.016 1.797 60,001 120,000
OR[7,16] 0.3115 0.3437 0.01492 0.02298 0.2047 1.219 60,001 120,000
OR[7,17] 0.8511 0.6209 0.01708 0.1888 0.6856 2.547 60,001 120,000
OR[7,18] 3.05 4.215 0.1368 0.2239 1.714 14.33 60,001 120,000
OR[8,9] 4.285 4.116 0.13 0.8094 3.101 15.29 60,001 120,000
OR[8,10] 1.825 2.953 0.1114 0.06651 0.8913 9.311 60,001 120,000
OR[8,11] 2.344 2.488 0.07862 0.3828 1.623 8.663 60,001 120,000
OR[8,12] 1.778 2.949 0.1098 0.06723 0.8737 9.341 60,001 120,000
OR[8,13] 54.1 250 7.15 0.3928 7.709 437.8 60,001 120,000
OR[8,14] 38.58 467.8 10.23 0.1029 3.557 226.3 60,001 120,000
OR[8,15] 3.366 3.382 0.1159 0.6569 2.438 11.92 60,001 120,000
OR[8,16] 0.9715 1.567 0.05868 0.03401 0.4878 4.693 60,001 120,000
OR[8,17] 2.707 3.643 0.1184 0.2615 1.635 12.61 60,001 120,000
OR[8,18] 9.49 19.25 0.6017 0.3936 4.032 53.97 60,001 120,000
OR[9,10] 0.4444 0.5035 0.02233 0.02804 0.2835 1.882 60,001 120,000
OR[9,11] 0.5686 0.2302 0.007678 0.239 0.5306 1.114 60,001 120,000
OR[9,12] 0.4333 0.5018 0.02191 0.03094 0.2805 1.759 60,001 120,000
OR[9,13] 13.6 61.38 1.756 0.1445 2.417 105.6 60,001 120,000
OR[9,14] 8.955 98.02 2.421 0.03736 1.17 54.48 60,001 120,000
OR[9,15] 0.8194 0.2235 0.006122 0.4373 0.795 1.327 60,001 120,000
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TABLE 124 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[9,16] 0.2376 0.2609 0.01146 0.01275 0.1516 0.9647 60,001 120,000
OR[9,17] 0.6426 0.4697 0.01298 0.1333 0.5216 1.873 60,001 120,000
OR[9,18] 2.139 2.853 0.08707 0.1799 1.305 9.181 60,001 120,000
OR[10,11] 3.074 4.322 0.2128 0.3113 1.847 14.04 60,001 120,000
OR[10,12] 1.008 0.276 0.008877 0.5775 0.9644 1.685 60,001 120,000
OR[10,13] 55.97 262 7.207 0.3638 8.582 383.7 60,001 120,000
OR[10,14] 37.52 470.2 11.27 0.09105 4.489 194 60,001 120,000
OR[10,15] 4.669 6.306 0.3041 0.4554 2.871 26.53 60,001 120,000
OR[10,16] 0.5831 0.2309 0.007426 0.2459 0.5486 1.149 60,001 120,000
OR[10,17] 3.557 6.237 0.2474 0.1934 1.878 17.05 60,001 120,000
OR[10,18] 16.09 45.9 2.105 0.3054 4.402 121.9 60,001 120,000
OR[11,12] 0.7888 0.9077 0.03755 0.0783 0.5294 2.995 60,001 120,000
OR[11,13] 26.38 112.3 3.388 0.2515 4.747 189.2 60,001 120,000
OR[11,14] 17.54 206.1 4.953 0.07379 2.26 92.65 60,001 120,000
OR[11,15] 1.599 0.5897 0.01878 0.7501 1.502 3.001 60,001 120,000
OR[11,16] 0.4352 0.478 0.02037 0.03298 0.2954 1.739 60,001 120,000
OR[11,17] 1.259 1.006 0.02827 0.2463 0.969 3.995 60,001 120,000
OR[11,18] 4.393 6.19 0.1776 0.2817 2.437 20.19 60,001 120,000
OR[12,13] 58.61 362.6 8.542 0.3793 9.009 409.6 60,001 120,000
OR[12,14] 40.73 655.4 14.48 0.09474 4.631 193 60,001 120,000
OR[12,15] 4.685 5.933 0.2691 0.4509 2.817 20.32 60,001 120,000
OR[12,16] 0.6139 0.2895 0.009711 0.235 0.5527 1.364 60,001 120,000
OR[12,17] 3.634 6.27 0.2406 0.2045 1.937 16.93 60,001 120,000
OR[12,18] 15.06 36.71 1.509 0.3086 4.474 119.3 60,001 120,000
OR[13,14] 5.53 39.52 0.9571 0.003667 0.4567 44.15 60,001 120,000
OR[13,15] 0.9641 2.463 0.1004 0.007295 0.3162 5.661 60,001 120,000
OR[13,16] 0.2245 0.5699 0.02051 0.001242 0.06062 1.593 60,001 120,000
OR[13,17] 0.7359 2.279 0.08093 0.005101 0.1999 4.611 60,001 120,000
OR[13,18] 2.564 9.984 0.3729 0.01042 0.4719 17.31 60,001 120,000
OR[14,15] 4.573 61.1 1.488 0.01533 0.6399 20.1 60,001 120,000
OR[14,16] 0.8251 3.825 0.1046 0.00282 0.1198 5.837 60,001 120,000
OR[14,17] 3.228 37.11 0.9332 0.01088 0.4266 14.55 60,001 120,000
OR[14,18] 11.66 192.3 3.894 0.01944 1.045 59.85 60,001 120,000
OR[15,16] 0.2941 0.3242 0.01412 0.02061 0.194 1.15 60,001 120,000
OR[15,17] 0.8049 0.5781 0.01617 0.1844 0.6472 2.337 60,001 120,000
OR[15,18] 2.859 3.935 0.1259 0.2136 1.645 13.11 60,001 120,000
OR[16,17] 6.769 12 0.4891 0.3975 3.357 35.34 60,001 120,000
OR[16,18] 29.51 82.34 3.567 0.5747 7.942 243.2 60,001 120,000
OR[17,18] 5.49 10.53 0.3723 0.2458 2.469 32.39 60,001 120,000
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Median ranks
TABLE 125 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 7.457 1.605 0.06546 4 8 10 60,001 120,000
rk.class[2] 3.591 2.242 0.08864 1 3 9 60,001 120,000
rk.class[3] 9.338 1.524 0.05377 6 9 12 60,001 120,000
rk.class[4] 4.774 2.818 0.09714 1 5 11 60,001 120,000
rk.class[5] 10.43 1.414 0.05074 7 11 13 60,001 120,000
rk.class[6] 4.989 2.772 0.1259 2 4 12 60,001 120,000
rk.class[7] 6.753 1.942 0.06629 3 7 11 60,001 120,000
rk.class[8] 4.741 2.78 0.1243 1 4 12 60,001 120,000
rk.class[9] 10.93 3.089 0.1193 2 12 13 60,001 120,000
rk.class[10] 8.913 4.313 0.1881 1 11 13 60,001 120,000
rk.class[11] 2.372 1.863 0.07739 1 2 8 60,001 120,000
rk.class[12] 6.763 2.945 0.09328 1 7 12 60,001 120,000
rk.class[13] 9.952 3.188 0.1145 2 11 13 60,001 120,000
TABLE 126 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 7.887 1.915 0.07426 4 8 12 60,001 120,000
rk[2] 3.761 2.776 0.1071 1 3 13 60,001 120,000
rk[3] 12.22 2.477 0.06913 7 12 17 60,001 120,000
rk[4] 12.11 2.432 0.06942 7 12 16 60,001 120,000
rk[5] 12.52 2.476 0.06783 7 13 17 60,001 120,000
rk[6] 11.73 2.851 0.07212 6 12 17 60,001 120,000
rk[7] 10.79 2.817 0.07826 5 11 16 60,001 120,000
rk[8] 5.227 3.785 0.1255 1 5 16 60,001 120,000
rk[9] 14.39 2.566 0.07931 8 15 18 60,001 120,000
rk[10] 5.667 4.145 0.1894 2 4 17 60,001 120,000
rk[11] 7.337 2.8 0.08787 3 7 15 60,001 120,000
rk[12] 5.38 4.108 0.1849 1 4 16 60,001 120,000
rk[13] 14.78 4.979 0.1917 2 17 18 60,001 120,000
rk[14] 11.89 6.55 0.2844 1 16 18 60,001 120,000
rk[15] 11.47 2.615 0.06606 6 11 16 60,001 120,000
rk[16] 2.55 2.49 0.1019 1 2 11 60,001 120,000
rk[17] 7.968 4.593 0.1354 1 7 17 60,001 120,000
rk[18] 13.32 5.238 0.1872 2 16 18 60,001 120,000
DOI: 10.3310/hta20430 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 43
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Skapinakis et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
307
Adults: acceptability (dropouts) – sensitivity analysis 2
(incomplete outcome data)
See Table 29 for a summary.
TABLE 127 Raw data used
Study r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] na[] t[,1] t[,2] t[,3] t[,4]
Anderson and
Rees, 2007157
3 17 4 21 NA NA NA NA 2 2 11 NA NA
Andersson et al.,
2012158
2 50 0 51 NA NA NA NA 2 11 14 NA NA
Belotto-Silva et al.,
2012160
33 88 18 70 NA NA NA NA 2 3 11 NA NA
Bergeron et al.,
2002161
22 73 22 77 NA NA NA NA 2 3 6 NA NA
Bisserbe et al.,
1997162
23 86 35 82 NA NA NA NA 2 6 9 NA NA
Chouinard et al.,
1990163
4 44 6 43 NA NA NA NA 2 1 6 NA NA
Cordioli et al.,
2003164
1 24 1 23 NA NA NA NA 2 2 11 NA NA
Denys et al.,
2003167
9 75 4 75 NA NA NA NA 2 5 8 NA NA
Foa et al., 2005171 12 32 20 47 16 37 14 33 4 1 9 10 12
Freeman et al.,
1994172
6 34 13 32 NA NA NA NA 2 4 9 NA NA
Freeston et al.,
1997173
0 14 3 15 NA NA NA NA 2 2 11 NA NA
GlaxoSmithKline,
2005174
20 77 28 82 28 82 NA NA 3 1 5 9 NA
Goodman et al.,
1989176
6 23 2 23 NA NA NA NA 2 1 4 NA NA
Goodman et al.,
1996177
17 80 23 80 NA NA NA NA 2 1 4 NA NA
Greist et al.,
2002178
14 69 9 75 NA NA NA NA 2 10 14 NA NA
Hollander et al.,
2003180
31 126 43 127 NA NA NA NA 2 1 4 NA NA
Hollander et al.,
2003181
15 89 14 88 20 86 19 85 4 1 5 5 5
Jenike et al.,
1997185
3 21 4 23 NA NA NA NA 2 1 3 NA NA
Kobak et al.,
2005189
9 30 8 30 NA NA NA NA 2 1 15 NA NA
Koran et al.,
1996190
8 37 15 42 NA NA NA NA 2 4 9 NA NA
Kronig et al.,
1999191
25 81 25 86 NA NA NA NA 2 1 6 NA NA
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TABLE 127 Raw data used (continued )
Study r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] na[] t[,1] t[,2] t[,3] t[,4]
López-Ibor et al.,
1996193
5 30 3 25 NA NA NA NA 2 3 9 NA NA
Montgomery
et al., 1993197
15 57 14 53 13 52 14 55 4 1 3 3 3
Montgomery
et al., 2001198
17 101 15 100 15 98 16 102 4 1 7 7 7
Mundo et al.,
2001200
19 115 26 112 NA NA NA NA 2 4 9 NA NA
Sousa et al.,
2006207
3 28 3 28 NA NA NA NA 2 6 11 NA NA
Stein et al.,
2007124
16 115 29 119 24 116 21 116 4 1 5 13 13
Tollefson et al.,
1994127
13 89 12 87 22 89 22 90 4 1 3 3 3
Zohar and Judge,
1996213
40 100 53 205 36 101 NA NA 3 1 5 9 NA
NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine,
5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine, 9= clomipramine, 10= BT, 11=CBT, 12=CT,
13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo;
t[i,2], type of treatment [i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4];
y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [1]; y[i,2], total
mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean
YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS
scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total number of patients for
arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of
patients for arm [4]; sd[i,1], SD of mean total score or change from baseline for arm [1]; sd[i,2], SD of mean total score or
change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3]; sd[i,4], SD of mean
total score or change from baseline for arm [4].
Key: intervention
1. Placebo (1).
2. Waitlist (2).
3. Fluoxetine (3).
4. Fluvoxamine (3).
5. Paroxetine (3).
6. Sertraline (3).
7. Citalopram (3).
8. Venlafaxine (4).
9. Clomipramine (5).
10. BT (6).
11. CBT (7).
12. BT+ clomipramine (8).
13. Escitalopram (3).
14. Psychological placebo (9).
15. Hypericum (10).
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TABLE 128 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[1,2] 0.5368 0.4823 0.01184 0.08188 0.3911 1.806 60,001 120,000
OR.D[1,3] 1.107 0.1536 0.002988 0.8368 1.098 1.435 60,001 120,000
OR.D[1,4] 0.5482 0.4165 0.007525 0.1029 0.4439 1.609 60,001 120,000
OR.D[1,5] 1.578 0.2737 0.004665 1.105 1.554 2.175 60,001 120,000
OR.D[1,6] 1.349 0.6253 0.01276 0.5019 1.227 2.91 60,001 120,000
OR.D[1,7] 0.8623 0.3524 0.0076 0.3689 0.8054 1.729 60,001 120,000
OR.D[1,8] 1.499 0.7573 0.01471 0.5177 1.335 3.386 60,001 120,000
OR.D[1,9] 0.6353 0.4454 0.009881 0.1439 0.5159 1.824 60,001 120,000
OR.D[1,10] 1.033 0.7204 0.01341 0.2466 0.8391 2.896 60,001 120,000
OR.D[2,3] 3.815 3.673 0.09655 0.6073 2.788 13.19 60,001 120,000
OR.D[2,4] 1.869 2.563 0.0522 0.1416 1.115 8.087 60,001 120,000
OR.D[2,5] 5.456 5.307 0.1369 0.8413 3.947 19.32 60,001 120,000
OR.D[2,6] 4.58 5.203 0.123 0.5442 3.133 17.44 60,001 120,000
OR.D[2,7] 2.586 2.153 0.05721 0.5407 2.029 8.078 60,001 120,000
OR.D[2,8] 5.132 5.82 0.1341 0.5515 3.441 20.35 60,001 120,000
OR.D[2,9] 2.14 2.932 0.07268 0.1828 1.331 8.937 60,001 120,000
OR.D[2,10] 3.588 4.987 0.1072 0.3084 2.14 15.8 60,001 120,000
OR.D[3,4] 0.4992 0.377 0.006642 0.09421 0.4054 1.454 60,001 120,000
OR.D[3,5] 1.439 0.2575 0.003114 1.001 1.419 2.002 60,001 120,000
OR.D[3,6] 1.234 0.5833 0.01131 0.4517 1.122 2.671 60,001 120,000
OR.D[3,7] 0.7845 0.3168 0.006195 0.3418 0.7308 1.563 60,001 120,000
OR.D[3,8] 1.373 0.711 0.01355 0.4659 1.219 3.129 60,001 120,000
OR.D[3,9] 0.582 0.4177 0.009214 0.1306 0.4704 1.69 60,001 120,000
OR.D[3,10] 0.9491 0.6783 0.01254 0.2175 0.7669 2.715 60,001 120,000
OR.D[4,5] 4.676 4.245 0.07812 0.9583 3.507 15.3 60,001 120,000
OR.D[4,6] 4.001 4.251 0.07371 0.5536 2.785 14.51 60,001 120,000
OR.D[4,7] 2.559 2.626 0.04798 0.4166 1.785 9.203 60,001 120,000
OR.D[4,8] 4.444 4.824 0.08092 0.6143 3.099 16.47 60,001 120,000
OR.D[4,9] 1.876 2.358 0.04325 0.1961 1.195 7.612 60,001 120,000
OR.D[4,10] 3.051 4.041 0.06462 0.3062 1.987 12.39 60,001 120,000
OR.D[5,6] 0.8661 0.3962 0.00754 0.3192 0.7938 1.839 60,001 120,000
OR.D[5,7] 0.559 0.2404 0.004717 0.2273 0.5175 1.143 60,001 120,000
OR.D[5,8] 0.9636 0.4861 0.009502 0.3366 0.8614 2.165 60,001 120,000
OR.D[5,9] 0.4083 0.2862 0.006212 0.09316 0.3321 1.166 60,001 120,000
OR.D[5,10] 0.673 0.4854 0.008825 0.1504 0.5407 1.922 60,001 120,000
OR.D[6,7] 0.7694 0.4893 0.009361 0.2154 0.6592 2.02 60,001 120,000
OR.D[6,8] 1.262 0.7268 0.01311 0.3817 1.095 3.066 60,001 120,000
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TABLE 128 Class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[6,9] 0.4793 0.2494 0.004438 0.1582 0.425 1.107 60,001 120,000
OR.D[6,10] 0.9297 0.8433 0.01443 0.1532 0.6931 3.107 60,001 120,000
OR.D[7,8] 2.018 1.363 0.02948 0.5075 1.673 5.575 60,001 120,000
OR.D[7,9] 0.8405 0.7029 0.01594 0.1544 0.6413 2.658 60,001 120,000
OR.D[7,10] 1.391 1.216 0.02328 0.2467 1.06 4.459 60,001 120,000
OR.D[8,9] 0.505 0.4269 0.009518 0.09524 0.3845 1.649 60,001 120,000
OR.D[8,10] 0.8652 0.8256 0.01346 0.1305 0.6307 2.967 60,001 120,000
OR.D[9,10] 2.438 2.821 0.04791 0.2808 1.604 9.457 60,001 120,000
TABLE 129 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[1,2] 0.5368 0.4823 0.01184 0.08188 0.3911 1.806 60,001 120,000
OR[1,3] 1.169 0.1838 0.003938 0.8761 1.146 1.592 60,001 120,000
OR[1,4] 1.097 0.1559 0.002968 0.808 1.092 1.434 60,001 120,000
OR[1,5] 1.132 0.1558 0.003222 0.8646 1.121 1.48 60,001 120,000
OR[1,6] 1.071 0.1659 0.003257 0.7602 1.067 1.423 60,001 120,000
OR[1,7] 1.082 0.19 0.003507 0.7187 1.077 1.49 60,001 120,000
OR[1,8] 0.5482 0.4165 0.007525 0.1029 0.4439 1.609 60,001 120,000
OR[1,9] 1.578 0.2737 0.004665 1.105 1.554 2.175 60,001 120,000
OR[1,10] 1.349 0.6253 0.01276 0.5019 1.227 2.91 60,001 120,000
OR[1,11] 0.8623 0.3524 0.0076 0.3689 0.8054 1.729 60,001 120,000
OR[1,12] 1.499 0.7573 0.01471 0.5177 1.335 3.386 60,001 120,000
OR[1,13] 1.11 0.1839 0.003213 0.7808 1.099 1.517 60,001 120,000
OR[1,14] 0.6353 0.4454 0.009881 0.1439 0.5159 1.824 60,001 120,000
OR[1,15] 1.033 0.7204 0.01341 0.2466 0.8391 2.896 60,001 120,000
OR[2,3] 3.991 3.791 0.09895 0.6527 2.937 13.81 60,001 120,000
OR[2,4] 3.794 3.701 0.097 0.5932 2.773 13.15 60,001 120,000
OR[2,5] 3.905 3.762 0.09781 0.6172 2.862 13.56 60,001 120,000
OR[2,6] 3.692 3.59 0.09489 0.5807 2.662 12.9 60,001 120,000
OR[2,7] 3.739 3.647 0.09542 0.5739 2.678 13.1 60,001 120,000
OR[2,8] 1.869 2.563 0.0522 0.1416 1.115 8.087 60,001 120,000
OR[2,9] 5.456 5.307 0.1369 0.8413 3.947 19.32 60,001 120,000
OR[2,10] 4.58 5.203 0.123 0.5442 3.133 17.44 60,001 120,000
OR[2,11] 2.586 2.153 0.05721 0.5407 2.029 8.078 60,001 120,000
OR[2,12] 5.132 5.82 0.1341 0.5515 3.441 20.35 60,001 120,000
OR[2,13] 3.832 3.737 0.09732 0.5977 2.802 13.37 60,001 120,000
OR[2,14] 2.14 2.932 0.07268 0.1828 1.331 8.937 60,001 120,000
continued
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TABLE 129 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[2,15] 3.588 4.987 0.1072 0.3084 2.14 15.8 60,001 120,000
OR[3,4] 0.9513 0.1428 0.001887 0.6309 0.9736 1.231 60,001 120,000
OR[3,5] 0.9816 0.1408 0.001805 0.6889 0.9904 1.287 60,001 120,000
OR[3,6] 0.9279 0.1403 0.002183 0.6145 0.9568 1.183 60,001 120,000
OR[3,7] 0.9381 0.166 0.002505 0.5664 0.969 1.254 60,001 120,000
OR[3,8] 0.475 0.3604 0.006235 0.08722 0.3866 1.368 60,001 120,000
OR[3,9] 1.371 0.2641 0.004059 0.8972 1.355 1.933 60,001 120,000
OR[3,10] 1.175 0.5591 0.01119 0.4245 1.065 2.573 60,001 120,000
OR[3,11] 0.7401 0.2838 0.005498 0.3331 0.6928 1.429 60,001 120,000
OR[3,12] 1.308 0.6796 0.01321 0.4356 1.159 2.983 60,001 120,000
OR[3,13] 0.9621 0.1596 0.002065 0.6226 0.9799 1.296 60,001 120,000
OR[3,14] 0.5536 0.3971 0.008822 0.1239 0.4479 1.616 60,001 120,000
OR[3,15] 0.9016 0.6488 0.01197 0.2064 0.7282 2.592 60,001 120,000
OR[4,5] 1.045 0.1606 0.001942 0.7871 1.012 1.458 60,001 120,000
OR[4,6] 0.9862 0.1509 0.001856 0.6917 0.9905 1.331 60,001 120,000
OR[4,7] 0.9956 0.1725 0.0022 0.6618 0.9961 1.396 60,001 120,000
OR[4,8] 0.5063 0.3878 0.006808 0.09506 0.4095 1.498 60,001 120,000
OR[4,9] 1.454 0.2553 0.003461 1.022 1.431 2.02 60,001 120,000
OR[4,10] 1.247 0.5898 0.01119 0.4577 1.13 2.704 60,001 120,000
OR[4,11] 0.7959 0.3325 0.006539 0.337 0.7346 1.629 60,001 120,000
OR[4,12] 1.387 0.7133 0.01317 0.4674 1.234 3.15 60,001 120,000
OR[4,13] 1.023 0.1789 0.00188 0.7168 1.002 1.463 60,001 120,000
OR[4,14] 0.5875 0.4199 0.008943 0.1324 0.4735 1.7 60,001 120,000
OR[4,15] 0.9589 0.687 0.01226 0.2199 0.7747 2.737 60,001 120,000
OR[5,6] 0.9545 0.143 0.002086 0.6513 0.9749 1.247 60,001 120,000
OR[5,7] 0.9639 0.1642 0.002669 0.5953 0.9834 1.306 60,001 120,000
OR[5,8] 0.4835 0.3548 0.006231 0.09376 0.3971 1.384 60,001 120,000
OR[5,9] 1.406 0.2432 0.00348 0.9812 1.391 1.931 60,001 120,000
OR[5,10] 1.206 0.5681 0.01112 0.4422 1.094 2.618 60,001 120,000
OR[5,11] 0.7681 0.3133 0.006304 0.3297 0.7112 1.549 60,001 120,000
OR[5,12] 1.34 0.6853 0.01281 0.456 1.194 3.065 60,001 120,000
OR[5,13] 0.9871 0.1463 0.00173 0.6905 0.9916 1.323 60,001 120,000
OR[5,14] 0.5689 0.4066 0.008892 0.1267 0.4592 1.653 60,001 120,000
OR[5,15] 0.9261 0.6579 0.01213 0.2148 0.7519 2.654 60,001 120,000
OR[6,7] 1.022 0.1854 0.00209 0.6825 1.003 1.475 60,001 120,000
OR[6,8] 0.5196 0.398 0.006908 0.09647 0.4196 1.524 60,001 120,000
OR[6,9] 1.494 0.2823 0.003616 1.026 1.468 2.14 60,001 120,000
OR[6,10] 1.281 0.6112 0.01176 0.4633 1.166 2.792 60,001 120,000
OR[6,11] 0.8147 0.3334 0.006708 0.3517 0.756 1.641 60,001 120,000
OR[6,12] 1.428 0.7528 0.0149 0.4745 1.261 3.296 60,001 120,000
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TABLE 129 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[6,13] 1.051 0.1945 0.002293 0.7376 1.012 1.553 60,001 120,000
OR[6,14] 0.6038 0.4332 0.009467 0.1343 0.4885 1.768 60,001 120,000
OR[6,15] 0.9866 0.7084 0.01321 0.2251 0.7914 2.783 60,001 120,000
OR[7,8] 0.5197 0.4061 0.007301 0.09568 0.4155 1.563 60,001 120,000
OR[7,9] 1.493 0.3328 0.004181 0.968 1.455 2.273 60,001 120,000
OR[7,10] 1.28 0.6299 0.01196 0.4493 1.159 2.853 60,001 120,000
OR[7,11] 0.8157 0.356 0.006692 0.3403 0.7491 1.697 60,001 120,000
OR[7,12] 1.426 0.7698 0.01575 0.4687 1.25 3.443 60,001 120,000
OR[7,13] 1.048 0.22 0.002709 0.7105 1.007 1.594 60,001 120,000
OR[7,14] 0.6042 0.4461 0.009913 0.1318 0.4899 1.769 60,001 120,000
OR[7,15] 0.9865 0.7245 0.01403 0.22 0.7862 2.868 60,001 120,000
OR[8,9] 4.676 4.245 0.07812 0.9583 3.507 15.3 60,001 120,000
OR[8,10] 4.001 4.251 0.07371 0.5536 2.785 14.51 60,001 120,000
OR[8,11] 2.559 2.626 0.04798 0.4166 1.785 9.203 60,001 120,000
OR[8,12] 4.444 4.824 0.08092 0.6143 3.099 16.47 60,001 120,000
OR[8,13] 3.291 2.989 0.05449 0.665 2.462 10.7 60,001 120,000
OR[8,14] 1.876 2.358 0.04325 0.1961 1.195 7.612 60,001 120,000
OR[8,15] 3.051 4.041 0.06462 0.3062 1.987 12.39 60,001 120,000
OR[9,10] 0.8661 0.3962 0.00754 0.3192 0.7938 1.839 60,001 120,000
OR[9,11] 0.559 0.2404 0.004717 0.2273 0.5175 1.143 60,001 120,000
OR[9,12] 0.9636 0.4861 0.009502 0.3366 0.8614 2.165 60,001 120,000
OR[9,13] 0.7191 0.1477 0.001776 0.4735 0.703 1.057 60,001 120,000
OR[9,14] 0.4083 0.2862 0.006212 0.09316 0.3321 1.166 60,001 120,000
OR[9,15] 0.673 0.4854 0.008825 0.1504 0.5407 1.922 60,001 120,000
OR[10,11] 0.7694 0.4893 0.009361 0.2154 0.6592 2.02 60,001 120,000
OR[10,12] 1.262 0.7268 0.01311 0.3817 1.095 3.066 60,001 120,000
OR[10,13] 0.9975 0.4961 0.009793 0.3615 0.8927 2.249 60,001 120,000
OR[10,14] 0.4793 0.2494 0.004438 0.1582 0.425 1.107 60,001 120,000
OR[10,15] 0.9297 0.8433 0.01443 0.1532 0.6931 3.107 60,001 120,000
OR[11,12] 2.018 1.363 0.02948 0.5075 1.673 5.575 60,001 120,000
OR[11,13] 1.483 0.6185 0.01323 0.6176 1.365 3.009 60,001 120,000
OR[11,14] 0.8405 0.7029 0.01594 0.1544 0.6413 2.658 60,001 120,000
OR[11,15] 1.391 1.216 0.02328 0.2467 1.06 4.459 60,001 120,000
OR[12,13] 0.9261 0.4948 0.00824 0.3177 0.8191 2.185 60,001 120,000
OR[12,14] 0.505 0.4269 0.009518 0.09524 0.3845 1.649 60,001 120,000
OR[12,15] 0.8652 0.8256 0.01346 0.1305 0.6307 2.967 60,001 120,000
OR[13,14] 0.586 0.4309 0.009998 0.1292 0.4709 1.713 60,001 120,000
OR[13,15] 0.9556 0.6968 0.0132 0.2162 0.7649 2.795 60,001 120,000
OR[14,15] 2.438 2.821 0.04791 0.2808 1.604 9.457 60,001 120,000
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Median ranks
TABLE 130 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 5.78 1.344 0.02774 3 6 8 60,001 120,000
rk.class[2] 2.664 2.226 0.05422 1 2 9 60,001 120,000
rk.class[3] 6.692 1.38 0.02303 4 7 9 60,001 120,000
rk.class[4] 2.837 2.135 0.0419 1 2 9 60,001 120,000
rk.class[5] 8.961 1.021 0.01685 7 9 10 60,001 120,000
rk.class[6] 7.226 2.173 0.04225 3 8 10 60,001 120,000
rk.class[7] 4.771 1.969 0.04022 2 4 9 60,001 120,000
rk.class[8] 7.578 2.311 0.04114 3 8 10 60,001 120,000
rk.class[9] 3.207 2.094 0.0453 1 3 9 60,001 120,000
rk.class[10] 5.285 2.857 0.05624 1 5 10 60,001 120,000
TABLE 131 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 7.092 2.338 0.05465 3 7 12 60,001 120,000
rk[2] 3.149 3.453 0.08171 1 2 14 60,001 120,000
rk[3] 10.17 2.411 0.03526 5 10 14 60,001 120,000
rk[4] 8.965 2.477 0.02875 4 9 13 60,001 120,000
rk[5] 9.624 2.378 0.03381 5 10 14 60,001 120,000
rk[6] 8.449 2.552 0.03386 4 8 13 60,001 120,000
rk[7] 8.675 2.786 0.03903 3 9 14 60,001 120,000
rk[8] 3.268 3.238 0.0601 1 2 14 60,001 120,000
rk[9] 13.78 1.326 0.01856 10 14 15 60,001 120,000
rk[10] 10.24 4.218 0.08325 3 12 15 60,001 120,000
rk[11] 5.78 3.485 0.06809 2 5 14 60,001 120,000
rk[12] 10.86 4.307 0.07552 3 13 15 60,001 120,000
rk[13] 9.121 2.662 0.03399 4 9 14 60,001 120,000
rk[14] 3.817 3.428 0.07177 1 3 14 60,001 120,000
rk[15] 7.009 4.923 0.09658 1 5 15 60,001 120,000
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Adults/acceptability (dropouts): sensitivity analysis 3 (blinding)
See Table 30 of the main report for a summary.
TABLE 132 Raw data used
Study r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] na[] t[,1] t[,2] t[,3] t[,4]
Albert et al., 2002155 1 26 7 47 NA NA NA NA 2 7 8 NA NA
Andersson et al.,
2012158
2 50 0 51 NA NA NA NA 2 10 14 NA NA
Belloch et al., 2008159 2 15 2 18 NA NA NA NA 2 9 11 NA NA
Belotto-Silva et al.,
2012160
33 88 18 70 NA NA NA NA 2 3 10 NA NA
Cordioli et al.,
2003164
1 24 1 23 NA NA NA NA 2 2 10 NA NA
Cottraux et al.,
2001166
3 33 2 32 NA NA NA NA 2 9 11 NA NA
Denys et al., 2003167 9 75 4 75 NA NA NA NA 2 5 7 NA NA
Emmelkamp and
Beens, 1991168
4 15 5 15 NA NA NA NA 2 9 11 NA NA
Emmelkamp
et al., 1988169
1 10 1 10 NA NA NA NA 2 9 11 NA NA
Foa et al., 2005171 12 32 20 47 16 37 14 33 4 1 8 9 12
Goodman et al.,
1989176
6 23 2 23 NA NA NA NA 2 1 4 NA NA
Jenike et al., 1990184 0 20 2 20 NA NA NA NA 2 1 4 NA NA
Nakatani et al.,
2005202
1 11 1 11 1 9 NA NA 3 4 9 14 NA
O’Connor et al.,
1999203
0 6 1 7 NA NA NA NA 2 2 10 NA NA
Perse et al., 1987205 2 10 2 10 NA NA NA NA 2 1 4 NA NA
Sousa et al., 2006207 3 28 3 28 NA NA NA NA 2 6 10 NA NA
Stein et al., 2007124 16 115 29 119 24 116 21 116 4 1 5 13 13
Whittal et al., 2005211 13 42 11 41 NA NA NA NA 2 9 11 NA NA
NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine,
5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine, 9= clomipramine, 10= BT, 11=CBT, 12=CT,
13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo;
t[i,2], type of treatment [i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4];
y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [1]; y[i,2], total
mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean
YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS
scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total number of patients for
arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of
patients for arm [4]; sd[i,1], SD of mean total score or change from baseline for arm [1]; sd[i,2], SD of mean total score or
change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3]; sd[i,4], SD of mean
total score or change from baseline for arm [4].
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Key: intervention
1. Placebo (1).
2. Waitlist (2).
3. Fluoxetine (3).
4. Fluvoxamine (3).
5. Paroxetine (3).
6. Sertraline (3).
7. Venlafaxine (4).
8. Clomipramine (5).
9. BT (6).
10. CBT (7).
11. CT (8).
12. BT+ clomipramine (9).
13. Escitalopram (3).
14. Psychological placebo (10).
TABLE 133 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[1,2] 152 4922 87.87 0.008968 0.4497 31.84 51,001 100,000
OR.D[1,3] 3979 1.23E+ 06 3875 0.4603 1.393 8.446 51,001 100,000
OR.D[1,4] 0.6071 0.6553 0.009367 0.1033 0.4765 1.792 51,001 100,000
OR.D[1,5] 1.613 1.243 0.02013 0.4567 1.365 4.242 51,001 100,000
OR.D[1,6] 1.454 0.9819 0.02283 0.389 1.23 3.832 51,001 100,000
OR.D[1,7] 73.75 1239 32.56 0.2699 1.13 32.32 51,001 100,000
OR.D[1,8] 1.401 1.288 0.02571 0.2702 1.102 4.305 51,001 100,000
OR.D[1,9] 1.534 1.585 0.01918 0.3576 1.245 4.265 51,001 100,000
OR.D[1,10] 0.7989 2.118 0.04562 0.01122 0.3155 4.512 51,001 100,000
OR.D[2,3] 32.22 1103 10.24 0.08203 3.185 147.4 51,001 100,000
OR.D[2,4] 11.11 83.76 2.895 0.01178 1.078 63.15 51,001 100,000
OR.D[2,5] 28.7 224 4.765 0.04023 3.027 173.3 51,001 100,000
OR.D[2,6] 23.47 169 3.246 0.0359 2.674 154.7 51,001 100,000
OR.D[2,7] 17.79 105.6 3.952 0.1951 2.643 96.55 51,001 100,000
OR.D[2,8] 22.5 164.5 2.995 0.02847 2.397 154.9 51,001 100,000
OR.D[2,9] 27.55 231.1 4.559 0.03399 2.699 168.1 51,001 100,000
OR.D[2,10] 10 88.01 1.697 0.006203 0.6522 58.37 51,001 100,000
OR.D[3,4] 0.5516 6.26 0.02648 0.03969 0.3283 1.64 51,001 100,000
OR.D[3,5] 1.548 21.95 0.08582 0.1324 0.9603 4.349 51,001 100,000
OR.D[3,6] 1.394 18.9 0.084 0.1135 0.8725 3.93 51,001 100,000
OR.D[3,7] 165.2 17080 104 0.2389 0.8059 10.16 51,001 100,000
OR.D[3,8] 1.339 17.54 0.08425 0.08769 0.7797 4.174 51,001 100,000
OR.D[3,9] 1.51 20.48 0.08574 0.1038 0.879 4.469 51,001 100,000
OR.D[3,10] 0.7554 19.39 0.1018 0.005801 0.2135 3.12 51,001 100,000
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TABLE 133 Class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[4,5] 4.067 5.741 0.07591 0.6797 2.888 14.33 51,001 100,000
OR.D[4,6] 3.969 7.597 0.09576 0.5143 2.581 15.37 51,001 100,000
OR.D[4,7] 162.5 5480 72.81 0.3688 2.529 77.18 51,001 100,000
OR.D[4,8] 3.851 10.3 0.1033 0.3951 2.334 15.66 51,001 100,000
OR.D[4,9] 4.291 28.47 0.1184 0.4971 2.638 16.23 51,001 100,000
OR.D[4,10] 2.209 11.24 0.1245 0.01927 0.6745 12.7 51,001 100,000
OR.D[5,6] 1.063 0.8671 0.01063 0.2796 0.9051 2.705 51,001 100,000
OR.D[5,7] 53.63 1217 23.62 0.1463 0.8476 25.91 51,001 100,000
OR.D[5,8] 1.027 1.064 0.01292 0.1933 0.825 3.082 51,001 100,000
OR.D[5,9] 1.174 21.38 0.06714 0.2696 0.9156 3.015 51,001 100,000
OR.D[5,10] 0.6488 2.325 0.03773 0.007115 0.2285 3.77 51,001 100,000
OR.D[6,7] 51.09 980.7 21.95 0.1649 0.9436 28.15 51,001 100,000
OR.D[6,8] 0.9692 0.419 0.006677 0.399 0.8962 1.974 51,001 100,000
OR.D[6,9] 1.261 1.79 0.01434 0.2964 1.01 3.552 51,001 100,000
OR.D[6,10] 0.6732 1.755 0.03503 0.008585 0.2545 3.894 51,001 100,000
OR.D[7,8] 1.511 2.605 0.04271 0.0287 0.9467 6.442 51,001 100,000
OR.D[7,9] 1.693 2.819 0.04429 0.03419 1.07 7.002 51,001 100,000
OR.D[7,10] 0.5852 1.228 0.02428 0.004288 0.2484 3.305 51,001 100,000
OR.D[8,9] 1.557 3.091 0.02495 0.2675 1.11 5.031 51,001 100,000
OR.D[8,10] 0.8188 2.603 0.04028 0.009494 0.2793 4.781 51,001 100,000
OR.D[9,10] 0.7617 3.158 0.04598 0.007292 0.2495 4.548 51,001 100,000
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TABLE 134 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[1,2] 152 4922 87.87 0.008968 0.4497 31.84 51,001 100,000
OR[1,3] 150.8 3586 68.23 0.4545 1.596 47.92 51,001 100,000
OR[1,4] 1.217 0.6273 0.01446 0.3597 1.111 2.71 51,001 100,000
OR[1,5] 1.72 0.8848 0.01686 0.6758 1.553 3.743 51,001 100,000
OR[1,6] 73.78 1696 31.3 0.3077 1.379 31.95 51,001 100,000
OR[1,7] 0.6071 0.6553 0.009367 0.1033 0.4765 1.792 51,001 100,000
OR[1,8] 1.613 1.243 0.02013 0.4567 1.365 4.242 51,001 100,000
OR[1,9] 1.454 0.9819 0.02283 0.389 1.23 3.832 51,001 100,000
OR[1,10] 73.75 1239 32.56 0.2699 1.13 32.32 51,001 100,000
OR[1,11] 1.401 1.288 0.02571 0.2702 1.102 4.305 51,001 100,000
OR[1,12] 1.534 1.585 0.01918 0.3576 1.245 4.265 51,001 100,000
OR[1,13] 1.471 0.689 0.01231 0.6171 1.345 3.052 51,001 100,000
OR[1,14] 0.7989 2.118 0.04562 0.01122 0.3155 4.512 51,001 100,000
OR[2,3] 34.22 264 10.73 0.2374 3.935 156.5 51,001 100,000
OR[2,4] 18.5 134.4 2.619 0.02751 2.502 122.5 51,001 100,000
OR[2,5] 32.51 244.1 9.505 0.05415 3.514 165.2 51,001 100,000
OR[2,6] 23.97 159.1 4.641 0.1471 3.286 138.2 51,001 100,000
OR[2,7] 11.11 83.76 2.895 0.01178 1.078 63.15 51,001 100,000
OR[2,8] 28.7 224 4.765 0.04023 3.027 173.3 51,001 100,000
OR[2,9] 23.47 169 3.246 0.0359 2.674 154.7 51,001 100,000
OR[2,10] 17.79 105.6 3.952 0.1951 2.643 96.55 51,001 100,000
OR[2,11] 22.5 164.5 2.995 0.02847 2.397 154.9 51,001 100,000
OR[2,12] 27.55 231.1 4.559 0.03399 2.699 168.1 51,001 100,000
OR[2,13] 27.22 192.5 7.15 0.04512 3.027 143.9 51,001 100,000
OR[2,14] 10 88.01 1.697 0.006203 0.6522 58.37 51,001 100,000
OR[3,4] 0.7975 0.8508 0.01561 0.01678 0.7818 2.066 51,001 100,000
OR[3,5] 1.117 1.496 0.02527 0.03745 0.9739 3.523 51,001 100,000
OR[3,6] 0.998 1.358 0.01299 0.1535 0.905 2.805 51,001 100,000
OR[3,7] 0.4126 0.6574 0.01098 0.008698 0.2753 1.595 51,001 100,000
OR[3,8] 1.143 1.597 0.02741 0.02543 0.8109 4.296 51,001 100,000
OR[3,9] 1.027 1.388 0.02688 0.02361 0.7378 3.823 51,001 100,000
OR[3,10] 0.7776 0.6861 0.007148 0.2685 0.6659 1.917 51,001 100,000
OR[3,11] 0.9895 1.62 0.02709 0.01931 0.6511 4.049 51,001 100,000
OR[3,12] 1.104 2.034 0.02713 0.02211 0.7441 4.324 51,001 100,000
OR[3,13] 0.9643 1.043 0.02005 0.03015 0.8941 2.856 51,001 100,000
OR[3,14] 0.4151 0.9116 0.01623 0.002788 0.17 2.337 51,001 100,000
OR[4,5] 1.757 1.566 0.03598 0.5864 1.268 5.632 51,001 100,000
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TABLE 134 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[4,6] 100.8 3975 44.84 0.3373 1.112 39.76 51,001 100,000
OR[4,7] 0.6237 0.8566 0.01435 0.08239 0.4301 2.36 51,001 100,000
OR[4,8] 1.643 1.742 0.02581 0.324 1.26 5.148 51,001 100,000
OR[4,9] 1.459 1.268 0.02568 0.2825 1.133 4.615 51,001 100,000
OR[4,10] 101.5 2850 47.36 0.2779 0.9784 38.56 51,001 100,000
OR[4,11] 1.41 1.592 0.02855 0.202 1.021 4.845 51,001 100,000
OR[4,12] 1.57 2.265 0.02606 0.2494 1.15 5.256 51,001 100,000
OR[4,13] 1.478 1.2 0.02542 0.5054 1.121 4.393 51,001 100,000
OR[4,14] 0.785 2.859 0.05705 0.01034 0.2822 4.699 51,001 100,000
OR[5,6] 45.35 1173 19.2 0.1867 0.9605 18.74 51,001 100,000
OR[5,7] 0.3742 0.3079 0.004739 0.07501 0.3054 1.066 51,001 100,000
OR[5,8] 1.102 1.129 0.01452 0.2359 0.8748 3.306 51,001 100,000
OR[5,9] 1.003 1.032 0.01642 0.1985 0.7967 3.013 51,001 100,000
OR[5,10] 44.66 887.9 19.56 0.1731 0.7456 17.27 51,001 100,000
OR[5,11] 0.9724 1.31 0.01864 0.1458 0.7106 3.291 51,001 100,000
OR[5,12] 1.07 1.631 0.01582 0.1884 0.7991 3.444 51,001 100,000
OR[5,13] 0.9188 0.4319 0.003572 0.4308 0.8998 1.647 51,001 100,000
OR[5,14] 0.5317 1.788 0.02894 0.0069 0.2026 2.868 51,001 100,000
OR[6,7] 0.5237 1.113 0.01673 0.01317 0.3253 2.155 51,001 100,000
OR[6,8] 1.436 2.266 0.03625 0.04136 0.9614 5.728 51,001 100,000
OR[6,9] 1.29 1.995 0.03352 0.03558 0.8692 5.076 51,001 100,000
OR[6,10] 1.13 1.371 0.02336 0.2315 0.8161 3.98 51,001 100,000
OR[6,11] 1.241 2.215 0.0338 0.03067 0.7737 5.315 51,001 100,000
OR[6,12] 1.398 2.809 0.03729 0.03484 0.8787 5.802 51,001 100,000
OR[6,13] 1.247 1.877 0.03297 0.04378 0.9897 4.4 51,001 100,000
OR[6,14] 0.5442 1.333 0.02444 0.003587 0.2063 3.131 51,001 100,000
OR[7,8] 4.067 5.741 0.07591 0.6797 2.888 14.33 51,001 100,000
OR[7,9] 3.969 7.597 0.09576 0.5143 2.581 15.37 51,001 100,000
OR[7,10] 162.5 5480 72.81 0.3688 2.529 77.18 51,001 100,000
OR[7,11] 3.851 10.3 0.1033 0.3951 2.334 15.66 51,001 100,000
OR[7,12] 4.291 28.47 0.1184 0.4971 2.638 16.23 51,001 100,000
OR[7,13] 3.887 5.254 0.058 0.7515 2.852 12.69 51,001 100,000
OR[7,14] 2.209 11.24 0.1245 0.01927 0.6745 12.7 51,001 100,000
OR[8,9] 1.063 0.8671 0.01063 0.2796 0.9051 2.705 51,001 100,000
OR[8,10] 53.63 1217 23.62 0.1463 0.8476 25.91 51,001 100,000
OR[8,11] 1.027 1.064 0.01292 0.1933 0.825 3.082 51,001 100,000
continued
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TABLE 134 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[8,12] 1.174 21.38 0.06714 0.2696 0.9156 3.015 51,001 100,000
OR[8,13] 1.235 1.519 0.01609 0.2701 0.9917 3.478 51,001 100,000
OR[8,14] 0.6488 2.325 0.03773 0.007115 0.2285 3.77 51,001 100,000
OR[9,10] 51.09 980.7 21.95 0.1649 0.9436 28.15 51,001 100,000
OR[9,11] 0.9692 0.419 0.006677 0.399 0.8962 1.974 51,001 100,000
OR[9,12] 1.261 1.79 0.01434 0.2964 1.01 3.552 51,001 100,000
OR[9,13] 1.413 1.623 0.024 0.2926 1.088 4.286 51,001 100,000
OR[9,14] 0.6732 1.755 0.03503 0.008585 0.2545 3.894 51,001 100,000
OR[10,11] 1.511 2.605 0.04271 0.0287 0.9467 6.442 51,001 100,000
OR[10,12] 1.693 2.819 0.04429 0.03419 1.07 7.002 51,001 100,000
OR[10,13] 1.496 1.557 0.0339 0.04613 1.2 4.728 51,001 100,000
OR[10,14] 0.5852 1.228 0.02428 0.004288 0.2484 3.305 51,001 100,000
OR[11,12] 1.557 3.091 0.02495 0.2675 1.11 5.031 51,001 100,000
OR[11,13] 1.732 3.124 0.03549 0.2743 1.219 5.876 51,001 100,000
OR[11,14] 0.8188 2.603 0.04028 0.009494 0.2793 4.781 51,001 100,000
OR[12,13] 1.45 2.263 0.02083 0.26 1.089 4.543 51,001 100,000
OR[12,14] 0.7617 3.158 0.04598 0.007292 0.2495 4.548 51,001 100,000
OR[13,14] 0.6143 2.41 0.03865 0.007926 0.2316 3.491 51,001 100,000
Median ranks
TABLE 135 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 5.418 1.917 0.05405 2 5 9 51,001 100,000
rk.class[2] 3.984 3.344 0.1012 1 2 10 51,001 100,000
rk.class[3] 7.261 2.131 0.04101 3 8 10 51,001 100,000
rk.class[4] 2.994 1.916 0.04307 1 2 8 51,001 100,000
rk.class[5] 7.046 2.182 0.04165 3 7 10 51,001 100,000
rk.class[6] 6.563 2.13 0.05017 2 7 10 51,001 100,000
rk.class[7] 6.274 2.66 0.07429 2 6 10 51,001 100,000
rk.class[8] 5.941 2.536 0.06181 2 6 10 51,001 100,000
rk.class[9] 6.526 2.477 0.04874 2 7 10 51,001 100,000
rk.class[10] 2.993 2.676 0.07246 1 2 10 51,001 100,000
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TABLE 136 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 6.415 2.601 0.07389 2 6 12 51,001 100,000
rk[2] 4.926 4.714 0.1413 1 2 14 51,001 100,000
rk[3] 10.39 3.102 0.07114 4 11 14 51,001 100,000
rk[4] 7.418 3.237 0.07896 2 7 13 51,001 100,000
rk[5] 10.12 2.676 0.05522 4 10 14 51,001 100,000
rk[6] 9.112 3.418 0.07303 2 10 14 51,001 100,000
rk[7] 3.345 2.514 0.0553 1 3 11 51,001 100,000
rk[8] 8.995 3.442 0.06933 3 9 14 51,001 100,000
rk[9] 8.296 3.405 0.08337 3 8 14 51,001 100,000
rk[10] 7.695 3.817 0.1051 2 7 14 51,001 100,000
rk[11] 7.492 3.872 0.09628 2 7 14 51,001 100,000
rk[12] 8.291 3.806 0.07692 2 8 14 51,001 100,000
rk[13] 8.951 2.766 0.05694 3 9 14 51,001 100,000
rk[14] 3.546 3.729 0.09996 1 2 14 51,001 100,000
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Children and adolescents: clinical effectiveness (Children’s Yale–Brown Obsessive–Compulsive Scale) –
sensitivity analysis 1 (low overall attrition)
See Table 38 for a summary.
TABLE 137 Raw data used
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Barrett et al., 2004217 24.04 24 4.14 8.36 22 6.93 NA NA NA NA NA NA 2 2 2 9 NA NA
Bolton et al., 2011219 23.3 24 8.3 9.5 36 8 NA NA NA NA NA NA 2 2 2 9 NA NA
de Haan et al., 1998220 17.6 10 11.8 9.1 12 9.1 NA NA NA NA NA NA 2 2 7 8 NA NA
DeVeaugh-Geiss et al., 1992221 –2.4 29 NA –10 31 NA NA NA NA NA NA NA 2 1 1 7 NA NA
Liebowitz et al., 2002226 18.55 22 11.44 14.71 21 8.73 NA NA NA NA NA NA 2 2 1 4 NA NA
March et al., 1998228 –3.4 95 7.99 –6.8 92 8.34 NA NA NA NA NA NA 2 1 1 6 NA NA
Neziroglu et al., 2000229 19.2 5 3.56 16.4 5 5.18 NA NA NA NA NA NA 2 2 5 10 NA NA
Piacentini et al., 2011230 17.2 22 10.04 13.3 49 9.31 NA NA NA NA NA NA 2 2 3 9 NA NA
Riddle et al., 1992231 14.8 6 7 13.6 7 5.7 NA NA NA NA NA NA 2 2 1 4 NA NA
Storch et al., 2011233 18.53 15 8.11 11.13 16 10.53 NA NA NA NA NA NA 2 2 2 9 NA NA
The Pediatric OCD Treatment
Study, 2004236
21.5 28 5.4 16.5 28 9.1 14 28 9.5 11.2 28 8.6 4 2 1 6 9 11
Williams et al., 2010235 19.6 10 6.42 12.09 11 7.46 NA NA NA NA NA NA 2 2 2 9 NA NA
NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine,
9= clomipramine, 10= BT, 11=CBT, 12=CT, 13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo; t[i,2], type of treatment
[i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4]; y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline
(negative) for arm [1]; y[i,2], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean YBOCS scores at end of
study (positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [4];
n[i,1], total number of patients for arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of patients for arm [4];
sd[i,1], SD of mean total score or change from baseline for arm [1]; sd[i,2], SD of mean total score or change from baseline for arm [2]; sd[i,3], SD of mean total score or change from
baseline for arm [3]; sd[i,4], SD of mean total score or change from baseline for arm [4].
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1. Placebo (1).
2. Waitlist (2).
3. Psychological placebo (3).
4. Fluoxetine (4).
5. Fluvoxamine (4).
6. Sertraline (4).
7. Clomipramine (5).
8. BT (6).
9. CBT (7).
10. BT+ fluvoxamine (8).
11. CBT+ sertraline (9).
TABLE 138 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[1,2] 2.471 4.254 0.04991 –6.717 2.678 10.43 60,001 120,000
class.mean.diff[1,3] –4.879 5.939 0.05252 –16.98 –4.833 6.948 60,001 120,000
class.mean.diff[1,4] –3.651 4.109 0.02343 –12.37 –3.65 5.012 60,001 120,000
class.mean.diff[1,5] –5.281 4.024 0.02711 –12.97 –5.438 3.279 60,001 120,000
class.mean.diff[1,6] –8.746 5.186 0.05006 –19.24 –8.693 1.434 60,001 120,000
class.mean.diff[1,7] –8.815 3.767 0.04254 –16.67 –8.731 –1.379 60,001 120,000
class.mean.diff[1,8] 0.2639 99.73 0.2666 –195.2 0.2606 196.1 60,001 120,000
class.mean.diff[1,9] –10.37 3.942 0.0225 –18.48 –10.34 –2.396 60,001 120,000
class.mean.diff[2,3] –7.35 5.144 0.0299 –17.29 –7.525 3.555 60,001 120,000
class.mean.diff[2,4] –6.122 5.605 0.04701 –17.24 –6.272 5.586 60,001 120,000
class.mean.diff[2,5] –7.752 5.155 0.04911 –17.15 –8.051 3.338 60,001 120,000
class.mean.diff[2,6] –11.22 4.622 0.03467 –20.2 –11.3 –1.699 60,001 120,000
class.mean.diff[2,7] –11.29 2.292 0.01522 –15.49 –11.43 –6.302 60,001 120,000
class.mean.diff[2,8] –2.207 99.82 0.2719 –197.7 –2.057 193.8 60,001 120,000
class.mean.diff[2,9] –12.84 4.905 0.03839 –22.23 –13.05 –2.42 60,001 120,000
class.mean.diff[3,4] 1.229 6.964 0.05114 –12.77 1.218 15.34 60,001 120,000
class.mean.diff[3,5] –0.4019 6.707 0.05144 –13.43 –0.5988 13.56 60,001 120,000
class.mean.diff[3,6] –3.867 6.664 0.04516 –17.32 –3.806 9.334 60,001 120,000
class.mean.diff[3,7] –3.936 4.597 0.02564 –13.3 –3.925 5.317 60,001 120,000
class.mean.diff[3,8] 5.143 99.92 0.2723 –190.4 5.036 201.1 60,001 120,000
class.mean.diff[3,9] –5.492 6.376 0.04277 –18.37 –5.508 7.428 60,001 120,000
class.mean.diff[4,5] –1.63 5.688 0.03357 –12.95 –1.782 10.29 60,001 120,000
class.mean.diff[4,6] –5.095 6.439 0.04859 –18.23 –5.069 7.824 60,001 120,000
class.mean.diff[4,7] –5.165 5.235 0.04034 –15.99 –5.112 5.531 60,001 120,000
class.mean.diff[4,8] 3.915 99.81 0.2666 –191.6 3.966 199.8 60,001 120,000
class.mean.diff[4,9] –6.72 5.336 0.02461 –17.73 –6.691 4.15 60,001 120,000
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TABLE 138 Class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[5,6] –3.465 4.932 0.04626 –13.73 –3.342 5.82 60,001 120,000
class.mean.diff[5,7] –3.534 4.916 0.04128 –13.94 –3.353 5.827 60,001 120,000
class.mean.diff[5,8] 5.545 99.8 0.2687 –190.2 5.557 201.4 60,001 120,000
class.mean.diff[5,9] –5.09 5.429 0.03003 –16.57 –4.93 5.561 60,001 120,000
class.mean.diff[6,7] –0.06935 4.832 0.03434 –9.674 –0.08316 9.604 60,001 120,000
class.mean.diff[6,8] 9.01 99.88 0.2713 –186.5 9.135 205.2 60,001 120,000
class.mean.diff[6,9] –1.625 6.011 0.04339 –13.52 –1.671 10.61 60,001 120,000
class.mean.diff[7,8] 9.079 99.81 0.2712 –186.3 9.163 204.8 60,001 120,000
class.mean.diff[7,9] –1.556 4.423 0.03107 –10.42 –1.609 7.512 60,001 120,000
class.mean.diff[8,9] –10.64 99.8 0.2678 –206.6 –10.73 185 60,001 120,000
TABLE 139 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[1,2] 2.471 4.254 0.04991 –6.717 2.678 10.43 60,001 120,000
treat.mean.diff[1,3] –4.879 5.939 0.05252 –16.98 –4.833 6.948 60,001 120,000
treat.mean.diff[1,4] –3.182 2.968 0.02477 –9.123 –3.215 2.866 60,001 120,000
treat.mean.diff[1,5] –3.642 6.385 0.02701 –17.44 –3.651 10.31 60,001 120,000
treat.mean.diff[1,6] –4.095 2.574 0.01928 –9.473 –4.04 1.102 60,001 120,000
treat.mean.diff[1,7] –5.281 4.024 0.02711 –12.97 –5.438 3.279 60,001 120,000
treat.mean.diff[1,8] –8.746 5.186 0.05006 –19.24 –8.693 1.434 60,001 120,000
treat.mean.diff[1,9] –8.815 3.767 0.04254 –16.67 –8.731 –1.379 60,001 120,000
treat.mean.diff[1,10] 0.2639 99.73 0.2666 –195.2 0.2606 196.1 60,001 120,000
treat.mean.diff[1,11] –10.37 3.942 0.0225 –18.48 –10.34 –2.396 60,001 120,000
treat.mean.diff[2,3] –7.35 5.144 0.0299 –17.29 –7.525 3.555 60,001 120,000
treat.mean.diff[2,4] –5.653 5.001 0.05007 –15.18 –5.845 4.865 60,001 120,000
treat.mean.diff[2,5] –6.113 7.448 0.04875 –21.47 –6.269 9.754 60,001 120,000
treat.mean.diff[2,6] –6.566 4.444 0.04359 –14.99 –6.748 2.867 60,001 120,000
treat.mean.diff[2,7] –7.752 5.155 0.04911 –17.15 –8.051 3.338 60,001 120,000
treat.mean.diff[2,8] –11.22 4.622 0.03467 –20.2 –11.3 –1.699 60,001 120,000
treat.mean.diff[2,9] –11.29 2.292 0.01522 –15.49 –11.43 –6.302 60,001 120,000
treat.mean.diff[2,10] –2.207 99.82 0.2719 –197.7 –2.057 193.8 60,001 120,000
treat.mean.diff[2,11] –12.84 4.905 0.03839 –22.23 –13.05 –2.42 60,001 120,000
treat.mean.diff[3,4] 1.697 6.507 0.05416 –11.24 1.662 14.9 60,001 120,000
treat.mean.diff[3,5] 1.237 8.525 0.05203 –16.21 1.204 18.89 60,001 120,000
treat.mean.diff[3,6] 0.784 6.073 0.04761 –11.36 0.7809 13.12 60,001 120,000
treat.mean.diff[3,7] –0.4019 6.707 0.05144 –13.43 –0.5988 13.56 60,001 120,000
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TABLE 139 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[3,8] –3.867 6.664 0.04516 –17.32 –3.806 9.334 60,001 120,000
treat.mean.diff[3,9] –3.936 4.597 0.02564 –13.3 –3.925 5.317 60,001 120,000
treat.mean.diff[3,10] 5.143 99.92 0.2723 –190.4 5.036 201.1 60,001 120,000
treat.mean.diff[3,11] –5.492 6.376 0.04277 –18.37 –5.508 7.428 60,001 120,000
treat.mean.diff[4,5] –0.4598 6.181 0.01977 –14.4 –0.1438 13.03 60,001 120,000
treat.mean.diff[4,6] –0.913 3.208 0.02058 –7.98 –0.5303 5.333 60,001 120,000
treat.mean.diff[4,7] –2.099 4.957 0.03573 –11.63 –2.261 8.27 60,001 120,000
treat.mean.diff[4,8] –5.564 5.862 0.05201 –17.46 –5.511 5.995 60,001 120,000
treat.mean.diff[4,9] –5.633 4.583 0.0439 –15.09 –5.557 3.418 60,001 120,000
treat.mean.diff[4,10] 3.446 99.76 0.2674 –192.1 3.492 199 60,001 120,000
treat.mean.diff[4,11] –7.189 4.714 0.02868 –16.81 –7.143 2.24 60,001 120,000
treat.mean.diff[5,6] –0.4533 6.174 0.01938 –14.45 –0.1494 13.01 60,001 120,000
treat.mean.diff[5,7] –1.639 7.493 0.03619 –17.22 –1.765 14.15 60,001 120,000
treat.mean.diff[5,8] –5.104 8.093 0.05014 –21.92 –5.037 11.51 60,001 120,000
treat.mean.diff[5,9] –5.173 7.174 0.04209 –20.44 –5.091 9.874 60,001 120,000
treat.mean.diff[5,10] 3.906 99.94 0.2665 –191.8 3.929 199.6 60,001 120,000
treat.mean.diff[5,11] –6.729 7.247 0.02775 –22.07 –6.672 8.425 60,001 120,000
treat.mean.diff[6,7] –1.186 4.666 0.0301 –10.21 –1.375 8.722 60,001 120,000
treat.mean.diff[6,8] –4.651 5.503 0.04559 –15.79 –4.608 6.166 60,001 120,000
treat.mean.diff[6,9] –4.72 3.962 0.03644 –12.9 –4.687 3.202 60,001 120,000
treat.mean.diff[6,10] 4.359 99.76 0.266 –191 4.419 200.1 60,001 120,000
treat.mean.diff[6,11] –6.276 4.071 0.01856 –14.61 –6.278 2.007 60,001 120,000
treat.mean.diff[7,8] –3.465 4.932 0.04626 –13.73 –3.342 5.82 60,001 120,000
treat.mean.diff[7,9] –3.534 4.916 0.04128 –13.94 –3.353 5.827 60,001 120,000
treat.mean.diff[7,10] 5.545 99.8 0.2687 –190.2 5.557 201.4 60,001 120,000
treat.mean.diff[7,11] –5.09 5.429 0.03003 –16.57 –4.93 5.561 60,001 120,000
treat.mean.diff[8,9] –0.06935 4.832 0.03434 –9.674 –0.08316 9.604 60,001 120,000
treat.mean.diff[8,10] 9.01 99.88 0.2713 –186.5 9.135 205.2 60,001 120,000
treat.mean.diff[8,11] –1.625 6.011 0.04339 –13.52 –1.671 10.61 60,001 120,000
treat.mean.diff[9,10] 9.079 99.81 0.2712 –186.3 9.163 204.8 60,001 120,000
treat.mean.diff[9,11] –1.556 4.423 0.03107 –10.42 –1.609 7.512 60,001 120,000
treat.mean.diff[10,11] –10.64 99.8 0.2678 –206.6 –10.73 185 60,001 120,000
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Median ranks
TABLE 140 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 7.268 1.042 0.00809 5 7 9 60,001 120,000
rk.class[2] 7.974 1.049 0.008874 5 8 9 60,001 120,000
rk.class[3] 5.095 1.939 0.01367 1 5 9 60,001 120,000
rk.class[4] 5.551 1.746 0.01018 2 6 9 60,001 120,000
rk.class[5] 4.854 1.675 0.01267 2 5 8 60,001 120,000
rk.class[6] 3.335 1.728 0.01424 1 3 7 60,001 120,000
rk.class[7] 3.156 1.264 0.009132 1 3 6 60,001 120,000
rk.class[8] 5.168 3.9 0.01086 1 7 9 60,001 120,000
rk.class[9] 2.598 1.455 0.009453 1 2 6 60,001 120,000
TABLE 141 Median ranks: individual effects
Intervention code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 9.028 1.221 0.00986 6 9 11 60,001 120,000
rk[2] 9.741 1.4 0.01252 6 10 11 60,001 120,000
rk[3] 5.932 2.619 0.02003 1 6 10 60,001 120,000
rk[4] 6.881 1.901 0.01429 3 7 10 60,001 120,000
rk[5] 6.491 2.716 0.01087 1 7 11 60,001 120,000
rk[6] 6.311 1.659 0.009755 3 6 9 60,001 120,000
rk[7] 5.552 2.245 0.01702 2 5 10 60,001 120,000
rk[8] 3.706 2.199 0.0186 1 3 9 60,001 120,000
rk[9] 3.397 1.542 0.01208 1 3 7 60,001 120,000
rk[10] 6.2 4.881 0.01359 1 9 11 60,001 120,000
rk[11] 2.76 1.678 0.01035 1 2 7 60,001 120,000
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Children and adolescents: clinical effectiveness (Children’s Yale–Brown Obsessive–Compulsive Scale) –
sensitivity analysis 2 (incomplete outcome data)
See Table 39 for a summary.
TABLE 142 Raw data used
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Bolton and Perrin, 2008218 21.1 10 5.9 13.9 10 10.74 NA NA NA NA NA NA 2 2 2 8 NA NA
Bolton et al., 2011219 23.3 24 8.3 9.5 36 8 NA NA NA NA NA NA 2 2 2 9 NA NA
de Haan et al., 1998220 17.6 10 11.8 9.1 12 9.1 NA NA NA NA NA NA 2 2 7 8 NA NA
DeVeaugh-Geiss et al., 1992221 –2.4 29 NA –10 31 NA NA NA NA NA NA NA 2 1 1 7 NA NA
Freeman et al., 2008223 17.1 20 7.57 14.45 22 8.16 NA NA NA NA NA NA 2 2 3 9 NA NA
Geller et al., 2001224 –5.2 32 7.4 –9.5 71 9.2 NA NA NA NA NA NA 2 1 1 4 NA NA
Liebowitz et al., 2002226 18.55 22 11.44 14.71 21 8.73 NA NA NA NA NA NA 2 2 1 4 NA NA
March et al., 1998228 –3.4 95 7.99 –6.8 92 8.34 NA NA NA NA NA NA 2 1 1 6 NA NA
Piacentini et al., 2011230 17.2 22 10.04 13.3 49 9.31 NA NA NA NA NA NA 2 2 3 9 NA NA
Riddle et al., 1992231 14.8 6 7 13.6 7 5.7 NA NA NA NA NA NA 2 2 1 4 NA NA
Riddle et al., 2001232 20.9 63 8.5 18.2 57 8.6 NA NA NA NA NA NA 2 2 1 5 NA NA
Storch et al., 2011233 18.53 15 8.11 11.13 16 10.53 NA NA NA NA NA NA 2 2 2 9 NA NA
Storch et al., 2013234 15.43 14 9.72 15.56 16 6.62 NA NA NA NA NA NA 2 2 11 12 NA NA
The Pediatric OCD Treatment
Study, 2004236
21.5 28 5.4 16.5 28 9.1 14 28 9.5 11.2 28 8.6 4 2 1 6 9 11
Williams et al., 2010235 19.6 10 6.42 12.09 11 7.46 NA NA NA NA NA NA 2 2 2 9 NA NA
NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine,
9= clomipramine, 10= BT, 11=CBT, 12=CT, 13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo; t[i,2], type of treatment
[i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4]; y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline
(negative) for arm [1]; y[i,2], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean YBOCS scores at end of study
(positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total
number of patients for arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of patients for arm [4]; sd[i,1], SD of mean total
score or change from baseline for arm [1]; sd[i,2], SD of mean total score or change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3];
sd[i,4], SD of mean total score or change from baseline for arm [4].
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Key: intervention (class)
1. Placebo (1).
2. Waitlist (2).
3. Psychological placebo (3).
4. Fluoxetine (4).
5. Fluvoxamine (4).
6. Sertraline (4).
7. Clomipramine (5).
8. BT (6).
9. CBT (7).
10. BT+ fluvoxamine (8).
11. CBT+ sertraline (9).
12. CBT+ placebo (10).
TABLE 143 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[1,2] 1.363 3.049 0.05907 –5.013 1.444 7.121 60,001 120,000
class.mean.diff[1,3] –5.085 3.408 0.06288 –11.91 –5.098 1.569 60,001 120,000
class.mean.diff[1,4] –3.548 2.208 0.01677 –8.156 –3.565 1.161 60,001 120,000
class.mean.diff[1,5] –6.145 2.705 0.03675 –11.25 –6.214 –0.5892 60,001 120,000
class.mean.diff[1,6] –9.581 4.048 0.07981 –17.62 –9.588 –1.608 60,001 120,000
class.mean.diff[1,7] –8.365 2.526 0.0484 –13.52 –8.269 –3.482 60,001 120,000
class.mean.diff[1,8] 0.4373 100.3 0.2885 –195.9 0.2245 197.4 60,001 120,000
class.mean.diff[1,9] –10.23 2.556 0.03305 –15.4 –10.18 –5.203 60,001 120,000
class.mean.diff[1,10] –10.06 4.455 0.06724 –18.84 –10.04 –1.324 60,001 120,000
class.mean.diff[2,3] –6.448 2.971 0.04237 –12.22 –6.502 –0.4866 60,001 120,000
class.mean.diff[2,4] –4.911 3.642 0.05624 –11.91 –5.009 2.769 60,001 120,000
class.mean.diff[2,5] –7.508 3.7 0.06175 –14.38 –7.615 0.277 60,001 120,000
class.mean.diff[2,6] –10.94 3.667 0.06444 –18.06 –10.93 –3.692 60,001 120,000
class.mean.diff[2,7] –9.727 1.92 0.02752 –13.36 –9.745 –5.811 60,001 120,000
class.mean.diff[2,8] –0.9256 100.3 0.294 –197.3 –1.027 195.9 60,001 120,000
class.mean.diff[2,9] –11.59 3.526 0.05615 –18.31 –11.63 –4.384 60,001 120,000
class.mean.diff[2,10] –11.42 5.085 0.07934 –21.21 –11.46 –1.213 60,001 120,000
class.mean.diff[3,4] 1.537 3.955 0.062 –6.206 1.52 9.541 60,001 120,000
class.mean.diff[3,5] –1.06 4.09 0.06442 –8.793 –1.139 7.256 60,001 120,000
class.mean.diff[3,6] –4.496 4.464 0.07391 –13.16 –4.444 4.25 60,001 120,000
class.mean.diff[3,7] –3.279 2.249 0.03004 –7.671 –3.273 1.118 60,001 120,000
class.mean.diff[3,8] 5.523 100.3 0.2939 –190.7 5.457 202.6 60,001 120,000
class.mean.diff[3,9] –5.142 3.815 0.05885 –12.49 –5.151 2.435 60,001 120,000
class.mean.diff[3,10] –4.97 5.277 0.07936 –15.19 –4.989 5.491 60,001 120,000
class.mean.diff[4,5] –2.597 3.469 0.0402 –9.328 –2.655 4.54 60,001 120,000
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TABLE 143 Class effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[4,6] –6.033 4.535 0.07846 –15.04 –6.033 2.981 60,001 120,000
class.mean.diff[4,7] –4.816 3.221 0.04684 –11.51 –4.736 1.559 60,001 120,000
class.mean.diff[4,8] 3.986 100.3 0.2891 –192.4 3.761 201.1 60,001 120,000
class.mean.diff[4,9] –6.68 3.239 0.03296 –13.41 –6.659 –0.1466 60,001 120,000
class.mean.diff[4,10] –6.507 4.878 0.06746 –16.16 –6.535 3.121 60,001 120,000
class.mean.diff[5,6] –3.436 3.95 0.07453 –11.41 –3.362 4.149 60,001 120,000
class.mean.diff[5,7] –2.219 3.42 0.05284 –9.22 –2.15 4.204 60,001 120,000
class.mean.diff[5,8] 6.583 100.3 0.2923 –189.9 6.298 203.6 60,001 120,000
class.mean.diff[5,9] –4.083 3.628 0.0451 –11.48 –4.054 2.863 60,001 120,000
class.mean.diff[5,10] –3.91 5.151 0.07278 –14.44 –3.836 5.87 60,001 120,000
class.mean.diff[6,7] 1.216 3.842 0.06653 –6.371 1.209 8.742 60,001 120,000
class.mean.diff[6,8] 10.02 100.4 0.2999 –186.6 9.879 207 60,001 120,000
class.mean.diff[6,9] –0.6469 4.525 0.07643 –9.481 –0.5944 8.237 60,001 120,000
class.mean.diff[6,10] –0.474 5.83 0.09455 –11.89 –0.4557 11.04 60,001 120,000
class.mean.diff[7,8] 8.802 100.3 0.2931 –187.7 8.671 205.9 60,001 120,000
class.mean.diff[7,9] –1.863 3.047 0.04461 –7.749 –1.912 4.25 60,001 120,000
class.mean.diff[7,10] –1.691 4.754 0.07025 –11.01 –1.702 7.813 60,001 120,000
class.mean.diff[8,9] –10.67 100.3 0.2919 –207.5 –10.56 185.8 60,001 120,000
class.mean.diff[8,10] –10.49 100.4 0.2988 –207.9 –10.35 185.9 60,001 120,000
class.mean.diff[9,10] 0.1729 3.673 0.05314 –7.111 0.1936 7.347 60,001 120,000
TABLE 144 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[1,2] 1.363 3.049 0.05907 –5.013 1.444 7.121 60,001 120,000
treat.mean.diff[1,3] –5.085 3.408 0.06288 –11.91 –5.098 1.569 60,001 120,000
treat.mean.diff[1,4] –3.59 1.493 0.02012 –6.527 –3.608 –0.5575 60,001 120,000
treat.mean.diff[1,5] –3.21 1.824 0.01881 –6.796 –3.282 0.5665 60,001 120,000
treat.mean.diff[1,6] –3.849 1.457 0.01748 –6.925 –3.797 –1.009 60,001 120,000
treat.mean.diff[1,7] –6.145 2.705 0.03675 –11.25 –6.214 –0.5892 60,001 120,000
treat.mean.diff[1,8] –9.581 4.048 0.07981 –17.62 –9.588 –1.608 60,001 120,000
treat.mean.diff[1,9] –8.365 2.526 0.0484 –13.52 –8.269 –3.482 60,001 120,000
treat.mean.diff[1,10] 0.4373 100.3 0.2885 –195.9 0.2245 197.4 60,001 120,000
treat.mean.diff[1,11] –10.23 2.556 0.03305 –15.4 –10.18 –5.203 60,001 120,000
treat.mean.diff[1,12] –10.06 4.455 0.06724 –18.84 –10.04 –1.324 60,001 120,000
treat.mean.diff[2,3] –6.448 2.971 0.04237 –12.22 –6.502 –0.4866 60,001 120,000
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TABLE 144 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[2,4] –4.952 3.313 0.0598 –11.14 –5.064 1.913 60,001 120,000
treat.mean.diff[2,5] –4.573 3.463 0.05694 –11.05 –4.669 2.673 60,001 120,000
treat.mean.diff[2,6] –5.212 3.132 0.05392 –11.14 –5.286 1.235 60,001 120,000
treat.mean.diff[2,7] –7.508 3.7 0.06175 –14.38 –7.615 0.277 60,001 120,000
treat.mean.diff[2,8] –10.94 3.667 0.06444 –18.06 –10.93 –3.692 60,001 120,000
treat.mean.diff[2,9] –9.727 1.92 0.02752 –13.36 –9.745 –5.811 60,001 120,000
treat.mean.diff[2,10] –0.9256 100.3 0.294 –197.3 –1.027 195.9 60,001 120,000
treat.mean.diff[2,11] –11.59 3.526 0.05615 –18.31 –11.63 –4.384 60,001 120,000
treat.mean.diff[2,12] –11.42 5.085 0.07934 –21.21 –11.46 –1.213 60,001 120,000
treat.mean.diff[3,4] 1.496 3.655 0.06534 –5.54 1.487 8.809 60,001 120,000
treat.mean.diff[3,5] 1.875 3.798 0.0631 –5.363 1.842 9.512 60,001 120,000
treat.mean.diff[3,6] 1.236 3.49 0.05974 –5.649 1.255 8.097 60,001 120,000
treat.mean.diff[3,7] –1.06 4.09 0.06442 –8.793 –1.139 7.256 60,001 120,000
treat.mean.diff[3,8] –4.496 4.464 0.07391 –13.16 –4.444 4.25 60,001 120,000
treat.mean.diff[3,9] –3.279 2.249 0.03004 –7.671 –3.273 1.118 60,001 120,000
treat.mean.diff[3,10] 5.523 100.3 0.2939 –190.7 5.457 202.6 60,001 120,000
treat.mean.diff[3,11] –5.142 3.815 0.05885 –12.49 –5.151 2.435 60,001 120,000
treat.mean.diff[3,12] –4.97 5.277 0.07936 –15.19 –4.989 5.491 60,001 120,000
treat.mean.diff[4,5] 0.3796 2.009 0.02054 –3.652 0.1615 4.763 60,001 120,000
treat.mean.diff[4,6] –0.2596 1.749 0.01835 –4.184 –0.093 3.129 60,001 120,000
treat.mean.diff[4,7] –2.556 3.06 0.04071 –8.389 –2.637 3.633 60,001 120,000
treat.mean.diff[4,8] –5.991 4.271 0.0814 –14.44 –5.982 2.48 60,001 120,000
treat.mean.diff[4,9] –4.775 2.846 0.05069 –10.58 –4.674 0.6795 60,001 120,000
treat.mean.diff[4,10] 4.027 100.3 0.2895 –192.2 3.917 200.9 60,001 120,000
treat.mean.diff[4,11] –6.638 2.862 0.03593 –12.41 –6.611 –1.025 60,001 120,000
treat.mean.diff[4,12] –6.465 4.648 0.07035 –15.64 –6.48 2.628 60,001 120,000
treat.mean.diff[5,6] –0.6391 1.982 0.01744 –5.16 –0.3132 3.009 60,001 120,000
treat.mean.diff[5,7] –2.935 3.26 0.04117 –9.154 –2.966 3.687 60,001 120,000
treat.mean.diff[5,8] –6.371 4.394 0.07759 –15.11 –6.364 2.291 60,001 120,000
treat.mean.diff[5,9] –5.154 3.018 0.04755 –11.34 –5.07 0.6257 60,001 120,000
treat.mean.diff[5,10] 3.647 100.3 0.2892 –192.8 3.437 200.6 60,001 120,000
treat.mean.diff[5,11] –7.018 3.045 0.03503 –13.23 –6.992 –1.057 60,001 120,000
treat.mean.diff[5,12] –6.845 4.756 0.06888 –16.18 –6.841 2.535 60,001 120,000
treat.mean.diff[6,7] –2.296 3.041 0.04011 –7.992 –2.375 4.008 60,001 120,000
treat.mean.diff[6,8] –5.732 4.171 0.07775 –13.95 –5.759 2.71 60,001 120,000
treat.mean.diff[6,9] –4.515 2.629 0.04471 –9.766 –4.472 0.6213 60,001 120,000
treat.mean.diff[6,10] 4.286 100.3 0.2887 –192 4.05 201.2 60,001 120,000
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TABLE 144 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[6,11] –6.379 2.655 0.0324 –11.66 –6.391 –1.043 60,001 120,000
treat.mean.diff[6,12] –6.206 4.519 0.0671 –15.09 –6.259 2.72 60,001 120,000
treat.mean.diff[7,8] –3.436 3.95 0.07453 –11.41 –3.362 4.149 60,001 120,000
treat.mean.diff[7,9] –2.219 3.42 0.05284 –9.22 –2.15 4.204 60,001 120,000
treat.mean.diff[7,10] 6.583 100.3 0.2923 –189.9 6.298 203.6 60,001 120,000
treat.mean.diff[7,11] –4.083 3.628 0.0451 –11.48 –4.054 2.863 60,001 120,000
treat.mean.diff[7,12] –3.91 5.151 0.07278 –14.44 –3.836 5.87 60,001 120,000
treat.mean.diff[8,9] 1.216 3.842 0.06653 –6.371 1.209 8.742 60,001 120,000
treat.mean.diff[8,10] 10.02 100.4 0.2999 –186.6 9.879 207 60,001 120,000
treat.mean.diff[8,11] –0.6469 4.525 0.07643 –9.481 –0.5944 8.237 60,001 120,000
treat.mean.diff[8,12] –0.474 5.83 0.09455 –11.89 –0.4557 11.04 60,001 120,000
treat.mean.diff[9,10] 8.802 100.3 0.2931 –187.7 8.671 205.9 60,001 120,000
treat.mean.diff[9,11] –1.863 3.047 0.04461 –7.749 –1.912 4.25 60,001 120,000
treat.mean.diff[9,12] –1.691 4.754 0.07025 –11.01 –1.702 7.813 60,001 120,000
treat.mean.diff[10,11] –10.67 100.3 0.2919 –207.5 –10.56 185.8 60,001 120,000
treat.mean.diff[10,12] –10.49 100.4 0.2988 –207.9 –10.35 185.9 60,001 120,000
treat.mean.diff[11,12] 0.1729 3.673 0.05314 –7.111 0.1936 7.347 60,001 120,000
Median ranks
TABLE 145 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 8.648 0.8166 0.01045 7 9 10 60,001 120,000
rk.class[2] 9.054 0.9307 0.01243 7 9 10 60,001 120,000
rk.class[3] 6.049 1.573 0.02325 3 6 9 60,001 120,000
rk.class[4] 6.821 1.339 0.01517 4 7 9 60,001 120,000
rk.class[5] 5.334 1.626 0.02244 2 5 8 60,001 120,000
rk.class[6] 3.359 1.859 0.03424 1 3 7 60,001 120,000
rk.class[7] 3.873 1.331 0.01948 1 4 6 60,001 120,000
rk.class[8] 5.719 4.398 0.01267 1 9 10 60,001 120,000
rk.class[9] 2.856 1.325 0.01815 1 3 6 60,001 120,000
rk.class[10] 3.287 1.987 0.02956 1 3 8 60,001 120,000
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TABLE 146 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 10.63 0.8384 0.01047 9 11 12 60,001 120,000
rk[2] 10.93 1.222 0.01717 7 11 12 60,001 120,000
rk[3] 6.699 2.218 0.0375 3 6 11 60,001 120,000
rk[4] 7.809 1.556 0.02128 4 8 10 60,001 120,000
rk[5] 8.164 1.645 0.01718 5 8 11 60,001 120,000
rk[6] 7.589 1.473 0.01721 4 8 10 60,001 120,000
rk[7] 5.689 2.069 0.02781 2 6 10 60,001 120,000
rk[8] 3.501 2.162 0.04068 1 3 9 60,001 120,000
rk[9] 3.935 1.45 0.02115 1 4 7 60,001 120,000
rk[10] 6.75 5.384 0.01547 1 11 12 60,001 120,000
rk[11] 2.872 1.381 0.0184 1 3 6 60,001 120,000
rk[12] 3.426 2.298 0.03362 1 3 10 60,001 120,000
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Children and adolescents: clinical effectiveness (Children’s Yale–Brown Obsessive–Compulsive Scale) –
sensitivity analysis 3 (blinding)
See Table 40 for a summary.
TABLE 147 Raw data used
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
Bolton et al., 2011219 23.3 24 8.3 9.5 36 8 NA NA NA NA NA NA 2 2 2 7 NA NA
Freeman et al., 2008223 17.1 20 7.57 14.45 22 8.16 NA NA NA NA NA NA 2 2 3 7 NA NA
Liebowitz et al., 2002226 18.55 22 11.44 14.71 21 8.73 NA NA NA NA NA NA 2 2 1 4 NA NA
Piacentini et al., 2011230 17.2 22 10.04 13.3 49 9.31 NA NA NA NA NA NA 2 2 3 7 NA NA
Riddle et al., 2001232 20.9 63 8.5 18.2 57 8.6 NA NA NA NA NA NA 2 2 1 5 NA NA
Storch et al., 2011233 18.53 15 8.11 11.13 16 10.53 NA NA NA NA NA NA 2 2 2 7 NA NA
Storch et al., 2013234 15.43 14 9.72 15.56 16 6.62 NA NA NA NA NA NA 2 2 8 9 NA NA
The Pediatric OCD
Treatment Study, 2004236
21.5 28 5.4 16.5 28 9.1 14 28 9.5 11.2 28 8.6 4 2 1 6 7 8
Williams et al., 2010235 19.6 10 6.42 12.09 11 7.46 NA NA NA NA NA NA 2 2 2 7 NA NA
NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine,
9= clomipramine, 10= BT, 11=CBT, 12=CT, 13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo; t[i,2], type of treatment
[i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4]; y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline
(negative) for arm [1]; y[i,2], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean YBOCS scores at end of study
(positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total
number of patients for arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of patients for arm [4]; sd[i,1], SD of mean total
score or change from baseline for arm [1]; sd[i,2], SD of mean total score or change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3];
sd[i,4], SD of mean total score or change from baseline for arm [4].
D
O
I:
1
0
.3
3
1
0
/h
ta
2
0
4
3
0
H
E
A
LT
H
T
E
C
H
N
O
LO
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
6
V
O
L.
2
0
N
O
.
4
3
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
6
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
S
k
a
p
in
a
k
is
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
3
3
3
Key: intervention (class)
1. Placebo (1).
2. Waitlist (2).
3. Psychological placebo (3).
4. Fluoxetine (4).
5. Fluvoxamine (4).
6. Sertraline (4).
7. CBT (5).
8. CBT+ sertraline (6).
9. CBT+ placebo (7).
TABLE 148 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
class.mean.diff[1,2] 3.103 4.279 0.05724 –5.736 3.191 11.54 61,001 129,600
class.mean.diff[1,3] –3.943 4.497 0.05359 –13.04 –3.963 5.258 61,001 129,600
class.mean.diff[1,4] –3.795 3.219 0.02787 –10.55 –3.782 2.974 61,001 129,600
class.mean.diff[1,5] –7.18 3.555 0.04741 –14.33 –7.206 0.08779 61,001 129,600
class.mean.diff[1,6] –9.972 3.442 0.03088 –16.91 –10 –2.862 61,001 129,600
class.mean.diff[1,7] –9.758 5.575 0.05763 –20.78 –9.741 1.458 61,001 129,600
class.mean.diff[2,3] –7.046 3.673 0.02754 –14.15 –7.139 0.6016 61,001 129,600
class.mean.diff[2,4] –6.898 4.989 0.05415 –16.72 –6.996 3.421 61,001 129,600
class.mean.diff[2,5] –10.28 2.417 0.02076 –14.83 –10.37 –5.221 61,001 129,600
class.mean.diff[2,6] –13.07 4.567 0.04721 –21.98 –13.16 –3.638 61,001 129,600
class.mean.diff[2,7] –12.86 6.334 0.06788 –25.26 –12.89 0.008206 61,001 129,600
class.mean.diff[3,4] 0.1485 5.165 0.05022 –10.34 0.1485 10.63 61,001 129,600
class.mean.diff[3,5] –3.237 2.788 0.02048 –8.806 –3.246 2.374 61,001 129,600
class.mean.diff[3,6] –6.029 4.778 0.04467 –15.67 –6.047 3.646 61,001 129,600
class.mean.diff[3,7] –5.815 6.489 0.0665 –18.68 –5.803 7.188 61,001 129,600
class.mean.diff[4,5] –3.385 4.379 0.04524 –12.36 –3.378 5.519 61,001 129,600
class.mean.diff[4,6] –6.177 4.328 0.03163 –15.06 –6.185 2.796 61,001 129,600
class.mean.diff[4,7] –5.964 6.165 0.0578 –18.28 –5.939 6.432 61,001 129,600
class.mean.diff[5,6] –2.792 3.9 0.03758 –10.6 –2.81 5.091 61,001 129,600
class.mean.diff[5,7] –2.578 5.867 0.0621 –14.14 –2.525 9.12 61,001 129,600
class.mean.diff[6,7] 0.2136 4.395 0.04491 –8.512 0.2153 8.938 61,001 129,600
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TABLE 149 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
treat.mean.diff[1,2] 3.103 4.279 0.05724 –5.736 3.191 11.54 61,001 129,600
treat.mean.diff[1,3] –3.943 4.497 0.05359 –13.04 –3.963 5.258 61,001 129,600
treat.mean.diff[1,4] –3.846 3.071 0.0307 –10.08 –3.821 2.399 61,001 129,600
treat.mean.diff[1,5] –3.268 2.696 0.02486 –8.812 –3.27 2.223 61,001 129,600
treat.mean.diff[1,6] –4.268 2.802 0.03029 –9.965 –4.217 1.422 61,001 129,600
treat.mean.diff[1,7] –7.18 3.555 0.04741 –14.33 –7.206 0.08779 61,001 129,600
treat.mean.diff[1,8] –9.972 3.442 0.03088 –16.91 –10 –2.862 61,001 129,600
treat.mean.diff[1,9] –9.758 5.575 0.05763 –20.78 –9.741 1.458 61,001 129,600
treat.mean.diff[2,3] –7.046 3.673 0.02754 –14.15 –7.139 0.6016 61,001 129,600
treat.mean.diff[2,4] –6.948 5.017 0.05902 –16.83 –7.039 3.328 61,001 129,600
treat.mean.diff[2,5] –6.371 4.811 0.05586 –15.88 –6.456 3.49 61,001 129,600
treat.mean.diff[2,6] –7.371 4.452 0.05062 –15.96 –7.468 1.824 61,001 129,600
treat.mean.diff[2,7] –10.28 2.417 0.02076 –14.83 –10.37 –5.221 61,001 129,600
treat.mean.diff[2,8] –13.07 4.567 0.04721 –21.98 –13.16 –3.638 61,001 129,600
treat.mean.diff[2,9] –12.86 6.334 0.06788 –25.26 –12.89 0.008206 61,001 129,600
treat.mean.diff[3,4] 0.09769 5.192 0.05513 –10.48 0.09801 10.5 61,001 129,600
treat.mean.diff[3,5] 0.6747 5.009 0.05222 –9.585 0.6688 10.71 61,001 129,600
treat.mean.diff[3,6] –0.3247 4.648 0.0465 –9.636 –0.3322 9.015 61,001 129,600
treat.mean.diff[3,7] –3.237 2.788 0.02048 –8.806 –3.246 2.374 61,001 129,600
treat.mean.diff[3,8] –6.029 4.778 0.04467 –15.67 –6.047 3.646 61,001 129,600
treat.mean.diff[3,9] –5.815 6.489 0.0665 –18.68 –5.803 7.188 61,001 129,600
treat.mean.diff[4,5] 0.5771 3.215 0.02133 –5.973 0.279 7.537 61,001 129,600
treat.mean.diff[4,6] –0.4224 3.286 0.02684 –7.602 –0.1731 6.282 61,001 129,600
treat.mean.diff[4,7] –3.335 4.417 0.05087 –12.21 –3.336 5.573 61,001 129,600
treat.mean.diff[4,8] –6.126 4.357 0.03743 –15 –6.131 2.769 61,001 129,600
treat.mean.diff[4,9] –5.913 6.179 0.06194 –18.22 –5.884 6.419 61,001 129,600
treat.mean.diff[5,6] –0.9994 3.068 0.02282 –7.796 –0.5784 4.947 61,001 129,600
treat.mean.diff[5,7] –3.912 4.194 0.04733 –12.31 –3.896 4.609 61,001 129,600
treat.mean.diff[5,8] –6.704 4.128 0.033 –14.98 –6.721 1.816 61,001 129,600
treat.mean.diff[5,9] –6.49 6.022 0.05815 –18.43 –6.527 5.726 61,001 129,600
treat.mean.diff[6,7] –2.912 3.743 0.04114 –10.37 –2.903 4.544 61,001 129,600
treat.mean.diff[6,8] –5.704 3.671 0.02713 –13.02 –5.727 1.755 61,001 129,600
treat.mean.diff[6,9] –5.49 5.729 0.05522 –16.8 –5.502 6.003 61,001 129,600
treat.mean.diff[7,8] –2.792 3.9 0.03758 –10.6 –2.81 5.091 61,001 129,600
treat.mean.diff[7,9] –2.578 5.867 0.0621 –14.14 –2.525 9.12 61,001 129,600
treat.mean.diff[8,9] 0.2136 4.395 0.04491 –8.512 0.2153 8.938 61,001 129,600
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Median ranks
TABLE 150 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 5.879 0.8012 0.008782 4 6 7 61,001 129,600
rk.class[2] 6.662 0.714 0.007736 5 7 7 61,001 129,600
rk.class[3] 4.332 1.189 0.01151 1 4 6 61,001 129,600
rk.class[4] 4.285 1.223 0.01049 1 4 7 61,001 129,600
rk.class[5] 2.799 0.9752 0.009909 1 3 5 61,001 129,600
rk.class[6] 1.85 0.905 0.008695 1 2 4 61,001 129,600
rk.class[7] 2.193 1.424 0.01474 1 2 6 61,001 129,600
TABLE 151 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 7.744 0.9853 0.01082 5 8 9 61,001 129,600
rk[2] 8.541 1.04 0.01128 5 9 9 61,001 129,600
rk[3] 5.303 1.899 0.02138 1 5 8 61,001 129,600
rk[4] 5.239 1.737 0.01652 2 5 8 61,001 129,600
rk[5] 5.641 1.567 0.01309 2 6 8 61,001 129,600
rk[6] 4.989 1.469 0.01242 2 5 8 61,001 129,600
rk[7] 3.137 1.399 0.01545 1 3 6 61,001 129,600
rk[8] 1.951 1.119 0.01031 1 2 5 61,001 129,600
rk[9] 2.456 1.907 0.01931 1 2 8 61,001 129,600
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Children and adolescents: clinical effectiveness (Children’s Yale–Brown Obsessive–Compulsive Scale) –
sensitivity analysis 4 (post hoc), excluding studies that have used a waitlist as control
This is a post hoc analysis.
TABLE 152 Raw data used
Study y[,1] n[,1] sd[,1] y[,2] n[,2] sd[,2] y[,3] n[,3] sd[,3] y[,4] n[,4] sd[,4] na[] out[] t[,1] t[,2] t[,3] t[,4]
de Haan et al., 1998220 17.6 10 11.8 9.1 12 9.1 NA NA NA NA NA NA 2 2 6 7 NA NA
DeVeaugh-Geiss et al., 1992221 –2.4 29 NA –10 31 NA NA NA NA NA NA NA 2 1 1 6 NA NA
Freeman et al., 2008223 17.1 20 7.57 14.45 22 8.16 NA NA NA NA NA NA 2 2 2 8 NA NA
Geller et al., 2001224 –5.2 32 7.4 –9.5 71 9.2 NA NA NA NA NA NA 2 1 1 3 NA NA
Liebowitz et al., 2002226 18.55 22 11.44 14.71 21 8.73 NA NA NA NA NA NA 2 2 1 3 NA NA
March et al., 1998228 –3.4 95 7.99 –6.8 92 8.34 NA NA NA NA NA NA 2 1 1 5 NA NA
Neziroglu et al., 2000229 19.2 5 3.56 16.4 5 5.18 NA NA NA NA NA NA 2 2 4 9 NA NA
Piacentini et al., 2011230 17.2 22 10.04 13.3 49 9.31 NA NA NA NA NA NA 2 2 2 8 NA NA
Riddle et al., 1992231 14.8 6 7 13.6 7 5.7 NA NA NA NA NA NA 2 2 1 3 NA NA
Riddle et al., 2001232 20.9 63 8.5 18.2 57 8.6 NA NA NA NA NA NA 2 2 1 4 NA NA
Storch et al., 2013234 15.43 14 9.72 15.56 16 6.62 NA NA NA NA NA NA 2 2 10 11 NA NA
The Pediatric OCD
Treatment Study, 2004236
21.5 28 5.4 16.5 28 9.1 14 28 9.5 11.2 28 8.6 4 2 1 5 8 10
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine, 5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine,
9= clomipramine, 10= BT, 11=CBT, 12=CT, 13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo; t[i,2], type of treatment
[i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4]; y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline
(negative) for arm [1]; y[i,2], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean YBOCS scores at end of study
(positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total
number of patients for arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of patients for arm [4]; sd[i,1], SD of mean total
score or change from baseline for arm [1]; sd[i,2], SD of mean total score or change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3];
sd[i,4], SD of mean total score or change from baseline for arm [4].
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Key
1. Placebo (1).
2. Psychological placebo (2).
3. Fluoxetine (3).
4. Fluvoxamine (3).
5. Sertraline (3).
6. Clomipramine (4).
7. BT (5).
8. CBT (6).
9. BT+ fluvoxamine (7).
10. Sertraline+CBT (8).
11. Placebo+CBT (9).
TABLE 153 Class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
D[2] –3.815 3.248 0.04646 –10.08 –3.845 2.654 101,001 186,000
D[3] –3.475 2.094 0.01409 –7.803 –3.513 1.013 101,001 186,000
D[4] –7.621 2.641 0.03338 –12.82 –7.61 –2.436 101,001 186,000
D[5] –16.08 5.547 0.1055 –26.99 –16.05 –5.252 101,001 186,000
D[6] –7.066 2.5 0.03558 –11.88 –7.105 –2.151 101,001 186,000
D[7] –5.892 3.626 0.0444 –13.01 –5.914 1.201 101,001 186,000
D[8] –9.898 2.383 0.02919 –14.5 –9.936 –5.157 101,001 186,000
D[9] –9.725 4.246 0.0648 –17.96 –9.716 –1.401 101,001 186,000
TABLE 154 Individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
d[2] –3.815 3.248 0.04646 –10.08 –3.845 2.654 101,001 186,000
d[3] –3.561 1.385 0.01635 –6.31 –3.564 –0.7715 101,001 186,000
d[4] –3.17 1.635 0.0186 –6.288 –3.24 0.2024 101,001 186,000
d[5] –3.725 1.299 0.01303 –6.36 –3.714 –1.192 101,001 186,000
d[6] –7.621 2.641 0.03338 –12.82 –7.61 –2.436 101,001 186,000
d[7] –16.08 5.547 0.1055 –26.99 –16.05 –5.252 101,001 186,000
d[8] –7.066 2.5 0.03558 –11.88 –7.105 –2.151 101,001 186,000
d[9] –5.892 3.626 0.0444 –13.01 –5.914 1.201 101,001 186,000
d[10] –9.898 2.383 0.02919 –14.5 –9.936 –5.157 101,001 186,000
d[11] –9.725 4.246 0.0648 –17.96 –9.716 –1.401 101,001 186,000
Please note that these figures can be directly compared with Table 37 using the correct key for the treatment. For example,
the posterior MD for CBT (treatment #8 in this table) is –7.06 (95% CrI –11.88 to –2.15) and this compares with a MD of
–8.66 (95% CrI –14.38 to –3.14) from Table 37 of the main text of the report.
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Median ranks
TABLE 155 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 8.771 0.5095 0.004998 7 9 9 101,001 186,000
rk.class[2] 6.852 1.472 0.01982 3 7 9 101,001 186,000
rk.class[3] 7.017 1.181 0.01059 4 7 9 101,001 186,000
rk.class[4] 4.436 1.615 0.0214 2 4 8 101,001 186,000
rk.class[5] 1.524 1.233 0.01822 1 1 5 101,001 186,000
rk.class[6] 4.633 1.35 0.01805 2 5 7 101,001 186,000
rk.class[7] 5.448 1.985 0.02561 2 6 9 101,001 186,000
rk.class[8] 2.945 1.156 0.01379 1 3 6 101,001 186,000
rk.class[9] 3.375 1.905 0.02738 1 3 8 101,001 186,000
TABLE 156 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 10.77 0.5484 0.005578 9 11 11 101,001 186,000
rk[2] 7.767 2.226 0.03217 3 8 11 101,001 186,000
rk[3] 7.969 1.473 0.0173 5 8 10 101,001 186,000
rk[4] 8.389 1.435 0.01459 5 9 10 101,001 186,000
rk[5] 7.819 1.391 0.01456 5 8 10 101,001 186,000
rk[6] 4.564 1.873 0.02389 2 4 9 101,001 186,000
rk[7] 1.55 1.372 0.01955 1 1 6 101,001 186,000
rk[8] 4.79 1.629 0.02138 2 5 9 101,001 186,000
rk[9] 5.913 2.565 0.03303 2 6 11 101,001 186,000
rk[10] 2.959 1.215 0.01403 1 3 6 101,001 186,000
rk[11] 3.512 2.227 0.0313 1 3 10 101,001 186,000
Please note that these figures can be directly compared with Table 37 of the main report using the correct key for the
treatment. For example, the posterior median rank for CBT (treatment #8 in this table) is 5 (95% CrI 2 to 9) and this
compares with a median rank of 3 (95% CrI 1 to 7) in Table 37.
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Children and adolescents: acceptability (dropouts) – sensitivity
analysis 1 (low overall attrition)
See Table 45 for a summary.
TABLE 157 Raw data used
Study r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] na[] t[,1] t[,2] t[,3] t[,4]
Asbahr et al., 2005216 1.5 21 0.5 21 NA NA NA NA 2 5 8 NA NA
Bolton and Perrin, 2008218 0.5 11 2.5 11 NA NA NA NA 2 2 7 NA NA
Bolton et al., 2011219 3 24 2 36 NA NA NA NA 2 2 8 NA NA
de Haan et al., 1998220 0.5 11 1.5 14 NA NA NA NA 2 6 7 NA NA
DeVeaugh-Geiss et al.,
1992221
2 29 4 31 NA NA NA NA 2 1 6 NA NA
Liebowitz et al., 2002226 4 22 1 21 NA NA NA NA 2 1 4 NA NA
March et al., 1990227 0.5 9 2.5 9 NA NA NA NA 2 1 6 NA NA
March et al., 1998228 13 95 18 92 NA NA NA NA 2 1 5 NA NA
Piacentini et al., 2011230 5 22 8 49 NA NA NA NA 2 3 8 NA NA
Riddle et al., 1992231 1 6 1 7 NA NA NA NA 2 1 4 NA NA
Storch et al., 2011233 0.5 16 2.5 17 NA NA NA NA 2 2 8 NA NA
The Pediatric OCD
Treatment Study, 2004236
7 28 2 28 3 28 3 28 4 1 5 8 9
Williams et al., 2010235 1 10 1 11 NA NA NA NA 2 2 8 NA NA
NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine,
5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine, 9= clomipramine, 10= BT, 11=CBT, 12=CT,
13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo;
t[i,2], type of treatment [i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4];
y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [1]; y[i,2], total
mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean
YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS
scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total number of patients for
arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of
patients for arm [4]; sd[i,1], SD of mean total score or change from baseline for arm [1]; sd[i,2], SD of mean total score or
change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3]; sd[i,4], SD of mean
total score or change from baseline for arm [4].
Key: intervention (class)
1. Placebo (1).
2. Waitlist (2).
3. Psychological placebo (3).
4. Fluoxetine (4).
5. Sertraline (4).
6. Clomipramine (5).
7. BT (6).
8. CBT (7).
9. CBT+ sertraline (8).
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TABLE 158 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[1,2] 2.004 47.63 0.1619 0.0234 0.4655 7.378 100,001 200,000
OR.D[1,3] 88.6 16,920 37.98 0.01715 0.6795 23.59 100,001 200,000
OR.D[1,4] 684,500 2.78 × 108 620,500 5.23 × 10–4 0.5795 448.1 100,001 200,000
OR.D[1,5] 8.66 154.5 0.4221 0.3588 3.12 36.01 100,001 200,000
OR.D[1,6] 549.4 82,090 215.8 0.2338 8.088 695.2 100,001 200,000
OR.D[1,7] 1.066 8.235 0.03168 0.04269 0.4677 4.388 100,001 200,000
OR.D[1,8] 3.44 437.9 0.9819 0.03391 0.5395 7.327 100,001 200,000
OR.D[2,3] 51,760 2.31 × 107 51,600 0.05413 1.464 46.74 100,001 200,000
OR.D[2,4] 4.72E+ 06 1.89 × 109 4.23 × 106 8.12 × 10–4 1.253 1366 100,001 200,000
OR.D[2,5] 144.4 12,320 31.54 0.2732 6.881 254.4 100,001 200,000
OR.D[2,6] 3556 442,300 2258 0.6616 17.25 1572 100,001 200,000
OR.D[2,7] 2.059 65.74 0.1484 0.1543 1 7.432 100,001 200,000
OR.D[2,8] 112.1 25,660 58.84 0.04329 1.134 36.74 100,001 200,000
OR.D[3,4] 3.44 × 106 1.21 × 109 2.70 × 106 4.15 × 10–4 0.8422 1197 100,001 200,000
OR.D[3,5] 10,220 3.81 × 106 8978 0.08597 4.645 328.6 100,001 200,000
OR.D[3,6] 19,690 3.17 × 106 7701 0.1442 12.25 2389 100,001 200,000
OR.D[3,7] 10.39 1595 3.596 0.04189 0.6821 10.91 100,001 200,000
OR.D[3,8] 903.2 224100 500.6 0.01527 0.7741 43.04 100,001 200,000
OR.D[4,5] 3.91 × 106 8.33 × 108 1.85 × 106 0.005661 5.669 8118 100,001 200,000
OR.D[4,6] 3.32 × 107 6.47 × 109 1.52 × 107 0.01022 15.05 43550 100,001 200,000
OR.D[4,7] 2.91 × 106 1.12 × 109 2.50 × 106 8.74 × 10–4 0.8002 1087 100,001 200,000
OR.D[4,8] 999,300 2.49 × 108 555,300 9.15 × 10–4 0.923 1347 100,001 200,000
OR.D[5,6] 83.25 4380 29.29 0.0845 2.501 180.1 100,001 200,000
OR.D[5,7] 0.8665 32.12 0.07764 0.005902 0.1475 2.731 100,001 200,000
OR.D[5,8] 26.11 10530 23.55 0.004559 0.1674 4.631 100,001 200,000
OR.D[6,7] 1.037 169.8 0.3847 6.35 × 10–4 0.05713 1.861 100,001 200,000
OR.D[6,8] 20.67 5441 12.17 4.50 × 10–4 0.0643 4.102 100,001 200,000
OR.D[7,8] 7.098 382.1 0.8866 0.06605 1.146 20.08 100,001 200,000
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TABLE 159 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[1,2] 2.004 47.63 0.1619 0.0234 0.4655 7.378 100,001 200,000
OR[1,3] 88.6 16,920 37.98 0.01715 0.6795 23.59 100,001 200,000
OR[1,4] 0.8653 5.695 0.01689 0.02994 0.4078 3.622 100,001 200,000
OR[1,5] 1.241 15.18 0.03805 0.1239 0.7938 4.08 100,001 200,000
OR[1,6] 8.66 154.5 0.4221 0.3588 3.12 36.01 100,001 200,000
OR[1,7] 549.4 82,090 215.8 0.2338 8.088 695.2 100,001 200,000
OR[1,8] 1.066 8.235 0.03168 0.04269 0.4677 4.388 100,001 200,000
OR[1,9] 3.44 437.9 0.9819 0.03391 0.5395 7.327 100,001 200,000
OR[2,3] 51,760 2.31 × 107 51,600 0.05413 1.464 46.74 100,001 200,000
OR[2,4] 35.04 5064 11.88 0.02154 0.851 32.7 100,001 200,000
OR[2,5] 9.823 567.3 1.408 0.1006 1.676 30.07 100,001 200,000
OR[2,6] 144.4 12,320 31.54 0.2732 6.881 254.4 100,001 200,000
OR[2,7] 3556 442,300 2258 0.6616 17.25 1572 100,001 200,000
OR[2,8] 2.059 65.74 0.1484 0.1543 1 7.432 100,001 200,000
OR[2,9] 112.1 25,660 58.84 0.04329 1.134 36.74 100,001 200,000
OR[3,4] 1408 510,700 1142 0.008377 0.5765 38.53 100,001 200,000
OR[3,5] 1087 261,300 582.5 0.03144 1.155 38.62 100,001 200,000
OR[3,6] 10,220 3.81 × 106 8978 0.08597 4.645 328.6 100,001 200,000
OR[3,7] 19,690 3.17 × 106 7701 0.1442 12.25 2389 100,001 200,000
OR[3,8] 10.39 1595 3.596 0.04189 0.6821 10.91 100,001 200,000
OR[3,9] 903.2 224,100 500.6 0.01527 0.7741 43.04 100,001 200,000
OR[4,5] 10.07 389.9 0.9028 0.1496 1.74 36.51 100,001 200,000
OR[4,6] 257 44,410 101.2 0.364 8.065 255 100,001 200,000
OR[4,7] 6226 402,100 3626 0.3259 21.21 3037 100,001 200,000
OR[4,8] 12.04 957.4 2.632 0.05211 1.163 32.01 100,001 200,000
OR[4,9] 36.51 5828 13.04 0.04467 1.339 48.11 100,001 200,000
OR[5,6] 31.28 1904 4.73 0.2996 4.02 82.71 100,001 200,000
OR[5,7] 1133 117,700 330.8 0.2693 10.45 1099 100,001 200,000
OR[5,8] 1.351 13 0.04127 0.06476 0.601 5.613 100,001 200,000
OR[5,9] 5.107 431.8 0.964 0.04742 0.6859 10.67 100,001 200,000
OR[6,7] 83.25 4380 29.29 0.0845 2.501 180.1 100,001 200,000
OR[6,8] 0.8665 32.12 0.07764 0.005902 0.1475 2.731 100,001 200,000
OR[6,9] 26.11 10,530 23.55 0.004559 0.1674 4.631 100,001 200,000
OR[7,8] 1.037 169.8 0.3847 6.35 × 10–4 0.05713 1.861 100,001 200,000
OR[7,9] 20.67 5441 12.17 4.50 × 10–4 0.0643 4.102 100,001 200,000
OR[8,9] 7.098 382.1 0.8866 0.06605 1.146 20.08 100,001 200,000
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Median ranks
TABLE 160 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 4.718 1.504 0.01493 2 5 7 100,001 200,000
rk.class[2] 3.238 1.793 0.0165 1 3 7 100,001 200,000
rk.class[3] 4.044 2.134 0.01497 1 4 8 100,001 200,000
rk.class[4] 3.814 2.477 0.01057 1 4 8 100,001 200,000
rk.class[5] 6.438 1.479 0.01284 2 7 8 100,001 200,000
rk.class[6] 7.125 1.44 0.01217 3 8 8 100,001 200,000
rk.class[7] 3.128 1.385 0.009781 1 3 6 100,001 200,000
rk.class[8] 3.495 1.948 0.01222 1 3 7 100,001 200,000
TABLE 161 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 5.523 1.667 0.01742 2 6 8 100,001 200,000
rk[2] 3.66 2.179 0.02084 1 3 8 100,001 200,000
rk[3] 4.599 2.555 0.01836 1 4 9 100,001 200,000
rk[4] 3.355 2.229 0.01983 1 3 8 100,001 200,000
rk[5] 4.82 1.842 0.01277 1 5 8 100,001 200,000
rk[6] 7.444 1.66 0.01503 2 8 9 100,001 200,000
rk[7] 8.128 1.631 0.01371 3 9 9 100,001 200,000
rk[8] 3.518 1.677 0.01318 1 3 7 100,001 200,000
rk[9] 3.953 2.31 0.01463 1 4 9 100,001 200,000
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Children and adolescents: acceptability (dropouts) – sensitivity
analysis 2 (incomplete outcome data)
See Table 46 for a summary.
TABLE 162 Raw data used
Study r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] na[] t[,1] t[,2] t[,3] t[,4]
Asbahr et al., 2005216 1.5 21 0.5 21 NA NA NA NA 2 6 9 NA NA
Bolton and Perrin, 2008218 0.5 11 2.5 11 NA NA NA NA 2 2 8 NA NA
Bolton et al., 2011219 3 24 2 36 NA NA NA NA 2 2 9 NA NA
de Haan et al., 1998220 0.5 11 1.5 14 NA NA NA NA 2 7 8 NA NA
DeVeaugh-Geiss et al., 1992221 2 29 4 31 NA NA NA NA 2 1 7 NA NA
Freeman et al., 2008223 5 20 6 22 NA NA NA NA 2 3 9 NA NA
Geller et al., 2001224 12 32 22 71 NA NA NA NA 2 1 4 NA NA
Liebowitz et al., 2002226 4 22 1 21 NA NA NA NA 2 1 4 NA NA
March et al., 1998228 13 95 18 92 NA NA NA NA 2 1 6 NA NA
Piacentini et al., 2011230 5 22 8 49 NA NA NA NA 2 3 9 NA NA
Riddle et al., 1992231 1 6 1 7 NA NA NA NA 2 1 4 NA NA
Riddle et al., 2001232 27 63 19 57 NA NA NA NA 2 1 5 NA NA
Storch et al., 2011233 0.5 16 2.5 17 NA NA NA NA 2 2 9 NA NA
Storch et al., 2013234 6 14 3 16 NA NA NA NA 2 10 11 NA NA
The Pediatric OCD Treatment
Study, 2004236
7 28 2 28 3 28 3 28 4 1 6 9 10
Williams et al., 2010235 1 10 1 11 NA NA NA NA 2 2 9 NA NA
NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine,
5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine, 9= clomipramine, 10= BT, 11=CBT, 12=CT,
13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo;
t[i,2], type of treatment [i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4];
y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [1]; y[i,2], total
mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean
YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS
scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total number of patients for
arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of
patients for arm [4]; sd[i,1], SD of mean total score or change from baseline for arm [1]; sd[i,2], SD of mean total score or
change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3]; sd[i,4], SD of mean
total score or change from baseline for arm [4].
Key: intervention (class)
1. Placebo (1).
2. Waitlist (2).
3. Psychological placebo (3).
4. Fluoxetine (4).
5. Fluvoxamine (4).
6. Sertraline (4).
7. Clomipramine (5).
8. BT (6).
9. CBT (7).
10. CBT+ sertraline (8).
11. CBT+ placebo (9).
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TABLE 163 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[1,2] 0.9409 8.238 0.0271 0.04177 0.4769 4.166 100,001 200,000
OR.D[1,3] 1.162 20.74 0.05403 0.05146 0.5519 4.709 100,001 200,000
OR.D[1,4] 323.1 74,690 167.2 0.05674 0.7056 7.78 100,001 200,000
OR.D[1,5] 4.559 31.82 0.1309 0.2264 2.013 20.91 100,001 200,000
OR.D[1,6] 130.6 11,210 55.65 0.2705 5.953 307.3 100,001 200,000
OR.D[1,7] 0.6984 2.111 0.01182 0.07205 0.4809 2.387 100,001 200,000
OR.D[1,8] 0.8992 4.497 0.01937 0.06399 0.519 3.502 100,001 200,000
OR.D[1,9] 0.9197 47.47 0.1255 0.006346 0.1373 2.595 100,001 200,000
OR.D[2,3] 2.362 16.71 0.04775 0.1402 1.159 10.14 100,001 200,000
OR.D[2,4] 693.5 140,500 313.1 0.06187 1.48 38.89 100,001 200,000
OR.D[2,5] 19.6 260.4 0.9916 0.258 4.276 99 100,001 200,000
OR.D[2,6] 546.2 100,600 378.3 0.7216 12.23 775.6 100,001 200,000
OR.D[2,7] 1.451 3.293 0.01678 0.2085 0.9965 5.226 100,001 200,000
OR.D[2,8] 4.23 172.5 0.4978 0.07702 1.073 17.45 100,001 200,000
OR.D[2,9] 7.159 916 2.08 0.008978 0.2873 10.88 100,001 200,000
OR.D[3,4] 1253 324,800 724.4 0.05251 1.285 32.02 100,001 200,000
OR.D[3,5] 44.45 6459 14.47 0.2018 3.748 92.32 100,001 200,000
OR.D[3,6] 525 70,130 275.8 0.3997 10.81 842 100,001 200,000
OR.D[3,7] 1.161 2.123 0.008579 0.208 0.8647 3.616 100,001 200,000
OR.D[3,8] 4.912 612.9 1.385 0.06947 0.9334 13.59 100,001 200,000
OR.D[3,9] 9.693 1846 4.138 0.008141 0.2491 8.657 100,001 200,000
OR.D[4,5] 2292 4.33 × 105 965.6 0.1206 2.9 83.47 100,001 200,000
OR.D[4,6] 1.10 × 104 1.64 × 106 3716 0.1866 8.626 893.3 100,001 200,000
OR.D[4,7] 891.5 222,800 501.7 0.03788 0.6786 11.68 100,001 200,000
OR.D[4,8] 1501 500,300 1136 0.03585 0.7311 15.94 100,001 200,000
OR.D[4,9] 512.7 151,200 340.3 0.004535 0.1964 9.29 100,001 200,000
OR.D[5,6] 30.75 618.7 5.422 0.1535 2.88 138.2 100,001 200,000
OR.D[5,7] 1.345 281.2 0.6446 0.01375 0.2306 3.039 100,001 200,000
OR.D[5,8] 1.186 57.18 0.1337 0.01204 0.2456 4.467 100,001 200,000
OR.D[5,9] 2.598 552.8 1.244 0.001577 0.06598 2.639 100,001 200,000
OR.D[6,7] 0.344 17.33 0.04053 0.001409 0.08033 1.582 100,001 200,000
OR.D[6,8] 0.5686 11.68 0.03208 0.001141 0.08434 2.951 100,001 200,000
OR.D[6,9] 1.336 220.7 0.5204 1.77 × 10–4 0.02216 1.646 100,001 200,000
OR.D[7,8] 2.403 28.68 0.08785 0.1208 1.076 10.36 100,001 200,000
OR.D[7,9] 3.044 271.4 0.6238 0.01256 0.2917 7.321 100,001 200,000
OR.D[8,9] 0.6063 7.055 0.01773 0.0269 0.2772 2.556 100,001 200,000
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TABLE 164 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[1,2] 0.9409 8.238 0.0271 0.04177 0.4769 4.166 100,001 200,000
OR[1,3] 1.162 20.74 0.05403 0.05146 0.5519 4.709 100,001 200,000
OR[1,4] 0.7185 0.5733 0.003248 0.1921 0.6427 1.702 100,001 200,000
OR[1,5] 0.8515 2.364 0.00837 0.18 0.6874 2.306 100,001 200,000
OR[1,6] 0.9138 0.9901 0.005231 0.2467 0.7994 2.183 100,001 200,000
OR[1,7] 4.559 31.82 0.1309 0.2264 2.013 20.91 100,001 200,000
OR[1,8] 130.6 11,210 55.65 0.2705 5.953 307.3 100,001 200,000
OR[1,9] 0.6984 2.111 0.01182 0.07205 0.4809 2.387 100,001 200,000
OR[1,10] 0.8992 4.497 0.01937 0.06399 0.519 3.502 100,001 200,000
OR[1,11] 0.9197 47.47 0.1255 0.006346 0.1373 2.595 100,001 200,000
OR[2,3] 2.362 16.71 0.04775 0.1402 1.159 10.14 100,001 200,000
OR[2,4] 4.048 85 0.293 0.1189 1.332 16.43 100,001 200,000
OR[2,5] 5.451 303.6 0.7032 0.1237 1.429 19.91 100,001 200,000
OR[2,6] 3.901 29.03 0.135 0.1811 1.673 18.02 100,001 200,000
OR[2,7] 19.6 260.4 0.9916 0.258 4.276 99 100,001 200,000
OR[2,8] 546.2 100,600 378.3 0.7216 12.23 775.6 100,001 200,000
OR[2,9] 1.451 3.293 0.01678 0.2085 0.9965 5.226 100,001 200,000
OR[2,10] 4.23 172.5 0.4978 0.07702 1.073 17.45 100,001 200,000
OR[2,11] 7.159 916 2.08 0.008978 0.2873 10.88 100,001 200,000
OR[3,4] 3.342 67.2 0.1859 0.1036 1.16 13.52 100,001 200,000
OR[3,5] 4.468 155.6 0.4065 0.1076 1.245 16.12 100,001 200,000
OR[3,6] 3.579 146 0.3305 0.161 1.453 14.04 100,001 200,000
OR[3,7] 44.45 6459 14.47 0.2018 3.748 92.32 100,001 200,000
OR[3,8] 525 70,130 275.8 0.3997 10.81 842 100,001 200,000
OR[3,9] 1.161 2.123 0.008579 0.208 0.8647 3.616 100,001 200,000
OR[3,10] 4.912 612.9 1.385 0.06947 0.9334 13.59 100,001 200,000
OR[3,11] 9.693 1846 4.138 0.008141 0.2491 8.657 100,001 200,000
OR[4,5] 1.589 7.636 0.02302 0.2631 1.031 5.289 100,001 200,000
OR[4,6] 1.713 8.746 0.02764 0.351 1.155 5.412 100,001 200,000
OR[4,7] 10.99 613.5 1.773 0.3015 3.197 44.76 100,001 200,000
OR[4,8] 281.9 29,060 112 0.3747 9.569 575 100,001 200,000
OR[4,9] 1.335 7.801 0.03151 0.1006 0.7536 5.269 100,001 200,000
OR[4,10] 1.919 35.42 0.09533 0.08909 0.8093 7.612 100,001 200,000
OR[4,11] 3.761 465.6 1.106 0.009238 0.2194 5.183 100,001 200,000
OR[5,6] 1.689 10.48 0.02893 0.2646 1.09 5.342 100,001 200,000
OR[5,7] 10.61 303.4 0.7695 0.2478 2.978 43.33 100,001 200,000
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TABLE 164 Individual effects (continued )
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[5,8] 232 14,570 74.32 0.3297 8.827 556.1 100,001 200,000
OR[5,9] 1.332 9.608 0.03469 0.08188 0.7004 5.164 100,001 200,000
OR[5,10] 2.526 133.9 0.32 0.07279 0.7585 7.397 100,001 200,000
OR[5,11] 5.982 1149 2.583 0.008041 0.2022 4.912 100,001 200,000
OR[6,7] 7.599 152.4 0.4333 0.249 2.535 33.89 100,001 200,000
OR[6,8] 188.7 13,640 73.49 0.3203 7.444 430.4 100,001 200,000
OR[6,9] 0.8856 1.744 0.01158 0.1004 0.6035 3.192 100,001 200,000
OR[6,10] 1.227 16.02 0.04059 0.08275 0.6481 4.863 100,001 200,000
OR[6,11] 1.85 310.7 0.7309 0.008378 0.1736 3.568 100,001 200,000
OR[7,8] 30.75 618.7 5.422 0.1535 2.88 138.2 100,001 200,000
OR[7,9] 1.345 281.2 0.6446 0.01375 0.2306 3.039 100,001 200,000
OR[7,10] 1.186 57.18 0.1337 0.01204 0.2456 4.467 100,001 200,000
OR[7,11] 2.598 552.8 1.244 0.001577 0.06598 2.639 100,001 200,000
OR[8,9] 0.344 17.33 0.04053 0.001409 0.08033 1.582 100,001 200,000
OR[8,10] 0.5686 11.68 0.03208 0.001141 0.08434 2.951 100,001 200,000
OR[8,11] 1.336 220.7 0.5204 1.77 × 10–4 0.02216 1.646 100,001 200,000
OR[9,10] 2.403 28.68 0.08785 0.1208 1.076 10.36 100,001 200,000
OR[9,11] 3.044 271.4 0.6238 0.01256 0.2917 7.321 100,001 200,000
OR[10,11] 0.6063 7.055 0.01773 0.0269 0.2772 2.556 100,001 200,000
Median ranks
TABLE 165 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 6.095 1.553 0.02176 3 6 9 100,001 200,000
rk.class[2] 4.004 2.131 0.02932 1 4 8 100,001 200,000
rk.class[3] 4.418 2.155 0.02419 1 4 9 100,001 200,000
rk.class[4] 4.886 2.138 0.01902 1 5 9 100,001 200,000
rk.class[5] 7.119 1.902 0.02102 2 8 9 100,001 200,000
rk.class[6] 8.213 1.55 0.02074 3 9 9 100,001 200,000
rk.class[7] 3.877 1.582 0.01946 1 4 7 100,001 200,000
rk.class[8] 4.272 2.058 0.02425 1 4 8 100,001 200,000
rk.class[9] 2.117 1.903 0.01846 1 1 8 100,001 200,000
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TABLE 166 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 7.678 1.802 0.02494 4 8 11 100,001 200,000
rk[2] 4.73 2.867 0.04154 1 4 10 100,001 200,000
rk[3] 5.226 2.898 0.03468 1 5 10 100,001 200,000
rk[4] 5.403 2.308 0.02558 1 5 10 100,001 200,000
rk[5] 5.733 2.417 0.02381 1 6 10 100,001 200,000
rk[6] 6.491 2.104 0.02158 2 7 10 100,001 200,000
rk[7] 8.794 2.463 0.02683 2 10 11 100,001 200,000
rk[8] 10.04 2.015 0.02746 3 11 11 100,001 200,000
rk[9] 4.523 2.189 0.02989 1 4 9 100,001 200,000
rk[10] 5.013 2.748 0.03233 1 5 10 100,001 200,000
rk[11] 2.369 2.431 0.02302 1 1 10 100,001 200,000
Children and adolescents: acceptability (dropouts) – sensitivity
analysis 3 (blinding)
See Table 47 for a summary.
TABLE 167 Raw data used
Study r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] r[,4] n[,4] na[] t[,1] t[,2] t[,3] t[,4]
Asbahr et al., 2005216 1.5 21 0.5 21 NA NA NA NA 2 6 7 NA NA
Bolton et al., 2011219 3 24 2 36 NA NA NA NA 2 2 7 NA NA
Freeman et al., 2008223 5 20 6 22 NA NA NA NA 2 3 7 NA NA
Liebowitz et al., 2002226 4 22 1 21 NA NA NA NA 2 1 4 NA NA
Piacentini et al., 2011230 5 22 8 49 NA NA NA NA 2 3 7 NA NA
Riddle et al., 2001232 27 63 19 57 NA NA NA NA 2 1 5 NA NA
Storch et al., 2011233 0.5 16 2.5 17 NA NA NA NA 2 2 7 NA NA
Storch et al., 2013234 6 14 3 16 NA NA NA NA 2 8 9 NA NA
The Pediatric OCD
Treatment Study, 2004236
7 28 2 28 3 28 3 28 4 1 6 7 8
Williams et al., 2010235 1 10 1 11 NA NA NA NA 2 2 7 NA NA
NA, not available.
Notes
t[i,1], type of treatment [i] per arm [1] – [i] takes the values 1= placebo, 2=waitlist, 3= fluoxetine, 4= fluvoxamine,
5= paroxetine, 6= sertraline, 7= citalopram, 8= venlafaxine, 9= clomipramine, 10= BT, 11=CBT, 12=CT,
13= hypericum, 14= fluvoxamine and CBT, 15= clomipramine and BT, 16= escitalopram, 17= psychological placebo;
t[i,2], type of treatment [i] per arm [2]; t[i,3], type of treatment [i] per arm [3]; t[i,4], type of treatment [i] per arm [4];
y[i,1], total mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [1]; y[i,2], total
mean YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [2]; y[i,3], total mean
YBOCS scores at end of study (positive) or mean change from baseline (negative) for arm [3]; y[i,4], total mean YBOCS
scores at end of study (positive) or mean change from baseline (negative) for arm [4]; n[i,1], total number of patients for
arm [1]; n[i,2], total number of patients for arm [2]; n[i,3], total number of patients for arm [3]; n[i,4], total number of
patients for arm [4]; sd[i,1], SD of mean total score or change from baseline for arm [1]; sd[i,2], SD of mean total score or
change from baseline for arm [2]; sd[i,3], SD of mean total score or change from baseline for arm [3]; sd[i,4], SD of mean
total score or change from baseline for arm [4].
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Key: intervention (class)
1. Placebo (1).
2. Waitlist (2).
3. Psychological placebo (3).
4. Fluoxetine (4).
5. Fluvoxamine (4).
6. Sertraline (4).
7. CBT (5).
8. CBT+ sertraline (6).
9. CBT+ placebo (7).
TABLE 168 Class effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR.D[1,2] 3.763 305.6 0.9887 0.008369 0.2633 4.365 91,001 200,000
OR.D[1,3] 82.62 19,310 44.19 0.01173 0.3215 5.323 91,001 200,000
OR.D[1,4] 372.9 54,740 121.5 0.006197 0.3773 15.56 91,001 200,000
OR.D[1,5] 1.043 40.1 0.1593 0.01888 0.2756 2.5 91,001 200,000
OR.D[1,6] 4.388 634.1 2.031 0.02267 0.3584 4.282 91,001 200,000
OR.D[1,7] 2549 906,900 2023 0.001884 0.09901 4.014 91,001 200,000
OR.D[2,3] 37.09 4857 10.85 0.09322 1.202 20.43 91,001 200,000
OR.D[2,4] 7017 1.49E+ 06 3328 0.01486 1.384 168.8 91,001 200,000
OR.D[2,5] 2.246 36.64 0.08773 0.1656 1.041 8.465 91,001 200,000
OR.D[2,6] 350.7 56,730 127.7 0.05515 1.332 47.05 91,001 200,000
OR.D[2,7] 40,130 1.12E+ 07 25,170 0.005716 0.3793 35.75 91,001 200,000
OR.D[3,4] 6359 1.40E+ 06 3131 0.01157 1.136 130.7 91,001 200,000
OR.D[3,5] 2.005 53.18 0.125 0.1408 0.8544 5.568 91,001 200,000
OR.D[3,6] 773.2 221,200 495.5 0.04658 1.104 32.98 91,001 200,000
OR.D[3,7] 49,850 2.04E+ 07 45,660 0.004622 0.3091 24.7 91,001 200,000
OR.D[4,5] 1407 168,400 372.8 0.01008 0.7556 50.93 91,001 200,000
OR.D[4,6] 1829 232,900 522.6 0.01211 0.974 87.08 91,001 200,000
OR.D[4,7] 5410 1.32E+ 06 2957 0.001433 0.2713 56.51 91,001 200,000
OR.D[5,6] 30.1 4063 9.31 0.08929 1.287 21.18 91,001 200,000
OR.D[5,7] 1781 433,200 979.3 0.007595 0.3615 18.66 91,001 200,000
OR.D[6,7] 449.2 191,700 427.9 0.01618 0.285 4.439 91,001 200,000
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TABLE 169 Individual effects
Interventions
compared Mean SD MC_error val2.5pc Median val97.5pc Start Sample
OR[1,2] 3.763 305.6 0.9887 0.008369 0.2633 4.365 91,001 200,000
OR[1,3] 82.62 19,310 44.19 0.01173 0.3215 5.323 91,001 200,000
OR[1,4] 0.7078 9.981 0.02973 0.01278 0.2972 2.497 91,001 200,000
OR[1,5] 1.361 39.79 0.09724 0.0647 0.542 3.524 91,001 200,000
OR[1,6] 2.148 550.9 1.256 0.03273 0.3309 2.428 91,001 200,000
OR[1,7] 1.043 40.1 0.1593 0.01888 0.2756 2.5 91,001 200,000
OR[1,8] 4.388 634.1 2.031 0.02267 0.3584 4.282 91,001 200,000
OR[1,9] 2549 906,900 2023 0.001884 0.09901 4.014 91,001 200,000
OR[2,3] 37.09 4857 10.85 0.09322 1.202 20.43 91,001 200,000
OR[2,4] 909.1 322,300 726.3 0.0211 1.063 49.41 91,001 200,000
OR[2,5] 759.3 114,200 268.3 0.07927 2.04 83.19 91,001 200,000
OR[2,6] 56.27 9489 22.25 0.07649 1.23 31.66 91,001 200,000
OR[2,7] 2.246 36.64 0.08773 0.1656 1.041 8.465 91,001 200,000
OR[2,8] 350.7 56,730 127.7 0.05515 1.332 47.05 91,001 200,000
OR[2,9] 40,130 1.12E+ 07 25170 0.005716 0.3793 35.75 91,001 200,000
OR[3,4] 326.9 50,620 116.6 0.01739 0.8772 36.11 91,001 200,000
OR[3,5] 472.8 64,440 151.3 0.0607 1.665 61.34 91,001 200,000
OR[3,6] 75.49 11,180 25.07 0.06565 1.011 21.89 91,001 200,000
OR[3,7] 2.005 53.18 0.125 0.1408 0.8544 5.568 91,001 200,000
OR[3,8] 773.2 221,200 495.5 0.04658 1.104 32.98 91,001 200,000
OR[3,9] 49,850 2.04E+ 07 45,660 0.004622 0.3091 24.7 91,001 200,000
OR[4,5] 94.89 12,400 29.51 0.1718 1.59 59.8 91,001 200,000
OR[4,6] 135.6 24,550 54.73 0.07889 1.074 32.55 91,001 200,000
OR[4,7] 55.09 9875 22.29 0.04075 0.9672 34.13 91,001 200,000
OR[4,8] 164.9 25,630 57.6 0.04778 1.253 54.58 91,001 200,000
OR[4,9] 2876 4.79E+ 05 1121 0.004735 0.3589 37.53 91,001 200,000
OR[5,6] 10.24 1850 4.172 0.04129 0.6941 6.434 91,001 200,000
OR[5,7] 20.95 5141 11.65 0.02488 0.5203 8.125 91,001 200,000
OR[5,8] 96.62 19,130 46.34 0.029 0.6658 14.55 91,001 200,000
OR[5,9] 1.35E+ 06 6.03E+ 08 1.35E+ 06 0.002772 0.1847 12.21 91,001 200,000
OR[6,7] 1.954 31.68 0.1074 0.07761 0.8458 7.118 91,001 200,000
OR[6,8] 7.992 449.5 1.027 0.07516 1.106 14.78 91,001 200,000
OR[6,9] 893.2 206,200 460.9 0.006087 0.3081 13.37 91,001 200,000
OR[7,8] 30.1 4063 9.31 0.08929 1.287 21.18 91,001 200,000
OR[7,9] 1781 433,200 979.3 0.007595 0.3615 18.66 91,001 200,000
OR[8,9] 449.2 191,700 427.9 0.01618 0.285 4.439 91,001 200,000
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
350
Median ranks
TABLE 170 Median ranks: class effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk.class[1] 6.162 1.207 0.01402 3 7 7 91,001 200,000
rk.class[2] 3.612 1.885 0.02214 1 3 7 91,001 200,000
rk.class[3] 4.006 1.792 0.01616 1 4 7 91,001 200,000
rk.class[4] 4.123 1.991 0.01434 1 4 7 91,001 200,000
rk.class[5] 3.587 1.341 0.01295 1 4 6 91,001 200,000
rk.class[6] 4.209 1.688 0.01611 1 4 7 91,001 200,000
rk.class[7] 2.3 1.794 0.01636 1 1 7 91,001 200,000
TABLE 171 Median ranks: individual effects
Intervention
code Mean SD MC_error val2.5pc Median val97.5pc Start Sample
rk[1] 7.961 1.434 0.01674 4 8 9 91,001 200,000
rk[2] 4.425 2.559 0.03144 1 4 9 91,001 200,000
rk[3] 4.918 2.445 0.02401 1 5 9 91,001 200,000
rk[4] 4.472 2.465 0.02435 1 4 9 91,001 200,000
rk[5] 6.116 2.142 0.01966 2 7 9 91,001 200,000
rk[6] 4.821 2.033 0.01934 1 5 9 91,001 200,000
rk[7] 4.374 1.862 0.02014 1 4 8 91,001 200,000
rk[8] 5.18 2.29 0.02194 2 5 9 91,001 200,000
rk[9] 2.733 2.384 0.02166 1 1 9 91,001 200,000
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Appendix 10 Economic evaluation
Office for National Statistics life tables stratified by age and gender
TABLE 172 Mortality rates between age x and (x + 1)
Age (years) Males Females
12 (mean age of children and adolescents) 0.0001 0.0001
13 0.0001 0.0001
14 0.0001 0.0001
15 0.0002 0.0001
16 0.0002 0.0001
17 0.0004 0.0002
18 0.0005 0.0002
36 (mean age of adults) 0.0011 0.0006
37 0.0012 0.0007
38 0.0013 0.0008
39 0.0014 0.0008
40 0.0016 0.0009
41 0.0016 0.0010
42 0.0018 0.0011
PubMed search strategy for longitudinal studies of the course
of obsessive–compulsive disorder symptom severity conducted
October 2014
Search Search term Hits
#1 Case control studies [MeSH Terms] 667,981
#2 Cohort studies [MeSH Terms] 1,355,328
#3 Case control [Text Word] 210,456
#4 Cohort analy*[Text Word] 4462
#5 Longitudinal [Text Word] 186,703
#6 #1 Or #2 Or #3 Or #4 Or #5 1,605,453
#7 #6 AND (obsessive*AND compulsi*) 1995
#8 #7 AND (yale Or brown or scale) 561
MeSH, Medical Subject Heading.
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Search strategy for studies of utility scores in patients with
obsessive–compulsive disorder conducted August 2014
Date Database Number of hits
Total hits this
database
Total hits
overall
5 August 2013 MEDLINE 1950 to present on Ovid 403 403
6 August 2013 MEDLINE In-Process & Other Non-Indexed
Citations – current week
44 44 447
Database: MEDLINE 1950 to present
Date of search: 5 August 2014.
Search strategy
1. exp quality of life/ (119,318)
2. quality of life.tw. (137,047)
3. life quality.tw. (3389)
4. hql.tw. (81)
5. (sf 36 or sf36 or sf thirtysix or sf thirty six or short form 36 or short form thirty six or short form
thirty-six or short form 36).tw. (15,158)
6. qol.tw. (17,845)
7. (euroqol or eq5d or eq 5d).tw. (3723)
8. qaly$.tw. (4832)
9. quality adjusted life year$.tw. (5700)
10. hye$.tw. (630)
11. health$ year$ equivalent$.tw. (38)
12. health utilit$.tw. (1062)
13. hui.tw. (643)
14. quality of wellbeing$.tw. (6)
15. quality of well being.tw. (323)
16. qwb.tw. (166)
17. (qald$ or qale$ or qtime$).tw. (110)
18. standard gamble$.tw. (650)
19. time trade off.tw. (728)
20. time tradeoff.tw. (199)
21. tto.tw. (576)
22. visual analog$ scale$.tw. (26,566)
23. discrete choice experiment$.tw. (414)
24. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or short form six or short form six).tw. (984)
25. health state$ utilit$.tw. (281)
26. health state$ value$.tw. (128)
27. health state$ preference$.tw. (83)
28. or/1-27 (213341)
29. obsessive compulsive disorder/ (11,322)
30. (obsess$ and (personalit$ or compuls$)).tw. (11,266)
31. or/29-30 (15,018)
32. 28 and 31 (403)
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Database: MEDLINE In-Process & Other Non-Indexed Citations – current week
Date of search: 6 August 2014.
Search strategy
1. exp quality of life/ (0)
2. quality of life.tw. (15,810)
3. life quality.tw. (385)
4. hql.tw. (5)
5. (sf 36 or sf36 or sf thirtysix or sf thirty six or short form 36 or short form thirty six or short form
thirty-six or short form 36).tw. (1455)
6. qol.tw. (2086)
7. (euroqol or eq5d or eq 5d).tw. (601)
8. qaly$.tw. (563)
9. quality adjusted life year$.tw. (649)
10. hye$.tw. (69)
11. health$ year$ equivalent$.tw. (1)
12. health utilit$.tw. (113)
13. hui.tw. (81)
14. quality of wellbeing$.tw. (2)
15. quality of well being.tw. (11)
16. qwb.tw. (6)
17. (qald$ or qale$ or qtime$).tw. (16)
18. standard gamble$.tw. (39)
19. time trade off.tw. (56)
20. time tradeoff.tw. (7)
21. tto.tw. (62)
22. visual analog$ scale$.tw. (3247)
23. discrete choice experiment$.tw. (80)
24. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or short form six or short form six).tw. (398)
25. health state$ utilit$.tw. (35)
26. health state$ value$.tw. (11)
27. health state$ preference$.tw. (10)
28. or/1-27 (20097)
29. obsessive compulsive disorder/ (0)
30. (obsess$ and (personalit$ or compuls$)).tw. (1072)
31. or/29-30 (1072)
32. 28 and 31 (44)
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Results of other sensitivity analyses: adults
TABLE 173 Low overall attrition
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
FLV+CBT 7273 3.221 57,144 89,352
CBT 7477 3.234 57,212 89,557
SSRIs 5845 3.195 58,045 89,990
VEN 5801 3.202 58,229 90,244
CLO 5719 3.223 58,744 90,975
CT 6579 3.335 60,131 93,486
BT 6713 3.343 60,139 93,566
CLO+ BT
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
TABLE 174 Low risk of bias in ‘incomplete outcome assessment’
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
CBT 7451 3.221 56,972 89,183
CLO 5894 3.180 57,711 89,514
SSRIs 5866 3.189 57,909 89,796
BT 6963 3.244 57,909 90,345
VEN 5846 3.191 57,965 89,870
CLO+ BT 6892 3.260 58,318 90,923
CT
FLV+CBT
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
TABLE 175 Low risk of bias in ‘blinding of outcome assessor’
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
CBT 7533 3.180 56,063 87,861
SSRIs 5937 3.172 57,495 89,210
VEN 5902 3.177 57,639 89,409
CLO 5894 3.181 57,721 89,528
BT 6915 3.271 58,514 91,228
CLO+ BT 6929 3.272 58,516 91,238
CT 6744 3.277 58,803 91,576
FLV+CBT
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
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TABLE 176 Definition of full response
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
CBT 7567 3.207 56,565 88,631
FLV+CBT 7306 3.196 56,619 88,582
SSRIs 5901 3.182 57,745 89,568
CLO 5869 3.188 57,897 89,779
VEN 5852 3.191 57,970 89,881
CLO+ BT 6891 3.274 58,579 91,314
CT 6707 3.286 59,021 91,885
BT 6820 3.297 59,111 92,076
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
TABLE 177 Cost of initial therapy (minimum)
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
FLV+CBT 6412 3.219 57,968 90,158
CBT 6498 3.238 58,267 90,649
SSRIs 5770 3.208 58,390 90,471
CLO 5737 3.215 58,563 90,713
VEN 5724 3.220 58,668 90,863
CLO+ BT 6186 3.299 59,799 92,792
CT 5986 3.313 60,272 93,401
BT 6119 3.320 60,291 93,495
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
TABLE 178 Transition from full to partial response
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
FLV+CBT 7047 3.255 58,051 90,601
CBT 7233 3.283 58,418 91,243
SSRIs 5585 3.254 59,494 92,033
CLO 5558 3.259 59,614 92,200
VEN 5521 3.266 59,801 92,462
CLO+ BT 6665 3.325 59,830 93,078
BT 6620 3.342 60,218 93,637
CT 6483 3.337 60,259 93,629
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
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TABLE 179 Change cost of long-term care
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
FLV+CBT 6615 3.219 57,765 89,955
CBT 6774 3.238 57,991 90,373
SSRIs 5237 3.208 58,924 91,004
CLO 5176 3.215 59,124 91,274
VEN 5137 3.220 59,254 91,450
CLO+ BT 5912 3.299 60,074 93,067
CT 5678 3.313 60,580 93,709
BT 5777 3.320 60,633 93,838
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
TABLE 180 Low cost of SSRI
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
FLV+CBT 7206 3.219 57,174 89,364
CBT 7428 3.238 57,337 89,719
SSRIs 5764 3.208 58,396 90,477
CLO 5751 3.215 58,549 90,699
VEN 5727 3.220 58,664 90,860
CLO+ BT 6778 3.299 59,208 92,201
CT 6590 3.313 59,668 92,797
BT 6715 3.320 59,695 92,899
CLO, clomipramine; FLV, fluvoxamine; VEN, venlafaxine.
Results of other sensitivity analyses: children and adolescents
TABLE 181 Low overall attrition
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
BT 6905 3.257 58,242 90,816
CLO 5578 3.266 59,735 92,392
SSRIs 5538 3.277 59,993 92,758
CBT 6615 3.339 60,166 93,556
SER+CBT 6562 3.350 60,437 93,936
CLO, clomipramine; SER, sertraline.
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TABLE 182 Low risk of bias in ‘incomplete outcome assessment’
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
BT 6780 3.268 58,580 91,259
CLO 5457 3.294 60,431 93,375
CBT 6469 3.365 60,829 94,478
SSRIs 5390 3.312 60,848 93,967
SER+CBT 6422 3.374 61,052 94,789
CLO, clomipramine; SER, sertraline.
TABLE 183 Low risk of bias in ‘blinding of outcome assessor’
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
CBT 6732 3.298 £59,223 £92,201
SSRIs 5610 3.259 £59,574 £92,166
SER+CBT 6618 3.319 £59,754 £92,940
CLO, clomipramine; SER, sertraline.
TABLE 184 Definition of full response
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
BT 6807 3.244 58,080 90,523
CLO 5590 3.263 59,677 92,311
SSRIs 5506 3.286 60,216 93,077
CBT 6572 3.343 60,289 93,719
SER+CBT 6518 3.354 60,561 94,101
CLO, clomipramine; SER, sertraline.
TABLE 185 Cost of initial therapy (minimum)
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
BT 6376 3.254 58,710 91,254
CLO 5508 3.280 60,094 92,895
SSRIs 5381 3.311 60,840 93,951
CBT 6017 3.368 61,347 95,028
SER+CBT 5976 3.376 61,549 95,311
CLO, clomipramine; SER, sertraline.
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TABLE 186 Transition from full to partial response
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
BT 6619 3.286 59,102 91,963
CLO 5360 3.315 60,931 94,077
CBT 6328 3.397 61,616 95,588
SER+CBT 6302 3.402 61,739 95,760
SSRIs 5220 3.350 61,776 95,274
CLO, clomipramine; SER, sertraline.
TABLE 187 Change cost of long-term care
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
BT 6073 3.254 59,014 91,557
CLO 4740 3.280 60,862 93,663
SSRIs 4515 3.311 61,707 94,818
CBT 5383 3.368 61,980 95,662
SER+CBT 5314 3.376 62,210 95,972
CLO, clomipramine; SER, sertraline.
TABLE 188 Low cost of SSRIs
Intervention Total costs, £ Total QALYs NMB (£20,000), £ NMB (£30,000), £
BT 6762 3.254 58,325 90,868
CLO 5515 3.280 60,087 92,888
SSRIs 5378 3.311 60,844 93,954
CBT 6459 3.368 60,905 94,586
SER+CBT 6418 3.376 61,107 94,869
CLO, clomipramine; SER, sertraline.
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